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A             INTRODUCTION 
In 2010, Richard Heck, Ei-ichi Negishi, and Akira Suzuki joined the prestigious circle of Nobel laureates 
for their roles in discovering and developing highly practical methodologies for C-C bond forming 
reactions.1 From their contributions the landscape of methods for organic synthesis irreversibly 
changed for chemists, both in academia and in industry. Until today, the transition metal-catalyzed 
transformations continue to find great attention from the chemical community. As Negishi picted out 
in his Nobel lecture, the goal of organic chemists in the 21st century is the synthesis of every imaginable 
compound to seek for new structures that could possibly solve mankind’s problems in the near or far 
future.2  
 
1 Overview 
Pd-catalyzed cross-coupling reactions between unsaturated halides and organometallics have found 
broad applications. Cross-coupling reactions using boronic acids or esters, known as Suzuki cross-
coupling reactions,3 have been extensively used due to the broad availability and relative air- and 
moisture-stability of unsaturated boronic acid derivatives.4 Nevertheless, the fast transmetalation of 
organozinc reagents to palladium compared to boronic acids often allows the achievement Negishi 
cross-couplings2 between a broad range of unsaturated halides and zinc organometallics under very 
mild conditions (Scheme 1).  
 
Scheme 1. General scheme of the Negishi cross-coupling reaction. 
The low toxicity of zinc salts, as well as the growing number of commercially available zinc reagents 
has increased their employment in cross-coupling reactions. Furthermore, it has been shown in several 
cases that expensive Pd-based catalytic systems can be replaced by other transition metals, such as Ni, 
Fe, Co or Cu, providing alternative pathways for successful cross-coupling reactions of various organic 
(pseudo)halides with all kinds of organometallic compounds.  
                                                          
1 "The Nobel Prize in Chemistry 2010". http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2010/; retrieved 
Feb 15 2016. 
2 E. Negishi, Angew. Chem. Int. Ed. 2011, 50, 6738. 
3 A. Suzuki, Angew. Chem. Int. Ed. 2011, 50, 6722. 
4 Boronic Acids. Preparation and Applications in Organic Synthesis and Medicine, 2nd ed., (Ed.: D. G. Hall), Wiley-VCH, 
Weinheim, 2005, pp. 1-122. 
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2 Preparation of Zinc Organometallics 
2.1 Oxidative Addition of Zinc Powder to Organic Halides 
Organozinc reagents can be prepared directly by the insertion of zinc powder to various aromatic and 
heterocyclic iodides or bromides.5 Thus, reduction of zinc chloride in THF using lithium naphthalenide 
provides highly activated zinc (Rieke-zinc).6 Alternatively the insertion of commercial zinc powder in 
the presence of lithium chloride proceeds readily with aryl iodides, as well as activated aryl or 
heteroaryl bromides.7 Hence, the bromo-triazene 1 inserts zinc in the presence of LiCl providing the 
zinc reagent 2 that leads to biphenyl 3 in 76% yield after Negishi cross-coupling with methyl 2-
iodobenzoate (Scheme 2).8 
 
Scheme 2. Regioselective insertion of zinc in the presence of LiCl. 
Also, 2,4-dibromothiazole (4) regioselectively inserts zinc dust in the presence of LiCl to afford the 
zincated thiazole 5, which undergoes a cross-coupling with 2-iodobenzaldehyde furnishing the 2-
arylated thiazole 6 in 85% yield (Scheme 3). 
 
Scheme 3. Regioselective insertion of zinc into 2,4-dibromothiazole 
                                                          
5 G. Dagousset, C. Francois, T. Léon, R. Blanc, E. Sansiaume-Dagousset, P. Knochel, Synthesis 2014, 46, 3133. 
6 a) R. D. Rieke, P. T. J. Li, T. P. Burns, S. T. Uhm, J. Org. Chem. 1981, 46, 4323. b) R. D. Rieke, Science 1989, 246, 1260. c) L. 
Zhu, R. M. Wehmeyer, R. D. Rieke, J. Org. Chem. 1991, 56, 1445. d) R. D. Rieke, M. V. Hanson, J. D. Brown, Q. J. Niu, J. Org. 
Chem. 1996, 61, 2726. 
7 A. Krasovskiy, V. Malakhov, A. Gavryushin, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 6040. 
8 N. Boudet, S. Sase, P. Sinha, C. Y. Liu, A. Krasovskiy, P. Knochel, J. Am. Chem. Soc. 2007, 129, 12358. 
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Addition of LiCl is not required, although it accelerates such Csp3-halide insertions as it plays a multiple 
role: it removes the oxide impurities on the surface of zinc and solubilizes the newly formed zinc 
reagent (RZnX) at the active site of the zinc surface by forming complexes of the type RZnX·LiCl. The 
metal activation effect of LiCl is quite general and other metallic powders such as Mg,9 In,10 Mn11 and 
Al12 are also efficiently activated by LiCl. It should be mentioned that the presence of additional Lewis 
acids, such as B(OR)313 or electron-transfer acceptors14 further accelerates the metal insertion. The 
intermediate radicals resulting from the zinc insertion do not allow a stereoselective formation of 
secondary alkylzinc reagents, such as in the case of the substituted cyclohexylzinc 8. However, the 
Negishi cross-coupling with methyl 4-iodobenzoate is stereoconvergent and produces the trans-
cyclohexane derivative 9 in 80% yield in the presence of RuPhos (2-dicyclohexylphosphino-2′,6′-
diisopropoxybiphenyl)15 (d.r. 96:4; Scheme 4).16  
 
Scheme 4. Stereoconvergent cross-coupling of a secondary alkylzink reagent. 
In the case of (Z)-alkenyl bromide 10, the zinc insertion appears to be stereoselective as a result of the 
chelate-stabilization as shown in intermediate 11. Subsequent Negishi cross-coupling affords 
(Z)-cinnamyl aldehyde 12 in 92% yield (Z:E > 99:1; Scheme 5).17 
                                                          
9 a) F. M. Piller, A. Metzger, M. A. Schade, B. A. Haag, A. Gavryushin, P. Knochel, Chem. – Eur. J. 2009, 15, 7192. b) F. M. Piller, 
P. Appukkuttan, A. Gavryushin, M. Helm, P. Knochel, Angew. Chem. Int. Ed. 2008, 47, 6802. 
10 a) Y. H. Chen, P. Knochel, Angew. Chem. Int. Ed. 2008, 47, 7648. b) Y. H. Chen, M. Sun, P. Knochel, Angew. Chem. Int. Ed. 
2009, 48, 2236. c) V. Papoian, T. Minehan, J. Org. Chem. 2008, 73, 7376. 
11 Z. Peng, P. Knochel, Org. Lett. 2011, 13, 3198. 
12 a) T. Bluemke, Y. H. Chen, Z. Peng, P. Knochel, Nat. Chem. 2010, 2, 313. b) K. Groll, T. D. Bluemke, A. Unsinn, D. Haas, P. 
Knochel, Angew. Chem. Int. Ed. 2012, 51, 11157. 
13 B. A. Haag, C. Saemann, A. Jana, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 7290. 
14 Z. L. Shen, P. Knochel, ACS Catal. 2015, 5, 2324. 
15 a) J. E. Milne, S. L. Buchwald, J. Am. Chem. Soc. 2004, 126, 13028. b) S. D. Walker, T. E. Barder, J. R. Martinelli, S. L. Buchwald, 
Angew. Chem. Int. Ed. 2004, 43, 1871. 
16 K. Moriya, P. Knochel, Org. Lett. 2014, 16, 924. 
17 C. Saemann, M. A. Schade, S. Yamada, P. Knochel, Angew. Chem. Int. Ed. 2013, 52, 9495. 
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Scheme 5. Stereoselective Negishi cross-coupling using an alkenylzinc reagent. 
Jackson18 showed that this method allows the preparation of chiral amino-acid derived zinc reagents, 
such as 13, starting from the readily available iodide 14. Negishi cross-coupling with 2-iodoaniline19 
provides the chiral lactam 15 in 85% yield (Scheme 6). 
 
Scheme 6. Preparation of Jackson’s zinc reagent in DMF. 
The reaction scope of such oxidative insertions was increased by replacing Zn with the bimetallic 
reagent couples Mg, ZnCl220 or Mg, Zn(OPiv)2.21 Under these conditions, the insertion is fast and highly 
regioselective. Thus, the tribromoarene 16 reacts solely in para-position with the metallic-cocktail Mg, 
ZnCl2, LiCl leading to zinc reagent 17 in high yield (Scheme 7).9 
 
Scheme 7. Preparation of a zinc organometallic using Mg, ZnCl2, LiCl. 
Benzylic zinc reagents are readily prepared by Zn, LiCl insertion20 and the method has been extended 
to a wide range of heterocyclic systems.22 The chloromethyl-pyridine 18 is converted to zinc reagent 
                                                          
18 A. J. Ross, H. L. Lang, R. F. W. Jackson, J. Org. Chem. 2010, 75, 245. 
19 G. Manolikakes, C. Muñoz Hernandez, M. A. Schade, A. Metzger, P. Knochel, J. Org. Chem. 2008, 73, 8422. 
20 a) A. Metzger, F. M. Piller, P. Knochel, Chem. Commun. 2008, 5824. b) C. Saemann, V. Dhayalan, P. R. Schreiner, P. Knochel, 
Org. Lett. 2014, 16, 2418. 
21 S. Bernhardt, G. Manolikakes, T. Kunz, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9205. 
22 N. M. Barl, E. Sansiaume-Dagousset, G. Monzon, A. J. Wagner, P. Knochel, Org. Lett. 2014, 16, 2422. 
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19, followed by Pd-PEPPSI-IPr-catalyzed23 cross-coupling with 2-bromopyridine providing the bis-
pyridine 20 in 78% yield (Scheme 8).  
 
Scheme 8. Preparation and cross-coupling of heterocyclic benzylic zinc reagents. 
Similarly, the chloromethyl isoxazole derivative 21 leads to zinc reagent 22 and Negishi cross-coupling 
using Pd-PEPPSI-IPr furnishes the desired product 23 in 87% yield (Scheme 9).24 
 
Scheme 9. Benzylic insertion into an isoxazole derivative. 
 
2.2 Metal-Catalyzed Preparation of Organozinc Reagents 
Gosmini25 further showed that the preparation of various polyfunctional arylzinc reagents is efficiently 
possible under Co-catalysis using cobalt halides. Also, Yoshikai has reported that CoCl2 catalyzes the 
zinc insertion into various aryl halides and that Pd-catalyzed cross-couplings can be subsequently 
achieved with these zinc reagents. Thus, 3-iodobenzonitrile (24) is converted to the corresponding zinc 
reagent 25 in 89% yield and subsequent Negishi cross-coupling provides the expected biphenyl 26 in 
high yield (Scheme 10).26 
                                                          
23 a) C. J. O’Brien, E. A. B. Kantchev, C. Valente, N. Hadei, G. A. Chass, A. Lough, A. C. Hopkinson, M. G. Organ, Chem. – Eur. J. 
2006, 12, 4743. b) M. G. Organ, S. Avola, I. Dubovyk, N. Hadei, E. A. B. Kantchev, C. J. O'Brien, C. Valente, Chem. – Eur. J. 
2006, 12, 4749. 
24 L. Klier, C. Diène, M. Schickinger, A. Metzger, A. J. Wagner, K. Karaghiosoff, I. Marek, P. Knochel, Chem. – Eur. J. 2014, 20, 
14096. 
25 a) I. Kazmierski, C. Gosmini, J. M. Paris, J. Périchon, Tetrahedron Lett. 2003, 44, 6417. b) C. Gosmini, M. Amatore, S. Claudel, 
J. Périchon, Synlett 2005, 2171. c) H. Fillon, C. Gosmini, J. Périchon, J. Am. Chem. Soc. 2003, 125, 3867. 
26 M. Y. Jin, N. Yoshikai, J. Org. Chem. 2011, 76, 1972. 
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Scheme 10. Cobalt-catalyzed zinc insertion to an aryl iodide. 
Yoshikai has also achieved impressive cascade reactions involving a 1,4-cobalt migration and 
subsequent palladium-catalyzed Negishi cross-couplings upon addition to an alkyne. This procedure 
allows the conversion of p-anisylzinc derivative 27 into the styrene derivative 28 via zinc intermediate 
29 in 70% overall yield (Scheme 11).27 
 
Scheme 11. 1,4-Cobalt migration and subsequent Negishi cross-coupling. 
 
2.3 Transmetalation of Magnesium, Aluminum or Lithium Organometallics 
The transmetalation of lithium, magnesium or aluminum12b organometallics is a well-established 
method for preparing various organozinc reagents. A site-selective Br/Mg-exchange28 of the 3,5-
dibromopyridine 30 using i-PrMgCl·LiCl leads to the corresponding Grignard reagent 31. 
Transmetalation with ZnCl2, followed by Negishi cross-coupling gives the bis-arylated pyridine 32 in 
88% yield (Scheme 12).29 
                                                          
27 B. H. Tan, J. Dong, N. Yoshikai, Angew. Chem. Int. Ed. 2012, 51, 9610. 
28 A. Krasovskiy, P. Knochel, Angew. Chem. Int. Ed. 2004, 43, 3333. 
29 C. Saemann, B. Haag, P. Knochel, Chem. – Eur. J. 2012, 18, 16145. 
INTRODUCTION 
 
9 
 
Scheme 12. Regioselective Br/Mg-exchange on a 3,5-dibromopyridine. 
A low-temperature I/Li-exchange of the aryl iodide 33 with n-BuLi provides, after transmetalation with 
the THF soluble salt ZnBr2·LiBr, bis-zinc reagent 34 that is employed in a diastereoselective Negishi 
cross-coupling for the preparation of canagliflozin (Scheme 13).30 
 
Scheme 13. Preparation of a bis-zinc reagent for the synthesis of canagliflozin. 
 
2.4 Preparation of Zinc Reagents by Directed Metalation 
The directed metalation31 of unsaturated, aromatic and heterocyclic molecules using various TMP-
bases (TMP = 2,2,6,6-tetramethylpiperidyl) of magnesium or zinc provides for the general preparation 
of the corresponding organometallic reagents.32 The use of TMPMgCl·LiCl (35)33 and the related zinc 
base TMPZnCl·LiCl (36)34 proved to be the most useful. Thus, 2,5-dichlorothieno[3,2-b]thiophene (37) 
is readily magnesiated by the addition of TMPMgCl·LiCl (35). Transmetalation with ZnCl2, followed by 
a Negishi cross-coupling reaction with 1-chloro-4-iodobenzene using Pd(dba)2 (dba = dibenzylidene-
                                                          
30 S. Lemaire, I. N. Houpis, T. Xiao, J. Li, E. Digard, C. Gozlan, R. Liu, A. Gavryushin, C. Diene, Y. Wang, V. Farina, P. Knochel, 
Org. Lett. 2012, 14, 1480. 
31 a) V. Snieckus, Chem. Rev. 1990, 90, 879. b) R. E. Mulvey, F. Mongin, M. Uchiyama, Y. Kondo, Angew. Chem. Int. Ed. 2007, 
46, 3802. c) D. Tilly, F. Chevallier, F. Mongin, P. C. Gros, Chem. Rev. 2014, 114, 1207. 
32 B. Haag, M. Mosrin, H. Ila, V. Malakhov, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9794. 
33 A. Krasovskiy, V. Krasovskaya, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 2958. 
34 M. Mosrin, P. Knochel, Org. Lett. 2009, 11, 1837. 
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acetone) and (o-furyl)3P (tfp)35 as a catalytic system leads to the mono-arylated thienothiophene 38 in 
91% yield (Scheme 14).36 
 
Scheme 14. Directed magnesiation of heterocyclic scaffolds with TMPMgCl·LiCl (35).  
Interestingly, 1,2-dimethylimidazole (39) is selectively magnesiated at the lateral methyl group 
furnishing zinc reagent 40 after transmetalation with ZnCl2, which then undergoes a smooth cross-
coupling with an aryl bromide affording the benzylated imidazole 41 in 91% yield (Scheme 15).37 
 
Scheme 15. Lateral metalation of 1,2-dimethylimidazole. 
In the case of aromatic substrates bearing C-H bonds of moderate acidity or sensitive functional 
groups, the use of TMP2Mg·2LiCl (42) can be advantageous. Thus, the magnesiation of the salicylic 
derivative (43) proceeds with TMP2Mg·2LiCl (42) and after transmetalation with ZnCl2 and Negishi 
cross-coupling with (E)-1-iodocyclohexene, the natural product 44 present in the essential oil of 
Pelargonium sidoides DC is obtained after hydrogenation and deprotection (Scheme 16).38  
 
 
Scheme 16. Magnesiation of a sensitive substrate with TMP2Mg·2LiCl (42).  
                                                          
35 a) V. Farina, S. R. Baker, D. Benigni, C. Sapino, Jr., Tetrahedron Lett. 1988, 29, 5739. b) V. Farina, B. Krishnan, J. Am. Chem. 
Soc. 1991, 113, 9585. 
36 T. Kunz, P. Knochel, Chem. – Eur. J. 2011, 17, 866. 
37 S. Duez, A. K. Steib, P. Knochel, Org. Lett. 2012, 14, 1951. 
38 G. C. Clososki, C. J. Rohbogner, P. Knochel, Angew. Chem. Int. Ed. 2007, 46, 7681. 
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Furthermore, the presence of a SF5-substituent decreases the metalation rate of ethyl benzoate 45 
and the use of TMP2Mg·2LiCl (42) is required to achieve a smooth magnesiation. After transmetalation 
with ZnCl2 and Negishi cross-coupling, the desired product 46 is obtained in 83% yield (Scheme 17).39 
 
Scheme 17. Magnesiation of a SF5-substituted substrate. 
The more covalent Zn-N bond in TMPZnCl·LiCl (36)34 combined with the high thermal stability of the 
resulting zinc reagents at up to 120 °C without noticeable decomposition allowed the performance of 
directed zincations under a wide range of conditions.40 Thus, indazoles, such as 47, which are prone to 
undergo ring fragmentation after lithiation or magnesiation, are efficiently zincated at the C-3 position 
using TMP2Zn·2MgCl2·2LiCl (48).41 After Negishi cross-coupling with an aryl iodide, the desired 3-
arylated indazole 49 is obtained in 71% yield (Scheme 18).42  
 
Scheme 18. Zincation of sensitive heterocycles using a TMP-zinc base. 
The zincation of various chlorinated or brominated pyrazines is readily realized using TMPZnCl·LiCl 
(36).43 However, the arylated pyrazine 50 is metalated best using TMPMgCl·LiCl (35) and after 
transmetalation with ZnCl2 and Pd-catalyzed Negishi acylation,44 the regioselectively substituted 
                                                          
39 A. Frischmuth, A. Unsinn, K. Groll, H. Stadtmueller, P. Knochel, Chem. – Eur. J. 2012, 18, 10234. 
40 M. Mosrin, G. Monzon, T. Bresser, P. Knochel, Chem. Commun. 2009, 5615. 
41 a) S. H. Wunderlich, P. Knochel, Angew. Chem. Int. Ed. 2007, 46, 7685. b) Z. Dong, G. C. Clososki, S. H. Wunderlich, A. Unsinn, 
J. Li, P. Knochel, Chem. – Eur. J. 2009, 15, 457. 
42 A. Unsinn, P. Knochel, Chem. Commun. 2012, 48, 2680. 
43 A. Unsinn, M. J. Ford, P. Knochel, Org. Lett. 2013, 15, 1128. 
44 E. Negishi, V. Bagheri, S. Chatterjee, F. T. Luo, J. A. Miller, A. T. Stoll, Tetrahedron Lett. 1983, 24, 5181. 
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pyrazine 51 is obtained in 71% yield. In a few steps it is converted into coelenterazine (52), a 
bioluminescent natural product found in the jellyfish Aequorea victoria (Scheme 19).45 
 
Scheme 19. Total synthesis of coelenterazine using a Negishi acylation. 
A regioselective arylation can be achieved combining the use of bases 35 or 36 with (or without) 
BF3·OEt2.46 Extension of this regioselectivity switch can be extended to other Lewis acids, such as MgCl2, 
as this Lewis acid allows a regioselective metalation of the chromone scaffold.47 The compatibility of a 
strong Lewis acid with magnesium amides is reminiscent of the concept of frustrated Lewis pairs 
(FLP).48 This methodology can be extended to lithium amides and it was recently found that TMPLi 
does not instantaneously react with ZnCl2 or MgCl2 allowing in situ trapping metalations followed by 
Negishi cross-couplings.49 Thus, mixing the ethyl 3-cyanobenzoate (53) with ZnCl2·2LiCl, cooling the 
mixture to -78 °C and adding TMPLi allows the regioselective lithiation at position 6 and the lithium 
intermediate is immediately transmetalated with ZnCl2. After a Negishi cross-coupling, the 
corresponding arylated product 54 is obtained in 87% yield (Scheme 20). 
 
Scheme 20. In situ trapping metalation and Negishi cross-coupling. 
                                                          
45 M. Mosrin, T. Bresser, P. Knochel, Org. Lett. 2009, 11, 3406. 
46 a) M. Jaric, B. A. Haag, A. Unsinn, K. Karaghiosoff, P. Knochel, Angew. Chem. Int. Ed. 2010, 49, 5451. b) M. Jaric, B. A. Haag, 
S. M. Manolikakes, P. Knochel, Org. Lett. 2011, 13, 2306. c) K. Groll, S. M. Manolikakes, X. M. du Jourdin, M. Jaric, A. 
Bredihhin, K. Karaghiosoff, T. Carell, P. Knochel, Angew. Chem. Int. Ed. 2013, 52, 6776. 
47 L. Klier, T. Bresser, T. A. Nigst, K. Karaghiosoff, P. Knochel, J. Am. Chem. Soc. 2012, 134, 13584. 
48 D. W. Stephan, G. Erker, Angew. Chem. Int. Ed. 2010, 49, 46. 
49 A. Frischmuth, M. Fernandez, N. M. Barl, F. Achrainer, H. Zipse, G. Berionni, H. Mayr, K. Karaghiosoff, P. Knochel, Angew. 
Chem. Int. Ed. 2014, 53, 7928. 
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However, performing these reactions not in batch, but in flow allows running these in situ trapping 
reactions at 0 °C.50 Most organozinc halides are sensitive to water and to moisture, however, tuning of 
the reaction conditions for preparing unsaturated zinc reagents by the addition of either magnesium 
salts, such as magnesium pivalate,51 or ligands, such as dioxane52 or bis-pyridine, this moisture stability 
can be considerably attenuated.53 Thus, the treatment of various aromatic or heterocyclic derivatives 
with TMPZnCl·Mg(OPiv)2·LiCl (55), obtained by mixing TMPMgCl·LiCl (35) with Zn(OPiv)2, readily 
provides solid zinc reagents that display considerable stability towards air and moisture after removal 
of all solvents.54  
 
Scheme 21. Preparation and Negishi cross-coupling of solid air-stable zinc reagents. 
In addition to their improved stability, these solid organozincs react very well in Negishi cross-
couplings. The reaction of 3-formyl-indole 56 with the base 55 furnishes the solid zinc reagent 57 and 
after Pd-catalyzed cross-coupling the polyfunctional 2-arylated indole 58 is obtained in 91% yield 
(Scheme 21).55 These zinc reagents were also proven to undergo copper-catalyzed acylation reactions 
and can be prepared from a broad range of polyfunctionalized substrates bearing groups, such as nitro, 
carboxy, cyano or formyl. Also, it should be mentioned that transition-metal free cross-couplings can 
be realized with various organozinc reagents especially with reactive benzylic zinc organometallics.56 
                                                          
50 a) T. P. Petersen, M. R. Becker, P. Knochel, Angew. Chem. Int. Ed. 2014, 53, 7933. b) M. R. Becker, P. Knochel, Angew. Chem. 
Int. Ed. 2015, 54, 12501. c) M. R. Becker, M. A. Ganiek, P. Knochel, Chem. Sci. 2015, 6, 6649. 
51 a) S. Bernhardt, G. Manolikakes, T. Kunz, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9205. b) C. I. Stathakis, S. Bernhardt, 
V. Quint, P. Knochel, Angew. Chem. Int. Ed. 2012, 51, 9428. c) M. Ellwart, P. Knochel, Angew. Chem. Int. Ed. 2015, 54, 10662. 
52 J. R. Colombe, S. Bernhardt, C. Stathakis, S. L. Buchwald, P. Knochel, Org. Lett. 2013, 15, 5754. 
53 A. B. Charette, J. F. Marcoux, C. Molinaro, A. Beauchemin, C. Brochu, É. Isabel, J. Am. Chem. Soc. 2000, 122, 4508. 
54 C. I. Stathakis, S. M. Manolikakes, P. Knochel, Org. Lett. 2013, 15, 1302. 
55 a) A. Hernan-Gomez, E. Herd, E. Hevia, A. R. Kennedy, P. Knochel, K. Koszinowski, S. M. Manolikakes, R. E. Mulvey, C. 
Schnegelsberg, Angew. Chem. Int. Ed. 2014, 53, 2706. b) S. M. Manolikakes, M. Ellwart, C. I. Stathakis, P. Knochel, Chem. – 
Eur. J. 2014, 20, 12289. 
56 a) Q. Chen, X. Mollat du Jourdin, P. Knochel, J. Am. Chem. Soc. 2013, 135, 4958. b) Q. Chen, T. Léon, P. Knochel, Angew. 
Chem. Int. Ed. 2014, 53, 8746. c) P. Quinio, D. S. Roman, T. Léon, S. William, K. Karaghiosoff, P. Knochel, Org. Lett. 2015, 17, 
4396. 
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3 Negishi Cross-Coupling Reactions 
3.1 Palladium-Catalyzed Negishi Cross-Coupling Reactions 
Negishi cross-couplings involve the use of organozinc reagents, an organic electrophile and a 
transition-metal catalyst. In recent years the variation of this transition-metal catalyst allowed to 
further broaden the synthetic scope of this important coupling procedure. The use of palladacycle 
precatalysts enables the performance of Negishi cross-couplings with a variety of substrates. Buchwald 
developed a new class of easily prepared, air- and moisture-stable aminobiphenyl-based palladacycle 
precatalysts capable of rapidly generating the catalytically active Pd(0)-L species under basic 
conditions, allowing Negishi cross-couplings to proceed at ambient temperature with low catalyst 
loading. Thus, the precatalyst palladacycle 59-L (L = XPhos) considerably facilitates the formation of the 
highly active palladium-species LPd(0) leading to fast Negishi cross-couplings at room temperature. 
The 2-zincated benzofuryl derived reagent 60 reacts with a chloropyrazole providing the complex 
polyfunctional heterocyclic compound 61 in 90% yield (Scheme 22).57 
 
Scheme 22. Pd-precatalyst facilitated Negishi cross-coupling. 
This strategy has been successfully applied to the performance of highly selective Negishi cross-
couplings of secondary alkylzinc species. A major difficulty of this transformation is undesired -
hydride elimination/migratory insertion that compete with the desired reductive elimination leading 
to isomerized side products. In order to suppress this isomerization, the rate of reductive elimination 
relative to -hydride elimination must be enhanced. Several research groups have addressed this issue 
by employing catalysts containing sterically-hindered phosphine ligands. A range of secondary alkylzinc 
                                                          
57 Y. Yang, N. J. Oldenhuis, S. L. Buchwald, Angew. Chem. Int. Ed. 2013, 52, 615. 
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reagents like 64 can be used with excellent results for the coupling of bromochromane 65 leading to 
the alkylated product 66 in 90% yield using the precatalyst 59-L (L = CPhos; Scheme 23).58  
 
Scheme 23. Pd-precatalyst for the cross-coupling of sec-alkylzinc reagents. 
Additionally, Organ59 and co-workers developed a series of new N-heterocyclic carbene-based Pd-
complexes, which were used for the Negishi cross-coupling of aryl and heteroaryl halides with a variety 
of secondary alkylzinc reagents. It was shown that Pd-PEPPSI-IPentCl (67) had unprecedented 
selectivity, leading only to the single isomer 68 for reactions of a variety of alkylzincs, such as 69, with 
highly functionalized (hetero)aromatic halides like 70 (Scheme 24).60 
 
Scheme 24. Negishi cross-coupling of secondary alkylzincs using Pd-PEPPSI-IPentCl.  
Interestingly, alkyl iodides such as i-PrI were found to accelerate Negishi cross-couplings.61 The 
reaction of diarylzinc reagent 71, prepared by a Br/Mg exchange, with aniline derivative 72 bearing a 
free NH2-group leading to the biphenyl 73 in 97% yield. In absence of i-PrI, a conversion of only 37% 
was observed (Scheme 25). 
                                                          
58 Y. Yang, K. Niedermann, C. Han, S. L. Buchwald, Org. Lett. 2014, 16, 4638. 
59 S. Çalimsiz, M. G. Organ, Chem. Commun. 2011, 47, 5181. 
60 M. Pompeo, R. D. J. Froese, N. Hadei, M. G. Organ, Angew. Chem. Int. Ed. 2012, 51, 11354. 
61 a) M. Kienle, P. Knochel, Org. Lett. 2010, 12, 2702. b) G. Manolikakes, P. Knochel, Angew. Chem. Int. Ed. 2009, 48, 205. 
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Scheme 25. i-PrI-accelerated Negishi cross-coupling. 
The mechanism of the Negishi cross-coupling has been carefully studied by Espinet62 and Koszinowski63 
using a combination of kinetic measurements, mass-spectrometry and NMR-methods. A structure-
reactivity relationship in Negishi cross-coupling reactions by Mayr64 showed that this reaction is 
accelerated by the presence of electron-acceptor substituted aryl bromides. On the other hand, the 
presence of an electron-acceptor substituent on the arylzinc halide diminishes the reaction rates. 
Additionally, Organ and co-workers65 investigated the role of halide salt additives in the Negishi 
reaction involving arylzinc reagents. It was shown that diarylzincs easily transmetallate to palladium in 
THF with no salt present, leading to the corresponding coupling products. In contrast, arylzinc halides 
fail to couple in THF without additional salt. However, unlike alkylzincs that form higher-order 
zincates66 in order to facilitate transmetallation, all that is needed for arylzincs is an increase in the 
solvent dielectric constant, which completely hempers the alkylzinc cross-coupling.  
The original reaction scope has been considerably extended, as the excellent functional group 
tolerance of zinc reagents allows the Negishi cross-coupling of various bromo-substituted 
alkoxycarbene complexes of chromium, molybdenum or tungsten complexes as shown by Dvorak.67 
Also, Dughera reported Negishi cross-couplings with arenediazonium o-benzenedisulfonimides.68 The 
combination of a Zr-catalyzed asymmetric carboalumination of alkenes (ZACA-reaction) with the 
Negishi cross-coupling allowed Negishi to prepare various chiral 1-alkanol derivatives in high 
enatiomeric purity.69 Remarkable cross-couplings between heterocyclic moieties could be achieved 
with the Negishi cross-coupling. Thus, Zhang showed that 3-amino-1H-1,2,4-triazoles, such as 74, were 
readily zincated with TMPZnCl·LiCl (36) and underwent a smooth Negishi cross-coupling with various 
                                                          
62 E. Gioria, J. M. Martinez-Ilarduya, P. Espinet, Organometallics 2014, 33, 4394. 
63 K. Boeck, J. E. Feil, K. Karaghiosoff, K. Koszinowski, Chem. – Eur. J. 2015, 21, 5548. 
64 Z. B. Dong, G. Manolikakes, L. Shi, P. Knochel, H. Mayr, Chem. – Eur. J. 2010, 16, 248. 
65 L. C. McCann, M. G. Organ, Angew. Chem. Int. Ed. 2014, 53, 4386. 
66 a) L. C. McCann, H. N. Hunter, J. A. C. Clyburne, M. G. Organ, Angew. Chem. Int. Ed. 2012, 51, 7024. b) H. N. Hunter, N. 
Hadei, V. Blagojevic, P. Patschinski, G. T. Achonduh, S. Avola, D. K. Bohme, M. G. Organ, Chem. – Eur. J. 2011, 17, 7845. 
67 T. Tobrman, I. Jurásková, D. Dvořák, Organometallics 2014, 33, 6593. 
68 M. Barbero, S. Cadamuro, S. Dughera, Tetrahedron 2014, 70, 8010. 
69 a) S. Xu, A. Oda, H. Kamada, E. Negishi, Proc. Natl. Acad. Sci. USA 2014, 111, 8368. b) S. Xu, C. T. Lee, H. Rao, E. Negishi, Adv. 
Synth. Catal. 2011, 353, 2981. 
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aryl or alkenyl bromides enabling a smooth conversion into the arylated derivative 75 in 85% yield 
(Scheme 26).70 
 
Scheme 26. Negishi cross-couplings of aminotriazole 74. 
Gosselin showed that TMPZnCl·LiCl (36) can also be employed for the zincation of pyridine oxides, such 
as 76. After a cross-coupling with a bromopyridine the desired bis-pyridine 77 was obtained in high 
yield (Scheme 27).71 
 
Scheme 27. Cross-Coupling of pyridinyl oxide 76. 
The zincation of pyridazine-3(2H)-ones, such as 78, with TMPZnCl·LiCl (36) allows for the preparation 
of functionalized heterocycles that are of high interest as pesticides (Scheme 28).72 
Scheme 28. Zincation and Negishi cross-coupling of pyridazinones. 
Highly diastereoselective Negishi cross-couplings have been achieved by the treatment of various 
cyclic organozinc reagents, such as 81a-c, with a range of aryl iodides in the presence of a palladium 
catalyst. The new carbon-carbon bond is formed preferentially via an intermediate having the C-Pd 
bond in an equatorial position, as shown in the intermediate structures 82a-c, leading in the case of 
                                                          
70 J. Shen, B. Wong, C. Gu, H. Zhang, Org. Lett. 2015, 17, 4678. 
71 F. Gosselin, S. J. Savage, N. Blaquiere, S. T. Staben, Org. Lett. 2012, 14, 862. 
72 T. Verhelst, Z. Liu, J. Maes, B. U. W. Maes, J. Org. Chem. 2011, 76, 9648. 
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1,2- and 1,4-disubstituted zinc reagents to the trans-disubstituted products 83a and 83c and in the 
case of 1,3-disubstituted zinc reagents to the cis-1,3-disubstituted product 83b (Scheme 29).73 
 
Scheme 29. Diastereoselective arylation of cyclohexane derivatives. 
This method can be extended to the stereoselective preparation of several types of piperidines,74 such 
as 84, and to the regioselective arylation of allylic amines as shown by Baudoin (Scheme 30).75 
 
Scheme 30. Regioselective arylation of allylamines. 
                                                          
73 T. Thaler, B. Haag, A. Gavryushin, K. Schober, E. Hartmann, R. M. Gschwind, H. Zipse, P. Mayer, P. Knochel, Nature Chem. 
2010, 2, 125. 
74 a) T. K. Beng, R. E. Gawley, Org. Lett. 2011, 13, 394. b) S. Seel, T. Thaler, K. Takatsu, C. Zhang, H. Zipse, B. F. Straub, P. Mayer, 
P. Knochel, J. Am. Chem. Soc. 2011, 133, 4774. 
75 A. Millet, O. Baudoin, Org. Lett. 2014, 16, 3998. 
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A broad range of catalytic systems are available and new catalysts and ligands are constantly reported. 
Thus, the N-heterocyclic precatalyst 85 proves to be especially efficient as it allows for Negishi cross-
coupling reactions of alkylzinc reagents, such as 86, or (hetero)arylzinc reagents with various 
(hetero)aryl halides like 87 under mild reaction conditions with low catalyst loading (Scheme 31).76 
 
Scheme 31. N-heterocyclic carbenes for Negishi cross-couplings. 
A range of important findings and mechanistic studies with practical applications have been reported 
and the difference observed in the role of salts in Negishi cross-couplings of arylzincs compared to 
alkylzincs has been studied in depth by Organ.65 
 
3.2 Negishi Cross-Coupling Reactions Using Nickel-Catalysts 
Although the use of palladium-catalysts ensures a broad applicability of the Negishi cross-coupling, 
environmental sustainability and cost concerns have led to the examination of other transition metal 
catalysts for these cross-couplings and the use of nickel has led to the most impressive developments. 
Standard nickel complexes, such as Ni(acac)2 in combination with DPE-Phos (89),77 were found to 
catalyze cross-couplings under milder conditions and a range of amino-substituted zinc reagents, such 
as 90, afforded polyfunctional amines of type 91 (Scheme 32).78 
                                                          
76 Z. Liu, N. Dong, M. Xu, Z. Sun, T. Tu, J. Org. Chem. 2013, 78, 7436. 
77 M. Kranenburg, Y. E. M. van der Burgt, P. C. J. Kamer, P. W. N. M. van Leeuwen, K. Goubitz, J. Fraanje, Organometallics 
1995, 14, 3081. 
78 L. Melzig, T. Dennenwaldt, A. Gavryushin, P. Knochel, J. Org. Chem. 2011, 76, 8891. 
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Scheme 32. Nickel-catalyzed Negishi cross-couplings. 
Other ligands besides phosphines also show high efficiency especially for the cross-coupling of 
secondary alkylzinc reagents as shown by Biscoe.79 Thus, the cross-coupling of functionalized zinc 
reagent 92 with 1-iodo-3,5-dimethylbenzene (93) provides the cross-coupling product 94 in 80% yield 
using terpyridine (95) as a ligand (Scheme 33).  
 
Scheme 33. Nickel-catalyzed Negishi cross-coupling using secondary alkylzinc reagents. 
Low-valent nickel readily inserts into the C-N bond of aziridines and they undergo smooth arylation 
with organozinc halides. This method can be applied to chiral aziridines, such as 96, or disubstituted 
aziridines like 97 providing stereoselectively polyfunctional amines, such as 98 and 99, in satisfactory 
yields and stereoselectivity (Scheme 34).80  
 
Scheme 34. Stereoselective Negishi cross-couplings with aziridines. 
Furthermore, the above method allows for the generation of molecules with quaternary centers.81 A 
remarkably simple and practical catalyst has been developed by Monfette82 simply by treating Ni(cod)2 
                                                          
79 A. Joshi-Pangu, M. Ganesh, M. R. Biscoe, Org. Lett. 2011, 13, 1218. 
80 C. Y. Huang, A. G. Doyle, J. Am. Chem. Soc. 2012, 134, 9541. 
81 C. Y. Huang, A. G. Doyle, J. Am. Chem. Soc. 2015, 137, 5638. 
82 J. Magano, S. Monfette, ACS Catal. 2015, 5, 3120. 
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and TMEDA with 2-chlorotoluene (100). This catalyst undergoes smooth Negishi cross-coupling 
reactions (Scheme 35).83 
 
Scheme 35. Convenient nickel catalyst for Negishi cross-couplings. 
Pincer-ligands are also popular ligands in the synthesis of Ni-complexes with good activity in Negishi 
cross-couplings even with unusual electrophiles, such as aryltrimethylammonium iodide.84 Remarkable 
cross-couplings of aryl-substituted tetrahydrofurans, tetrahydropyrans, as well as lactones have been 
reported by Jarvo.85 Thus, the ring opening of (R)-101 in the presence of Me2Zn provides (S)-102 in 
98% ee, which can be converted in two subsequent steps to the antidyslipidemia agent (S)-103 (Scheme 
36). 
 
Scheme 36. Nickel-catalyzed Negishi cross-coupling. 
Jarvo has also shown that these Ni-catalyzed cross-couplings of benzylic ethers and esters are general 
and are part of the modern tool-box for Negishi or Kumada cross-couplings. A range of catalytic 
asymmetric syntheses using Pfaltz’s chiral bis(oxazoline)-type ligand86 104 are known and allow for 
                                                          
83 X. Q. Zhang, Z. X. Wang, J. Org. Chem. 2012, 77, 3658. 
84 E. J. Tollefson, D. D. Dawson, C. A. Osborne, E. R. Jarvo, J. Am. Chem. Soc. 2014, 136, 14951. 
85 E. J. Tollefson, L. E. Hanna, E. R. Jarvo, Acc. Chem. Res. 2015, 48, 2344. 
86 C. C. Bausch, A. Pfaltz, in Privileged Chiral Ligands and Catalysts (Ed.: Q. L. Zhou), Wiley-VCH, Weinheim, 2011, p. 221. 
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stereoconvergent Negishi arylations and alkenylations of racemic α-bromonitriles87 of type 105 and 
other carbonyl derivatives,88 as well as benzylic alcohols89 or propargylic bromides (Scheme 37).90 
 
Scheme 37. Enantioselective Negishi cross-coupling reactions. 
Remarkably, Fu also reported an enantioselective cyclization/Negishi cross-coupling reaction with alkyl 
electrophiles.91 The use of strongly donating bis-dialkylphosphine nickel moieties efficiently promotes 
the Negishi cross-coupling reactions under practical and mild conditions as demonstrated by Gosmini 
and Mézailles.92 Interestingly, it has been shown that Ni(II)-complexes that are relevant to Negishi 
cross-coupling reactions can be characterized both, structurally and spectroscopically.93 
 
3.3 Negishi Cross-Coupling Reactions Using other Transition-Metal Catalysts 
Although palladium and nickel are by far the most used metal catalysts for Negishi cross-couplings, a 
few other metallic salts, such as Cu, Fe and Co derivatives have been reported to promote efficiently 
Negishi cross-couplings. A quite general Negishi cross-coupling procedure involving the copper-
catalyzed coupling between alkyl-, aryl- and alkynyl-zinc reagents with a range of heteroaryl iodides 
has been reported by Giri.94 Thus, reaction of iodopyridazine (106) with the amino-substituted zinc 
compound 107 provides the desired coupling product 108 in 62% yield (Scheme 38). 
                                                          
87 a) J. T. Binder, C. J. Cordier, G. C. Fu, J. Am. Chem. Soc. 2012, 134, 17003. b) J. Choi, G. C. Fu, J. Am. Chem. Soc. 2012, 134, 
9102. 
88 Y. Liang, G. C. Fu, J. Am. Chem. Soc. 2014, 136, 5520. 
89 H. Q. Do, E. R. R. Chandrashekar, G. C. Fu, J. Am. Chem. Soc. 2013, 135, 16288. 
90 N. D. Schley, G. C. Fu, J. Am. Chem. Soc. 2014, 136, 16588. 
91 H. Cong, G. C. Fu, J. Am. Chem. Soc. 2014, 136, 3788. 
92 E. Nicolas, A. Ohleier, F. D’Accriscio, A. F. Pecharman, M. Demange, P. Ribagnac, J. Ballester, C. Gosmini, N. Mezailles, Chem. 
– Eur. J. 2015, 21, 7690. 
93 a) B. Zheng, F. Tang, J. Luo, J. W. Schultz, N. P. Rath, L. M. Mirica, J. Am. Chem. Soc. 2014, 136, 6499. b) L. Jin, J. Xin, Z. 
Huang, J. He, A. Lei, J. Am. Chem. Soc. 2010, 132, 9607. c) J. Xin, G. Zhang, Y. Deng, H. Zhang, A. Lei, Dalton Trans. 2015, 44, 
19777. 
94 S. Thapa, A. Kafle, S. K. Gurung, A. Montoya, P. Riedel, R. Giri, Angew. Chem. Int. Ed. 2015, 54, 8236. 
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Scheme 38. Ligand-free copper-catalyzed Negishi cross-coupling. 
Also, iron-catalyzed cross-couplings have been reported using organozinc reagents, showing that 
monophosphines are excellent ligands for coupling alkyl bromides with diphenylzinc derivatives.95 Of 
special interest is the Fe(I)-catalyzed cross-coupling procedure described by Bedford.96 The readily 
available catalyst 109 allows a smooth cross-coupling between cycloheptyl bromide (110) and 
fluoroarylzinc reagents (ArF) providing the coupled product 111 in quantitative yield (Scheme 39).  
 
Scheme 39. Negishi cross-coupling reactions catalyzed by iron. 
More convenient catalysts, such as 112a-b, have been used especially for the cross-coupling of benzylic 
halides and cycloalkyl bromides with arylzinc derivatives with great success.97  
Cobalt salts have been used in Negishi cross-couplings as well and Gosmini has shown that the 
treatment of CoBr2 with zinc and allyl bromide in MeCN and TFA, followed by the addition of the 
coupling partners, provides the cross-coupling products, such as 113, in good yields (Scheme 40).98 
                                                          
95 C. A. Brown, T. A. Nile, M. F. Mahon, R. L. Webster, Dalton Trans. 2015, 44, 12189. 
96 C. J. Adams, R. B. Bedford, E. Carter, N. J. Gower, M. F. Haddow, J. N. Harvey, M. Huwe, M. A. Cartes, S. M. Mansell, C. 
Mendoza, D. M. Murphy, E. C. Neeve, J. Nunn, J. Am. Chem. Soc. 2012, 134, 10333. 
97 R. B. Bedford, E. Carter, P. M. Cogswell, N. J. Gower, M. F. Haddow, J. N. Harvey, D. M. Murphy, E. C. Neeve, J. Nunn, Angew. 
Chem. Int. Ed. 2013, 52, 1285. 
98 a) J. M. Begouin, M. Rivard, C. Gosmini, Chem. Commun. 2010, 46, 5972. b) J. M. Begouin, C. Gosmini, J. Org. Chem. 2009, 
74, 3221. 
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Scheme 40. Negshi cross-coupling reactions catalyzed by cobalt(II) bromide. 
The methodology developed by Gosmini can be efficiently used to couple various organozinc halides 
with bromoalkynes.99 Thus, the treatment of functionalized aryl bromides, such as 114, with 
CoBr2(phen) and zinc dust produces a zinc reagent that smoothly reacts with various bromoalkynes, 
such as 115, to afford the desired cross-coupling product 116 in 85% yield (Scheme 41).  
 
Scheme 41. Cobalt-catalyzed formation of zinc organometallics and Negishi cross-coupling. 
Recently, it was shown by Soper et al. that a cobalt(III) complex bearing redox-active amidophenolate 
ligands is a possible catalyst for a Negishi-type cross-coupling of various alkyl halides, such as Et-Br with 
PhZnBr (Scheme 42).100  
                                                          
99 M. Corpet, X.-Z. Bai, C. Gosmini, Adv. Synth. Catal. 2014, 356, 2937. 
100 A. L. Smith, K. I. Hardcastle, J. D. Soper, J. Am. Chem. Soc. 2010, 132, 14358. 
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Scheme 42. Attempts towards a redox-active and ligand-mediated cobalt-catalyzed Negishi cross-coupling. 
Though only 15% yield of the desired coupling product was afforded, it was shown that cobalt 
possesses interesting reactivities and is indeed a possible replacement of other transition metals 
privileged for this reaction. 
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4 Applications of Negishi Cross-Couplings in Natural Product Synthesis 
In the total synthesis of isodesmosine (122) the employment of a regioselective Negishi cross-coupling 
reaction proved to be critical.101 The readily prepared tri-iodopyridine 117 undergoes a selective 
Negishi cross-coupling with Jackson’s zinc reagent 11818 leading to the desired product 119 in 46% 
yield. A Sonogashira cross-coupling converts 119 into monoiodide 120 and a subsequent Negishi cross-
coupling with 118 provides the tris-alkylated product 121 that was further converted to isodesmosine 
(122) in a few steps (Scheme 43). 
 
Scheme 43. Preparation of isodesmosine via Negishi cross-coupling reactions. 
Mazet used Negishi cross-couplings in an impressive way for the preparation of complex steroid 
derivatives.102 The alkenyl triflate 123 was phenylated using PhZnCl to provide the corresponding 
alcohol 124 in 98% yield after DIBAL-reduction (Scheme 44).  
 
Scheme 44. Negishi cross-coupling reaction for the synthesis of complex steroid derivatives. 
The enantioselective construction of pyrrolidines is important due to the range of highly 
pharmaceutically active molecules bearing such a ring system. O'Brien and Campos have developed a 
general methodology for the preparation of various chiral pyrrolidines using s-BuLi/(-)-sparteine or its 
                                                          
101 Y. Koseki, T. Sugimura, K. Ogawa, R. Suzuki, H. Yamada, N. Suzuki, Y. Masuyama, Y. Y. Lin, T. Usuki, Eur. J. Org. Chem. 2015, 
2015, 4024. 
102 H. Li, C. Mazet, J. Am. Chem. Soc. 2015, 137, 10720. 
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surrogate to obtain a chiral pyrrolidylzinc reagent, which is readily employed in a Negishi cross-
coupling with retention of configuration. This general method is illustrated in a synthesis of (S)-
nicotine. The metalation of pyrrolidine 125 with s-BuLi in the presence of the chiral sparteine-surrogate 
126 and the diamine 17, followed by transmetalation to zinc and cross-coupling with 3-bromopyridine 
provides (S)-nicotine (128) after deprotection and methylation (Scheme 45).103 
 
Scheme 45. Synthesis of (S)-nicotine via Negishi cross-coupling. 
Gademann used a Negishi cross-coupling with success to perform the first total synthesis of the 
piericidin related natural products Mer-A2026B and JBIR-02.104 Thus, the reaction of the complex 
carbonate 129 with the pyridylzinc reagent 130 leads to the desired Negishi cross-coupling product 
131 in 69% yield and Mer-A2026B is afforded after deprotection (Scheme 46). 
 
Scheme 46. Synthesis of Mer-A2026B via Negishi cross-coupling. 
                                                          
103 G. Barker, J. L. McGrath, A. Klapars, D. Stead, G. Zhou, K. R. Campos, P. O’Brien, J. Org. Chem. 2011, 76, 5936. 
104 J. Hoecker, K. Gademann, Org. Lett. 2013, 15, 670. 
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Finally, the synthesis of the anti-inflammatory pro-resolving lipid 132 has been achieved using a Negishi 
cross-coupling between two C(sp3)-bonds. Thus, the cross-coupling between the unsaturated bromide 
133 and zinc reagent 134 provides the desired cross-coupling product 135 in 70% yield affording the 
drug 132 after a few steps (Scheme 47).105 
 
Scheme 47. Complex Negishi cross-coupling for the synthesis of an anti-inflammatory pro-resolving lipid. 
Due to the mild conditions required to form new carbon-carbon bonds, the Negishi cross-coupling has 
found an increased number of synthetic applications. Although palladium is still the most commonly 
used metal catalyst for these cross-couplings, alternative metals, such as nickel, cobalt and iron may 
be useful complement methodologies in the future regarding toxicity, as well as ecological and price 
aspects. The broad and constantly increasing availability of zinc organometallics should further expand 
the use of the Negishi cross-coupling in organic synthesis. 
  
                                                          
105 J. E. Tungen, M. Aursnes, J. Dalli, H. Arnardottir, C. N. Serhan, T. V. Hansen, Chem. – Eur. J. 2014, 20, 14575. 
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5 Objectives 
The aim of the first part of this thesis was the development of a convenient method for the metalation 
and functionalization of sensitive 5-membered N,O-heterocycles. These scaffolds are of great interest 
due to their biological activities and the appearance of this moiety in several pharmaceutical agents. 
However, these heterocycles are sensitive scaffolds as they are prone to undergo ring fragmentation 
under lithiation conditions. Therefore, the deprotonation using zinc amide bases is an important 
method for the functionalization of these sensitive heterocycles as a variety of functional groups can 
be tolerated. First a general method for the regiocontrolled introduction of all substitutents should be 
investigated to achieve a complete functionalization of the oxazole scaffold (Scheme 48). 
 
Scheme 48. General pathway for the complete functionalization of oxazole. 
Also, oxazolines represent an important class of 5-membered heterocycles. Especially, 2-aryloxazolines 
exhibit a range of interesting biological activities. By now, the synthesis of functionalized 2-arylated 
oxazolines involves highly prefunctionalized starting materials or expensive reagents, respectively. 
Therefore, a procedure for a convenient preparation of 2-arylated oxazolines should be developed. 
Zincation of oxazoline using metal amide bases and reaction with electrophiles should provide the 
desired 2-substituted compounds. Additionally, 2-aryloxazolines should be further functionalized via 
directed metalation with amide bases using the oxazoline moiety as a directing group (Scheme 49). 
 
Scheme 49. Desired arylation of oxazoline and its use as a directing group for further functionalizations. 
 
Additionally, due to its 7-membered ring scaffold the tropolone ring shows a range of interesting 
activitities, such as antioxidant properties. Up to date, the synthesis of functionalized tropolones is 
limited due to the harsh reaction conditions of current methods. Hence, a method for the smooth 
functionalization of the tropolone scaffold would be desirable. Metalation using metal amide bases 
and reaction of the generated organometallic species with various electrophiles should provide 
functionalized tropolones (Scheme 50). 
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Scheme 50. Intended metalation and functionalization of tropolone derivatives. 
The second part of the thesis deals with the replacement of expensive and/or toxic Pd and Ni catalysts 
by environmentally more benign metals, such as cobalt. A general method for the cobalt-catalyzed 
cross-coupling of organozinc reagents prepared via directed metalation with primary and secondary 
alkyl halides should be investigated. Special attention should be drawn to the coupling of secondary 
alkyl halides without rearrangement from branched to unbranched (Scheme 51). 106 
 
Scheme 51. Cobalt-catalyzed cross-coupling of organometallic reagents prepared via direct metalation with alkyl halides. 
Furthermore, a Negishi cross-coupling reaction of (hetero)aryl halides with arylzinc reagents under 
cobalt catalysis should be investigated. 107 The Negishi cross-coupling represents an indispensable tool 
for organic chemistry due to the unique reactivity and the high functional group tolerance of 
organiczinc reagents. The replacement of Pd- and Ni-catalysts employed in this reaction by 
environmentally benign metals, such as cobalt, is therefore highly appreciated (Scheme 52). 
 
Scheme 52. Intended cobalt-catalyzed cross-coupling of (hetero)aryl halides and arylzinc reagents. 
 
                                                          
106 This project was developed in cooperation with Jeffrey M. Hammann, see: J. M. Hammann, D. Haas, P. Knochel, Angew. 
Chem. Int. Ed. 2015, 54, 4478–4481 and Jeffrey M. Hammann, Dissertation, LMU Munich. 
107 This project was developed in cooperation with Jeffrey M. Hammann, see: D. Haas, J. M. Hammann, F. H. Lutter, P. Knochel, 
Angew. Chem. Int. Ed. 2016, 55, 3809–3812 and Jeffrey M. Hammann, Dissertation, LMU Munich. 
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B             RESULTS AND DISCUSSION 
1 Regioselective Functionalization of the Oxazole Scaffold Using TMP-
Bases of Mg and Zn 
1.1 Introduction 
The synthesis of oxazoles is an important task in organic chemistry as this structural motif can be found 
in many biologically active compounds such as analgesic, antibiotic, and anticancer agents.108 In 
Ageroplas®, an antithrombotic agent developed by Merck KGAa, the oxazole derivative acts as a 
platelet aggregation inhibitor.109 Pfizer’s Darglitazone also includes this key structural unit in its 
peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, which exhibits insulin-sensitizing 
effects, by showing an improved glycemic and lipidemic control. As a further application, Darglitazone 
is a possible active substance for the treatment of metabolic disorders, such as type 2 diabetes 
mellitus.110 In addition, GlaxoSmithKline investigated the activity of Retosiban, which also bears an 
oxazole moiety, as an oxytocin receptor antagonist and is currently being developed for the treatment 
of preterm labour (Figure 1).111 
 
Figure 1. Pharmaceuticals containing an oxazole core. 
To date, the preparation of highly functionalized oxazoles involves condensation reactions such as the 
Fischer112 or the Robinson-Gabriel synthesis.113 However, these methods have some limitations, such 
as poor regioselectivity in the ring construction, multistep syntheses of the starting materials, and 
                                                          
108 a) P. Wipf, Chem. Rev. 1995, 95, 2115. b) M. Lautens, A. Roy, Org. Lett. 2000, 2, 555. c) P.-Y.Coqueron, C. Didier, M. A. 
Ciufolini, Angew. Chem. Int. Ed. 2003, 42, 1411. d) B. S. Lucas, V. Gopalsamuthiram, S. D. Burke, Angew. Chem. Int. Ed. 
2007, 46, 769. e) E. Merkul, T. J. J. Müller, Chem. Commun. 2006, 4817. f) D. Davyt, G. Serra, Mar. Drugs 2010, 8, 2755. g) 
H. D. Silva, W. P. Henry, C. U. Pitman, Jr., Synthesis 2012, 44, 3337. 
109 The Merck Index, 12th Edition, p. 3432. 
110 B. Hulin, D. A. Clark, S. W. Goldstein, R. E. McDermott, P. J. Dambek, W. H. Kappeler, C. H. Lamphere, D. M. Lewis, J. P. 
Rizzi, J. Med. Chem. 1992, 35, 1853. 
111 J. Liddle, M. J. Allen, A. D. Borthwick, D. P. Brooks, D. E. Davies, R. M. Edwards, A. M. Exall, C. Hamlett, W. R. Irving, A. M. 
Mason, G. P. McCafferty, F. Nerozzi, S. Peace, J. Philp, D. Pollard, M. A. Pullen, S. S. Shabbir, S. L. Sollis, T. D. Westfall, P. M. 
Woollard, C. Wu, D. M. B. Hickey, Bioorg. Med. Chem. Lett. 2008, 18, 90. 
112 a) E. Fischer, Ber. 1896, 29, 205. b) J. W. Cornforth, R. H. Cornforth, J. Am. Chem. Soc. 1949, 1028. 
113 a) R. Robinson, J. Chem. Soc. 1909, 95, 2167. b) S. Gabriel, Ber. 1910, 43, 1283. c) I. J. Turchi, M. J. S. Dewar, Chem. Rev. 
1975, 75, 389. 
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harsh reaction conditions. Additionally, C-H arylation is another approach for the functionalization of 
oxazoles. The method shows great potential and its scope is constantly increasing.114 The difficulties of 
selective functionalization have been addressed by the development of alternative methods, in 
particular metalations of the oxazole scaffold. Indeed, there are many reports of successful lithiations 
of oxazoles at the C-2 position.115 However, the direct functionalization of these heterocycles by 
lithiation is difficult due to side reactions such as ring opening to the corresponding isonitrile.116 
Although a few lithiation reactions at positions C-5 or C-4 have been reported,117 these metalations 
require very low reaction temperatures, as well as prefunctionalized starting materials and do not 
tolerate the reaction of oxazole derivatives containing sensitive functional groups. Knochel and co-
workers have shown that TMPZnCl·LiCl (36)34 and TMPMgCl·LiCl (35)33 are exceptionally active and 
chemoselective metal amide bases, allowing in particular for the metalation of sensitive heterocycles.  
 
Scheme 53. Successive metalations of oxazole (136) in position 2, 5, or 4 using TMP-bases of Mg and Zn. 
                                                          
114 a) C. Verrier, P. Lassalas, L. Théveau, G. Quéguiner, F. Trécourt, F. Marsais, C. Hoarau, Beilstein J. Org. Chem. 2011, 7, 1584. 
b) N. A. Strotman, H. R. Chobanian, Y. Guo, J. He, J. E. Wilson, Org. Lett. 2010, 12, 3578. c) L. Théveau, C. Verrier, P. Lassalas, 
T. Martin, G. Dupas, O. Querolle, L. Van Hijfte, F. Marsais, C. Hoarau, Chem. – Eur. J. 2011, 17, 14450. d) L. Ackermann, A. 
Althammer, S. Fenner, Angew. Chem. Int. Ed. 2009, 48, 201. 
115 a) J. C. Hodges, W. C. Patt, C. J. Connolly, J. Org. Chem. 1991, 56, 449. b) N. K. Harn, C. J. Gramer, B. A. Anderson, 
Tetrahedron Lett. 1995, 36, 9453. c) E. Vedejs, S. D. Monahan, J. Org. Chem. 1996, 61, 5192. d) B. A. Anderson, N. K. Harn, 
Synthesis 1996, 583. e) B. A. Anderson, L. M. Becke, R. N. Booher, M. E. Flaugh, N. K. Harn, T. J. Kress, D. L. Varie, J. P. 
Wepsiec, J. Org. Chem. 1997, 62, 8634. f) A. B. Smith, III, K. P. Minibiole, S. Freeze, , Synlett 2001, 1739. g) M. R. Reeder, H. 
E. Gleaves, S. A. Hoover, R. J. Imbordino, J. Pangborn, Org. Process Res. Dev. 2003, 7, 696. h) D. R. Williams, L. Fu, Org. Lett. 
2010, 12, 808. 
116 a) A. I. Meyers, E. W. Collington, J. Am. Chem. Soc. 1970, 92, 6676. b) A. Dondoni, G. Fantin, M. Fogagnolo, A. Medici, P. 
Pedrini, Synthesis 1987, 1987, 693. c) T. L. Gilchrist, Adv. Heterocycl. Chem. 1987, 41, 4. d) B. Iddon, Heterocycles 1994, 37, 
1321. e) E. Crowe, F. Hossner, M. J. Hughes, Tetrahedron Lett. 1995, 51, 8889. f) E. Vedejs, L. M. Luchetta, J. Org. Chem. 
1999, 64, 1011. g) O. Bayh, H. Awad, F. Mongin, C. Hoarau, L. Bischoff, F. Trécourt, G. Quéguiner, F. Marsais, F. Blanco, B. 
Abarca, R. Ballesteros, J. Org. Chem. 2005, 70, 5190. h) R. A. Miller, R. M. Smith, B. Marcune, J. Org. Chem. 2005, 70, 9074. 
i) M. C. Pirrung, S. Ghorai, J. Am. Chem. Soc. 2006, 128, 11772. 
117 a) A. I. Meyers, J. P. Lawson, Tetrahedron Lett. 1981, 22, 3163. b) D. R. Williams, D. A. Brooks, K. G. Meyer, M. Pagel, 
Tetradedron Lett. 1998, 39, 8023. c) B. Li, R. A. Buzon, Z. Zhang, Org. Process Res. Dev. 2007, 11, 951. d) K. Lee, C. M. 
Counceller, J. P. Stambuli, Org. Lett. 2009, 11, 1457. 
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Thus, successive zincations and/or magnesiations in positions 2, 5 or 4 of oxazole (136) and reaction 
with various electrophiles lead via 2-substituted (137) and 2,5-disubstituted oxazoles (138) to 
completely functionalized 2,4,5-trisubstituted oxazole derivatives of type 139 (Scheme 53). 
 
1.2 Zincation of Oxazole in Position C-2 
Thus, treatment of oxazole (136) with TMPZnCl·LiCl (36; 1.2 equiv) leads within 1 h at 0 °C to the 
quantitative formation of the corresponding 2-oxazolylzinc reagent (140), which is perfectly stable at 
25 °C.  The zincated species reacts smoothly with a variety of electrophiles (E1-X) under mild reaction 
conditions affording 2-functionalized oxazoles of type 137 (Scheme 54). 
 
Scheme 54. Metalation of oxazole (136) using TMPZnCl·LiCl (36). 
The prepared 2-oxazolylzinc reagent (140) successfully undergoes Negishi cross-coupling reactions118 
using Pd(dba)2 and Farina’s ligand ((o-furyl)3P)35 with ethyl 4-iodobenzoate or ethyl 4-bromobenzoate 
to afford the corresponding cross-coupling product 137a in 92% or 89% yield, respectively (Table 1, 
entry 1). Other para-substituted aryl iodides, such as 1-chloro-4-iodobenzene, 4-iodobenzotrifluoride, 
4-iodoanisole or 4-iodobenzontrile also react in the cross-coupling reaction providing the products 
137b-e in 74-90% yield (entries 2-5). The cross-coupling also works well when using aryl iodides 
substituted with electron-withdrawing groups, such as 1-iodo-3-nitro-benzene, or other meta-
substituted electrophiles, such as 3-iodobenzonitrile affording the expected products in 82-94% yield 
(entries 6 and 7). Remarkably, also the ortho-substituted 2-iodobenzaldehyde reacts in this cross-
coupling furnishing the desired cross-coupling product 137h in 79% yield (entry 8). The 2-oxazolylzinc 
reagent (140) is successfully employed in Pd-catalyzed Negishi acylation reactions44 with benzoyl 
chloride, 3-chlorobenzoyl chloride and 4-fluorobenzoyl chloride providing the ketones 137i-k in 61-
86% yield (entries 9-11). The 2-zincated oxazole also reacts after transmetalation with CuCN·2LiCl119 in 
a copper(I)-mediated allylation reaction with ethyl 2-(bromomethyl)acrylate120 to furnish the allylated 
oxazole 137l in 78% yield (entry 12). 
                                                          
118 a) E. Negishi, L. F. Valente, M. Kobayashi, J. Am. Chem. Soc. 1980, 102, 3298. b) E. Negishi, M. J. Kobayashi, J. Org. Chem. 
1980, 45, 5223. c) E. Negishi, Acc. Chem. Res. 1982, 15, 340. 
119 P. Knochel, M. C. P. Yeh, S. C. Berk, J. Talbert, J. Org. Chem. 1988, 53, 2390. 
120 J. Villieras, M. Rambaud, Synthesis 1982, 924. 
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Table 1. Regioselective metalation of oxazole (136) using TMPZnCl·LiCl (36) and quenching with electrophiles. 
Entry Electrophile E1-X Product / Yielda  Entry Electrophile E1-X Product / Yielda 
1 
  
 7 
 
 
 
X = I, 50 °C, 4 h 
X = Br, 50 °C, 6 h 
137a, 92%b 
          80%c 
  50 °C, 4 h 137g, 82%b 
2 
  
 8 
  
 50 °C, 2 h 137b, 83%
b   50 °C, 2 h 137h, 79%b 
3 
  
 9 
  
 25 °C, 4 h 137c, 74%b   25 °C, 3 h 137i, 73%d 
4 
  
 10 
  
 25 °C, 6 h 137d, 90%b   25 °C, 4 h 137j, 86%d 
5 
  
 11 
  
 25 °C, 4 h 137e, 87%b   25 °C, 4 h 137k, 61%d 
6 
  
 12 
  
 50 °C, 1 h 137f, 94%b   25 °C, 1 h 137l, 78%e 
aIsolated yield of analytically pure product. bPd-catalyzed cross-coupling using 3 mol% Pd(dba)2 and 6 mol% P(o-furyl)3. cPd-catalyzed cross-
coupling using 4 mol% Pd(PPh3)4. dPd-catalyzed acylation reaction using 4 mol% Pd(PPh3)4. eThe zinc reagent was transmetalated using 
CuCN∙2LiCl. 
Sensitive functionalities, such as an ester (entries 1, 12), a nitrile (entries 5, 7) or an aldehyde (entry 8) 
are well tolerated during this cross-coupling procedure and the 2-functionalized oxazoles are afforded 
in high yields. 
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1.3 Zincation or Magnesiation of 2-Arylated Oxazole Derivatives 
A second metalation of the 2-substituted oxazoles of type 137 occurs at the C-5 position and is readily 
achieved by adding either TMPMgCl·LiCl (35) or TMPZnCl·LiCl (36). The 5-zincated species is produced 
within 2 h at 50 °C by the reaction of 2-substituted oxazoles of type 137 with TMPZnCl·LiCl (36, 1.2 
equiv). The corresponding zinc reagent (141) reacts with a variety of electrophiles (E2-X) to yield highly 
functionalized 2,5-disubstituted oxazole derivatives of type 138 (Scheme 55). 
 
Scheme 55. Metalation of 2-aryloxazoles (137) using TMPZnCl∙LiCl (36). 
The zinc derivative of 137a is subjected to Negishi cross-couplings with 1-chloro-4-iodobenzene or 4-
iodobenzonitrile to provide the bisarylated oxazoles 138a and 138b in 83-92% yield (Table 2, entries 1, 
2). After zincation of 137a and 137e and transmetalation with CuCN·2LiCl, a copper(I)-mediated 
allylation with allyl bromide or 3-bromocyclohexene leads to the desired oxazoles 138c and 138d in 
76-79% yield (entries 3, 4). Pd-catalyzed acylation of 137a or 137b with benzoyl chloride, 4-
fluorobenzoyl chloride, or 3,4-difluorobenzoyl chloride provides the corresponding oxazolyl ketones 
138e-h in 76-98% yield (entries 5-8). Furthermore, after zincation and reaction with iodine, the 2-
substituted oxazole 137b undergoes a regioselective Sonogashira reaction121 in situ with 
phenylacetylene in the presence of 3 mol% Pd(dba)2, 6 mol% P(o-furyl)3, 4 mol% CuI, and TEA as solvent 
to afford the 2,5-disubstituted oxazole 138i in 80% yield (entry 9).  
Table 2. Regioselective zincation of 2-aryloxazoles of type 137 using TMPZnCl·LiCl (36). 
Entry Substrate Electrophile E2-X Product / Yielda 
1 
   
 137a 50 °C, 2 h 138a, 92%
b 
                                                          
121 a) K. Sonogashira, Y. M. Tohda, N. Hagihara, Tetrahedron Lett. 1975, 16, 4467. b) R. Chinchilla, C. Najera, Chem. Rev. 2007, 
107, 874. c) H. Doucet, J.-C. Hierso, Angew. Chem. Int. Ed. 2007, 46, 834. d) R. Chinchilla, C. Najera, Chem. Soc. Rev. 2011, 
40, 5084. e) K. Sonogashira, in Metal-catalyzed Cross-Coupling Reactions (Eds.: F. Diederich, P. J. Stang), Wiley-VCH, 
Weinheim, 1998. 
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Entry Substrate Electrophile E2-X Product / Yielda 
2 
   
 137a 50 °C, 6 h 138b, 83%
b 
3 
 
 
 
 137a 25 °C,  1 h 138c, 79%c 
4 
 
 
 
 137e 25 °C, 1 h 138d, 76%c 
5 
  
 
 137b 25 °C, 2 h 138e, 76%d 
6 
  
 
 137b 25 °C, 4 h 138f, 86%d 
7 
  
 
 137a 25 °C, 4  138g, 98%d 
8 
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Entry Substrate Electrophile E2-X Product / Yielda 
 137a 25 °C, 1 h 138h, 87%d 
9 
   
 137b 25 °C, 1 h 138i, 80%e 
aIsolated yield of analytically pure product. bPd-catalyzed cross-coupling using 3 mol% Pd(dba)2 and 6 mol% P(o-furyl)3. cThe zinc reagent was 
transmetalated using CuCN∙2LiCl. dPd-catalyzed cross-coupling using 4 mol% Pd(PPh3)4. ePd-catalyzed crosscoupling using 3 mol% Pd(dba)2 
and 6 mol% P(o-furyl)3, 4 mol%. 
Alternatively, the 5-magnesiated species can be prepared by reaction with TMPMgCl·LiCl (35). Thus, 
treatment of the 2-arylated oxazoles 137a and 137b with TMPMgCl·LiCl (35, 1.2 equiv) leads to the 
quantitative formation of the 5-magnesiated oxazole of type 142 within 0.5 h at -40 °C. The 
oxazolylmagnesium reagents of type 142 readily react with various electrophiles, such as NC-CO2Et, 
MeSO2SMe,122 TsCN, or TMSCl to provide the 2,5-disubstituted oxazoles 138j-n in 72-93% yield 
(Scheme 56).  
 
Scheme 56. Metalation of 2-aryloxazoles (137) using TMPMgCl·LiCl (35) and subsequent reaction with electrophiles. 
Remarkably, the metalation of 2-substituted oxazole derivatives with the mild amide-base 
TMPZnCl·LiCl (36) can be performed at 50 °C, whereas the use of TMPMgCl·LiCl (35) requires more 
accurate temperature control as the reaction temperature should be -40 °C. Moreover, the 
                                                          
122 The thiomethylgroup can be subjected to cross-coupling reactions, see: L. S. Liebeskind, J. Srogl, Org. Lett. 2002, 4, 979. 
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regioselectivity of the second metalation and functionalization of 2-substituted oxazoles is supported 
by X-Ray data of compounds 138j and 138l showing exclusive formation of the 2,5-disubstituted 
derivatives.123 Exceptionally, no regioisomers are detected during the reaction showing the advantage 
of the currend methodology over known procedures that deal with the problem of regioselectivity. 
 
1.4 Zincation of 2,5-Disubstituted Oxazole Derivatives 
The prepared 2,5-disubstituted oxazoles of type 138 can be further metalated at the C-4 position using 
TMPZnCl·LiCl (36, 1.2 equiv) to afford the expected 4-zincated species of type 143 within 3-5 h at 50 °C. 
These zincated polyfunctional oxazoles react with various electrophiles (E3-X) and undergo Negishi 
cross-couplings, Pd-catalyzed acylation reactions, or copper(I)-mediated allylations (Scheme 57). 
 
Scheme 57. Metalation of oxazole derivatives of type 138 in position 4 using TMPZnCl·LiCl (36) and subsequent reaction 
with electrophiles. 
Thus, after the zincation of the 2,5-substituted oxazole 138a, Negishi cross-couplings were performed 
with various aryl iodides, such as 1-iodo-4-(trifluoromethyl)benzene and 4-iodobenzonitrile, furnishing 
the desired 2,4,5-arylated oxazoles 139a and b in 73-82% yield (Table 3, entries 1, 2). Similarly, the 
keto-substituted oxazole 138g is an excellent substrate for a Negishi cross-coupling reaction with 4-
iodoanisole and provides the desired trisubstituted oxazole 139c in 76% yield. Furthermore, the 5-
acylated oxazole 138e undergoes a Pd-catalyzed Negishi acylation with benzoyl chloride, affording the 
trisubstituted oxazole 139d in 78% yield (entry 4). Also, the allylation of the zincated oxazole derived 
from 138f with 3-bromocyclohexene in the presence of CuCN·2LiCl leads to the expected trisubstituted 
oxazole 139e in 74% (entry 5). Finally, the oxazole 138m is arylated by our standard procedure with 1-
chloro-4-iodobenzene, furnishing the 5-silyloxazole 139f in 84% yield.124 
                                                          
123 See Appendix for x-ray structures of compounds 138j and 138l. 
124 For removal of the TMS-group on heterocycles, see: C. Dunst, P. Knochel, J. Org. Chem. 2011, 76, 6972. 
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Table 3. Zincation of oxazole derivatives of type 138 at the C-4 position using TMPZnCl·LiCl (36) and subsequent reaction 
with electrophiles. 
Entry Substrate / Metalation conditions Electrophile E2-X Product / Yielda 
1 
  
 
 138a, 50 °C, 6 h 50 °C, 8 h 139a, 82%
b 
2 
  
 
 138a 50 °C, 6 h 139b, 73%
b 
3 
 
 
 
 138g, 50 °C, 3 h 50 °C, 6 h 139c, 76%b 
4 
 
 
 
 
 138e, 50 °C, 3 h 25 °C, 3 h 139d, 78%c 
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Entry Substrate / Metalation conditions Electrophile E2-X Product / Yielda 
5 
 
 
 
 138f, 50 °C, 3 h 25 °C, 2 h 139e, 74%d 
6 
  
 
 138m, 50 °C, 5 h 50 °C, 6 h 139f, 84%b 
aIsolated yield of analytically pure product. bPd-catalyzed cross-coupling using 3 mol% Pd(dba)2 and 6 mol% P(o-furyl)3. cPd-catalyzed acylation 
reaction using 4 mol% Pd(PPh3)4. dThe zinc reagent was transmetalated using CuCN∙2LiCl. 
This new general method for performing multiple regioselective metalations of oxazole (136) via 
successive reactions using either TMPMgCl·LiCl (35) or TMPZnCl·LiCl (36) leads to a variety of oxazole 
derivatives. Regiocontrolled introduction of all substituents allows for the preparation of highly 
functionalized oxazoles. 
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2 Zincation of 4,4-Dimethyloxazoline Using TMPZnCl·LiCl. A New 
Preparation of 2-Aryloxazolines 
2.1 Introduction 
Oxazolines are an important class of heterocycles found in pharmaceuticals that display cytotoxic, 
antitumor, neuroprotective, antibiotic, or antifungal activities.125 Servier developed the prescription 
drug Rilmenidine (Albarel®), used for the treatment of hypertension, containing a 2-aminooxazoline 
moiety.126 RO-5166017 is another example with an oxazoline motif; it is an agonist for the trace amine-
associated receptor 1 (TAAR), which is currently being investigated by Hoffmann-La Roche for 
prevention of stress-induced hyperthermia.127 Additionally, Sanofi-Aventis marketed the oxazoline-
containing glucocorticoid Deflazacort (Calcort®), which is prescribed as an anti-inflammatory and 
immunosuppressant. It is also effective for a potential treatment of Duchenne muscular dystrophy 
(Figure 2).128 
 
Figure 2: Pharmaceuticals containing an oxazoline moiety 
The oxazoline scaffold also possesses great utility in organic synthesis129 since this moiety is present in 
several ligands for asymmetric catalysis130 and was also found to be an excellent ortho-directing 
                                                          
125 a) S. Yamamoto, N. Okujo, Y. Fujita, M. Saito, T. Yoshida, S. Shinoda, J. Biochem. 1993, 113, 538. b) H. Shitakawa, S. 
Nakajima, M. Hirayama, H. Kondo, K. Kojiri, Chem. Abstr. 2000, 132, 150670. c) M. R. Prinsep, R. E. Moore, I. A. Levine, G. 
M. L. Patterson, J. Nat. Prod. 1992, 55, 140. 
126 a) P. Bousquet, J. Feldman, Drugs 1999, 58, 799. b) A. Remková, H. Kratochvíl‘ová, J. Hum. Hypertens. 2002, 16, 549. 
127 F. G. Revel, J.-L. Moreau, R. R. Gainetdinov, A. Bradaia, T. D. Sotnikova, R. Mory, S. Durkin, K. G. Zbinden, R. Norcross, C. A. 
Meyer, V. Metzler, S. Chaboz, L. Ozmen, G. Trube, B. Pouzet, B. Bettler, M. G. Caron, J. G. Wettstein, M. C. Hoener, Proc. 
Natl. Acad. Sci. USA 2011, 108, 8485. 
128 H. Möllmann, G. Hochhaus, S. Rohatagi, J. Barth, H. Derendorf, Pharm. Res. 1995, 12, 1096. 
129 a) M. Reuman, A. I. Meyers, Tetrahedron 1985, 41, 837. b) A. I. Meyers, E. D. Mihelich, Angew. Chem. Int. Ed. 1976, 15, 
270. c) J. A. Frump, Chem. Rev. 1971, 71, 483. 
130 H. A. McManus, P. J. Guiry, Chem. Rev. 2004, 104, 4151. 
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group.131,32 However, the direct lithiation of oxazolines at the C-2 position132 is difficult due to a facile 
fragmentation of these sensitive heterocycles leading to isonitriles of type 145 (Scheme 58).133,116a 
 
Scheme 58. Ring opening of 4,4-dimethyloxazoline (144) upon lithiation. 
2-Aryloxazolines can be prepared using several methods, such as condensations134 or similar multi-
component reactions,135 as well as C–H activations using diverse transition-metal catalysts.136 
However, to date the direct zincation and transition-metal catalyzed cross-coupling of the oxazoline 
scaffold for the synthesis of 2-substituted oxazolines has not yet been reported. This reaction is 
especially interesting, as particularly 2-aryloxazolines often exhibit potential biological activity.137  
 
2.2 Metalation of 4,4-Dimethyloxazoline 
The highly active sterically hindered zinc base TMPZnCl·LiCl (36)34 has proven to be especially efficient 
for the metalation of sensitive heterocycles, such as oxazole, and moreover displays an excellent 
functional group tolerance. Thus, treatment of 4,4-dimethyloxazoline (144) with TMPZnCl·LiCl (36, 1.1 
equiv) leads smoothly to the formation of the corresponding 4,4-dimethyloxazolinylzinc species (146) 
within 1 h at 0 °C in 94% yield as determined by GC-analysis after allylation.138 In contrast to the 
corresponding lithium derivative (Scheme 58), this zinc reagent is perfectly stable at 25 °C and shows 
no tendency to undergo a ring fragmentation. Thus, the zinc reagent (146) undergoes smooth carbon–
carbon bond formation with various electrophiles leading to 2-substituted oxazolines of type 147 in 
64-92% yield (Scheme 59). 
                                                          
131 For examples, see: a) S. Oi, E. Aizawa, Y. Ogino, Y. Inoue, J. Org. Chem. 2005, 70, 3113. b) P. Beak, A. Tse, J. Hawkins, C. W. 
Chen, S. Mills, Tetrahedron 1983, 39, 1983. 
132 L. Degennaro, V. Capriati, C. Carlucci, S. Florio, R. Luisi, I. Nuzzo, C. Cuocci, Tetrahedron 2009, 65, 8745. 
133 a) F. Gerhart, U. Schöllkopf, Tetrahedron Lett. 1968, 9, 6231. b) S. R. Neal, A. Ellern, A. D. Sadow, J. Organomet. Chem. 
2010, 696, 228. 
134 a) G. A. Molander, W. Febo-Ayala, L. Jean-Gerard, Org. Lett. 2009, 11, 3830. b) P. Garg, S. Chaudhary, M. D. Milton, J. Org. 
Chem. 2014, 79, 8668. c) I. Mohammadpoor-Baltork, A. R. Khosropour, S. F. Hojati, Synlett 2005, 2747. d) M. Brandstätter, 
F. Roth, N. W. Luedtke, J. Org. Chem. 2015, 80, 40. 
135 a) X.-F. Wu, H. Neumann, S. Neumann, M. Beller, Chem. – Eur. J. 2012, 18, 13619. b) L. Fan, E. Lobkovsky, B. Ganem, Org. 
Lett. 2007, 9, 2015. 
136 a) S. H. Kim, S. Chang, Org. Lett. 2010, 12, 1868. b) L. Ackermann, S. Barfuesser, C. Kornhaass, A. R. Kapdi, Org. Lett. 2011, 
13, 3082. c) S. H. Wiedemann, R. G. Bergman, J. A. Ellman, Org. Lett. 2004, 6, 1685. 
137 For examples, see: a) V. Padmavathi, K. Mahesh, G. D. Reddy, A. Padmaja, Eur. J. Med. Chem. 2010, 45, 3178. b) M. Tsuda, 
M. Yamakawa, S. Oka, Y. Tanaka, Y. Hoshino, Y. Mikami, A. Sato, H. Fujiwara, Y. Ohizumi, J. i. Kobayashi, J. Nat. Prod. 2005, 
68, 462. c) Q. Li, K. W. Woods, A. Claiborne, S. L. Gwaltney, II, K. J. Barr, G. Liu, L. Gehrke, R. B. Credo, Y. H. Hui, J. Lee, R. B. 
Warner, P. Kovar, M. A. Nukkala, N. A. Zielinski, S. K. Tahir, M. Fitzgerald, K. H. Kim, K. Marsh, D. Frost, S.-C. Ng, S. Rosenberg, 
H. L. Sham, Bioorg. Med. Chem. Lett. 2002, 12, 465. 
138 Compare Table 4, entry 13; C14H30 was used as an internal standard. 
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Scheme 59. Metalation of 4,4-dimethyloxazoline (144) using TMPZnCl·LiCl (36) via zinc intermediate 146 and reaction 
with electrophiles (E-X). 
Negishi cross-coupling reactions118 of the oxazolinylzinc reagent (146) with electron-rich and -poor 
para-functionalized aryl bromides and iodides (FG = CF3, CO2Et, CN, OMe, Cl) using Pd(dba)2 (3 mol%) 
or Pd(OAc)2 (3 mol%) and SPhos (6 mol%)139 furnished the corresponding 2-aryloxazolines 147a-e in 
71-92% yield (Table 4, entries 1–5). The oxazolinylzinc species (146) also reacts with the disubstituted 
diethyl 5-bromoisophthalate to provide the desired product (147f) in 68% yield (entry 6). Additionally, 
a cross-coupling reaction with 3-iodocyclohexenone affords the oxazoline (147g) in 68% yield (entry 
7). Moreover, after transmetalation with CuCN·2LiCl,119 acylation reactions employing various acid 
chlorides afford 2-acyl-2-oxazolines.140 Thus, the reaction with benzoyl chloride leads to the acylated 
oxazoline (147h) in 69% yield (entry 8). The 4,4-dimethyloxazolinylzinc reagent (146) also reacts well 
in Negishi acylation reactions44 with various electron-poor benzoyl chlorides bearing halogen-
substituents, such as F, Br, and I, as well as 2-thiophenecarbonyl chloride to provide the ketones (147i-
l) in 64-76% yield (entries 9-12). In addition, after transmetalation with CuCN·2LiCl, the zincated 
species undergoes a Cu-mediated allylation reaction with 3-bromocyclohexene affording the allylated 
product (147m) in 79% yield (entry 13). Finally, an in situ performed Sonogashira reaction121 with 
phenylacetylene in the presence of Pd(dba)2 (3 mol%), Farina's ligand35 (P(o-furyl)3, 6 mol%), CuI (4 
mol%) and TEA (1.2 equiv) afforded the 2-substituted oxazoline (147n) in 79% yield (entry 14). 
Table 4. 2-Substituted 4,4-dimethyloxazolines of type 147 obtained by zincation using TMPZnCl·LiCl (36) and reaction with 
electrophiles. 
Entry Electrophile E1-X  Product / Yielda  Entry Electrophile E1-X Product / Yielda 
1 
  
 
8 
  
 
X = I, 50 °C, 4 h 
X = Br, 50 °C, 3 h 
147a, 79%b 
          77%c 
 
 
-40 to 25 °C, 2 h 147h, 69%d 
                                                          
139 a) T. E. Barder, S. D. Walker, J. R. Martinelli, S. L. Buchwald, J. Am. Chem. Soc. 2005, 127, 4685. b) K. L. Billingsley, K. W. 
Anderson, S. L. Buchwald, Angew. Chem. Int. Ed. 2006, 45, 3484. 
140 V. Capriati, S. Florio, R. Luisi, V. Russo, A. Salomone, Tetrahedron Lett. 2000, 41, 8835. 
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Entry Electrophile E1-X  Product / Yielda  Entry Electrophile E1-X Product / Yielda 
2 
  
 
9 
  
 
X = I, 50 °C, 4 h 
X = Br, 50 °C, 3 h 
147b, 78%b 
          92%c 
 
 
-40 to 25 °C, 2 h 147i, 76%d 
3 
  
 
10 
  
 
X = I, 50 °C, 4 h 
X = Br, 50 °C, 2 h 
147c, 80%b 
          87%c 
 
 -40 to 25 °C, 4 h 147j, 71%d 
4 
  
 
11 
  
 50 °C, 4 h 147d, 82%c   -40 to 25 °C, 4 h 147k, 65%d 
5 
  
 
12 
  
 50 °C, 2 h 147e, 71%c   -40 to 25 °C, 2 h 147l, 64%
d 
6 
  
 
13 
 
 
 50 °C, 8 h 147f, 68%c   -40 to 25 °C, 6 h 147m, 79%d 
7 
  
 
14 
  
 25 °C, 1 h 147g, 68%b   25 °C, 4 h 147n, 71%e 
aIsolated yield of analytically pure product. bPd-catalyzed cross-coupling using 3 mol% Pd(OAc)2 and 6 mol% SPhos. cPd-catalyzed cross-
coupling using 3 mol% Pd(dba)2 and 6 mol% SPhos. dA Transmetalation with CuCN·2LiCl was performed. ePd-catalyzed cross-coupling using 3 
mol% Pd(dba)2, 6 mol% P(o-furyl)3, 4 mol% CuI and NEt3 (1.2 equiv). 
The simple, mild and efficient procedure for the zincation of 4,4-dimethyloxazoline (144) in the C-2 
position using TMPZnCl·LiCl (36) affords a stable oxazolinylzinc reagent (146). Subsequent Negishi 
cross-couplings with various aryl iodides and bromides and Cu-mediated acylation and allylation 
reactions provide a variety of 2-functionalized 4,4-dimethyloxazolines of type 147. 
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2.3 Oxazoline as a Directing Group for Further Functionalizations 
Oxazolines serve as a useful activating and directing group in directed metalations,141 thus facilitating 
ortho-metalation. The imino-functionality of the oxazoline moiety directs by coordination to the 
organometallic reagent and also stabilizes the resulting metal species by cyclic coordination.142 
Although, Meyers143 and Gschwend144 extensively examined the ortho-lithiation of 2-arylated 
oxazolines, we anticipated that the use of TMP-bases, such as TMPMgCl·LiCl (35) or TMP2Mg·2LiCl (42), 
will be advantageous for the synthesis of highly functionalized arenes of type 149 (Scheme 60). 
 
Scheme 60. Functionalization of 4,4-dimethyloxazoline (144) and its use as a directing group for further functionalizations 
using TMP-bases. 
Magnesiation of the 2-arylated oxazolines, such as 147b or 147c, is possible within 1.5 h at 0 °C using 
TMPMgCl·LiCl (35)145 and the corresponding magnesium reagents reacted with a variety of 
electrophiles (E1-X) affording ortho-functionalized aryloxazolines of type 148 (  Scheme 61). 
                                                          
141 a) A. I. Meyers, E. D. Mihelich, J. Org. Chem. 1975, 40, 3158. b) H. A. Chiong, Q.-N. Pham, O. Daugulis, J. Am. Chem. Soc. 
2007, 129, 9879. c) X. Chen, J.-J. Li, X.-S. Hao, C. E. Goodhue, J.-Q. Yu, J. Am. Chem. Soc. 2006, 128, 78. d) S. T. Chadwick, A. 
Ramirez, L. Gupta, D. B. Collum, J. Am. Chem. Soc. 2007, 129, 2259. 
142 The Chemistry of Heterocycles (Ed.: I. J. Turchi), John Wiley & Sons Inc, Hoboken, NJ, 1986, p. 971. 
143 T. G. Gant, A. I. Meyers, Tetrahedron 1994, 50, 2297. 
144 H. W. Gschwend, A. Hamdan, J. Org. Chem. 1975, 40, 2008. 
145 a) J. H. C. Batista, F. M. dos Santos, L. A. Bozzini, R. Vessecchi, A. R. M. Oliveira, G. C. Clososki, Eur. J. Org. Chem. 2015, 
2015, 967. b) E. Bellamy, O. Bayh, C. Hoarau, F. Trécourt, G. Quéguiner, F. Marsais, Chem. Commun. 2010, 46, 7043. 
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  Scheme 61. ortho-Metalation of 2-aryloxazolines of type xx using TMPMgCl·LiCl (35). 
The generated oxazolinylmagnesium reagents of 147b and 147c were reacted with Cl-CO2Et, Tos-CN, 
or benzaldehyde to afford the desired ortho-functionalized aryloxazolines 148a-d in 62-91% yield 
(Table 5, entries 1-4). Moreover, a Cu-mediated acylation could be performed by addition of 
CuCN·2LiCl and reaction with 2-thiophenecarbonyl chloride or benzoyl chloride to yield the 
corresponding ketones 148e-f in 83% and 91% yield, respectively (entries 5 and 6). After 
transmetalation with ZnCl2 and Pd-catalyzed cross-coupling with ethyl 4-iodobenzoate or 1-chloro-4-
iodobenzene, the biaryls 148g-h were afforded in 90-93% yield (entries 7 and 8). Likewise, after 
transmetalation with CuCN·2LiCl an allylation reaction with allyl bromide or 3-bromocyclohexene was 
performed and the products 148i-j were isolated in 87-98% yield (entries 9 and 10). 
Table 5. ortho-Magnesiation of 2-arylated oxazolines (147) using TMPMgCl·LiCl (35). 
Entry 
Electrophile  
E1-X 
Product / Yielda  Entry 
Electrophile  
E1-X 
Product / Yielda 
1  
 
 6 
 
 
 
0 to 25 °C, 2 h 148a, 91%   -25 to 25 °C, 3 
h 
148f, 91%b 
2  
 
 7 
 
 
 
0 to 25 °C, 2 h 148b, 83%   25 °C, 4 h 148g, 90%c 
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Entry 
Electrophile  
E1-X 
Product / Yielda  Entry 
Electrophile  
E1-X 
Product / Yielda 
3 
 
 
 8 
 
 
 0 to 25 °C, 2 h 148c, 92%   0 to 25 °C, 2 h 148h, 93%c 
4  
 
9  
 
 0 to 25 °C, 2 h 148d, 62%   0 to 25 °C, 2 h 148i, 87%b 
5 
 
 
 10 
 
 
 -25 to 25 °C, 3 h 148e, 83%b   0 to 25 °C, 2 h 148j, 98%b 
aIsolated yield of analytically pure product. bA transmetalation with CuCN·2LiCl was performed. cAfter transmetalation with ZnCl2, a Pd-
catalyzed cross-coupling using 3 mol% Pd(dba)2 and 6 mol% P(o-furyl)3 was performed. 
Additionally, ortho-functionalized 2-aryloxazolines of type 148 reacted in a second metalation step 
using TMP2Mg·2LiCl (42) within 1.5 h at -20 °C. The newly generated magnesium reagent reacted with 
I2 to afford the iodinated compound 149a in 70% yield. Transmetalation of the magnesium species 
using CuCN·2LiCl, followed by addition of allyl bromide furnished the desired oxazoline 149b in 87% 
yield. Moreover, the ortho-functionalized oxazoline 148h reacted in a Negishi cross-coupling reaction 
with 4-iodobenzotrifluoride yielding the bisarylated substrate 149c in 78% yield (Scheme 62). 
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Scheme 62. Second ortho-metalation of 2-aryloxazolines. 
As shown by Weinreb et al., oxazolines can be converted to carboxylic acids and new ortho,ortho'-
disubstituted benzoic acids can be obtained after deprotection using standard methods.146 
  
                                                          
146 a) P. Kocienski, Protecting Groups, 3rd ed., Georg Thieme Verlag, Stuttgart, 2005. b) K. J. Edgar, C. K. Bradsher, J. Org. 
Chem. 1982, 47, 1585. c) J. I. Levin, S. M. Weinreb, Tetrahedron Lett. 1982, 23, 2347. 
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3 Metalation and Functionalization of the Tropolone Scaffold Using 
TMPZnCl·LiCl 
3.1 Introduction 
Tropone (150, 2,4,6-cycloheptatrien-1-one) and its derivative tropolone (151, 2-hydroxy-2,4,6-cyclo-
heptatrien-1-one)147 are 7-membered rings representing non-benzenoid aromatics with a six π-
electron system (Scheme 63).148 These scaffolds are of great importance not only because of their 
peculiar aromatic properties. Also, the tropolone moiety is known to strongly chelate metal ions which 
is key for the high biological activity, thus these scaffolds are found in many natural products exhibiting 
interesting properties.149 
 
Scheme 63. Tropone (150) and tropolone (151) 
Purpurogallin, a tropolone derivative with a [7]annulene structure, was found to act as an inhibitor of 
the TLR1/TLR2 pathway,150 which is important for the regulation of innate immunity and a target for 
the treatment of immune disorders. Hinokitiol, also called -Thujaplicin, is another natural product 
containing this moiety and is used as an antibacterial as it displays inhibitory effects on Chlamydia 
trachomatis.151 The probably most well-known example containing a tropolone moiety is colchicine, 
which is extracted from Colchicum autumnale (meadow saffron). It can be used in low dose152 for the 
treatment of gout, as well as e.g. pericarditis and atrial fibrillation (Figure 3).153 
 
Figure 3. Natural tropolone analogues. 
                                                          
147 P. L. Pauson, Chem. Rev. 1955, 55, 9. 
148 M. J. S. Dewar, Nature 1945, 150, 50. 
149S. N. Ononye, M. D. VanHeyst, E. Z. Oblak, W. Zhou, M. Ammar, A. C. Anderson, D. L. Wright, ACS Med. Chem. Lett. 2013, 
4, 757. 
150 K. Cheng, X. Wang, S. Zhang, H. Yin, Angew. Chem. Int. Ed. 2012, 51, 12246. 
151 H. Yamano, T. Yamazaki, K. Sato, S. Shiga, T. Hagiwara, K. Ouchi, T. Kishimoto, Antimicrob. Agents Chemother. 2005, 2519. 
152 LD50(oral) = 6 mg/kg (mouse); colchicine; MSDS No. AC227120000; Thermo Fisher Scientific: Waltham, USA, Sep 3, 2014. 
153 P. M. Dewick, Medicinal Natural Products. A Biosynthetic Approach, 3rd ed., John Wiley & Sons Ltd., West Sussex, 2009. 
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The synthesis of tropolones usually starts from cycloheptanone deriatives or relies on the ring 
enlargement of various benzene derivatives. However, to date the direct functionalization of the 
tropolone moiety using organometallic reagents has not been reported yet. Berg and Bladh have 
shown that treatment of 2-methoxy-5-aryltropone (152) with LDA at -78 °C induces ring contraction to 
yield the corresponding p-methoxycarbonylphenyl derivative (153) (Scheme 64).154 
 
Scheme 64. Ring contraction of 2-methoxy-5-aryltropone (152) upon addition of LDA. 
 
3.2 Metalation and Functionalization of 5-Bromo-2-methoxytropone Using 
TMPZnCl·LiCl 
The mild and sterically hindered zinc base TMPZnCl·LiCl (36)34 has proven to be especially efficient for 
the metalation of sensitive compounds and displays an excellent functional group tolerance. 
Particularly, the sensitive keto group should remain unaffected by using a zinc derivative of the TMP-
bases as reactions with various organometallic reagents could favor a 1,2-addition to the ketone or 
result in decomposition. Treatment of 5-bromo-2-methoxytropone (154, 5-bromo-2-
methoxycyclohepta-2,4,6-trien-1-one) with TMPZnCl·LiCl (36) at -30 °C leads within 0.5 h to the 
corresponding zinc reagent which reacts with a range of electrophiles to afford the desired α'-
functionalized tropolone derivatives of type 155 (Scheme 65). 
 
Scheme 65. Metalation of 5-bromo-2-methoxytropone (154) using TMPZnCl·LiCl (36) and reaction with electrophiles. 
The newly generated zinc reagent reacted with I2 or Br2 to afford the halogenated compounds 155a,b 
in 98% and 74% yield, respectively. Negishi cross-coupling reactions118 of the organozinc reagent with 
electron-rich and -poor aryl iodides (FG = OMe, CN, NMe2, NO2, CO2Et) using Pd(dba)2 (3 mol%) and 
                                                          
154 U. Berg, H. Bladh, Acta Chem. Scand. 1998, 52, 1380. 
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P(o-furyl)3 (6 mol%) furnished the corresponding arylated 5-bromo-2-methoxytropones 155d-g in 67-
89% yield (Table 6, entries 3-7). 
Table 6. Metalation of 5-bromo-2-methoxytropone (154) and reaction with various electrophiles. 
Entry 
Electrophile 
E-X 
Product / Yielda  Entry 
Electrophile 
E-X 
Product / Yielda 
1  
 
 5 
 
 
  155a, 98%    155e, 67%
b 
2  
 
 6 
 
 
  155b, 74%    155f, 89%
b 
3 
 
 
 7 
 
 
  155c, 70%b    155g, 73%b 
4 
 
 
    
  155d, 81%
b     
aIsolated yield of analytically pure product. bA Pd-catalyzed cross-coupling using 3 mol% Pd(dba)2 and 6 mol% P(o-furyl)3 was performed. 
 
3.3 Metalation and Functionalization of 2-Benzyloxytropone using TMPZnCl·LiCl 
Similarly to the brominated 2-methoxytropone (154), the metalation of 2-benzyloxytropone (156, 2-
(benzyloxy)cyclohepta-2,4,6-trien-1-one) is also possible within 10 min using TMPZnCl·LiCl (36) at 0 °C. 
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The resulting zinc reagent reacts with a variety of electrophiles producing functionalized tropolones of 
type 157. 
 
Scheme 66. Metalation of 2-benzyloxytropone (156) using TMPZnCl·LiCl (36) and subsequent reaction with electrophiles 
E-X. 
Reactions of the newly generated zinc reagent with electrophiles, such as I2 or 1,2-
dibromotetrachloroethane, afforded the halogenated compounds 157a,b in 83-89% yield (Table 7, 
entries 1, 2). Moreover, the zinc reagent reacted in a Cu-mediated allylation reaction with 3-
bromocyclohexene using CuCN·2LiCl to obtain the allylated tropolone derivative 157c in 94% yield 
(entry 3). Additionally, Cu-mediated acylation reactions with benzoyl chloride or cyclopropane-
carbonyl chloride produced the ketones 157d,e in 76% and 68% yield, respectively (entries 4, 5). The 
zinc reagent of 156 also reacted in various Negishi cross-coupling reactions with (E)-1-iodooct-1-ene, 
various para-functionalized aryliodides and 2-iodothiophene using Pd(dba)3 (3 mol%) and P(o-furyl)3 
(6 mol%) as a catalytic system affording the corresponding coupling products in 75-91% yield (entry 6-
11). 
Table 7. Metalation of 2-benzyloxytropone (156) and quenching with electrophiles. 
Entry 
Electrophile 
E-X 
Product / Yielda  Entry 
Electrophile 
E-X 
Product / Yielda 
1  
 
 7 
 
 
  157a, 89%    157g, 77%
c 
2  
 
 8 
 
 
  157b, 83%    157h, 83%
c 
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Entry 
Electrophile 
E-X 
Product / Yielda  Entry 
Electrophile 
E-X 
Product / Yielda 
3 
 
 
 9 
 
 
  157c, 94%
b    157i, 91%c 
4 
 
 
 10 
 
 
  157d, 76%b    157j, 77%
c 
5 
  
 11 
 
 
  157e, 68%b    157k, 80%c 
6 
 
 
    
  157f, 75%c     
aIsolated yield of analytically pure product. bA transmetalation with CuCN·2LiCl was performed. cA Pd-catalyzed cross-coupling using 3 mol% 
Pd(dba)2 and 6 mol% P(o-furyl)3 was performed. 
The reaction of few tropolone derivatives with several lithium and Grignard reagents is known.155 In a 
similar fashion, treatment of 2-benzyloxy-7-aryl-tropone of type 157 with a Grignard reagent leads via 
158 to the 2,7-diarylated tropone derivatives of type 159 in good yield (Scheme 67).  
                                                          
155 a) T. Nozoe, T. Mukai, J. Minegishi, Proc. Jpn. Acad. 1951, 27, 419. b) T. Mukai, Bull. Chem. Soc. Jpn. 1958, 31, 852. 
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Scheme 67. Grignard Addition to 7-arylated 2-benzyloxytropones of type 157. 
Reaction of the tropolones 157h or 157i with phenylmagnesium chloride (1.2 equiv) results in 
substitution of the benzyloxygroup affording the 2,7-diarylated tropones 159a and 159b in 62% and 
72% yield,156 respectively. Reaction of tropolone derivative 157i with p-anisylmagnesium bromide (1.2 
equiv) selectively produces the 2,7-diarylated compound 159c in 61% yield (Scheme 67).  
                                                          
156 X-ray analysis of compound 159c did show exclusive formation of the α,α'-arylated tropone derivative. 
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4 Cobalt-Catalyzed Negishi Cross-Coupling Reactions of (Hetero)Aryl-
zinc Reagents with Primary and Secondary Alkyl Bromides and 
Iodides 
4.1 Introduction 
Transition metal-catalyzed cross-coupling reactions are valuable tools for C-C bond-forming reactions 
and have found many applications for the syntheses of biologically active molecules.157 As already 
previously mentioned, Pd- or Ni-catalyzed cross-coupling reactions dominate this field, but have 
several drawbacks, for example the toxicity158 and high price of the metal,159 as well as the requirement 
of sophisticated ligands to achieve a broad reaction scope. Recently, cross-coupling reactions with 
cobalt catalysts were found to be a valuable alternative.160 However, despite the spectacular advances 
of Co-catalyzed coupling reactions between C(sp2) and C(sp3) centers by using magnesium reagents,161 
no Co-catalyzed Negishi-type98,99 coupling reactions using arylzinc reagents have been described 
(Scheme 68). 
 
Scheme 68. Co-catalyzed cross-coupling of arylzinc reagents and alkyl halides 
Knochel and co-workers have reported a range of synthetic methods for the preparation of 
polyfunctional unsaturated zinc reagents.162,32 In particular, the directed metalation163,31a of 
polyfunctional heterocycles and aromatic substrates has a broad reaction scope, and sterically 
hindered bases,164,31b such as TMP2Zn·2MgCl2·2LiCl (48),41 have given a straight forward entry to a range 
                                                          
157 a) Metal-Catalyzed Cross-Coupling Reactions, 2nd ed., (Eds.: A. de Meijere, F. Diederich), Wiley-VCH, Weinheim, 2004. b) 
Organotransition Metal Chemistry (Ed.: J. F. Hartwig), University Science Books, Sausalito, CA, 2010. 
158 a) Handbook on the Toxicology of Metals (Eds.: L. Friberg, G. F. Nordberg, V. B. Vouk), Elsevier, Amsterdam, 1986. b) M. N. 
Hughes, in Comprehensive Coordination Chemistry (Eds.: G. Wilkinson, R. D. Gillard, J. A. McCleverty), Pergamon Press, 
Oxford, 1987, pp. 643-648. 
159 world markt prices: Pd 8000 $/lb, Co 10 $/lb; http://www.infomine.com/; retrieved 11th April 2016. 
160 a) H. Shinokubo, K. Oshima, Eur. J. Org. Chem. 2004, 2081. b) H. Yorimitsu, K. Oshima, Pure Appl. Chem. 2006, 78, 441. c) 
C. Gosmini, J.-M. Begouin, A. Moncomble, Chem. Commun. 2008, 3221. d) G. Cahiez, A. Moyeux, Chem. Rev. 2010, 110, 
1435. e) J. Yang, N. Yoshikai, J. Am. Chem. Soc. 2014, 136, 16748. 
161 For selected cobalt-catalyzed cross-coupling reactions using organomagnesium reagents, see: a) G. Cahiez, H. Avedissian, 
Tetrahedron Lett. 1998, 39, 6159. b) K. Wakabayashi, H. Yorimitsu, K. Oshima, J. Am. Chem. Soc. 2001, 123, 5374. c) H. 
Ohmiya, H. Yorimitsu, K. Oshima, Org. Lett. 2006, 8, 3093. d) G. Cahiez, C. Chaboche, C. Duplais, A. Moyeux, Org. Lett. 2009, 
11, 277. e) L. Nicolas, P. Angibaud, I. Stansfield, P. Bonnet, L. Meerpoel, S. Reymond, J. Cossy, Angew. Chem. Int. Ed. 2012, 
51, 11101. f) J. Zeng, K. M. Liu, X. F. Duan, Org. Lett. 2013, 15, 5342. g) C. F. Despiau, A. P. Dominey, D. C. Harrowven, B. 
Linclau, Eur. J. Org. Chem. 2014, 2014, 4335. 
162 a) P. Knochel, W. Dohle, N. Gommermann, F. F. Kneisel, F. Kopp, T. Korn, I. Sapountzis, V. A. Vu, Angew. Chem. Int. Ed. 
2003, 42, 4302. b) T. Klatt, J. T. Markiewicz, C. Saemann, P. Knochel, J. Org. Chem. 2014, 79, 4253. 
163 a) P. Beak, R. A. Brown, J. Org. Chem. 1982, 47, 34. b) P. Beak, A. Tse, J. Hawkins, C. W. Chen, S. Mills, Tetrahedron 1983, 
39, 1983. c) Y. Zhao, V. Snieckus, J. Am. Chem. Soc. 2014, 136, 11224. d) K. Groom, S. M. S. Hussain, J. Morin, C. Nilewski, 
T. Rantanen, V. Snieckus, Org. Lett. 2014, 16, 2378. 
164 a) D. R. Armstrong, W. Clegg, S. H. Dale, E. Hevia, L. M. Hogg, G. W. Honeyman, R. E. Mulvey, Angew. Chem. Int. Ed. 2006, 
45, 3775. b) A. J. Martinez-Martinez, A. R. Kennedy, R. E. Mulvey, C. T. O'Hara, Science 2014, 346, 834. 
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of unsaturated and highly reactive diorganozinc compounds. In order to establish a cobalt-catalyzed 
Negishi cross-coupling it has been envisioned that diarylzinc reagents prepared by a directed C-H 
zincation using TMP2Zn·2MgCl2·2LiCl (48) can be employed in a cross-coupling reaction with various 
primary and secondary alkyl halides (Scheme 69). 
 
Scheme 69. Metalation reaction using TMP2Zn (48) and cobalt-catalyzed cross-coupling of the diarylzinc species.  
(MgCl2 and LiCl are omitted for the sake of clarity) 
 
4.2 Design of the Coupling Procedure 
In preliminary experiments, we have examined the cross-coupling of the diarylzinc reagent (161, which 
was generated by a directed metalation of ethyl 3-fluorobenzoate (160)165 using TMP2Zn·2MgCl2·2LiCl 
(48, 0.6 equiv), with c-Hex-I in the presence of various metal catalysts (Table 8).  
Table 8. Optimization of the reaction conditions for the Co-catalyzed cross-coupling. 
 
 
Entry Catalyst (mol%) Additive (mol%) Yield of 162ab 
1 FeCl2 (20) 4-fluorostyrene (50) 0 
2 FeCl2 (20) TMEDA (30) 13 
3 Co(acac)2 (20) 4-fluorostyrene (50) 0 
4 Co(acac)2 (20) TMEDA (30) 18 
5 CoCl2 (20) 4-fluorostyrene (50) 42 
6 CoCl2 (20) TMEDA (30) 84 
 
                                                          
165 As a consequence of its electron-acceptor properties, the fluoro-substituent facilitates the zincation, as well as the cobalt-
catalyzed cross-coupling reaction and therefore ethyl 3-fluorobenzoate was chosen as the model substrate. 
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7 CoCl2·2LiCl (20) TMEDA (30) 94 (87)c 
8 CoCl2·2LiCl (20) 4-fluorostyrene (50) 38 
9 CoCl2·2LiCl (20) Ligand L1d 40 
10 CoCl2·2LiCl (10) TMEDA (30) 33 
aMgCl2 and LiCl are omitted for the sake of clarity. bDetermined by GC using undecane (C11H24) as an internal standard. cYield of isolated 
product. dL1 = trans-N,N,N',N'-tetramethylcyclohexane-1,2-diamine. 
The addition of the zinc species to c-Hex-I in the presence of Co(acac)2 or FeCl2166 resulted in the 
exclusive formation of the protonated zinc species (160) when using 4-fluorostyrene (50 mol%) as an 
additive (Table 8, entries 1 and 3).167 Moderate yields of 162a (13-18%) were obtained using N,N,N',N'-
tetramethylethane-1,2-diamine (TMEDA, 30 mol%) as a ligand (entries 2 and 4). Switching to CoCl2 
(20 mol%) and 4-fluorostyrene (50 mol%) or TMEDA (30 mol%) in THF at 0 °C furnished the desired 
cross-coupling product 162a in 42% and 84% yield, respectively (entries 5 and 6). Significant 
improvements were achieved by using the THF-soluble CoCl2·2LiCl (20 mol%)168 and TMEDA (30 mol%), 
which afforded the desired coupling product 162a in 87% isolated yield (entry 7). Further variation of 
the ligand169 or lowering the amount of the catalyst loading from 20 mol% to 10 mol% led only to a 
decrease in the yield (entries 7-10). 
 
4.3 Cobalt-Catalyzed Cross-Coupling of Zincated Ethyl 3-fluorobenzoate with Various 
Alkyl Halides 
With these optimized reaction conditions in hand, we have performed a range of alkylations using 
various primary and secondary alkyl halides to afford alkylated benzoates of type 162 (Scheme 70). 
 
Scheme 70. Zincation of ethyl 3-fluorobenzoate (160) and cobalt-catalyzed cross-coupling with alkyl halides. 
The reaction of the zincated species 161 with primary alkyl iodides led to the polyfunctional alkylated 
benzoates (162a-c) in 58-77% yield (Table 1, entries 1–3). Remarkably, the ortho,ortho’ substituents 
present in the diarylzinc species (161) did not disturb the cross-coupling and most of the reactions 
                                                          
166 B. Barré, L. Gonnard, R. Campagne, S. Reymond, J. Marin, P. Ciapetti, M. Brellier, A. Guerinot, J. Cossy, Org. Lett. 2014, 16, 
6160. 
167 A. K. Steib, T. Thaler, K. Komeyama, P. Mayer, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 3303. 
168 a) J. M. Hammann, A. K. Steib, P. Knochel, Org. Lett. 2014, 16, 6500. b) G. Cahiez, C. Chaboche, C. Duplais, A. Giulliani, A. 
Moyeux, Adv. Synth. Catal. 2008, 350, 1484. 
169 H. Ohmiya, H. Yorimitsu, K. Oshima, J. Am. Chem. Soc. 2006, 128, 1886. 
RESULTS AND DISCUSSION 
 
60 
were complete within 6 h at 0 °C. Primary alkyl bromides have also been successfully coupled, but with 
somewhat lower yields (entries 2-4), whereas cyclohexyl chloride only gave trace amounts of the 
desired product (compare entry 4). Functional groups, such as an ester or a nitrile, are well-tolerated 
in these cross-coupling reactions and products such as 162c-d were isolated. Interestingly, also 
secondary alkyl iodides reacted smoothly to provide the alkylation products 162a,e-j in 55-79% yield 
(entries 4-10). In no case did we observe rearrangement products (branched to unbranched; see entry 
5 and Table 10).170,80,88 When an oxygen substituent was present in α-position of the carbon-iodine 
bond, excellent diastereoselectivities were observed (up to d.r. 99:1, see entries 8-10) and the 
products 162h-j were isolated in 55-69% yield. Additionally, this cross-coupling can also be performed 
with heterocyclic alkyl iodides, thereby leading to the expected products 162g and 162j in 79% and 
55% yield, respectively (see entries 7 and 10). 
Table 9. Scope of various primary and secondary alkyl iodides or bromides. 
Entry Alk-X Product / Yielda  Entry Alk-X Product / Yielda 
1 
 
 
 6 
 
 
  162b, 63%    162f, 79%, d.r. 50:50
d 
2  
 
 7 
 
 
  
162c, 58% (X = I) 
             38% (X = Br) 
   
162g, 79% 
 
3 
 
 
 8 
  
  
162d, 71% (X = I) 
              51% (X = Br) 
   
162h, 68%, d.r. 99:1d 
 
       
                                                          
170 a) K. Tamao, Y. Kiso, K. Sumitani, M. Kumada, J. Am. Chem. Soc. 1972, 94, 9268. b) T. Hayashi, M. Konishi, Y. Kobori, M. 
Kumada, T. Higuchi, K. Hirotsu, J. Am. Chem. Soc. 1984, 106, 158. 
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Entry Alk-X Product / Yielda  Entry Alk-X Product / Yielda 
4 
 
 
 9 
  
  
162a, 61% (X = Br) 
              2% (X = Cl)b 
   
162i, 69%, d.r. 99:1e 
 
5 
 
 
 10 
  
  162e, 70%, d.r. 50:50c    162j, 55%, d.r. 99:1e 
 aIsolated yield of analytically pure product. bThe yield was determined by GC using C11H24 as an internal standard. cThe starting material was 
99:1 syn/anti. dThe starting material was 75:25 cis/trans. eThe starting material was 99:1 trans/cis.  
 
4.4 Cobalt-Catalyzed Cross-Coupling of Di(hetero)arylzinc Reagents with Alkyl 
Iodides 
The reaction scope of this Co-catalyzed alkylation is quite broad and a range of diarylzinc reagents 
prepared by a directed deprotonation using TMP2Zn·2MgCl2·2LiCl (48, 0.6 equiv) provided the isolated 
alkylated products 163a-m in 51–88% yield (Table 10). Thus, this sequential one-pot metalation/cross-
coupling procedure could be extended to other 1,3-disubstituted aromatic compounds: the zincation 
of 3-fluorobenzonitrile using 48 (0.6 equiv) proceeds within 12 h at 25 °C, and the subsequent coupling 
reactions with secondary alkyl iodides provide the desired products 163a-c in 52-84% yield (entries 1-
3). Remarkably, diheteroarylzinc reagents generated by directed zincation using 48 also undergo the 
alkylation reactions in good yields to afford the expected products 163d-m (51-88% yield, entries 4-
13). Thus, zincated benzofurans or benzothiophenes reacted with secondary alkyl iodides such as c-
Hex-I, i-Pr-I, or n-Bu-I to furnish the corresponding cross-coupling products 163d-g in 61-72% yield 
(entries 4-7).  
Table 10. Cobalt-catayzed cross-coupling of various diaryl- and diheteroarylzinc reagents with alkyl iodides. 
Entry Zinc species Alk-X Product / Yielda 
1 
 
 
 
 
  163a, 84% 
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Entry Zinc species Alk-X Product / Yielda 
2 
 
 
 
 
  
163b, 63%b 
3 
 
 
 
   163c, 52% 
4 
   
   163d, 71% 
5 
 
 
 
   163e, 61% 
6 
 
 
 
   163f, 63% 
7 
   
   163g, 72% 
8 
 
 
 
  
 
163h, 69% 
9 
 
 
 
  
 
163i, 61% 
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Entry Zinc species Alk-X Product / Yielda 
10 
 
 
 
  
 
163j, 76% 
11 
  
 
  
 
163k, 66% 
12 
  
 
 
  163l, 88% 
13 
 
 
 
 
  163m, 51% 
aIsolated yield of analytically pure product. bThe starting material was 99:1 syn/anti, the product was 50:50 syn/anti. 
The metalation of benzofuran with TMP2Zn·2MgCl2·2LiCl (48, 0.6 equiv) was complete within in 12 h at 
25 °C, thereby providing the corresponding zinc reagent. This species undergoes the Co-catalyzed 
cross-coupling with n-Bu-I to afford the substituted benzofuran 163f in 63% yield (entry 6). This 
alkylated benzofuran (163f) is a key intermediate for the synthesis of amiodarone, an active 
antiarrhythmic agent.171 Similarly, 3,6-dimethoxypyridazine was zincated using 48 (0.6 equiv, 4 h, 
25 °C), and the cross-coupling with 2-iodopropane or c-Hex-I afforded the desired polyfunctional 
hetereocycles 163h,i in 69% and 61% yield, respectively (entries 8 and 9). Coumarin is also an excellent 
substrate and its zincation is complete within 1 h at 25 °C. After alkylation with various primary and 
secondary alkyl iodides, the substituted coumarins 163j-l were obtained in up to 88% yield (entries 10-
12). Similarly, the regioselective zincation of thiochromone (-40 °C, 1 h)47 at the -position to sulfur 
followed by a Co-catalyzed alkylation with 2-iodobutane led to the desired product 163m in 51% yield 
(entry 13). 
                                                          
171 a) K. M. Zareba, Drugs Today 2006, 42, 75. b) H. R. Ha, B. Stieger, G. Grassi, H. R. Altorfer, F. Follath, Eur. J. Clin. Pharmacol. 
2000, 55, 807. c) M. Witczak, H. Kwiecien, Synth. Commun. 2005, 35, 2223. 
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5 Mild Cobalt-Catalyzed Negishi Cross-Couplings of (Hetero)arylzinc 
Reagents with (Hetero)aryl Halides 
5.1 Introduction 
The formation of C(sp2)-C(sp2) bonds is of great interest for the synthesis of biologically active 
molecules and particularly the Negishi cross-coupling has attracted a lot of attention as a wide range 
of polyfunctional zinc reagents are available.172 As already mentioned above, price and toxicity issues 
of transition metals, such as Ni and Pd, have encouraged the search for alternative metal sources, such 
as cobalt160,173 and iron.174 Bedford and co-workers demonstrated that the use of iron(I) complexes in 
Negishi cross-couplings leads to great efficiency.96,97 Gosmini and Begouin showed that organozinc 
reagents can be generated in situ and cross-coupled with heteroaryl halides in a one-pot procedure.98 
Yoshikai and co-workers reported impressive organometallic cascade reactions, where arylzinc 
reagents were generated by Co-catalysis and then underwent cross-coupling with aryl iodides in the 
presence of a Pd catalyst.27 Furthermore, Hayashi and co-workers reported cobalt-catalyzed 
asymmetric C(sp2)-C(sp) couplings.175 
 
Scheme 71. Cobalt-catalyzed cross-coupling of aryl halides with arylzinc reagents. 
We have shown that arylzinc reagents that are prepared by directed metalation undergo smooth 
C(sp2)-C(sp3) cross-couplings with primary and secondary alkyl halides. Whereas this reaction proceeds 
under mild conditions, it suffers from a limited scope with respect to the arylzinc reagent, and the 
extension of this approach to C(sp2)-C(sp2) couplings under the reported reaction conditions was 
difficult.  
 
                                                          
172 Handbook of Functionalized Organometallics: Applications in Synthesis (Ed.: P. Knochel), Wiley-VCH, Weinheim, 2004. 
173 For representative examples, see: a) T. J. Korn, P. Knochel, Angew. Chem. Int. Ed. 2005, 44, 2947. b) T. Hatakeyama, S. 
Hashimoto, K. Ishizuka, M. Nakamura, J. Am. Chem. Soc. 2009, 131, 11949. c) M. Moselage, N. Sauermann, S. C. Richter, L. 
Ackermann, Angew. Chem. Int. Ed. 2015, 54, 6352. d) J. Li, L. Ackermann, Angew. Chem. Int. Ed. 2015, 54, 8551. e) J. Wu, 
N. Yoshikai, Angew. Chem. Int. Ed. 2016, 55, 336. 
174 For selected reviews on iron-catalysis, see: a) C. Bolm, Nat Chem 2009, 1, 420. b) A. Fürstner, Angew. Chem. Int. Ed. 2009, 
48, 1364. c) W. M. Czaplik, M. Mayer, J. Cvengroš, A. J. von Wangelin, ChemSusChem 2009, 2, 396. d) E. Nakamura, N. 
Yoshikai, J. Org. Chem. 2010, 75, 6061. 
175 a) T. Sawano, K. Ou, T. Nishimura, T. Hayashi, Chem. Commun. 2012, 48, 6106. b) T. Sawano, K. Ou, T. Nishimura, T. Hayashi, 
J. Org. Chem. 2013, 78, 8986. 
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5.2 Design of the Procedure 
A new set of reaction conditions that enables smooth cross-couplings of various arylzinc reagents with 
(hetero)aryl chlorides or bromides within a few hours at room temperature was pursued. In a 
preliminary experiment, we treated 2-bromoquinoline (164) with para-anisylzinc chloride (165a, 1.2 
equiv) in the presence of CoCl2·2LiCl (5 mol%) and observed the formation of the desired cross-coupling 
product (166) in 65% yield. However, aside from the desired cross-coupling we observed extensive side 
reactions, including homocoupling. To improve the reaction outcome, we were inspired by the recent 
work of Miller and co-workers, who showed that the addition of potassium formate plays an important 
role in Suzuki reactions.176 We anticipated that this salt could generate a more selective cobalt species 
with equal or superior catalytic activity. To our delight, the addition of HCO2Na (50 mol%) led to an 
improved yield of 88% of the isolated product 166 (Scheme 72). 
 
Scheme 72. Cobalt-catalyzed cross-coupling of 2-bromoquinoline (164) and p-MeOC6H4ZnCl (165a) with and without 
sodium formate. 
Preliminary kinetic studies showed that the main effect of HCO2Na is to considerably reduce the 
occurrence of side reactions, thus, as anticipated, leading to more selective cross-couplings and higher 
reaction yields.177 This effect proved to be general, and a broader screen of reaction conditions using 
2-bromopyridine (167) showed that cobalt halides, such as CoCl2 or CoBr2, as well as Co(acac)2, and 
Co(acac)3 gave good results (Table 11, entries 1-5). In particular, CoCl2·2LiCl,168 which is conveniently 
soluble in THF, afforded product 168 in excellent yield in the presence of HCO2Na (entry 7). 
Table 11. Optimization of the reaction conditions for the Co-catalyzed cross-coupling 
 
                                                          
176 W. D. Miller, A. H. Fray, J. T. Quatroche, C. D. Sturgill, Org. Proc. Res. Dev. 2007, 11, 359. 
177 Premixing of CoCl2·2LiCl and HCO2Na in THF using the same stoichiometry as in the standard reaction led to the same 
reaction outcome than the one-pot procedure (also, compare table 9, entry 7). For preliminary kinetic studies, see the 
experimental part for details. 
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Entry Catalyst Additive Homocoupling [%] Yield of 168b 
1 CoCl2 - 14 82 
2 CoCl2c - 18 76 
3 CoBr2 - 14 78 
4 Co(acac)2 - 10 72 
5 Co(acac)3 - 14 80 
6 CoCl2·2LiCl - 13 83 (79)d 
7 CoCl2·2LiCl HCO2Na 12 94 (87)d 
8 CoCl2·2LiCl PivONa 14 96 
9 CoCl2·2LiCl DMPU 12 84 
10 CoCl2·2LiCl TMEDA 7 51 
11 CoCl2·2LiCl DMBAe 5 16 
12 Co(acac)3 HCO2Na 16 89 
13 - HCO2Na - - 
14 CrCl2 - traces traces 
15 FeCl2 - traces 17 
aMgCl2 and LiCl are omitted for the sake of clarity. 5 mol% of the indicated catalyst and 50 mol% of the indicated additive were used. 
bDetermined by GC using undecane (C11H24) as an internal standard. c99.99% purity. dYield of isolated product. e2,6-Dimethylbenzoic acid. 
Interestingly, when sodium pivalate (t-BuCO2Na = PivONa) was used as an additive, the reaction was 
equally efficient, showing that HCO2Na does not act as a reducing agent, but rather as a ligand.178 
Control experiments using ultrapure CoCl2 (99.99%) confirmed that the Co salts are the active catalysts 
and that metal impurities do not play a role (compare with entry 2). Polar solvents, such as N,N’-
dimethylpropylene urea (DMPU), or the use of a typical additive, such as N,N,N’,N’-
tetramethylethylenediamine (TMEDA) or 2,5-dimethylbenzoic acid, did not improve the reaction 
outcome (entries 9-11). The use of Co(acac)3 instead of CoCl2·2LiCl was not advantageous (entry 12). 
Furthermore, we confirmed that HCO2Na alone did not catalyze this coupling by additional metal 
impurities (entry 13). Additional control experiments indicated that Cr179 and Fe180 salts are not good 
catalysts for this reaction (entries 14 and 15). 
 
                                                          
178 We propose that the halide ligands in CoCl2·2LiCl are replaced by carboxylate ligands (HCO2-), which provides a more 
selective cobalt catalyst. In fact, halide ligands mostly lead to tetrahedral coordination (see, for example: N. S. Gill, F.  B. 
Taylor, Inorg. Synth. 1967, 9,136), whereas carboxylate ligands lead to an octahedral coordination (see, for example: a) A. 
Kaufmann, C. Afshar, M. Rossi, D. E. Zacharias, J. P. Glusker, Struct. Chem. 1993, 4, 191; b) G. Aromí, A. S. Batsanov, P. 
Christian, M. Helliwell, A. Parkin, S. Parsons, A. A. Smith, G. A. Timco, R. E. P. Winpenny, Chem. Eur. J. 2003, 9, 5142). 
Furthermore, whereas CoCl2·2LiCl in THF is a blue solution, the addition of HCO2Na leads to a pink solution, which is typical 
for a coordination change. 
179 A. K. Steib, O. M. Kuzmina, S. Fernandez, D. Flubacher, P. Knochel, J. Am. Chem. Soc. 2013, 135, 15346. 
180 O. M. Kuzmina, A. K. Steib, D. Flubacher, P. Knochel, Org. Lett. 2012, 14, 4818. 
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5.3 Cobalt-Catalyzed Cross-Coupling of 2-Halogenated Aromatic Ketones 
The reaction scope of this cross-coupling proved to be quite broad. Thus, 2-halogenated, functionalized 
aceto- and benzophenones (169a-g) underwent the cobalt-catalyzed cross-coupling with a range of 
aryl- and heteroarylzinc reagents (165a-h), yielding the corresponding ketones (170a-j) in 61-98% yield 
(Table 12). 2-Chloro- and 2-bromoacetophenone (169a-b) reacted with zinc reagents bearing various 
functional groups, providing the expected products 170a-b in 65-74% yield (entries 1 and 2). 
Interestingly, zinc reagents with a dimethylamino substituent or a cyano group (165d-e) were well 
tolerated as they reacted with 2-chlorobenzophenone (169c) to give 170c and 170d in 73% and 98% 
yield, respectively (entries 3 and 4). Remarkably, various other 2-chlorinated aromatic ketones (169d-
g) underwent the cross-coupling with both electron-rich and -poor arylzinc reagents, yielding the 
desired products in 61-89% yield (entries 5-10). Heterocyclic zinc reagents, such as 165h, provided the 
new ketones 170h and 170j in 61% and 62% yield, respectively (entries 8 and 10). 
Table 12. Cobalt-catalyzed cross-coupling reactions between 2-chlorinated aromatic ketones and arylzinc reagents. 
Entry Electrophile Zinc reagent Product / Yielda 
1 
  
 
 
169a (X = Cl) 
169b (X = Br) 
165b 
 
170a, 65% (X = Cl) 
           74% (X = Br) 
2 
  
 
 169a 165c 170b, 67% 
3 
 
 
 
 169c 165d 170c, 73% 
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Entry Electrophile Zinc reagent Product / Yielda 
4 
  
 
 169c 165e 170d, 98% 
5 
 
 
 
 169d 165a 170e, 76% 
6 
  
 
 169e 165f 170f, 68% 
7 
 
 
 
 169f 165g 170g, 89% 
8 
  
 
 169f 165h 170h, 61% 
9 
 
 
 
 169g 165g 170i, 73% 
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Entry Electrophile Zinc reagent Product / Yielda 
10 
  
 
 169g 165h 170j, 62% 
aYield of isolated product. TBS = tert-butyldimethylsilyl 
 
5.4 Cobalt-Catalyzed Cross-Coupling of 2-Chloropyridines 
Furthermore, a range of 2,3-disubstituted N-heterocyclic chlorides can also be readily employed in this 
reaction (Table 13, entries 1-4). p-MeOC6H4ZnCl (165a) reacted smoothly with ethyl 2-chloronicotinate 
(171a), leading to the 2,3-disubstituted pyridine 172a in 70% yield (entry 1). The coupling of the 
electron-rich arylzinc reagents 165i and 165d with methyl 2-chloronicotinate (171b) afforded pyridines 
172b and 172c in 71% and 91% yield, respectively (entries 2 and 3). Similarly, the cross-coupling of 2-
chloronicotinonitrile (161c) and an organozinc reagent bearing a OMOM group (165j; MOM = 
methoxymethyl) led to the desired pyridine 172d in 60% yield (entry 4). Furthermore, 2,5-disubstituted 
N-heterocyclic chlorides were also good substrates: the ester-substituted pyridine 171d reacted 
smoothly with the arylzinc reagents 165a and 165c to yield the desired compounds 172e,f in 89% and 
88% yield, respectively (entries 5 and 6). Moreover, the 2,5-disubstituted pyridines 171e,f were 
coupled with various arylzinc reagents delivering the arylated pyridines 172g-j in 73-86% yield (entries 
7-10). 
Table 13. Cobalt-catalyzed cross-coupling reactions between 2-chloropyridines and arylzinc reagents. 
Entry Electrophile Zinc reagent Product / Yielda 
1 
  
 
 171a 165a 172a, 70% 
2 
  
 
 171b 165i 172b, 71% 
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Entry Electrophile Zinc reagent Product / Yielda 
3 
 
 
 
 171b 165d 172c, 91% 
4 
 
 
 
 171c 165j 172d, 60% 
5 
  
 
 171d 165a 172e, 89% 
6 
  
 
 171d 165c 172f, 88% 
7 
  
 
 171e 165b 172g, 86% 
8 
   
 171e 165k 172h, 73% 
9 
   
 171f 165f 172i, 84% 
10 
  
 
 171f 165a 172j, 84% 
aYield of isolated product. 
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5.5 Cobalt-Catalyzed Cross-Coupling of Various N-Heterocycles 
Moreover, halogenated quinolines, pyrimidines, and triazines also proved to be good substrates for 
this cross-coupling (Table 14). Substituted quinolines, such as 2-bromoquinoline-3-carbonitrile (173a) 
and ethyl 2-bromoquinoline-4-carboxylate (173b), can be rapidly coupled with the organozinc reagents 
165f and 165a to provide the corresponding arylated quinolines 174a and 174b in 92% and 65% yield, 
respectively (entries 1 and 2). Pyrimidines, which are common scaffolds of pharmaceuticals,181 were 
readily obtained by the coupling of 2-chloro- or 2-bromopyrimidine (173c-f) in 65-92% yield (entries 3-
6). Triazines are also of great importance as building blocks for materials and agrochemicals.182 The 
cross-coupling of 2-chloro-4,6-diphenyl-1,3,5-triazine (173g) with the arylzinc reagent 165m led to the 
desired product 174g in 61% yield (entry 7).  
Table 14. Cobal-catalyzed cross-coupling between halogenated N-heterocycles and various arylzinc reagents. 
Entry Electrophile Zinc reagent Product / Yielda 
1 
   
 173a 165f 174a, 92% 
2 
 
 
 
 173b 165a 174b, 65% 
3 
   
 173c 165f 174c, 92% 
    
                                                          
181 M. E. Welsch, S. A. Snyder, B. R. Stockwell, Curr. Opin. Chem. Bio. 2010, 14, 347. 
182 a) H. Zhong, H. Lai, Q. Fang, J. Phys. Chem. C 2011, 115, 2423. b) R. V. Patel, Y.-S. Keum, S. W. Park, Mini-Rev. Med. Chem. 
2014, 14, 768. 
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Entry Electrophile Zinc reagent Product / Yielda 
4 
   
 173d 165l 174d, 86% 
5 
  
 
 173e 165c 174e, 76% 
6 
  
 
 173f 165l 174f, 65% 
7 
  
 
 173g 165m 174g, 61% 
aYield of isolated product. 
 
The cross-coupling of 4,6-dichloropyrimidine (175) with p-MeOC6H4ZnCl (165a; 2.4 equiv) afforded the 
bisarylated compound 176 in 73% yield on gram scale (Scheme 73). 
 
Scheme 73. Cobalt-catalyzed cross-coupling reaction between 4,6-dichloropyrimidine (175) and p-MeOC6H4ZnCl (165a). 
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The synthesis of heteroaryl–heteroaryl cross-coupling products is a challenge. When Pd or Ni catalysts 
are used, catalyst deactivation is often observed owing to chelation of the reagents with the catalyst.183 
However, in the presence of THF-soluble CoCl2·2LiCl (5 mol%) and sodium formate (50 mol%), the 
cross-coupling of 2-bromopyrimidine (173c) with (1-methyl-1H-indol-5-yl)zinc chloride (165h) or 
thiophen-3-ylzinc chloride (165n) proceeded smoothly to afford the heteroaryl compounds 177a and 
177b in 72 and 61% yield, respectively (Scheme 74). 
 
Scheme 74. Cobalt-catalyzed heteroaryl-heteroaryl cross-coupling of 2-bromopyrimidine (173c) and heteroarylzinc 
reagents. 
 
  
                                                          
183 a) C. Kaes, A. Katz, M. W. Hosseini, Chem. Rev. 2000, 100, 3553. b) Comprehensive Coordination Chemistry II, Vol. 1 (Eds.: 
J. A. McCleverty, T. J. Meyer), Elsevier, Oxford, 2004. 
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6 Summary 
This work was focused on the chemo- and regioselective functionalization of sensitive heterocycles, 
such as oxazole and oxazolines via direct metalation. We have developed a new general method for 
performing multiple regioselective metalations of oxazole scaffold via successive reactions using 
TMPMgCl·LiCl (35) or TMPZnCl·LiCl (36) leading to a variety of new highly functionalized oxazole 
derivatives with the regiocontrolled introduction of all substituents (Scheme 75). 
 
Scheme 75. Multiple regioselective metalations of oxazole using TMPZnCl·LiCl and reaction with electrophiles. 
Moreover, we have reported a simple and efficient method for the zincation of 4,4-dimethyl-oxazoline 
in position 2 using TMPZnCl·LiCl (36). The resulting oxazolinylzinc reagents were arylated via Negishi 
cross-couplings with various aryl iodides and bromides under mild conditions. Additionally, Cu-
mediated acylation and allylation reactions proceeded readily to yield 2-substituted 4,4-
dimethyloxazolines in up to 92% yield (Scheme 76).  
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Scheme 76. Preparation of 2-substituted 4,4-dimethyloxazolines via directed metalation and reaction with electrophiles. 
Since oxazolines serve as a useful directing group in metalation reactions, further functionalization 
using TMPMgCl·LiCl (35) or TMP2Mg·2LiCl (42) and reaction with various electrophiles led to a variety 
of ortho,ortho'-disubstituted 2-aryloxazolines in good yields (Scheme 77). 
 
Scheme 77. ortho-Metalation of 2-aryloxazolines using TMP-bases of magnesium. 
Additionally, we have reported a simple and fast method for the zincation of 2-methoxy- and 2-
benzyloxytropones using TMPZnCl·LiCl (36). The generated organozinc reagents reacted with a variety 
of electrophiles in Cu-mediated allylation and acylation reactions, as well as in Pd-catalyzed Negishi 
cross-coupling reactions providing the α'-functionalized tropolones in very good yields (Scheme 78).  
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Scheme 78. Zincation and functionalization of tropolone derivatives. 
Furthermore, cross-coupling reactions of arylzinc reagents with aryl and alkyl halides under cobalt-
catalysis have been investigated. We have developed a new cobalt-catalyzed cross-coupling of 
polyfunctional diaryl- and diheteroarylzinc reagents prepared via directed metalation using 
TMP2Zn·2MgCl2·2LiCl (48) with primary and secondary alkyl iodides or bromides using the highly 
soluble cobalt salt CoCl2·2LiCl. Remarkably, no rearrangement of the secondary alkyl group could be 
observed for the alkyl halides employed in this procedure. This cross-coupling proceeds under mild 
conditions and is compatible with various functional groups and hetereocyclic scaffolds (Scheme 79). 
 
Scheme 79. Cobalt-catalyzed cross-coupling of zincated (hetero)arenes with primary and secondary alkyl halides. 
Also, we have developed a new, practical, cobalt-catalyzed, sodium formate promoted C(sp2)-C(sp2) 
cross-coupling reaction between N-heterocyclic chlorides or bromides and halogenated aromatic 
ketones with various (hetero)arylzinc reagents. The use of sodium formate was the key to the success 
of these cobalt-catalyzed cross-couplings (Scheme 80). 
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Scheme 80. Cobalt-catalyzed cross-coupling of (hetero)aryl halides with (hetero)arylzinc reagents. 
  
  
 
 
 
 
 
 
 
 
 
C EXPERIMENTAL PART 
  
  
  
EXPERIMENTAL PART 
 
81 
C             EXPERIMENTAL PART 
1 General Considerations 
All reactions were carried out with magnetic stirring and in flame-dried glassware under argon 
atmosphere using Schlenk technique. Syringes used to transfer reagents and solvents were purged 
with argon prior to use.  
1.1 Solvents 
CH2Cl2 was predried over CaCl2 and distilled from CaH2. 
DME was predried over CaCl2 and distilled from sodium benzophenone ketyl under argon atmosphere. 
DMF was refluxed over CaH2 (14 h), distilled from CaH2 and stored over 4 Å MS under argon 
atmosphere. 
DMPU was predried over CaH2 (4 h) and distilled. 
TEA was dried over KOH and distilled. 
THF was continuously refluxed and distilled from sodium benzophenone ketyl under nitrogen and 
stored over 4 Å MS under argon atmosphere. 
TMEDA was predried over CaH2 (12 h) and distilled from sodium benzophenone ketyl under argon 
atmosphere. 
Solvents for reaction workups and column chromatography were distilled prior to use. 
 
1.2 Reagents 
Commercially available starting materials were used without further purification. 
TMPH was distilled from CaH2 under argon prior to use. 
i-PrMgCl·LiCl was purchased as a solution in THF from Rockwood Lithium GmbH as a 14% solution in 
THF and was titrated with I2 prior to use. 
n-BuLi was purchased as a solution in hexane from Rockwood Lithium GmbH. 
ZnCl2 solution in THF (1.0 M) was prepared by drying ZnCl2 (40.9 g, 300 mmol) in a Schlenk-flask under 
high vacuum at 150 °C for 4 h. After cooling to 25 °C, anhydrous THF was added until a total volume of 
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300 mL was reached. The suspension was left stirring overnight at 25 °C and after 12 h the salts had 
completely dissolved. The stirring was stopped and the solution was left for some hours to become 
completely clear. The solution was stored over 4 Å MS under argon upon use.  
CuCN·2LiCl solution in THF (1.0 M) was prepared by drying LiCl (17.0 g, 400 mmol) and CuCN (17.9 g, 
200 mmol) in a Schlenk-flask under high vacuum at 150 °C for 4 h. After cooling to 25 °C, anhydrous 
THF was added until a total volume of 200 mL was reached. The suspension was left stirring overnight 
at 25 °C and after 12 h the salts had completely dissolved. The stirring was stopped and the solution 
was left for some more time to become completely clear. The solution was stored under argon upon 
use. 
CoCl2·2LiCl solution in THF (1.0 M) was prepared by drying LiCl (8.5 g, 200 mmol) in a Schlenk-flask 
under high vacuum at 130 °C for 3 h. After cooling to 25 °C, anhydrous CoCl2 (13.0 g, 100 mmol) was 
added and the salts were further heated to 130 °C for 5 h under high vacuum. After cooling to 25 °C 
anhydrous THF (100 mL) was added. The mixture was vigorously stirred until all solids were dissolved 
and the reagent was obtained as a dark blue solution.  
Preparation of TMPMgCl·LiCl (35)33 
A 250 mL Schlenk-flask was charged with i-PrMgCl·LiCl (120 mmol, 100 mL, 1.2 M in THF). Freshly 
distilled 2,2,6,6-tetramethylpiperidine (TMPH; 126 mmol, 23.9 mL) was added dropwise at 25 °C and 
the mixture was stirred for 48 h.  
Preparation of TMPZnCl·LiCl (36)34 
A 250 mL Schlenk-flask was charged with freshly distilled TMPH (60 mmol, 10 mL) dissolved in THF 
(60 mL). The solution was cooled to -40 °C and n-BuLi (60 mmol, 25 mL, 2.4 m in hexane) was added 
dropwise. The reaction was allowed to warm slowly to -10 °C within 1 h. ZnCl2 (66 mmol, 66 mL, 1 m 
in THF) was added dropwise and the resulting solution was stirred for 0.5 h at -10 °C and then 0.5 h at 
25 °C. The solvents were removed in vacuo to afford a light yellow solid and freshly distilled THF was 
added under vigorous stirring until the salts were completely dissolved.  
Preparation of TMP2Mg·2LiCl (42)38 
A 500 mL Schlenk-flask was charged with TMPH (7.1 g, 50 mmol) dissolved in THF (50 mL). The solution 
was cooled to -40 °C and n-BuLi (2.4 M in n-hexane, 50 mmol) was added at once. The resulting mixture 
was stirred for 15 min at -40 °C and at 0 °C for further 0.5 h. TMPMgCl·LiCl (35, 43.5 mL, 1.15 M in THF, 
50 mmol) is added and the mixture is stirred at 0 °C for 0.5 h and then at 25 °C for 1 h. The solvents 
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are removed in vacuo and the resulting pale-brown solid is dissolved in dry THF and stirred for 10 min 
at 25 °C.  
Preparation of TMP2Zn·2MgCl2·2LiCl (48)41 
A 500 mL Schlenk-flask was charged with TMPMgCl·LiCl (35, 348 mL, 400 mmol) and cooled to 0 °C. A 
solution of ZnCl2 (1.0 M in THF, 200 mL, 200 mmol) was added over a period of 15 min. The mixture 
was stirred for 2 h at 0 °C and was then concentrated in vacuo. 
The content of organometallic reagent was determined either by the method of Paquette184 using i-
PrOH and 1,10-phen as indicator (organolithium reagents) or the method of Knochel185 using I2 in THF 
(organomagnesium and -zinc reagents). 
TMP-Bases were titrated against benzoic acid using 4-(phenylazo)diphenylamine as indicator in THF. 
 
1.3 Chromatography 
Flash column chromatography was performed using silica gel 60 (40 – 63 μm 230-400 mesh ASTM) 
from Merck. 
Thin layer chromatography (TLC) was performed using aluminum plates covered with SiO2 (Merck 60, 
F-254) and visualized either by UV detection or by staining with KMnO4 solution (1.5 g KMnO4, 10 g 
K2CO3, 1.25 mL 10% NaOH solution in 200 mL H2O). 
 
1.4 Analytical Data 
NMR spectra were recorded on Varian VXR 400S, Bruker Avance III HD 400 MHz and Bruker AMX 600 
instruments. Chemical shifts () are reported in parts per million (ppm) relative to the residual solvent 
peak of CHCl3 (H= 7.26,C= 77.0). For the characterization of the observed signal multiplicities the 
following abbreviations were used: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), sept 
(septet), m (multiplet), br (broad). 
Mass spectra and high resolution mass spectra (HRMS) were recorded on a Finnigan MAT 95Q (EI) or 
a Thermo Finnigan LTQ FT instrument (ESI). Electron impact ionization (EI) was conducted with an 
electron energy of 70 eV. Electrospray ionization (ESI) was conducted with an IonMax ion-source 
equipped with an ESI head. It was performed with a voltage of 4 kV at the spray capillary tube, a heating 
filament temperature of 250 °C and a nitrogen flow of 25 units. 
                                                          
184 H. S. Lin, A. Paquette, Synth. Commun. 1994, 24, 2503. 
185 A. Krasovskiy, P. Knochel, Synthesis 2006, 5, 890. 
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Gas Chromatography (GC) was performed withmachines of the types Hewlett-Packard 6890 or 5890 
Series II (Hewlett Packard, 5% phenylmethylpolysiloxane; column length: 15 m, diameter: 0.25 mm; 
film thickness: 0.25 m). For the combination of gas chromatography with mass spectroscopic 
detection, a GC-MS from Hewlett Packard of type 6890/MSD 5973 was used. 
Infrared spectra (IR) were recorded from 4500 cm-1 to 650 cm-1 on a Perkin Elmer Spectrum BX-59343 
instrument. For detection a Smiths Detection Dura SamplIR II Diamond ATR sensor was used. The 
absorption bands (𝜈) are reported in wave numbers (cm-1). 
Melting points (m.p.) were measured using a Büchi B-540 apparatus and are uncorrected. 
Single Crystal X-Ray Diffraction Studies were performed with the CrysAlis CCD software and CrysAlis 
RED software was used for data reduction. Absorption correction using the SCALE3 ABSPACK multiscan 
methodc) was applied. The structures were solved with SHELXS-97, refined with SHELXL-97 and finally 
checked using PLATON. Details for data collection and structure refinement are summarized in the 
appendix section. Single crystals of the corresponding compounds, suitable for X-ray diffraction, were 
obtained by slow evaporation of a hexane/CH2Cl2 solution. The crystals were introduced into 
perfluorinated oil and a suitable single crystal was carefully mounted on the top of a thin glass wire. 
Data collection was performed with an Oxford Xcalibur 3 diffractometer equipped with a Spellman 
generator (50 kV, 40 mA) and a Kappa CCD detector, operating with Mo-Kα radiation (λ = 0.71071 Ǻ).   
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2 Regioselective Functionalization of the Oxazole Scaffold Using TMP-
Bases of Mg and Zn 
2.1 Typical Procedures 
Typical procedure for the metalation of oxazole derivatives using TMPZnCl·LiCl (36) (TP-1): 
A dry and argon-flushed Schlenk-tube was charged with a solution of the oxazole derivative (1.0 equiv.) 
in dry THF (1.0 M solution). TMPZnCl·LiCl (36, 1.2 equiv.) was added dropwise at the given temperature 
and the reaction mixture was stirred for the indicated time. The completion of metalation was checked 
by GC analysis of reaction aliquots quenched with a solution of I2 in dry THF. 
Typical procedure for the metalation of oxazole derivatives using TMPMgCl·LiCl (35) (TP-2): 
A dry and argon-flushed Schlenk-tube was charged with a solution of the oxazole derivative (1.0 equiv.) 
in dry THF (1.0 M solution). TMPMgCl·LiCl (35, 1.2 equiv.) was added dropwise at -40 °C and the 
reaction mixture was stirred for 0.5 h. The completion of metalation was checked by GC analysis of 
reaction aliquots quenched with a solution of I2 in dry THF. 
 
2.2 Metalation of Oxazole and Oxazole Derivatives and Subsequent Reaction with 
Electrophiles 
Ethyl 4-(oxazol-2-yl)benzoate (137a) 
 
Preparation from ethyl 4-iodobenzoate: 
Ethyl 4-(oxazol-2-yl)benzoate (137a) was prepared according to TP-1 from oxazole (136, 663 mg, 
9.6 mmol) and TMPZnCl·LiCl (36, 14.0 mL, 11.2 mmol, 0.8 M solution in THF) at 0 °C. The reaction 
mixture was stirred for 1 h, then Pd(dba)2 (138 mg, 0.24 mmol), P(o-furyl)3 (111 mg, 0.48 mmol) and 
ethyl 4-iodobenzoate (2.21 g, 8.0 mmol) were added. The reaction mixture was stirred at 50 °C for 4 h 
and was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 75 mL). The 
combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography on silica gel (CH2Cl2/diethyl ether 20:1) 
yielding 137a (1.59 g, 92%) as colorless crystals. 
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Preparation from ethyl 4-bromobenzoate: 
Pd(PPh3)4 (46 mg, 0.04 mmol) and ethyl 4-bromobenzoate (229 mg, 1.0 mmol) were added to the 
freshly prepared zinc reagent (1.2 mmol). The reaction mixture was heated to 50 °C for 6 h and is then 
quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined organic 
phases are dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography on silica gel (CH2Cl2/diethyl ether 20:1) yielding 137a 
(174 mg, 80%) as colorless crystals.  
m.p.: 69 – 72 °C 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.17 - 8.07 (m, 4 H), 7.75 (d, J = 0.8 Hz, 1 H), 7.28 (d, J = 0.8 Hz, 1 
H), 4.40 (q, J = 7.1 Hz, 2 H), 1.41 (t, J = 7.1 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 165.9, 161.1, 139.2, 131.9, 131.1, 130.0, 128.9, 126.2, 61.2, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 3127, 2979, 1708, 1556, 1412, 1362, 1277, 1261, 1178, 1141, 1126, 1106, 1095, 
1077, 1056, 1021, 1013, 920, 913, 875, 871, 859, 853, 844, 833, 776, 756, 716, 688, 666, 658, 654. 
MS (EI, 70 eV): m/z (%) = 217 (21), 189 (10), 173 (6), 172 (51), 144 (11), 89 (7), 70 (8), 61 (12), 45 (11), 
43 (100). 
HR-MS (EI, 70 eV): [C12H11NO3], calcd.: 217.0739; found: 217.0732. 
 
2-(4-Chlorophenyl)oxazole (137b) 
 
2-(4-Chlorophenyl)oxazole (137b) was prepared according to TP-1 from oxazole (136, 83 mg, 
1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) at 0 °C. The reaction 
mixture was stirred for 1 h, then Pd(dba)2 (17 mg, 0.03 mmol), P(o-furyl)3 (14 mg, 0.06 mmol) and 1-
chloro-4-iodobenzene (238 mg, 1.0 mmol) were added. The reaction mixture was stirred at 50 °C for 2 
h and was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The 
combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography on silica gel (i-hexane:CH2Cl2 2:1) yielding 
137b (180 mg, 83%) as colorless solid. 
m.p.: 81 – 83 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.01 – 7.96 (m, 2 H), 7.71 (d, J = 0.8 Hz, 1 H), 7.47 - 7.41 (m, 2 H), 
7.24 (d, J = 0.8 Hz, 1 H). 
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13C-NMR (75 MHz, CDCl3, ppm): δ = 126.0, 127.6, 128.6, 129.1, 136.4, 138.8, 161.1. 
FT-IR (ATR, cm-1): 𝜈 = 3154, 3129, 1915, 1605, 1515, 1479, 1450, 1406, 1261, 1136, 1105, 1088, 1068, 
1055, 1009, 918, 912, 833, 768, 749, 730, 694, 678, 663, 659. 
MS (EI, 70 eV): m/z (%) = 181 (29), 180 (14), 179 (100), 153 (27), 151 (66), 150 (14), 126 (12), 124 (51), 
123 (17), 97 (10), 89 (55), 83 (13), 73 (11), 71 (18), 69 (14), 57 (20), 55 (25), 50 (10), 44 (82), 43 (20), 42 
(16), 41 (15). 
HR-MS (EI, 70 eV): [C9H6ClNO], calcd.: 179.0138; found: 179.0131. 
 
2-(4-(Trifluoromethyl)phenyl)oxazole (137c) 
 
2-(4-(trifluoromethyl)phenyl)oxazole (137c) was prepared according to TP-1 from oxazole (136, 83 mg, 
1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) at 0 °C. The reaction 
mixture was stirred for 1 h, then Pd(dba)2 (17 mg, 0.03 mmol), P(o-furyl)3 (14 mg, 0.06 mmol) and 1-
iodo-4-(trifluoromethyl)benzene (272 mg, 1.0 mmol) were added. The reaction mixture was stirred at 
25 °C for 4 h and was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). 
The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by flash column chromatography on silica gel (i-hexane:CH2Cl2 2:1) 
yielding 137c (158 mg, 74%) as a light yellow solid. 
m.p.: 59 – 61 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.16 (d, J = 8.3 Hz, 2 H), 7.76 (s, 1 H), 7.72 (d, J = 8.3 Hz, 2 H), 7.28 
(s, 1 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 160.6, 139.3, 131.9 (q, J = 33 Hz), 130.6, 128.8, 126.6, 125.8 (q, 
J = 3.9 Hz) 123.8 (q, J = 272 Hz).  
FT-IR (ATR, cm-1): 𝜈 = 3176, 3144, 3058, 2638, 2102, 1941, 1711, 1620, 1588, 1561, 1523, 1504, 1495, 
1416, 1322, 1298, 1266, 1241, 1188, 1160, 1127, 1100, 1070, 1051, 1012, 921, 914, 895, 884, 846, 774, 
758, 747, 710, 697. 
MS (EI, 70 eV): m/z (%) = 213 (100), 185 (78), 184 (24), 171 (17), 158 (92), 157 (11), 145 (16), 137 (21), 
101 (25), 99 (12), 89 (27), 75 (94), 73 (21), 59 (22), 55 (13), 50 (9), 44 (15), 43 (16), 41 (23). 
HR-MS (EI, 70 eV): [C10H6F3NO], calcd.: 213.0401; found: 213.0388. 
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2-(4-Methoxyphenyl)oxazole (137d) 
 
2-(4-Methoxyphenyl)oxazole (137d) was prepared according to TP-1 from oxazole (136, 83 mg, 
1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) at 0 °C. The reaction 
mixture was stirred for 1 h, then Pd(dba)2 (17 mg, 0.03 mmol), P(o-furyl)3 (14 mg, 0.06 mmol) and 1-
iodo-4-methoxybenzene (234 mg, 1.0 mmol) were added. The reaction mixture was stirred at 25 °C for 
6 h and was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The 
combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography on silica gel (CH2Cl2/diethyl ether 20:1) 
yielding 137d (158 mg, 90%) as colorless oil. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.01 – 7.95 (m, 2 H), 7.65 (d, J = 0.8 Hz, 1 H), 7.19 (d, J = 0.8 Hz, 1 
H), 7.00 – 6.94 (m, 2 H), 3.85 (s, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 162.0, 161.3, 137.97, 128.2, 128.0, 120.4, 114.2, 55.3.  
FT-IR (ATR, cm-1): 𝜈 = 2940, 2837, 1721, 1663, 1609, 1586, 1561, 1523, 1493, 1463, 1441, 1423, 1365, 
1303, 1248, 1172, 1139, 1101, 1073, 1059, 1024, 952, 918, 835, 797, 766, 735, 705, 662. 
MS (EI, 70 eV): m/z (%) = 176 (12), 175 (100), 132 (45), 120 (48), 119 (24), 105 (10), 104 (19), 91 (49), 
90 (19), 89 (15), 77 (61), 76 (28), 75 (12), 65 (12), 64 (15), 63 (29), 62 (14), 50 (50). 
HR-MS (EI, 70 eV): [C10H9NO2], calcd.: 175.0633; found: 175.0618. 
 
4-(Oxazol-2-yl)benzonitrile (137e) 
 
4-(Oxazol-2-yl)benzonitrile (137e) was prepared according to TP-1 from oxazole (136, 83 mg, 
1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) at 0 °C. The reaction 
mixture was stirred for 1 h, then Pd(dba)2 (17 mg, 0.03 mmol), P(o-furyl)3 (14 mg, 0.06 mmol) and 4-
iodobenzenonitrile (229 mg, 1.0 mmol) were added. The reaction mixture was stirred at 25 °C for 4 h 
and was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The 
combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography on silica gel (CH2Cl2/i-hexane 5:1) yielding 
137e (148 mg, 87%) as a colorless solid. 
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m.p.: 82 – 84 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.18 - 8.12 (m, 2 H), 7.78 (d, J = 0.8 Hz, 1 H), 7.77 - 7.73 (m, 2 H), 
7.31 (d, J = 0.8 Hz, 1 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 160.1, 139.7, 132.6, 131.2, 129.1, 126.8, 118.3, 113.7. 
FT-IR (ATR, cm-1): 𝜈 = 3159, 3126, 2924, 2854, 2229, 1946, 1717, 1658, 1578, 1512, 1489, 1480, 1409, 
1315, 1263, 1182, 1144, 1110, 1102, 1080, 1070, 1057, 1026, 1018, 1003, 976, 921, 913, 898, 877, 866, 
860, 846, 772, 758, 741, 704. 
MS (EI, 70 eV): m/z (%) = 171 (9), 170 (100), 143 (5), 142 (54), 141 (7), 116 (4), 115 (44), 114 (14), 102 
(4), 88 (5), 75 (3). 
HR-MS (EI, 70 eV): [C10H6O1N2], calcd.: 170.0480; found: 170.0463. 
 
2-(3-Nitrophenyl)oxazole (137f) 
 
2-(3-Nitrophenyl)oxazole (137f) was prepared according to TP-1 from oxazole (136, 83 mg, 1.2 mmol) 
and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) at 0 °C. The reaction mixture is stirred 
for 1 h, then Pd(dba)2 (17 mg, 0.03 mmol), P(o-furyl)3 (14 mg, 0.06 mmol) and 1-iodo-3-nitrobenzene 
(249 mg, 1.0 mmol) were added. The reaction mixture was stirred at 50 °C for 1 h and was then 
quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined organic 
phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography on silica gel (CH2Cl2:i-hexane 20:1) yielding 137f (179 mg, 
94%) as a light yellow solid. 
m.p.: 95 – 97 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.90 – 8.87 (m, 1 H), 8.38 (ddd, J = 7.8, 1.6, 1.1 Hz, 1 H), 8.30 (ddd, 
J = 8.3, 2.3, 1.1 Hz, 1 H), 7.79 (d, J = 0.8 Hz, 1 H), 7.70 – 7.62 (m, 1 H), 7.31 (d, J = 0.8 Hz, 1 H).  
13C-NMR (75 MHz, CDCl3, ppm): δ = 159.7, 148.6, 139.6, 131.9, 130.0, 129.0, 129.0, 124.7, 121.3. 
FT-IR (ATR, cm-1): 𝜈 = 3159, 3137, 3088, 2868, 1745, 1595, 1525, 1479, 1446, 1347, 1286, 1266, 1256, 
1166, 1138, 1117, 1103, 1082, 1065, 1052, 998, 932, 913, 904, 882, 868, 814, 767, 760, 739, 710, 671, 
657. 
MS (EI, 70 eV): m/z (%) = 190 (64), 144(25), 116 (29), 115 (14), 102 (12), 90 (13), 89 (100), 88 (15), 87 
(11), 86 (10), 77 (10), 76 (14), 75 (10), 63 (34), 62 (17), 50 (10). 
HR-MS (EI, 70 eV): [C9H6N2O3], calcd.: 190.0378; found: 190.0370. 
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3-(Oxazol-2-yl)benzonitrile (137g) 
 
3-(Oxazol-2-yl)benzonitrile (137g) was prepared according to TP-1 from oxazole (136, 83 mg, 
1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) at 0 °C. The reaction 
mixture was stirred for 1 h, then Pd(dba)2 (17 mg, 0.03 mmol), P(o-furyl)3 (14 mg, 0.06 mmol) and 3-
iodobenzonitrile (229 mg, 1.0 mmol) were added. The reaction mixture was stirred at 50 °C for 4 h and 
was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined 
organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography on silica gel (CH2Cl2:i-hexane 5:1) yielding 137g 
(139 mg, 82%) as a colorless solid. 
m.p.: 87 – 89 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.33 - 8.31 (m, 1 H), 8.26 (dq, J = 7.9, 0.9 Hz, 1 H), 7.76 (d, J = 0.9 
Hz, 1 H), 7.71 (ddd, J = 7.8, 2.0, 0.8 Hz, 1 H), 7.61 - 7.55 (m, 1 H), 7.27 ppm (d, J = 0.9 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 159.7, 139.5, 133.4, 130.2, 129.8, 129.7, 128.9, 128.7, 118.0, 
113.3. 
FT-IR (ATR, cm-1): 𝜈 = 3159, 3132, 2230, 1553, 1512, 1476, 1463, 1458, 1438, 1406, 1369, 1356, 1279, 
1267, 1183, 1175, 1169, 1147, 1117, 1091, 1078, 1072, 1062, 1053, 998, 928, 913, 906, 863, 825, 807, 
785, 761, 724, 678. 
MS (EI, 70 eV): m/z (%) = 170 (100), 143 (9), 142 (77), 141 (10), 114 (14), 97 (10), 83 (11), 71 (12), 57 
(30), 55 (21), 44 (67), 43 (15), 41 (22).  
HR-MS (EI, 70 eV): [C10H6N2O], calcd.: 170.0480; found: 170.0482. 
 
2-(Oxazol-2-yl)benzaldehyde (137h) 
 
2-(Oxazol-2-yl)benzaldehyde (137h) was prepared according to TP-1 from oxazole (136, 83 mg, 
1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) at 0 °C. The reaction 
mixture was stirred for 1 h, then Pd(dba)2 (17 mg, 0.03 mmol), P(o-furyl)3 (14 mg, 0.06 mmol) and 2-
iodobenzaldehyde (232 mg, 1.0 mmol) were added. The reaction mixture was stirred at 50 °C for 2 h 
and was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The 
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combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography on silica gel (CH2Cl2) yielding 137h (137 
mg, 79%) as colorless oil. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 10.88 (d, J = 0.83 Hz, 1 H), 8.03 (ddd, J = 7.53, 3.52, 1.38 Hz, 2 H), 
7.82 (d, J = 0.83 Hz, 1 H), 7.73 - 7.63 (m, 1 H), 7.62 - 7.52 (m, 1 H), 7.33 (d, J = 0.83 Hz, 1 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 192.6, 159.7, 139.6, 134.7, 133.4, 130.4, 129.0, 128.9, 128.7, 
128.2. 
FT-IR (ATR, cm-1): 𝜈 = 3179, 3062, 2914, 1687, 1653, 1597, 1556, 1512, 1480, 1439, 1398, 1352, 1273, 
1250, 1190, 1130, 1114, 1096, 1077, 1051, 1034, 1005, 996, 919, 888, 850, 822, 773, 757, 733, 707. 
MS (EI, 70 eV): m/z (%) = 173 (1), 146 (6), 145 (63), 117 (25), 116 (7), 90 (34), 89 (21), 88 (5), 73 (6), 70 
(11), 63 (7), 61 (16), 45 (15), 43 (100), 42 (5). 
HR-MS (EI, 70 eV): [C10H7O2N1], calcd.: 173.0477; found: 173.0462. 
 
Oxazol-2-yl(phenyl)methanone (137i) 
 
Oxazol-2-yl(phenyl)methanone (137i) was prepared according to TP-1 from oxazole (136, 83 mg, 
1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) at 0 °C. The reaction 
mixture was stirred for 1 h, then Pd(PPh3)4 (46 mg, 0.04 mmol) and benzoyl chloride (141 mg, 
1.0 mmol) were added. The reaction mixture was stirred at 25 °C for 3 h and was then quenched with 
sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined organic phases were dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography on silica gel (CH2Cl2:i-hexane 10:1) yielding 137i (126 mg, 73%) as a colorless 
solid. 
m.p.: 54 – 56 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.53 – 8.43 (m, 2 H), 7.92 (d, J = 0.7 Hz, 1 H), 7.71 – 7.59 (m, 1 H), 
7.60 – 7.47 (m, 2 H), 7.43 (d, J = 0.7 Hz, 1 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 178.9, 157.8, 141.5, 135.0, 134.0, 130.8, 129.1, 128.5. 
FT-IR (ATR, cm-1): 𝜈 = 3147, 3128, 3057, 2922, 2850, 1791, 1698, 1661, 1628, 1597, 1579, 1574, 1538, 
1476, 1445, 1373, 1341, 1313, 1293, 1287, 1274, 1225, 1187, 1177, 1138, 1120, 1089, 1079, 1070, 
1035, 1025, 999, 972, 958, 940, 931, 915, 900, 869, 841, 811, 796, 737, 714, 690, 681. 
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MS (EI, 70 eV): m/z (%) = 173 (5), 146 (4), 145 (30), 117 (3), 106 (9), 105 (100), 89 (2), 78 (4), 75 (3), 74 
(4), 62 (2), 58 (1), 52 (2), 50 (10). 
HR-MS (EI, 70 eV): [C10H7NO2], calcd.: 173.0477; found: 173.0474. 
 
(3-Chlorophenyl)(oxazol-2-yl)methanone (137j) 
 
(3-Chlorophenyl)(oxazol-2-yl)methanone (137j) wa prepared according to TP-1 from oxazole (136, 83 
mg, 1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) at 0 °C. The reaction 
mixture was stirred for 1 h, then Pd(PPh3)4 (46 mg, 0.04 mmol) and 3-chlorobenzoyl chloride (175 mg, 
1.0 mmol) were added. The reaction mixture was stirred at 25 °C for 4 h and was then quenched with 
sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined organic phases were dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography on silica gel (CH2Cl2:i-hexane 1:1) yielding 137j (179 mg, 86%) as a colorless 
solid. 
m.p.: 121 – 123 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.53 – 8.50 (m, 1 H), 8.44 – 8.39 (m, 1 H), 7.93 (s, 1 H), 7.63 (ddd, 
J = 8.0, 2.1, 1.1 Hz, 1 H), 7.50 (t, J = 7.9 Hz, 1 H), 7.46 (s, 1 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 177.3, 157.4, 141.8, 136.4, 134.8, 133.9, 130.8, 129.8, 129.2, 129.0. 
FT-IR (ATR, cm-1): 𝜈 = 3153, 3134, 3094, 3069, 1651, 1590, 1565, 1541, 1480, 1474, 1417, 1374, 1299, 
1289, 1274, 1261, 1176, 1162, 1147, 1124, 1095, 1085, 964, 922, 906, 886, 803, 767, 758, 674, 659. 
MS (EI, 70 eV): m/z (%) = 208 (10), 179 (9), 139 (100), 127 (16), 111 (48), 109 (10), 97 (17), 96 (10), 85 
(12), 83 (16), 81 (19), 77 (11), 75 (24), 71 (15), 70 (10), 69 (29), 67 (11), 57 (41), 56 (14), 55 (27), 43 (27), 
41 (25). 
HR-MS (EI, 70 eV): [C10H6ClNO2], calcd.: 208.0160; found: 208.0156 [M+H]+. 
 
(4-Fluorophenyl)(oxazol-2-yl)methanone (137k) 
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(4-Fluorophenyl)(oxazol-2-yl)methanone (137k) was prepared according to TP-1 from oxazole (136, 
83 mg, 1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) at 0 °C. The reaction 
mixture is stirred for 1 h, then Pd(PPh3)4 (46 mg, 0.04 mmol) and 4-fluorobenzoyl chloride (191 mg, 
1.0 mmol) were added. The reaction mixture was stirred at 25 °C for 2 h and was then quenched with 
sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined organic phases were dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography on silica gel (CH2Cl2) yielding 137k (179 mg, 86%) as a colorless solid. 
m.p.: 118 – 121 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.63 – 8.55 (m, 2 H), 7.92 (d, J = 0.7 Hz, 1 H), 7.43 (d, J = 0.6 Hz, 1 
H), 7.25 – 7.15 (m, 2 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 177.1, 166.4 (d, J = 256.9 Hz), 157.9, 141.6, 133.8 (d, J = 9.5 Hz), 
131.3 (d, J = 3.0 Hz), 129.0, 115.7 (d, J = 21.9 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 3149, 3123, 3091, 3065, 1651, 1590, 1565, 1541, 1480, 1474, 1417, 1374, 1299, 
1289, 1274, 1261, 1176, 1162, 1147, 1124, 1095, 1085, 964, 922, 906, 886, 803, 767, 758, 674, 659. 
MS (EI, 70 eV): m/z (%) = 191 (3), 183 (4), 163 (12), 140 (8), 123 (100), 95 (34), 83 (7), 7 (12), 74 (8), 71 
(7), 69 (8), 59 (9), 57 (12), 55 (8), 45 (7), 44 (15), 43 (9), 41 (9). 
HR-MS (EI, 70 eV): [C10H6FNO2], calcd.: 191.0383; found: 191.0382. 
 
Ethyl 2-(oxazol-2-ylmethyl)acrylate (137l) 
 
Ethyl 2-(oxazol-2-ylmethyl)acrylate (137l) was prepared according to TP-1 from oxazole (136, 83 mg, 
1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) at 0 °C. The reaction 
mixture was stirred for 1 h and was submitted to an allylation reaction by adding CuCN·2LiCl (1.4 mmol, 
1.4 mL, 1 M solution in THF). The reaction mixture was stirred for 20 min and then ethyl 2-
(bromomethyl)acrylate (193 mg, 1.0 mmol) was added. The reaction was allowed to warm to 25 °C, 
stirred for 1 h and was then quenched with aq. NH4Cl/NH3 (10:1) solution and extracted with CH2Cl2 
(3 x 25 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography on silica gel 
(CH2Cl2/diethyl ether 10:1) yielding 137l (141 mg, 78%) as colorless oil. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.57 (d, J = 0.8 Hz, 1 H), 7.03 (d, J = 0.8 Hz, 1 H), 6.36 (dd, J = 1.6, 
0.8 Hz, 1 H), 5.67 (dt, J = 1.4, 0.9 Hz, 1 H), 4.20 (q, J = 7.1 Hz, 2 H), 3.81 (dd, J = 1.3, 0.8 Hz, 2 H), 1.26 (t, 
J = 7.1 Hz, 3 H). 
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13C-NMR (75 MHz, CDCl3, ppm): δ = 165.9, 161.9, 138.6, 135.1, 127.7, 127.2, 61.0, 31.0, 14.1. 
FT-IR (ATR, cm-1): 𝜈 = 2981, 2938, 1711, 1635, 1611, 1573, 1526, 1476, 1465, 1445, 1422, 1400, 1391, 
1368, 1330, 1299, 1247, 1190, 1142, 1113, 1097, 1071, 1023, 952, 913, 902, 859, 818, 753, 723, 705, 
687, 680, 660, 656. 
MS (EI, 70 eV): m/z (%) = 181 (23), 136 (49), 135 (67), 109 (22), 108 (41), 107 (100), 80 (10), 74 (37), 59 
(38), 53 (21), 45 (32), 43 (20), 41 (14). 
HR-MS (EI, 70 eV): [C9H11NO3], calcd.: 181.0739; found: 181.0736. 
 
Ethyl 4-(5-(4-chlorophenyl)oxazol-2-yl)benzoate (138a)  
 
Ethyl 4-(5-(4-chlorophenyl)oxazol-2-yl)benzoate (138a) was prepared according to TP-1 from ethyl 4-
(oxazol-2-yl)benzoate (137a, 261 mg, 1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M 
solution in THF) at 50 °C. The reaction was stirred for 0.5 h, then Pd(dba)2 (17 mg, 0.03 mmol), P(o-
furyl)3 (14 mg, 0.06 mmol) and 1-chloro-4-iodobenzene (238 mg, 1.0 mmol) were added and the 
reaction mixture was stirred at 50 °C for 2 h and was then quenched with sat. aq. NH4Cl solution and 
extracted with CH2Cl2 (3 x 25 mL). The combined organic phases were dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The crude product was purified by flash column chromatography 
on silica gel (CH2Cl2) yielding 138a (302 mg, 92%) as a colorless solid. 
m.p.: 110 – 114 °C.  
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.16 (s, 4 H), 7.70 – 7.65 (m, 2 H), 7.48 (s, 1 H), 7.47 – 7.40 (m, 2 
H), 4.42 (q, J = 7.1 Hz, 2 H), 1.43 (t, J = 7.1 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 165.9, 160.4, 151.0, 134.6, 131.9, 130.9, 130.1, 129.3, 126.2, 126.1, 
125.6, 124.2, 61.3, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 3106, 2979, 1707, 1680, 1478, 1413, 1404, 1367, 1305, 1296, 1273, 1244, 1185, 
1170, 1166, 1139, 1127, 1104, 1091, 1055, 1024, 1015, 952, 938, 879, 866, 853, 841, 823, 777, 760, 
716, 692, 682, 675. 
MS (EI, 70 eV): m/z (%) = 330 (6), 329 (33), 328 (16), 327 (100), 301 (6), 299 (17), 284 (13), 283 (7), 282 
(35), 254 (7), 219 (6), 209 (5), 199 (8), 191 (8), 111 (6), 89 (8). 
HR-MS (EI, 70 eV): [C18H14ClNO3], calcd.: 327.0662; found: 327.0660. 
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Ethyl 4-(5-(4-cyanophenyl)oxazol-2-yl)benzoate (138b) 
 
Ethyl 4-(5-(4-cyanophenyl)oxazol-2-yl)benzoate (138b) was prepared according to TP-1 from ethyl 4-
(oxazol-2-yl)benzoate (137a, 261 mg, 1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M 
solution in THF) at 50 °C. The reaction was stirred for 0.5 h, then Pd(dba)2 (17 mg, 0.03 mmol), P(o-
furyl)3 (14 mg, 0.06 mmol) and 4-iodobenzonitrile (229 mg, 1.0 mmol) were added. The reaction 
mixture was stirred at 50 °C for 3 h and was then quenched with sat. aq. NH4Cl solution and extracted 
with CH2Cl2 (3 x 25 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography on silica gel 
(CH2Cl2) yielding 138b (264 mg, 83%) as a colorless solid. 
m.p.: 178 – 181 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.17 (s, 4 H), 7.86 – 7.80 (m, 2 H), 7.78 – 7.71 (m, 2 H), 7.63 (s, 1 
H), 4.42 (q, J = 7.1 Hz, 2 H), 1.43 (t, J = 7.1 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 165.8, 161.4, 150.0, 132.9, 132.4, 131.6, 130.4, 130.1, 126.5, 126.3, 
124.5, 118.4, 111.9, 61.4, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 3110, 2971, 2905, 2227, 1711, 1642, 1610, 1408, 1358, 1307, 1291, 1266, 1248, 
1182, 1174, 1166, 1102, 1090, 1072, 1056, 1013, 954, 937, 924, 872, 865, 844, 833, 776, 741, 715, 675. 
MS (EI, 70 eV): m/z (%) = 319 (24), 318 (100), 290 (31), 274 (20), 273 (73), 245 (10), 190 (26), 102 (12), 
57 (11), 55 (10). 
HR-MS (EI, 70 eV): [C19H14N2O3], calcd.: 318.1004; found: 318.1001. 
 
Ethyl 4-(5-allyloxazol-2-yl)benzoate (138c) 
 
Ethyl 4-(5-allyloxazol-2-yl)benzoate (138c) was prepared according to TP-1 from ethyl 4-(oxazol-2-
yl)benzoate (137a, 261 mg, 1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) 
at 50 °C. The reaction was stirred for 0.5 h and the freshly prepared zinc reagent was then submitted 
to an allylation reaction by adding CuCN·2LiCl (1.4 mmol, 1.4 mL, 1 M solution in THF). The reaction 
mixture was stirred for 20 min and then allyl bromide (121 mg, 1.0 mmol) was added. The reaction 
mixture was allowed to warm to 25 °C, stirred for 1 h and was then quenched with aq. NH4Cl/NH3 
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(10:1) solution and extracted with CH2Cl2 (3 x 25 mL). The combined organic phases were dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica gel (CH2Cl2/diethyl ether 20:1) yielding 138c (203 mg, 79%) as a colorless 
solid. 
m.p.: 145 – 147 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.16 – 8.00 (m, 4 H), 6.93 (t, J = 1.1 Hz, 1 H), 5.96 (m, 1 H), 5.34 – 
5.17 (m, 2 H), 4.40 (q, J = 7.1 Hz, 2 H), 3.51 (ddd, J = 6.5, 2.7, 1.4 Hz, 2 H), 1.41 (t, J = 7.1 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 166.0, 160.1, 151.5, 132.2, 131.5, 131.3, 130.0, 125.8, 124.8, 118.1, 
61.2, 30.2, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 3118, 3079, 2979, 1941, 1714, 1643, 1614, 1592, 1462, 1435, 1409, 1367, 1306, 
1268, 1243, 1173, 1166, 1121, 1101, 1091, 1063, 1015, 1000, 988, 953, 933, 921, 916, 908, 859, 823, 
786, 776, 760, 752, 738, 715, 689. 
MS (EI, 70 eV): m/z (%) = 258 (18), 257 (100), 216 (23), 215 (10), 212 (33), 188 (47), 177 (21), 160 (21), 
82 (11), 54 (17). 
HR-MS (EI, 70 eV): [C15H15NO3], calcd.: 257.1052; found: 257.1041. 
 
4-(5-(Cyclohex-2-en-1-yl)oxazol-2-yl)benzonitrile (138d) 
 
4-(5-(Cyclohex-2-en-1-yl)oxazol-2-yl)benzonitrile (138d) was prepared according to TP-1 from 4-
(oxazol-2-yl)benzonitrile (137e, 1.2 mmol, 204 mg) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M 
solution in THF) at 50 °C. The reaction was stirred for 0.5 h, and the freshly prepared zinc reagent was 
then submitted to an allylation reaction by adding CuCN·2LiCl (1.4 mmol, 1.4 mL, 1 M solution in THF). 
The reaction mixture was stirred for 20 min and then 3-bromocyclohexene (161 mg, 1.0 mmol) was 
added. The reaction mixture was allowed to warm to 25 °C, stirred for 1 h and was then quenched with 
aq. NH4Cl/NH3 (10:1) solution and extracted with CH2Cl2 (3 x 25 mL). The combined organic phases 
were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified 
by flash column chromatography on silica gel (i-hexane:diethyl ether 2:1) yielding 138d (190 mg, 76%) 
as a colorless solid. 
m.p.: 132 – 134 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.13 - 8.07 (m, 2 H), 7.75 - 7.69 (m, 2 H), 6.91 (d, J = 1.1 Hz, 1 H), 
6.06 - 5.87 (m, 1 H), 5.83 - 5.67 (m, 1 H), 3.64 - 3.55 (m, 1 H), 2.17 - 1.98 (m, 3 H), 1.90 - 1.57 (m, 3 H). 
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13C-NMR (75 MHz, CDCl3, ppm): δ = 158.9, 157.1, 132.5, 131.5, 130.3, 126.4, 125.0, 124.4, 118.4, 113.1, 
33.1, 27.7, 24.8, 20.1.  
FT-IR (ATR, cm-1): 𝜈 = 2945, 2926, 2864, 2225, 1729, 1688, 1612, 1586, 1567, 1543, 1490, 1446, 1410, 
1361, 1351, 1292, 1282, 1251, 1244, 1202, 1183, 1146, 1120, 1109, 1098, 1083, 1064, 1043, 1018, 
1004, 979, 884, 877, 847, 834, 826, 780, 770, 740, 727, 701, 674, 656. 
MS (EI, 70 eV): m/z (%) = 251 (14), 250 (100), 249 (6), 222 (19), 169 (15), 142 (10), 141 (52), 130 (70), 
120 (23), 114 (28), 104 (11), 102 (18), 94 (23), 80 (12), 79 (16), 77 (10), 66 (24), 53 (13), 43 (17). 
HR-MS (EI, 70 eV): [C16H14O1N2], calcd.: 250.1106; found: 250.1104. 
 
(2-(4-Chlorophenyl)oxazol-5-yl)(phenyl)methanone (138e) 
 
(2-(4-Chlorophenyl)oxazol-5-yl)(phenyl)methanone (138e) was prepared according to TP-1 from 2-(4-
chlorophenyl)oxazole (137b, 216 mg, 1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M 
solution in THF) at 50 °C. The reaction is stirred for 0.5 h, then Pd(PPh3)4 (46 mg, 0.04 mmol) and 
benzoyl chloride (141 mg, 1.0 mmol) were added. The reaction mixture was stirred at 25 °C for 2 h and 
was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined 
organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography on silica gel (i-hexane:diethyl ether 3:1) yielding 
138e (216 mg, 76%) as a colorless solid. 
m.p.: 121 – 123 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.17 - 8.11 (m, 2 H), 8.02 - 7.96 (m, 2 H), 7.86 (s, 1 H), 7.70 - 7.62 
(m, 1 H), 7.60 - 7.54 (m, 2 H), 7.54 - 7.48 (m, 2 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 181.4, 163.8, 149.1, 138.3, 137.6, 136.8, 133.3, 129.4, 129.0, 128.8, 
128.8, 124.7. 
FT-IR (ATR, cm-1): 𝜈 = 3072, 3055, 2925, 1911, 1636, 1597, 1578, 1550, 1523, 1472, 1459, 1446, 1406, 
1350, 1315, 1306, 1291, 1278, 1260, 1242, 1172, 1153, 1134, 1114, 1090, 1075, 1012, 996, 976, 957, 
946, 936, 895, 868, 850, 830, 808, 792, 742, 720, 694, 676. 
MS (EI, 70 eV): m/z (%) = 285 (20), 284 (10), 283 (56), 219 (6), 178 (100), 150 (46), 123 (15), 105 (7), 88 
(4), 77 (19), 69 (8), 57 (3), 55 (3), 45 (4), 44 (19), 43 (39), 42 (2), 41 (3). 
HR-MS (EI, 70 eV): [C16H10O2N1Cl1], calcd.: 283.0400; found: 283.0397. 
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(2-(4-Chlorophenyl)oxazol-5-yl)(4-fluorophenyl)methanone (138f) 
 
(2-(4-Chlorophenyl)oxazol-5-yl)(4-fluorophenyl)methanone (138f) was prepared according to TP-1 
from 2-(4-chlorophenyl)oxazole (137b, 216 mg, 1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 
0.8 M solution in THF) at 50 °C. The reaction was stirred for 0.5 h, then Pd(PPh3)4 (46 mg, 0.04 mmol) 
and 4-fluorobenzoyl chloride (159 mg, 1.0 mmol) were added. The reaction mixture was stirred at 
25 °C for 4 h and was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). 
The combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by flash column chromatography on silica gel (CH2Cl2:i-hexane 3:1) 
yielding 138f (259 mg, 86%) as a colorless solid. 
m.p.: 152 – 154 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.18 – 8.09 (m, 2 H), 8.09 – 7.99 (m, 2H ), 7.87 (s, 1H), 7.57 – 7.42 
(m, 2 H), 7.30 – 7.18 (m, 2 H).  
13C-NMR (75 MHz, CDCl3, ppm): δ = 179.7, 165.9 (d, J = 255.7 Hz), 163.8, 149.0, 138.4, 137.4, 133.0 (d, 
J = 2.9 Hz), 131.6 (d, J = 9.4 Hz), 129.4, 128.7, 124.6, 116.1 (d, J = 22.0 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 3118, 2167, 1908, 1638, 1598, 1583, 1522, 1506, 1470, 1406, 1356, 1344, 1309, 
1296, 1235, 1177, 1164, 1156, 1095, 1012, 996, 945, 900, 842, 829, 812, 761, 738, 702, 694. 
MS (EI, 70 eV): m/z (%) = 303 (25), 302 (14), 301 (64), 181 (36), 180 (11), 178 (100), 152 (28), 150 (76), 
123 (30), 43 (12). 
HR-MS (EI, 70 eV): [C16H9ClFNO2], calcd.: 301.0306; found: 301.0300. 
 
Ethyl 4-(5-benzoyloxazol-2-yl)benzoate (138g) 
 
Ethyl 4-(5-benzoyloxazol-2-yl)benzoate (138g) was prepared according to TP-1 from ethyl 4-(oxazol-2-
yl)benzoate (137a, 261 mg, 1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M solution in THF) 
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at 50 °C. The reaction was stirred for 0.5 h, then Pd(PPh3)4 (46 mg, 0.04 mmol) and benzoyl chloride 
(141 mg, 1.0 mmol) were added. The reaction mixture was stirred at 25 °C for 4 h and was then 
quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined organic 
phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography on silica gel (i-hexane:diethyl ether 3:2) yielding 138g 
(315 mg, 98%) as a colorless solid. 
m.p.: 118 – 120 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.30 - 8.23 (m, 2 H), 8.23 - 8.15 (m, 2 H), 8.05 - 7.97 (m, 2 H), 7.90 
(s, 1 H), 7.71 - 7.63 (m, 1 H), 7.62 - 7.52 (m, 2 H), 4.42 (q, J = 7.1 Hz, 2 H), 1.43 (t, J = 7.1 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 181.4, 165.7, 163.7, 149.4, 137.5, 136.7, 133.4, 133.3, 130.1, 129.8, 
129.0, 128.8, 127.4, 61.4, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 3131, 3066, 2980, 1708, 1643, 1598, 1577, 1526, 1480, 1448, 1413, 1356, 1303, 
1269, 1248, 1224, 1179, 1174, 1160, 1104, 1075, 1016, 996, 972, 956, 947, 886, 861, 794, 781, 734, 
718, 694, 678. 
MS (EI, 70 eV): m/z (%) = 322 (9), 321 (50), 276 (9). 217 (11), 216 (100), 189 (7), 188 (61), 161 (3), 160 
(29), 143 (10), 133 (10), 115 (17), 105 (15), 88 (8), 77 (27). 
HR-MS (EI, 70 eV): [C19H15O4N1], calcd.: 321.1001; found: 321.1003. 
 
Ethyl 4-(5-(3,4-difluorobenzoyl)oxazol-2-yl)benzoate (138h) 
 
Ethyl 4-(5-(3,4-difluorobenzoyl)oxazol-2-yl)benzoate (138h) was prepared according to TP-1 from ethyl 
4-(oxazol-2-yl)benzoate (137a, 261 mg, 1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M 
solution in THF) at 50 °C. The reaction was stirred for 0.5 h, then Pd(PPh3)4 (46 mg, 0.04 mmol) and 3,4-
difluorobenzoyl chloride (177 mg, 1.0 mmol) were added. The reaction mixture was stirred at 25 °C for 
1 h and was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The 
combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography on silica gel (CH2Cl2:i-hexane 5:1) yielding 
138h (311 mg, 87%) as a light yellow solid. 
m.p.: 145 – 148 °C. 
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1H-NMR (300 MHz, CDCl3, ppm): δ = 8.30 – 8.16 (m, 4 H), 7.95 (s, 1 H), 7.94 – 7.83 (m, 2 H), 7.43 – 7.31 
(m, 1 H), 4.43 (q, J = 7.2 Hz, 2 H), 1.43 (q, J = 7.2 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 178.5, 165.6, 163.9, 155.6 (d, J = 12.8 Hz), 152.2 (dd, J = 12.9, 2.6 
Hz), 148.8 (d, J = 12.5 Hz), 137.7, 133.5, 133.4 (d, J = 4.9 Hz), 130.2, 129.6, 127.4, 126.1 (dd, J = 7.5, 3.7 
Hz), 118.6 (dd, J = 18.6, 1.8 Hz), 117.9 (d, J = 18.0 Hz), 61.5, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 3123, 2986, 1719, 1704, 1652, 1646, 1530, 1514, 1481, 1415, 1314, 1285, 1277, 
1240, 1164, 1128, 1112, 1106, 1017, 957, 859, 841, 825, 779, 753, 724. 
MS (EI, 70 eV): m/z (%) = 359 (2), 358 (12), 357 (58), 312 (14), 216 (100), 189 (8), 188 (63), 160 (23), 
133 (10),, 115 (12).  
HR-MS (EI, 70 eV): [C19H13F2NO4], calcd.: 357.0813; found: 357.0806. 
 
2-(4-Chlorophenyl)-5-(phenylethynyl)oxazole (138i) 
 
2-(4-chlorophenyl)-5-(phenylethynyl)oxazole (138i) was prepared according to TP-1 from 2-(4-
chlorophenyl)oxazole (137b, 216 mg, 1.2 mmol) and TMPZnCl·LiCl (36, 1.75 mL, 1.4 mmol, 0.8 M 
solution in THF) at 50 °C. The reaction was stirred for 0.5 h, then iodine (355 mg, 1.4 mmol) dissolved 
in dry THF (1 mL) was added dropwise at 0 °C and the resulting mixture was stirred for 1 h at 25 °C. To 
the solution of in situ generated 2-(4-chlorophenyl)-5-iodooxazole, CuI (8 mg, 0.04 mmol), Pd(dba)2 
(17 mg, 0.03 mmol), P(o-furyl) (14 mg, 0.06 mmol), TEA (2 mL) and phenylacetylene (103 mg, 
1.0 mmol) were successively added. The reaction mixture was stirred at 25 °C for 1 h and was then 
quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined organic 
phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography on silica gel (i-hexane:diethyl ether 10:1) yielding 138i 
(224 mg, 80%) as a colorless solid. 
m.p.: 103 – 105 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.05 – 7.99 (m, 2 H), 7.59 – 7.53 (m, 2 H), 7.48 – 7.43 (m, 2 H), 
7.41 (s, 1 H), 7.41 – 7.38 (m, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 160.9, 137.0, 135.0, 132.6, 131.5, 129.3, 129.2, 128.5, 127.9, 125.4, 
121.5, 98.0, 75.9. 
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FT-IR (ATR, cm-1): 𝜈 = 2920, 2213, 1692, 1678, 1603, 1596, 1582, 1564, 1534, 1486, 1475, 1451, 1444, 
1403, 1380, 1306, 1280, 1246, 1179, 1162, 1136, 1111, 1092, 1070, 1026, 1012, 998, 977, 916, 886, 
850, 836, 815, 812, 755, 734, 687. 
MS (EI, 70 eV): m/z (%) = 282 (6), 281 (30), 280 (17), 279 (99), 226 (5), 225 (29) , 224 (15), 223 (100), 
222 (6), 190 (7), 189 (46), 140 (6), 139 (5), 129 (5), 126 (6), 114 (7), 113 (7), 111 (8), 88 (9). 
HR-MS (EI, 70 eV): [C17H10O1N1Cl1], calcd.: 279.0451; found: 279.0445. 
 
Ethyl 2-(4-(ethoxycarbonyl)phenyl)oxazole-5-carboxylate (138j) 
 
Ethyl 2-(4-(ethoxycarbonyl)phenyl)oxazole-5-carboxylate (138j) was prepared according to TP-2 from 
ethyl 4-(oxazol-2-yl)benzoate (137a, 261 mg, 1.2 mmol) and TMPMgCl·LiCl (35, 1.26 mL, 1.4 mmol, 
1.11 M solution in THF). Ethyl cyanoformate (99 mg, 1.0 mmol) was added at -40 °C to the freshly 
prepared magnesium reagent. The reaction mixture was allowed to warm to 25 °C, stirred for 1 h and 
was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined 
organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography on silica gel (CH2Cl2/diethyl ether 90:1) to yield 
138j (269 mg, 93%) as colorless crystals. 
m.p.: 85 – 87 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.25 – 8.13 (m, 4 H), 7.87 (s, 1 H), 4.43 (q, J = 7.1 Hz, 2 H), 4.42 (q, 
J = 7.1 Hz, 2 H), 1.43 (t, J = 7.1 Hz, 3 H), 1.42 (t, J = 7.1 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 165.7, 163.1, 157.7, 142.9, 135.4, 133.0, 130.1, 130.0, 127.1, 61.6, 
61.4, 14.3, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 3130, 2978, 2921, 2167, 1725, 1703, 1535, 1414, 1369, 1301, 1293, 1270, 1254, 
1184, 1155, 1147, 1109, 1097, 1072, 1026, 1017, 981, 941, 897, 872, 863, 851, 826, 808, 781, 765, 721, 
692, 681, 672, 666. 
MS (EI, 70 eV): m/z (%) = 290 (18), 289 (100), 261 (18), 244 (52), 233 (14), 217 (19), 216 (92), 189 (13), 
188 (87), 160 (29), 133 (13), 115 (14), 88 (9). 
HR-MS (EI, 70 eV): [C15H15NO5], calcd.: 289.0950; found: 289.0944. 
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Ethyl 4-(5-(methylthio)oxazol-2-yl)benzoate (138k) 
 
Ethyl 4-(5-(methylthio)oxazol-2-yl)benzoate (138k) was prepared according to TP-2 from ethyl 4-
(oxazol-2-yl)benzoate (137a, 261 mg, 1.2 mmol) and TMPMgCl·LiCl (35, 1.26 mL, 1.4 mmol, 1.11 M 
solution in THF). Then S-methyl methanethiolsulfonate (126 mg, 1.0 mmol) was added at -40 °C to the 
freshly prepared magnesium reagent. The reaction mixture was allowed to warm to 25 °C, stirred for 
1 h and was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The 
combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography on silica gel (i-hexane:ethyl acetate 3:2) 
to yield 138k (190 mg, 72%) as a light yellow solid. 
m.p.: 69 – 71 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.23 – 7.87 (m, 4 H), 7.22 (s, 1 H), 4.41 (q, J = 7.1 Hz, 2 H), 2.50 (s, 
3 H), 1.42 (t, J = 7.1 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 165.9, 162.8, 146.9, 132.0, 131.8, 130.8, 130.0, 126.1, 61.3, 18.8, 
14.3. 
FT-IR (ATR, cm-1): 𝜈 = 2993, 2976, 2928, 1710, 1680, 1612, 1581, 1547, 1455, 1409, 1367, 1306, 1291, 
1269, 1247, 1241, 1174, 1167, 1138, 1103, 1092, 1063, 1013, 1004, 978, 962, 933, 870, 861, 841, 789, 
777, 721, 691. 
MS (EI, 70 eV): m/z (%) = 264 (9), 263 (52), 218 (18), 216 (23), 194 (12), 193 (100), 189 (9), 188 (59), 
165 (8), 163 (8), 160 (26), 152 (11), 133 (10), 115 (13), 88 (8). 
HR-MS (EI, 70 eV): [C13H13NO3S], calcd.: 263.0616; found: 263.0613. 
 
Ethyl 4-(5-cyanooxazol-2-yl)benzoate (138l) 
 
Ethyl 4-(5-cyanooxazol-2-yl)benzoate (138l) was prepared according to TP-2 from ethyl 4-(oxazol-2-
yl)benzoate (137a, 261 mg, 1.2 mmol) and TMPMgCl·LiCl (35, 1.26 mL, 1.4 mmol, 1.11 M solution in 
THF). Then p-toluenesulfonyl cyanide (181 mg, 1.0 mmol) was added at -40 °C to the freshly prepared 
magnesium reagent. The reaction mixture was allowed to warm to 25 °C, stirred for 1 h and was then 
quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined organic 
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phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo.  The crude product was 
purified by flash column chromatography on silica gel (i-hexane:diethyl ether 5:1) to yield 138l 
(216 mg, 89%) as colorless crystals. 
m.p.: 94 – 96 °C. 
1H-NMR (300 MHz, CDCl3, ppm): 8.25 – 8.12 (m, 4 H), 7.85 (s, 1 H), 4.43 (q, J = 7.1 Hz, 2 H), 1.43 (t, J = 
7.1 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 165.5, 163.8, 139.1, 133.7, 130.2, 129.0, 127.3, 124.8, 109.2, 61.5, 
14.3. 
FT-IR (ATR, cm-1): 𝜈 = 3135, 2987, 2940, 2234, 1720, 1711, 1585, 1488, 1409, 1293, 1274, 1247, 1173, 
1135, 1126, 1106, 1088, 1017, 984, 969, 894, 864, 856, 778, 721, 688. 
MS (EI, 70 eV): m/z (%) = 243 (4), 242 (32), 215 (6), 214 (43), 198 (17), 197 (100), 170 (7), 169 (21), 149 
(13), 141 (11), 114 (16), 71 (14), 69 (11), 57 (23), 55 (11), 45 (11), 43 (16). 
HR-MS (EI, 70 eV): [C13H10N2O3], calcd.: 242.0691; found: 242.0680. 
 
Ethyl 4-(5-(trimethylsilyl)oxazol-2-yl)benzoate (138m) 
 
Ethyl 4-(5-(trimethylsilyl)oxazol-2-yl)benzoate (138m) is prepared according to TP-2 from ethyl 4-
(oxazol-2-yl)benzoate (137a, 261 mg, 1.2 mmol) and TMPMgCl·LiCl (35, 1.26 mL, 1.4 mmol, 1.11 M 
solution in THF). Then chlorotrimethylsilane (109 mg, 1.0 mmol) is added at -40 °C to the freshly 
prepared magnesium reagent. The reaction mixture is allowed to warm to 25 °C, stirred for 1 h and 
was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined 
organic phases are dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude 
product is purified by flash column chromatography on silica gel (CH2Cl2/diethyl ether 99:1) to yield 
138m (249 mg, 86%) as a colorless solid. 
m.p.: 69 – 71 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.14 (s, 4 H), 7.36 (s, 1 H), 4.41 (q, J = 7.2 Hz, 2 H), 1.43 (t, 
J = 7.2 Hz, 3 H), 0.36 (s, 9 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 166.0, 164.4, 156.4, 137.5, 131.7, 131.4, 130.0, 126.4, 61.2, 14.3, 
-1.8. 
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FT-IR (ATR, cm-1): 𝜈 = 2959, 2902, 1706, 1668, 1612, 1581, 1550, 1475, 1411, 1365, 1307, 1290, 1271, 
1247, 1229, 1175, 1137, 1121, 1105, 1090, 1062, 1016, 959, 937, 867, 837, 777, 763, 756, 721, 690, 
662. 
MS (EI, 70 eV): m/z (%) = 290 (17), 289 (90), 275 (7), 274 (39), 248 (28), 244 (14), 177 (9), 130 (13), 100 
(8), 99 (100), 73 (68), 45 (8), 43 (7). 
HR-MS (EI, 70 eV): [C15H19NO3Si], calcd.: 289.1134; found: 289.1130. 
 
2-(4-Chlorophenyl)-5-(trimethylsilyl)oxazole (138n) 
 
2-(4-Chlorophenyl)-5-(trimethylsilyl)oxazole (138n) was prepared according to TP-2 from 2-(4-
chlorophenyl)oxazole (137b, 216 mg, 1.2 mmol) and TMPMgCl·LiCl (35, 1.26 mL, 1.4 mmol, 1.11 M 
solution in THF). Then chlorotrimethylsilane (109 mg, 1.0 mmol) was added at -40 °C to the freshly 
prepared magnesium reagent. The reaction mixture was allowed to warm to 25 °C, stirred for 1 h and 
was then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 25 mL). The combined 
organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo.  The crude 
product was purified by flash column chromatography on silica gel (CH2Cl2) to yield 138n (206 mg, 82%) 
as a colorless solid. 
m.p.: 47 – 49 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.00 – 7.96 (m, 2 H), 7.45 – 7.38 (m, 2 H), 7.28 (s, 1 H), 0.32 (s, 9 
H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 164.4, 155.7, 137.3, 136.2, 129.0, 127.8, 126.3, -1.8. 
FT-IR (ATR, cm-1): 𝜈 = 3124, 3069, 2953, 2881, 1915, 1658, 1604, 1595, 1582, 1552, 1471, 1453, 1404, 
1314, 1272, 1250, 1226, 1135, 1109, 1090, 1063, 1012, 960, 951, 939, 832, 756, 736, 696, 667, 662, 
656. 
MS (EI, 70 eV): m/z (%) = 253 (20), 251 (68), 238 (15), 236 (42), 210 (21), 149 (19), 139 (12), 99 (100), 
97 (13), 83 (14), 81 (12), 73 (80), 71 (17), 70 (10), 69 (18), 67 (10), 59 (10), 57 (29), 55 (25), 45 (11), 44 
(46), 43 (22), 41 (28). 
HR-MS (EI, 70 eV): [C12H14ClNOSi], calcd.: 251.0533; found: 251.0530. 
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Ethyl 4-(5-(4-chlorophenyl)-4-(4-(trifluoromethyl)phenyl)oxazol-2-yl)benzoate (139a) 
 
Ethyl 4-(5-(4-chlorophenyl)-4-(4-(trifluoromethyl)phenyl)oxazol-2-yl)benzoate (139a) was prepared 
according to TP-1 from ethyl 4-(5-(4-chlorophenyl)oxazol-2-yl)benzoate (138a, 197 mg, 0.6 mmol) and 
TMPZnCl·LiCl (36, 0.88 mL, 0.7 mmol, 0.8 M solution in THF) at 50 °C. The reaction was stirred for 5 h, 
then Pd(dba)2 (9 mg, 0.02 mmol), P(o-furyl)3 (7 mg, 0.03 mmol) and 1-iodo-4-(trifluoromethyl)-
benzene (136 mg, 0.5 mmol) were added. The reaction mixture was stirred at 50 °C for 8 h and was 
then quenched with sat. aq. NH4Cl solution and extracted with CH2Cl2 (3 x 15 mL). The combined 
organic phases were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography on silica gel (CH2Cl2:i-hexane 1:2) yielding 139a 
(193 mg, 82%) as a colorless solid. 
m.p.: 129 – 132 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.27 – 8.10 (m, 4 H), 7.91 – 7.75 (m, 2 H), 7.72 – 7.52 (m, 4 H), 
7.47 – 7.35 (m, 2 H), 4.42 (q, J = 7.1 Hz, 2 H), 1.43 (t, J = 7.1 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 165.9, 159.7, 146.2, 136.1, 135.6, 135.4, 131.4 (d, J = 126.6 Hz), 
130.4 (d, J = 32.6 Hz), 130.1, 129.3, 128.2 (d, J = 4.3 Hz), 126.6, 126.3, 125.7 (q, J = 3.8 Hz), 124.1 (q, J 
= 286.1 Hz), 122.2, 118.6, 61.3, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 2983, 2919, 2851, 1704, 1614, 1590, 1484, 1408, 1369, 1323, 1309, 1276, 1241, 
1169, 1115, 1104, 1093, 1066, 1016, 1011, 966, 882, 863, 852, 842, 832, 787, 776, 765, 746, 735, 725, 
715, 699, 693, 677, 667, 662. 
MS (EI, 70 eV): m/z (%) =  474 (11), 473 (38), 472 (34), 471 (100), 443 (5), 426 (10), 370 (9), 272 (7), 233 
(26), 232 (5), 201 (7), 209 (7), 199 (18), 165 (6), 164 (5), 163 (5), 138 (5).  
HR-MS (EI, 70 eV): [C25H17ClF3NO3], calcd.: 471.0849; found: 471.0844. 
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Ethyl 4-(5-(4-chlorophenyl)-4-(4-cyanophenyl)oxazol-2-yl)benzoate (139b) 
 
Ethyl 4-(5-(4-chlorophenyl)-4-(4-cyanophenyl)oxazol-2-yl)benzoate (139b) was prepared according to 
TP-1 from ethyl 4-(5-(4-chlorophenyl)oxazol-2-yl)benzoate (138a, 197 mg, 0.6 mmol) and TMPZnCl·LiCl 
(36, 0.88 mL, 0.7 mmol, 0.8 M solution in THF) at 50 °C. The reaction was stirred for 5 h, thenPd(dba)2 
(9 mg, 0.02 mmol), P(o-furyl)3 (7 mg, 0.03 mmol) and 4-iodobenzonitrile (115 mg, 0.5 mmol) were 
added. The reaction mixture was stirred at 50 °C for 6 h and was then quenched with sat. aq. NH4Cl 
solution and extracted with CH2Cl2 (3 x 15 mL). The combined organic phases were dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica gel (CH2Cl2:i-hexane 2:1) yielding 139b (157 mg, 73%) as a colorless solid. 
m.p.: 132 – 134 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.22 – 8.15 (m, 4 H), 7.88 – 7.82 (m, 2 H), 7.73 – 7.67 (m, 2 H), 
7.63 – 7.56 (m, 2 H), 7.47 – 7.41 (m, 2 H), 4.43 (q, J = 7.1 Hz, 2 H), 1.44 (t, J = 7.1 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 165.8, 159.9, 146.7, 136.5, 135.7, 135.6, 132.5, 132.3, 130.4, 130.1, 
129.4, 128.4, 128.3, 126.5, 126.3, 118.6, 112.0, 61.4, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 3101, 2961, 2913, 2215, 1707, 1637, 1601, 1396, 1299, 1259, 1237, 1162, 1124, 
1133, 1091, 1071, 1045, 1007, 957, 933, 918, 881, 843, 832, 767, 714, 673. 
MS (EI, 70 eV): m/z (%) = 431 (11), 430 (38), 429 (30), 428 (100), 383 (11), 327 (12), 272 (9), 209 (8), 
199 (16), 191 (7), 190 (41), 111 (6). 
HR-MS (EI, 70 eV): [C25H17ClN2O3], calcd.: 428.0928; found: 428.0913. 
 
Ethyl 4-(5-benzoyl-4-(4-methoxyphenyl)oxazol-2-yl)benzoate (139c) 
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Ethyl 4-(5-benzoyl-4-(4-methoxyphenyl)oxazol-2-yl)benzoate (139c) was prepared according to TP-1 
from ethyl 4-(5-benzoyloxazol-2-yl)benzoate (138g, 193 mg, 0.6 mmol) and TMPZnCl·LiCl (36, 0.88 mL, 
0.7 mmol, 0.8 M solution in THF) at 50 °C. The reaction was stirred for 3 h, then Pd(dba)2 (9 mg, 
0.02 mmol), P(o-furyl)3 (7 mg, 0.03 mmol) and 4-iodoanisole (117 mg, 0.5 mmol) were added. The 
reaction mixture was stirred at 50 °C for 6 h and was then quenched with sat. aq. NH4Cl solution and 
extracted with CH2Cl2 (3 x 15 mL). The combined organic phases were dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The crude product was purified by flash column chromatography 
on silica gel (i-hexane:diethyl ether 4:1) yielding 139c (162 mg, 76%) as a colorless solid. 
m.p.: 135 – 137 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.25 - 8.20 (m, 2 H), 8.19 - 8.13 (m, 4 H), 8.01 - 7.92 (m, 2 H), 7.64 
- 7.56 (m, 1 H), 7.49 (t, J = 7.60 Hz, 2 H), 7.00 - 6.92 (m, 2 H), 4.42 (q, J = 7.19 Hz, 2 H) 3.86 (s, 3 H) 1.42 
(t, J = 7.19 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 183.1, 165.7, 161.1, 160.6, 148.9, 143.2, 137.7, 133.0, 132.8, 131.0, 
130.1, 130.0, 129.5, 128.4, 127.2, 122.8, 113.7, 61.4, 55.3, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 3052, 3006, 2969, 2927, 2842, 1713, 1643, 1581, 1535, 1501, 1487, 1467, 1444, 
1412, 1363, 1317, 1303, 1289, 1266, 1255, 1231, 1182, 1174, 1160, 1114, 1102, 1027, 1015, 1003, 958, 
895, 858, 835, 809, 798, 794, 780, 749, 725, 717, 700, 692, 682, 666. 
MS (EI, 70 eV): m/z (%) = 429 (6), 428 (22), 427 (100), 426 (7), 382 (4), 148 (6), 147 (58), 119 (28), 105 
(15), 77 (10). 
HR-MS (EI, 70 eV): [C26H21O5N1], calcd.: 427.1420; found: 427.1415. 
 
(2-(4-Chlorophenyl)oxazole-4,5-diyl)bis(phenylmethanone) (139d) 
 
(2-(4-Chlorophenyl)oxazole-4,5-diyl)bis(phenylmethanone) (139d) was prepared according to TP-1 
from (2-(4-chlorophenyl)oxazol-5-yl)(phenyl)methanone (138e, 170 mg, 0.6 mmol) and TMPZnCl·LiCl 
(36, 0.88 mL, 0.7 mmol, 0.8 M solution in THF) at 50 °C. The reaction was stirred for 3 h and was then 
allowed to cool to 25 °C. Pd(PPh3)4 (28 mg, 0.02 mmol) and benzoyl chloride (141 mg, 0.5 mmol) were 
added, the reaction mixture was stirred at 25 °C for 3 h and was then quenched with sat. aq. NH4Cl 
solution and extracted with CH2Cl2 (3 x 15 mL). The combined organic phases were dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash column 
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chromatography on silica gel (i-hexane:diethyl ether 4:1) yielding 139d (151 mg, 78%) as a colorless 
solid. 
m.p.: 137 – 139 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.17 - 8.12 (m, 2 H), 7.98 - 7.93 (m, 2 H), 7.91 - 7.87 (m, 2 H), 7.61 
- 7.54 (m, 2 H), 7.54 - 7.48 (m, 2 H), 7.46 - 7.40 (m, 4 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 187.9, 182.0, 161.7, 148.0, 144.6, 138.6, 136.2, 136.1, 133.9, 
133.8, 129.9, 129.5, 129.3, 128.8, 128.7, 128.6, 124.2.  
FT-IR (ATR, cm-1): 𝜈 = 3088, 3063, 2958, 1912, 1719, 1681, 1668, 1633, 1595, 1579, 1548, 1536, 1474, 
1448, 1405, 1355, 1303, 1279, 1267, 1243, 1216, 1187, 1172, 1154, 1111, 1088, 1071, 1028, 1010, 
1000, 954, 944, 894, 882, 849, 828, 797, 751, 742, 734, 709, 694, 684, 675, 664. 
MS (EI, 70 eV): m/z (%) = 387 (5), 285 (2), 284 (12), 283 (5), 282 (40), 178 (6), 106 (6), 105 (100), 78 (5), 
77 (46), 51 (6), 45 (3), 44 (7). 
HR-MS (EI, 70 eV): [C23H14O3N1Cl1], calcd.: 387.0662; found: 387.0659. 
 
(2-(4-Chlorophenyl)-4-(cyclohex-2-en-1-yl)oxazol-5-yl)(4-fluorophenyl)methanone (139e) 
 
(2-(4-Chlorophenyl)-4-(cyclohex-2-en-1-yl)oxazol-5-yl)(4-fluorophenyl)methanone (139e) was 
prepared according to TP-1 from (2-(4-chlorophenyl)oxazol-5-yl)(4-fluorophenyl)methanone (138f, 
0.6 mmol, 181 mg) and TMPZnCl·LiCl (36, 0.88 mL, 0.7 mmol, 0.8 M solution in THF) at 50 °C. The 
reaction was stirred for 3 h and was then allowed to cool to 25 °C. The freshly prepared zinc reagent 
was submitted to an allylation reaction by adding CuCN·2LiCl (0.7 mmol, 0.7 mL, 1 M solution in THF). 
The reaction mixture was stirred for 20 min at 25 °C and then 3-bromocyclohexene (81 mg, 0.5 mmol) 
was added. The reaction mixture was stirred for 2 h and was then quenched with aq. NH4Cl/NH3 (10:1) 
solution and extracted with CH2Cl2 (3 x 15 mL). The combined organic phases were dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica gel (i-hexane:diethyl ether 10:1) yielding 139e (141 mg, 74%) as a colorless 
solid. 
m.p.: 128 – 130 °C. 
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1H-NMR (300 MHz, CDCl3, ppm): δ = 8.17 - 8.07 (m, 2 H), 8.07 - 8.01 (m, 2 H), 7.50 - 7.42 (m, 2 H), 7.28 
- 7.17 (m, 2 H), 6.00 - 5.86 (m, 1 H), 5.80 - 5.59 (m, 1 H), 4.36 - 4.07 (m, 1 H) 2.36 - 1.62 (m, 6 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 181.0, 165.6 (d, J = 255.0 Hz), 161.0, 156.7, 144.0, 137.9, 133.7 (d, 
J = 2.9 Hz), 132.0 (d, J = 9.3 Hz), 129.3, 128.9, 128.7, 127.3, 125.0, 115.7 (d, J = 22.0 Hz), 34.3, 28.2, 
24.7, 21.6. 
FT-IR (ATR, cm-1): 𝜈 = 3075, 3025, 2927, 2836, 1638, 1597, 1578, 1552, 1534, 1504, 1475, 1409, 1362, 
1312, 1296, 1286, 1250, 1233, 1178, 1173, 1158, 1140, 1118, 1106, 1092, 1013, 986, 917, 900, 876, 
849, 834, 810, 792, 786, 762, 744, 736, 725, 708, 662, 652. 
MS (EI, 70 eV): m/z (%) = 384 (8), 383 (33), 382 (24), 381 (100), 380 (9), 353 (9), 352 (10), 258 (7), 244 
(7), 242 (12), 230 (7), 216 (7), 215 (7), 188 (6), 140 (6), 139 (19), 123 (62), 121 (20), 95 (23), 91 (11), 77 
(15). 
HR-MS (EI, 70 eV): [C22H17O2N2Cl1F1], calcd.: 381.0932; found: 381.0929. 
 
Ethyl 4-(4-(4-chlorophenyl)-5-(trimethylsilyl)oxazol-2-yl)benzoate (139f) 
 
Ethyl 4-(4-(4-chlorophenyl)-5-(trimethylsilyl)oxazol-2-yl)benzoate (139f) was prepared according to 
TP-1 from ethyl 4-(5-(trimethylsilyl)oxazol-2-yl)benzoate (138m, 174 mg, 0.6 mmol) and TMPZnCl·LiCl 
(36, 0.88 mL, 0.7 mmol, 0.8 m solution in THF) at 50 °C. The reaction was stirred for 5 h, then Pd(dba)2 
(9 mg, 0.02 mmol), P(o-furyl)3 (7 mg, 0.03 mmol) and 1-chloro-4-iodobenzene (238 mg, 0.5 mmol) 
were added. The reaction mixture was stirred at 50 °C for 6 h and was then quenched with sat. aq. 
NH4Cl solution and extracted with CH2Cl2 (3 x 15 mL). The combined organic phases were dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica gel (CH2Cl2) yielding 139f (168 mg, 84%) as a colorless solid. 
m.p.: 114 – 116 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.21 - 8.12 (m, 4 H), 7.64 - 7.58 (m, 2 H), 7.45 - 7.38 (m, 2 H), 4.42 
(q, J = 7.0 Hz, 2 H), 1.23 - 1.63 (t, J = 7.0 Hz, 3 H), 0.37 (s, 9 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 166.0, 163.4, 151.2, 150.5, 134.2, 131.8, 131.4, 131.2, 130.0, 129.4, 
128.6, 126.4, 61.2, 14.3, -1.1. 
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FT-IR (ATR, cm-1): 𝜈 = 3114, 2948, 2896, 1907, 1680, 1594, 1571, 1553, 1436, 1459, 1403, 1316, 1286, 
1263, 1212, 1155, 1117, 1090, 1058, 1010, 958, 942, 938, 831, 776, 752, 736, 694, 683, 660, 652. 
MS (EI, 70 eV): m/z (%) = 402 (10), 401 (42), 400 (28), 399 (100), 386 (23), 385 (14), 384 (55), 224 (11), 
211 (17), 209 (47), 177 (12), 149 (11), 73 (42). 
HR-MS (EI, 70 eV): [C21H22O3N1Cl1Si1], calcd.: 399.1057; found: 399.1056. 
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3 Zincation of 4,4-Dimethyloxazoline Using TMPZnCl·LiCl. A New 
Preparation of 2-Aryloxazolines 
3.1 Typical Procedures 
Typical procedure for the zincation of 4,4-dimethyloxazoline (144) using TMPZnCl·LiCl (36) (TP-3): 
A dry and argon-flushed Schlenk flask was charged with a solution of 4,4-dimethyloxazoline (144, 
1.0 equiv) in dry THF (1.0 M solution). The solution was cooled to 0 °C and TMPZnCl·LiCl (36, 1.2 equiv) 
was added dropwise. The reaction was stirred for 1 h at 0 °C to yield the corresponding 4,4-
dimethyloxazolinylzinc reagent (146). The completion of metalation was checked by GC analysis of 
reaction aliquots quenched with a solution of 3-bromoyclohexene and CuCN·2LiCl in dry THF. 
 
Typical procedure for the ortho-metalation of 2-aryloxazolines using TMPMgCl·LiCl (35) (TP-4): 
A dry and argon-flushed Schlenk flask was charged with a solution of the oxazoline derivative of type 
147 (1.0 equiv) in dry THF (1.0 M solution). The solution was cooled to 0 °C and TMPMgCl·LiCl (35, 1.2 
equiv) was added dropwise. The reaction was stirred for 1 h at 0 °C to yield the corresponding 
magnesium reagent. The completion of metalation was checked by GC analysis of reaction aliquots 
quenched with a solution of I2 in dry THF. 
Typical procedure for the ortho'-metalation of functionalized 2-aryloxazolines using TMP2Mg·2LiCl 
(42) (TP-5): 
A dry and argon-flushed Schlenk-flask was charged with a solution of the oxazoline derivative of type 
148 (1.0 equiv) in dry THF (1.0 M solution). The solution was cooled to -20 °C and TMP2Mg·2LiCl (42, 
1.2 equiv) was added dropwise. The reaction mixture was stirred for 1.5 h at -20 °C to afford the 
corresponding magnesium reagent. The completion of metalation was checked by GC analysis of 
reaction aliquots quenched with a solution of I2 in dry THF.  
 
3.2 Zincation of 4,4-Dimethyloxazoline and Subsequent Reaction with Electrophiles 
4,4-Dimethyl-2-(4-(trifluoromethyl)phenyl)oxazoline (147a) 
 
 
Preparation from 1-iodo-4-(trifluoromethyl)benzene: 
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4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3 and was then subjected to a Pd-catalyzed cross-coupling 
reaction by addition of 1-iodo-4-(trifluoromethyl)benzene (272 mg, 1.0 mmol), Pd(OAc)2 (7 mg, 
3 mol%) and SPhos (25 mg, 6 mol%). The reaction was stirred for 4 h at 50 °C and was then quenched 
with sat. aq. NH4Cl solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was 
purified by column chromatography on silica (i-hexane:ethyl acetate 5:1) to afford 147a (192 mg, 
0.79 mmol, 79%) as colorless crystals. 
Preparation from 1-bromo-4-(trifluoromethyl)benzene: 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3 and is then subjected to a Pd-catalyzed cross-coupling 
reaction by addition of 1-bromo-4-(trifluoromethyl)benzene (225 mg, 1.0 mmol), Pd(dba)2 (17 mg, 
3 mol%) and SPhos (25 mg, 6 mol%). The reaction was stirred for 3 h at 50 °C and was then quenched 
with sat. aq. NH4Cl solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was 
purified by column chromatography on silica (i-hexane:ethyl acetate 5:1) to afford 147a (187 mg, 
0.77 mmol, 77%) as colorless crystals. 
m.p.: 34 – 36 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.97 - 8.16 (d, J = 8.2 Hz, 2 H), 7.58 - 7.74 (d, J = 8.2 Hz, 2 H), 4.16 
(s, 2 H), 1.41 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 160.9, 132.8 (q, J = 33.0 Hz), 131.4, 128.6, 125.2 (q, J = 4.2 Hz), 
123.8 (q, J = 272.1 Hz), 79.3, 67.9, 28.4. 
FT-IR (ATR, cm-1): 𝜈 = 2970, 2930, 1651, 1620, 1581, 1521, 1463, 1412, 1386, 1367, 1355, 1323, 1298, 
1249, 1216, 1166, 1128, 1107, 1069, 1016, 989, 963, 921, 870, 852, 818, 774, 754, 687, 664. 
MS (EI, 70 eV): m/z (%) = 243 (3), 242 (2), 230 (4), 229 (12), 228 (100), 224 (6), 214 (3), 200 (22), 173 
(19), 172 (62), 171 (4), 121 (3), 95 (3), 57 (3), 57 (7), 42 (5). 41 (6). 
HR-MS (EI, 70 eV): [C12H12F3NO], calc.: 243.0871; found: 243.0868. 
 
Ethyl 4-(4,4-dimethyloxazolinyl)benzoate (147b) 
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Preparation from ethyl 4-iodobenzoate: 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3 and was then subjected to a Pd-catalyzed cross-coupling 
reaction by addition of ethyl 4-iodobenzoate (276 mg, 1.0 mmol), Pd(OAc)2 (7 mg, 3 mol%) and SPhos 
(25 mg, 6 mol%). The reaction was stirred for 3 h at 50 °C and was then quenched with sat. aq. NH4Cl 
solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (i-hexane:diethyl ether 2:1) to afford 147b (193 mg, 0.78 mmol, 79%) as a 
yellow oil. 
Preparation from ethyl 4-bromobenzoate: 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3 and was then subjected to a Pd-catalyzed cross-coupling 
reaction by addition of ethyl 4-bromobenzoate (229 mg, 1.0 mmol), Pd(dba)2 (17 mg, 3 mol%) and 
SPhos (25 mg, 6 mol%). The reaction was stirred for 5 h at 50 °C and was then quenched with sat. aq. 
NH4Cl solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (i-hexane:diethyl ether 2:1) to afford 147b (228 mg, 0.92 mmol, 77%) as a 
yellow oil. 
1H-NMR (300 MHz, CDCl3, ppm):  = 8.04 - 8.13 (m, 2 H), 7.97 - 8.04 (m, 2 H), 4.40 (q, J = 7.2 Hz, 2 H), 
4.14 (s, 2 H), 1.32 - 1.50 (m, 9 H). 
13C-NMR (75 MHz, CDCl3, ppm):  = 166.0, 161.4, 132.7, 131.9, 129.4, 128.2, 79.3, 67.8, 61.2, 28.3, 
14.3.  
FT-IR (ATR, cm-1): 𝜈 = 2970, 2930, 2361, 2340, 1716, 1648, 1613, 1463, 1409, 1365, 1354, 1310, 1299, 
1269, 1215, 1190, 1173, 1102, 1064, 1018, 990, 965, 922, 867, 849, 780, 710, 678. 
MS (EI, 70 eV): m/z (%) = 247 (3), 246 (1), 233 (14), 232 (100), 217 (13), 204 (11), 202 (9), 176 (21), 159 
(4), 148 (14), 130 (5), 103 (5), 102 (4), 76 (4). 
HR-MS (EI, 70 eV): [C14H17NO3], calc.: 247.1208; found: 247.1203 
 
4-(4,4-Dimethyloxazolinyl)benzonitrile (147c) 
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Preparation from 4-iodobenzonitrile: 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3 and was then subjected to a Pd-catalyzed cross-coupling 
reaction by addition of 4-iodobenzonitrile (229 mg, 1.0 mmol), Pd(OAc)2 (7 mg, 3 mol%) and SPhos 
(25 mg, 6 mol%). The reaction was stirred for 5 h at 50 °C and was then quenched with sat. aq. NH4Cl 
solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (CH2Cl2:diethyl ether 5:1) to afford 147c (160 mg, 0.80 mmol, 80%) as a white 
solid. 
Preparation from 4-bromobenzonitrile: 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3 and was then subjected to a Pd-catalyzed cross-coupling 
reaction by addition of 4-bromobenzonitrile (182 mg, 1.0 mmol), Pd(dba)2 (17 mg, 3 mol%) and SPhos 
(25 mg, 6 mol%). The reaction was stirred for 2 h at 50 °C and was then quenched with sat. aq. NH4Cl 
solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (CH2Cl2:diethyl ether 5:1) to afford 147c (174 mg, 0.87 mmol, 87%) as a white 
solid. 
m.p.: 107 – 108 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.96 - 8.14 (d, J = 8.3 Hz, 2 H), 7.60 - 7.81 (d, J = 8.3 Hz, 2 H), 4.15 
(s, 2 H), 1.39 (s, 6 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 160.5, 132.2, 132.0, 128.8, 118.2, 114.6, 79.5, 68.0, 28.3. 
FT-IR (ATR, cm-1): 𝜈 = 2972, 2906, 2229, 1930, 1641, 1610, 1564, 1502, 1462, 1408, 1383, 1357, 1320, 
1310, 1292, 1250, 1218, 1186, 1111, 1071, 1017, 952, 924, 872, 845, 831, 820, 741, 676. 
MS (EI, 70 eV): m/z (%) = 204 (3), 200 (3), 199 (2), 186 (14), 185 (100), 170 (28), 157 (21), 130 (7), 129 
(59), 128 (5), 102 (21), 75 (6), 74 (9), 59 (13), 57 (9), 45 (9), 44 (14), 43 (5), 42 (11), 41 (15). 
HR-MS (EI, 70 eV): [C12H12N2O], calc.: 200.0950; found: 200.0942. 
 
2-(4-Methoxyphenyl)-4,4-dimethyloxazoline (147d) 
 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3 and was then subjected to a Pd-catalyzed cross-coupling 
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reaction by addition of 4-bromoanisole (187 mg, 1.0 mmol), Pd(OAc)2 (7 mg, 3 mol%) and SPhos 
(25 mg, 6 mol%). The reaction was stirred for 3 h at 50 °C and was then quenched with sat. aq. NH4Cl 
solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (CH2Cl2:diethyl ether 4:1) to afford 147d (168 mg, 0.82 mmol, 82%) as a 
colorless liquid. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.84 - 7.91 (m, 2 H), 6.86 - 6.94 (m, 2 H), 4.08 (s, 2 H), 3.84 (s, 3 
H), 1.37 (s, 6 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 161.9, 161.8, 129.8, 120.5, 113.5, 79.0, 67.4, 55.3, 28.4. 
FT-IR (ATR, cm-1): 𝜈 = 2975, 1733, 1701, 1684, 1602, 1575, 1468, 1458, 1447, 1402, 1380, 1366, 1307, 
1296, 1276, 1256, 1216, 1189, 1154, 1059, 1034, 1029, 992, 968, 927, 914, 901, 806, 794, 778, 742, 
715, 691, 662. 
MS (EI, 70 eV): m/z (%) = 205 (13), 191 (13), 190 (100), 175 (11), 162 (29), 135 (9), 134 (36), 133 (13), 
119 (5), 103 (6), 97 (6), 92 (6), 91 (8), 90 (7), 77 (5), 69 (5), 57 (5), 40 (5).  
HR-MS (EI, 70 eV): [C12H15NO2], calc.: 205.1103; found: 205.1102. 
 
Synthesis of 2-(4-chlorophenyl)-4,4-dimethyloxazoline (147e) 
 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3 and was then subjected to a Pd-catalyzed cross-coupling 
reaction by addition of 4-bromo-1-chlorobenzene (191 mg, 1.0 mmol), Pd(OAc)2 (7 mg, 3 mol%) and 
SPhos (25 mg, 6 mol%). The reaction was stirred for 2 h at 50 °C and was then quenched with sat. aq. 
NH4Cl solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (CH2Cl2:diethyl ether 9:1) to afford 147e (149 mg, 0.71 mmol, 71%) as a white 
solid. 
m.p.: 79 – 81 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.83 - 7.97 (m, 2 H), 7.31 - 7.53 (m, 2 H), 4.11 (s, 2 H), 1.38 (s, 6 
H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 161.2, 137.3, 129.5, 128.5, 126.5, 79.2, 67.7, 28.4. 
FT-IR (ATR, cm-1): 𝜈 = 2968, 2929, 1650, 1599, 1492, 1463, 1404, 1352, 1312, 1297, 1246, 1214, 1186, 
1173, 1090, 1062, 1015, 989, 963, 920, 870, 839, 820, 731, 678. 
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MS (EI, 70 eV): m/z (%) = 211 (2), 209 (7), 196 (30), 195 (10), 194 (100), 181 (5), 179 (16), 168 (6), 166 
(18), 142 (14), 140 (15), 139 (11), 138 (50), 111 (12), 102 (9), 75 (12), 71 (9), 57 (5), 50 (5), 42 (6), 41 
(12).  
HR-MS (EI, 70 eV): [C11H12ClNO], calc.: 209.0607; found: 209.0596. 
 
Diethyl 5-(4,4-dimethyloxazolinyl)isophthalate (147f) 
 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3 and was then subjected to a Pd-catalyzed cross-coupling 
reaction by addition of diethyl 5-bromoisophthalate (301 mg, 1.0 mmol), Pd(OAc)2 (7 mg, 3 mol%) and 
SPhos (25 mg, 6 mol%). The reaction was stirred for 8 h at 50 °C and was then quenched with sat. aq. 
NH4Cl solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (CH2Cl2:diethyl ether 2:1) to afford 147f (217 mg, 0.68 mmol, 68%) as a 
yellowish solid. 
m.p.: 83 – 85 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.69 - 8.85 (m, 3 H), 4.43 (q, J = 7.0 Hz, 4 H), 4.18 (s, 2 H), 1.30 - 
1.50 (m, 12 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 165.1, 133.1, 131.4, 79.5, 67.9, 61.5, 28.3, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 2969, 2932, 1716, 1674, 1651, 1598, 1468, 1440, 1397, 1374, 1365, 1354, 1331, 
1267, 1231, 1207, 1137, 1104, 1086, 1027, 999, 978, 939, 923, 901, 864, 817, 782, 764, 732, 721, 710, 
663. 
MS (EI, 70 eV): m/z (%) = 319 (2), 318 (3), 306 (3), 305 (19), 304 (100), 289 (17), 276 (13), 274 (15), 249 
(4), 248 (17),246 (4), 220 (7), 202 (6), 192 (9), 174 (4), 43 (4), 41 (4). 
HR-MS (EI, 70 eV): [C17H20NO], calc.: 318.1341; found: 318.1330 [M-H+]. 
 
3-(4,4-Dimethyloxazolinyl)cyclohex-2-en-1-one (147g) 
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4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3 and was then subjected to a Pd-catalyzed cross-coupling 
reaction by addition of 3-iodocyclohex-2-en-1-one (222 mg, 1.0 mmol), Pd(OAc)2 (7 mg, 3 mol%) and 
SPhos (25 mg, 6 mol%). The reaction was stirred for 1 h 25 °C and was then quenched with sat. aq. 
NH4Cl solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (CH2Cl2:diethyl ether 2:1) to afford 147g (131 mg, 0.68 mmol, 68%) as a 
yellow oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.56 (t, J = 1.7 Hz, 1 H), 4.03 (s, 2 H), 2.68 (td, J = 6.0, 1.7 Hz, 2 H), 
2.36 - 2.54 (m, 2 H), 1.97 - 2.14 (m, 2 H), 1.34 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 199.9, 161.8, 146.7, 130.5, 79.0, 68.1, 37.7, 28.2, 25.6, 22.3. 
FT-IR (ATR, cm-1): 𝜈 = 2963, 2928, 1668, 1644, 1598, 1537, 1463, 1455, 1432, 1418, 1364, 1346, 1326, 
1317, 1275, 1252, 1237, 1203, 1187, 1135, 1063, 1020, 953, 904, 890, 702. 
MS (EI, 70 eV): m/z (%) = 195 (1), 194 (3), 193 (21), 178 (100), 165 (4), 164 (8), 163 (30), 150 (18), 134 
(7), 123 (3), 122 (22), 108 (3), 107 (4), 93 (5), 67 (4), 66 (3), 65 (3), 41 (4).  
HR-MS (EI, 70 eV): [C11H15NO2], calc.: 193.1103; found: 193.1133. 
 
(4,4-Dimethyloxazolinyl)(phenyl)methanone (147h) 
 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3. The reaction mixture was cooled to -40 °C, CuCN·2LiCl 
(1.4 mL, 1.4 mmol, 1 M solution in THF) was added and the reaction was stirred for 15 min at this 
temperature. Then, benzoyl chloride (141 mg, 1.0 mmol) was added, the reaction is allowed to warm 
to 25 °C over 2 h and was then quenched with sat. aq. NH4Cl/NH3 solution, extracted with CH2Cl2 and 
dried over Na2SO4. The crude product was purified by column chromatography on silica (CH2Cl2:i-
hexane 8:1) to afford 147h (130 mg, 0.64 mmol, 64%) as a colorless liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.23 - 8.31 (m, 2 H), 7.59 - 7.67 (m, 1 H), 7.46 - 7.53 (m, 2 H), 4.16 
(s, 2 H), 1.45 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 184.0, 157.6, 134.8, 134.2, 130.6, 128.5, 78.9, 69.2, 28.2. 
FT-IR (ATR, cm-1): 𝜈 = 2975, 1733, 1701, 1684, 1602, 1575, 1468, 1458, 1447, 1402, 1380, 1366, 1307, 
1296, 1276, 1256, 1216, 1189, 1154, 1059, 1034, 1029, 992, 968, 927, 914, 901, 806, 794, 778, 742, 
715, 691, 662. 
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MS (EI, 70 eV): m/z (%) = 205 (10), 204 (33), 203 (5), 189 (6), 188 (4), 175 (10), 160 (8), 119 (9), 106 (9), 
105 (100), 77 (36), 73 (11), 57 (5), 51 (8), 45 (8).  
HR-MS (EI, 70 eV): [C12H14NO2], calc.: 204.1019; found: 204.1018 [M+H+]. 
 
 (3,4-Difluorophenyl)(4,4-dimethyloxazolinyl)methanone (147i) 
 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3. The reaction mixture was cooled to -40 °C, CuCN·2LiCl 
(1.4 mL, 1.4 mmol, 1 M solution in THF) was added and the reaction was stirred for 15 min at this 
temperature. Then, 3,4-difluorobenzoyl chloride (177 mg, 1.0 mmol) was added, the reaction was 
allowed to warm to 25 °C over 2 h and was then quenched with sat. aq. NH4Cl/NH3 solution, extracted 
with CH2Cl2 and dried over Na2SO4. The crude product was purified by column chromatography on silica 
(CH2Cl2:i-hexane 8:1) to afford 147i (182 mg, 0.76 mmol, 76%) as a white solid. 
m.p.: 55 – 56 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.23 - 8.33 (m, 1 H), 8.20 (ddd, J = 8.6, 4.2, 1.7 Hz, 1 H), 7.19 - 7.33 
(m, 1 H), 4.15 (s, 2 H), 1.45 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 180.9, 157.2, 155.8, 155.6, 153.2, 153.1, 151.3, 151.2, 148.8, 
148.7, 131.7, 131.7, 131.7, 128.2, 128.2, 128.1, 128.1, 120.3, 120.1, 117.5, 117.4, 78.8, 69.4, 28.1, 24.6.  
FT-IR (ATR, cm-1): 𝜈 = 2971, 2361, 1721, 1689, 1679, 1617, 1602, 1515, 1469, 1432, 1420, 1399, 1382, 
1366, 1330, 1283, 1272, 1257, 1242, 1216, 1198, 1146, 1119, 1056, 1035, 998, 979, 958, 947, 932, 920, 
889, 871, 864, 828, 798, 787, 774, 758, 704, 668, 656. 
MS (EI, 70 eV): m/z (%) = 240 (5), 239 (10), 225 (4), 211 (4), 196 (4), 190 (4), 158 (4), 142 (8), 141 (100), 
140 (4), 113 (28), 109 (4), 97 (6), 95 (4), 91 (4), 83 (5), 81 (4), 73 (9), 69 (7), 63 (5), 57 (7), 56 (4), 55 (6), 
42 (5), 40 (4). 
HR-MS (EI, 70 eV): [C12H11F2NO2], calc.: 239.0758; found: 239.0744. 
 
(2-Bromophenyl)(4,4-dimethyloxazolinyl)methanone (147j) 
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4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3. The reaction mixture was cooled to -40 °C, CuCN·2LiCl 
(1.4 mL, 1.4 mmol, 1 M solution in THF) was added and the reaction was stirred for 15 min at this 
temperature. Then, 2-bromobenzoyl chloride (219 mg, 1.0 mmol) was added, the reaction was allowed 
to warm to 25 °C over 4 h and was then quenched with sat. aq. NH4Cl/NH3 solution, extracted with 
CH2Cl2 and dried over Na2SO4. The crude product was purified by column chromatography on silica 
(CH2Cl2:i-hexane 8:1) to afford 147j (200 mg, 0.71 mmol, 71%) as a yellowish solid. 
m.p.: 57 – 59 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.63 (dd, J = 7.7, 1.3 Hz, 1 H), 7.58 - 7.61 (m, 1 H), 7.35 - 7.45 (m, 
2 H), 4.19 (s, 2 H), 1.40 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 186.4, 157.9, 138.0, 133.5, 132.9, 130.7, 127.3, 120.7, 79.9, 69.0, 
27.7. 
FT-IR (ATR, cm-1): 𝜈 = 2973, 1740, 1691, 1636, 1586, 1461, 1435, 1386, 1364, 1324, 1284, 1262, 1227, 
1186, 1165, 1064, 1048, 1023, 981, 970, 955, 934, 905, 873, 860, 819, 782, 754, 724, 688. 
MS (ESI, 70 eV): m/z (%) = 285 (11), 284 (88), 283 (12), 282 (86), 185 (100), 183 (82), 170 (5). 
HR-MS (ESI, 70 eV): [C12H12BrNO2], calc.: 282.0130; found: 282.0125 [M+H+]. 
 
(2-Iodophenyl)(4,4-dimethyloxazolinyl)methanone (147k) 
 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3. The reaction mixture was cooled to -40 °C, CuCN·2LiCl 
(1.4 mL, 1.4 mmol, 1 M solution in THF) was added and the reaction was stirred for 15 min at this 
temperature. Then, 2-iodobenzoyl chloride (266 mg, 1.0 mmol) was added, the reaction was allowed 
to warm to 25 °C over 6 h and was then quenched with sat. aq. NH4Cl/NH3 solution, extracted with 
CH2Cl2 and dried over Na2SO4. The crude product was purified by column chromatography on silica 
(CH2Cl2:i-hexane 8:2) to afford 147k (241 mg, 0.65 mmol, 65%) as a yellowish solid. 
m.p.: 69 – 72 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.89 - 7.95 (m, 1 H), 7.58 (dd, J = 7.7, 1.6 Hz, 1 H), 7.46 (td, J = 7.6, 
1.0 Hz, 1 H), 7.20 (td, J =7.7, 1.7 Hz, 1 H), 4.19 (s, 2 H), 1.41 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 187.3, 157.4, 141.2, 140.2, 132.8, 130.5, 127.9, 92.8, 79.8, 69.1, 
27.7. 
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FT-IR (ATR, cm-1): 𝜈 = 2971, 1737, 1693, 1625, 1581, 1462, 1431, 1386, 1380, 1366, 1324, 1301, 1283, 
1259, 1227, 1216, 1187, 1166, 1118, 1062, 1046, 1017, 986, 968, 949, 939, 903, 860, 816, 793, 781, 
748, 723, 680. 
MS (EI, 70 eV): m/z (%) = 330 (1), 315 (1), 314 (1), 286 (1), 271 (1), 260 (1), 257 (1), 247 (1), 245 (1), 
232 (7), 231 (100), 203 (10), 202 (67). 174 (27), 1448 (28), 76 (32), 55 (10), 50 (10). 
HR-MS (EI, 70 eV): [C12H12INO2], calc.: 329.9985; found: 329.9984 [M+H+]. 
 
(4,4-Dimethyloxazolinyl)(thiophen-2-yl)methanone (147l) 
 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) is metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3. The reaction mixture was cooled to -40 °C, CuCN·2LiCl 
(1.4 mL, 1.4 mmol, 1 M solution in THF) was added and the reaction was stirred for 15 min at this 
temperature. Then, thiophene-2-carbonyl chloride (147 mg, 1.0 mmol) was added, the reaction was 
allowed to warm to 25 °C over 2 h and was then quenched with sat. aq. NH4Cl/NH3 solution, extracted 
with CH2Cl2 and dried over Na2SO4. The crude product was purified by column chromatography on silica 
(CH2Cl2 100%) to afford 147l (134 mg, 0.64 mmol, 64%) as a yellow liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.38 (dd, J = 3.9, 1.2 Hz, 1 H), 7.77 (dd, J = 4.9, 1.0 Hz, 1 H), 7.18 
(td, J = 4.9, 3.9 Hz, 1 H), 4.16 (s, 2 H), 1.44 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 175.3, 157.6, 140.7, 137.3, 136.8, 128.5, 79.2, 69.1, 28.1. 
FT-IR (ATR, cm-1): 𝜈 = 2974, 2931, 1736, 1689, 1681, 1649, 1614, 1582, 1548, 1525, 1513, 1501, 1467, 
1440, 1430, 1407, 1380, 1360, 1344, 1301, 1277, 1257, 1233, 1220, 1187, 1153, 1079, 1049, 990, 972, 
944, 915, 879, 846, 833, 794, 782, 714, 664. 
 MS (EI, 70 eV): m/z (%) = 209 (9), 112 (6), 111 (100), 83 (5), 83 (10), 71 (5), 70 (19), 69 (7), 57 (12), 56 
(8), 55 (11), 43 (9), 43 (5), 41 (14).  
HR-MS (EI, 70 eV): [C10H11NO2S], calc.: 209.0510; found: 209.0505. 
 
2-(Cyclohex-2-en-1-yl)-4,4-dimethyloxazoline (147m) 
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4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3. The reaction mixture was cooled to -40 °C, CuCN·2LiCl 
(1.4 mL, 1.4 mmol, 1 M solution in THF) was added and the reaction was stirred for 15 min at this 
temperature. Then, 3-bromocyclohex-1-ene (161 mg, 1.0 mmol) was added, the reaction was allowed 
to warm to 25 °C over 4 h and was then quenched with sat. aq. NH4Cl/NH3 solution, extracted with 
CH2Cl2 and dried over Na2SO4. The crude product was purified by column chromatography on silica (i-
hexane:ethyl acetate 6:1) to afford 147m (142 mg, 0.79 mmol, 79%) as colorless crystals. 
m.p.: 40 – 42 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.93 – 5.81 (m, 1H), 5.74 (d, J = 10.3 Hz, 1H), 3.92 (s, 2H), 3.17 – 
2.98 (m, 1H), 2.13 – 1.46 (m, 6H), 1.28 (s, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ= 167.9, 129.4, 125.2, 79.0, 66.8, 35.2, 28.4, 28.3, 26.4, 24.7, 20.8. 
FT-IR (ATR, cm-1): 𝜈 = 3110, 2964, 2944, 2926, 2909, 2866, 2834, 1659, 1611, 1477, 1463, 1450, 1437, 
1428, 1399, 1367, 1351, 1315, 1301, 1286, 1251, 1208, 1189, 1156, 1138, 1118, 1104, 1068, 1037, 996, 
980, 958, 950, 915, 898, 878, 857, 843, 832, 823, 736, 702, 657. 
MS (EI, 70 eV): m/z (%) = 180 (20), 179 (100), 178 (87), 165 (6), 164 (66), 152 (5), 151 (8), 150 (57), 148 
(8), 138 (5), 134 (5), 124 (6), 113 (8), 108 (6), 95 (5), 81 (13)79 (6). 
HR-MS (EI, 70 eV): [C11H17NO], calc.: 179.1310; found: 179.1294. 
 
4,4-Dimethyl-2-(phenylethynyl)oxazoline (147n) 
 
4,4-Dimethyloxazoline (144, 119 mg, 1.2 mmol) was metalated with TMPZnCl·LiCl (36, 1.21 mL, 
1.4 mmol, 1.16 M solution) according to TP-3. Iodine (355 mg, 1.4 mmol) dissolved in dry THF (1 mL) 
was then added dropwise at 0 °C and the resulting mixture was stirred for 1 h at 0 °C. To the solution 
of the in situ prepared 2-iodo-4,4-dimethyloxazoline, CuI (8 mg, 0.04 mmol), Pd(dba)2 (17 mg, 0.03 
mmol), P(o-furyl) (14 mg, 0.06 mmol), TEA (2 mL) and phenylacetylene (206 mg, 2.0 mmol) were 
successively added. The reaction mixture was stirred at 25 °C for 1 h and was then quenched with sat. 
aq. NH4Cl solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by 
column chromatography on silica (i-hexane:diethyl ether 6:1) to afford 147n (141 mg, 0.85 mmol, 71%) 
as yellowish liquid. 
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.53 - 7.58 (m, 2 H), 7.33 - 7.44 (m, 3 H), 4.04 (s, 2 H), 1.35 (s, 6 
H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 148.2, 132.4, 130.0, 128.4, 120.4, 89.2, 78.9, 77.7, 67.9, 28.1. 
FT-IR (ATR, cm-1): 𝜈 = 2969, 2929, 2896, 2231, 1627, 1597, 1574, 1491, 1474, 1460, 1444, 1385, 1364, 
1352, 1312, 1248, 1230, 1187, 1143, 1097, 1070, 999, 974, 928, 896, 820, 786, 755, 688. 
MS (EI, 70 eV): m/z (%) = 200 (3), 199 (16), 185 (13), 184 (100), 170 (6), 169 (41), 157 (4), 156 (32), 129 
(14), 128 (81), 127 (38), 115 (5), 101 (8), 100 (7), 84 (16), 77 (15), 75 (11), 74 (6), 63 (5), 57 (6), 54 (9), 
51 (12), 50 (5), 42 (9). 
HR-MS (EI, 70 eV): [C13H13NO], calc.: 199.0997; found: 199.0990. 
 
 
3.3 Magnesiation of Aryloxazolines and Reaction with Electrophiles 
Ethyl 5-cyano-2-(4,4-dimethyloxazolinyl)benzoate (148a) 
 
4-(4,4-Dimethyloxazolinyl)benzonitrile (147c, 200 mg, 1.0 mmol) was metalated with TMPMgCl·LiCl 
(35, 1.08 mL, 1.2 mmol, 1.11 M solution in THF) according to TP-4. Ethyl chloroformate (98 mg, 0.9 
mmol) was added and the reaction mixture was allowed to warm to 25 °C over 2 h. The reaction 
mixture was quenched with sat. aq. NH4Cl solution, extracted with CH2Cl2 and dried over Na2SO4. The 
crude product was purified by column chromatography on silica (i-hexane:ethyl acetate 2:1) to afford 
148a (223 mg, 0.82 mmol, 91%) as a white solid. 
m.p.:  111 – 112 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.99 (d, J = 1.7 Hz, 1 H), 7.87 (d, J = 8.0 Hz, 1 H), 7.78 (d, J = 8.0 Hz, 
1 H), 4.37 (q, J = 7.2 Hz, 2 H), 4.14 (s, 2 H), 1.40 (s, 6 H), 1.38 (t, J = 7.2 Hz, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 165.6, 160.9, 134.0, 133.7, 132.5, 132.1, 130.7, 117.2, 114.5, 80.9, 
68.3, 62.2, 28.0, 14.1. 
FT-IR (ATR, cm-1): 𝜈 = 2981, 2970, 2234, 1731, 1649, 1475, 1470, 1462, 1404, 1388, 1363, 1354, 1314, 
1297, 1258, 1187, 1139, 1121, 1104, 1049, 1020, 985, 962, 930, 860, 842, 818, 788, 768, 749, 682, 673. 
MS (EI, 70 eV): m/z (%) = 272 (4), 258 (10), 257 (70), 227 (11), 214 (11), 213 (87), 212 (14), 211 (100), 
185 (8), 173 (30), 156 (6), 129 (8), 128  (7), 127 (13), 101 (9), 97 (6), 83 (6), 71 (6), 69 (8), 57 (8), 55 (9), 
44 (6), 41 (8). 
HR-MS (EI, 70 eV): [C15H16N2O3], calc.: 272.1161; found: 272.1147. 
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4-(4,4-Dimethyloxazolinyl)isophthalonitrile (148b) 
 
4-(4,4-Dimethyloxazolinyl)benzonitrile (147c, 200 mg, 1.0 mmol) was metalated with TMPMgCl·LiCl 
(35, 1.08 mL, 1.2 mmol, 1.11 M solution in THF) according to TP-4. p-Toluenesulfonyl cyanide (163 mg, 
0.9 mmol) was added and the reaction mixture was allowed to warm to 25 °C over 2 h. The reaction 
mixture was quenched with sat. aq. NH4Cl/NH3 solution, extracted with CH2Cl2 and dried over Na2SO4. 
The crude product was purified by column chromatography on silica (i-hexane:ethyl acetate 2:1) to 
afford 148b (169 mg, 0.75 mmol, 83%) as a white solid. 
m.p.:  123 – 125 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.21 (d, J = 8.2 Hz, 1 H), 8.03 – 8.01 (m, 1 H), 7.89 (ddd, J = 8.2, 
1.7 Hz, 1 H), 4.23 (s, 2 H), 1.42 (s, 6 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 158.3, 137.6, 135.3, 134.1, 131.1, 116.1, 115.6, 115.4, 113.2, 80.9, 
68.8, 28.1. 
FT-IR (ATR, cm-1): 𝜈 = 3073, 3051, 2974, 2362, 2237, 1651, 1501, 1464, 1365, 1353, 1311, 1292, 1273, 
1217, 1182, 1139, 1049, 986, 965, 930, 924, 912, 856, 818, 758, 684, 675. 
MS (EI, 70 eV): m/z (%) = 225 (11), 211 (15), 210 (90), 195 (40), 155 (12), 154 (70), 149 (31), 127 (12), 
123 (15), 113 (18), 112 (16), 111 (27), 109 (17), 99 (13), 97 (38), 95 (24), 85 (29), 84 (11), 83 (39), 82 
(14), 81 (38), 79 (12), 71 (58), 70 (26), 69 (90), 67 (21), 59 (12), 57 (100), 56 (26), 55 (58), 45 (15), 44 
(87), 43 (58), 43 (43), 42 (37), 41 (65).  
HR-MS (EI, 70 eV): [C13H11N3O], calc.: 225.0902; found: 225.0900. 
 
4-(4,4-Dimethyloxazolinyl)-3-(hydroxy(phenyl)methyl)benzonitrile (148c) 
 
4-(4,4-Dimethyloxazolinyl)benzonitrile (147c, 200 mg, 1.0 mmol) was metalated with TMPMgCl·LiCl 
(35, 1.08 mL, 1.2 mmol, 1.11 M solution in THF) according to TP-4. Benzaldehyde (95 mg, 0.9 mmol) 
was added and the reaction mixture was allowed to warm to 25 °C over 2 h. The reaction mixture was 
quenched with sat. aq. NH4Cl solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product 
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was purified by column chromatography on silica (i-hexane:ethyl acetate 2:1) to afford 148c (254 mg, 
0.83 mmol, 92%) as a white solid. 
m.p.:  103 – 105 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.90 (d, J = 8.1 Hz, 1 H), 7.58 (d, J = 8.0 Hz, 1 H), 7.39 (br, 1 H), 7.32 
(s, 1 H), 7.30 – 7.19 (m, 5 H), 5.93 (s, 1 H), 4.04 (d, J = 8.2 Hz, 1 H), 3.95 (d, J = 8.2 Hz, 1 H), 1.31 (s, 3 H), 
1.05 (s, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 161.0, 146.2, 141.5, 133.4, 131.1, 131.1, 131.0, 128.2, 127.4, 126.6, 
118.0, 114.8, 79.1, 73.6, 68.5, 28.4, 27.8. 
FT-IR (ATR, cm-1): 𝜈 = 3184, 2966, 2230, 1644, 1454, 1404, 1359, 1314, 1283, 1206, 1187, 1077, 1065, 
1040, 1024, 963, 947, 938, 920, 846, 826, 785, 756, 746, 740, 700, 662. 
MS (EI, 70 eV): m/z (%) = 307 (11), 306 (46), 275 (18), 235 (20), 234 (100), 233 (20), 229 (17), 219 (10), 
200 (11), 190 (18), 185 (12), 158 (11), 155 (11), 130 (11), 105 (13), 77 (12). 
HR-MS (EI, 70 eV): [C19H18N2O2], calc.: 306.1368; found: 306.1375. 
 
Ethyl 3-cyano-4-(4,4-dimethyloxazolinyl)benzoate (148d) 
 
Ethyl 4-(4,4-dimethyloxazolinyl)benzoate (147b, 247 mg, 1.0 mmol) was metalated with TMPMgCl·LiCl 
(35, 1.08 mL, 1.2 mmol, 1.11 M solution in THF) according to TP-4. p-Toluenesulfonyl cyanide (163 mg, 
0.9 mmol) was added and the reaction mixture was allowed to warm to 25 °C over 2 h. The reaction 
mixture was quenched with sat. aq. NH4Cl/NH3 solution, extracted with CH2Cl2 and dried over Na2SO4. 
The crude product was purified by column chromatography on silica (i-hexane:ethyl acetate 1:1) to 
afford 148d (152 mg, 0.56 mmol, 62%) as colorless crystals. 
m.p.: 56 – 58 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.37 (d, J = 1.7 Hz, 1 H), 8.21 (dd, J = 8.2, 1.7 Hz, 1 H), 8.08 (d, J = 
8.2 Hz, 1 H), 4.39 (q, J = 7.2 Hz, 2 H), 4.18 (s, 2 H), 1.39 (s, 6 H), 1.39 (t, J = 7.2 Hz, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 164.1, 159.0, 135.4, 134.0, 133.0, 133.0, 130.4, 116.9, 112.1, 79.9, 
68.6, 62.0, 28.2, 14.2. 
FT-IR (ATR, cm-1): 𝜈 = 2970, 2228, 1715, 1633, 1462, 1403, 1368, 1356, 1312, 1286, 1253, 1248, 1216, 
1181, 1122, 1108, 1058, 1020, 985, 955, 932, 920, 910, 875, 821, 792, 772, 744, 714, 676. 
MS (EI, 70 eV): m/z (%) = 273 (5), 272 (25), 271 (11), 258 (25), 257 (100), 243 (13), 242 (57), 229 (22), 
227 (23), 202 (11), 207 (71), 174 (10), 173 (45), 128 (15). 
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HR-MS (EI, 70 eV): [C15H16N2O3], calc.: 272.1161; found: 272.1153. 
 
4-(4,4-Dimethyloxazolinyl)-3-(thiophene-2-carbonyl)benzonitrile (148e) 
 
4-(4,4-Dimethyloxazolinyl)benzonitrile (147c, 200 mg, 1.0 mmol) was metalated with TMPMgCl·LiCl 
(35, 1.08 mL, 1.2 mmol, 1.11 M solution in THF) according to TP-4. The reaction mixture was cooled to 
-25 °C and CuCN·2LiCl (1.2 mL, 1.2 mmol, 1 M solution) was added and stirring was continued for 0.5 
h. Then 2-thiophenecarbonyl chloride (132 mg, 0.9 mmol) was added and the reaction was allowed to 
warm to 25 °C over 3 h. The reaction mixture was quenched with sat. aq. NH4Cl/NH3 solution, extracted 
with CH2Cl2 and dried over Na2SO4. The crude product was purified by column chromatography on silica 
(i-hexane:ethyl acetate 1:1) to afford 148e (233 mg, 0.75 mmol, 83%) as colorless crystals. 
m.p.:  143 – 145 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.04 (d, J = 8.0 Hz, 1 H), 7.82 (dd, J = 8.1, 1.7 Hz, 1 H), 7.79 (d, J = 
1.6 Hz, 1 H), 7.72 (dd, J = 4.9, 1.2 Hz, 1 H), 7.21 (dd, J = 3.9, 1.2 Hz, 1 H), 7.07 (dd, J = 4.9, 3.8 Hz, 1 H), 
3.80 (s, 2 H), 1.12 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 186.5, 159.7, 144.0, 140.5, 134.9, 134.3, 133.4, 131.6, 130.9, 
130.1, 128.1, 117.4, 114.9, 79.9, 68.4, 27.7. 
FT-IR (ATR, cm-1): 𝜈 = 2963, 2926, 2232, 1649, 1418, 1409, 1353, 1299, 1265, 1254, 1188, 1052, 1045, 
953, 932, 912, 857, 803, 759, 736, 728, 679, 658. 
MS (EI, 70 eV): m/z (%) = 311 (4), 310 (20), 282 (18), 281 (100), 266 (10), 265 (55), 237 (13), 227 (13), 
211 (32), 196 (24), 155 (28), 127 (18), 111 (25), 55 (31), 41 (16). 
HR-MS (EI, 70 eV): [C17H14N2O2S], calc.: 310.0776; found: 310.0774. 
 
3-Benzoyl-4-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)benzonitrile (148f) 
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4-(4,4-Dimethyloxazolinyl)benzonitrile (147c, 200 mg, 1.0 mmol) was metalated with TMPMgCl·LiCl 
(35, 1.08 mL, 1.2 mmol, 1.11 M solution in THF) according to TP-4. The reaction mixture was cooled to 
-25 °C and CuCN·2LiCl (1.2 mL, 1.2 mmol, 1 M solution) was added and stirring was continued for 0.5 
h. Then benzoyl chloride (127 mg, 0.9 mmol) was added and the reaction was allowed to warm to 25 
°C over 3 h. The reaction mixture was quenched with sat. aq. NH4Cl/NH3 solution, extracted with CH2Cl2 
and dried over Na2SO4. The crude product was purified by column chromatography on silica (i-
hexane:ethyl acetate 3:2) to afford 148f (250 mg, 0.82 mmol, 91%) as white solid. 
m.p.: 115 – 117 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.04 (d, J = 8.0 Hz, 1 H), 7.83 (dd, J = 8.1, 1.7 Hz, 1 H), 7.77 (d, J = 
1.6 Hz, 1 H), 7.70 – 7.65 (m, 2 H), 7.59 – 7.52 (m, 1 H), 7.48 – 7.39 (m, 2 H), 3.67 (s, 2 H), 1.03 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 194.3, 159.8, 140.8, 136.8, 133.3, 133.3, 132.0, 130.8, 130.0, 
129.1, 128.6, 117.4, 115.1, 79.7, 68.3, 27.6. 
FT-IR (ATR, cm-1): 𝜈 = 2963, 2899, 2235, 1670, 1652, 1598, 1451, 1358, 1316, 1296, 1282, 1257, 1196, 
1177, 1129, 1053, 980, 971, 957, 928, 875, 858, 828, 768, 709, 699, 686, 652. 
MS (EI, 70 eV): m/z (%) = 304 (1), 289 (10), 276 (25), 275 (100), 245 (6), 221 (7), 218 (5), 211 (5), 190 
(13), 155 (12), 127 (6), 105 (5), 77 (7). 
HR-MS (EI, 70 eV): [C19H16N2O2], calc.: 304.1212; found: 304.1214. 
 
Ethyl 5'-cyano-2'-(4,4-dimethyloxazolinyl)-[1,1'-biphenyl]-4-carboxylate (148g) 
 
4-(4,4-Dimethyloxazolinyl)benzonitrile (147c, 200 mg, 1.0 mmol) was metalated with TMPMgCl·LiCl 
(35, 1.08 mL, 1.2 mmol, 1.11 M solution in THF) according to TP-4. Then, ethyl 4-iodobenzoate (248 mg, 
0.9 mmol), Pd(dba)2 (17 mg, 0.03 mmol) and P(o-furyl)3 (14 mg, 0.06 mmol) were added. The reaction 
mixture was stirred for 4 h at 25 °C and was then quenched with sat. aq. NH4Cl solution, extracted with 
CH2Cl2 and dried over Na2SO4. The crude product was purified by column chromatography on silica (i-
hexane:diethyl ether 1:1) to afford 148g (282 mg, 0.81 mmol, 90%) as a yellowish solid. 
m.p.: 92 – 94 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.14 – 8.06 (m, 2 H), 7.93 (d, J = 7.9 Hz, 1 H), 7.71 (dd, J = 7.9, 1.6 
Hz, 1 H), 7.68 – 7.66 (m, 1 H), 7.46 – 7.39 (m, 2 H), 4.41 (q, J = 7.2 Hz, 2 H), 3.84 (s, 2 H), 1.42 (t, J = 7.1 
Hz, 3 H), 1.30 (s, 6 H). 
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13C-NMR (750 MHz, CDCl3, ppm): δ = 166.2, 162.1, 143.3, 142.0, 133.6, 131.8, 131.2, 131.0, 130.3, 
129.5, 128.3, 117.8, 114.6, 80.0, 67.9, 61.2, 27.9, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 2967, 2361, 2340, 1718, 1706, 1648, 1606, 1292, 1273, 1178, 1103, 1074, 1039, 
1019, 959, 864, 776, 760, 713, 700, 668. 
MS (EI, 70 eV): m/z (%) = 349 (4), 348 (22), 347 (100), 333 (3), 319 (3), 305 (3), 303 (7), 293 (3), 245 (5), 
231 (8), 203 (5), 176 (5). 
HR-MS (EI, 70 eV): [C21H20N2O3], calc.: 348.1474; found: 348.1423. 
 
4'-Chloro-6-(4,4-dimethyloxazolinyl)-[1,1'-biphenyl]-3-carbonitrile (148h) 
 
4-(4,4-Dimethyloxazolinyl)benzonitrile (147c, 200 mg, 1.0 mmol) was metalated with TMPMgCl·LiCl 
(35, 1.08 mL, 1.2 mmol, 1.11 M solution in THF) according to TP-4. Then, 1-chloro-4-iodobenzene 
(215 mg, 0.9 mmol), Pd(dba)2 (17 mg, 3 mol%) and P(o-furyl)3 (14 mg, 6 mol%) were added. The 
reaction mixture was stirred for 4 h at r.t. and was then quenched with sat. aq. NH4Cl solution, 
extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (i-hexane:diethyl ether 1:1) to afford 148h (260 mg, 0.84 mmol, 93%) as a 
yellowish solid. 
m.p.: 96 – 97 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.87 (d, J = 8.1 Hz, 1 H), 7.68 (dd, J = 7.9, 1.3 Hz, 1 H), 7.64 (s, 1 H), 
7.40 (d, J = 8.3 Hz, 2 H), 7.29 (d, J = 8.3 Hz, 2 H), 3.86 (s, 2 H), 1.30 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 161.7, 141.6, 137.3, 134.4, 133.5, 132.2, 131.1, 130.7, 129.5, 
128.5, 117.9, 114.3, 79.7, 68.0, 27.9. 
FT-IR (ATR, cm-1): 𝜈 = 2967, 2928, 2231, 1653, 1484, 1462, 1410, 1392, 1365, 1350, 1308, 1213, 1179, 
1091, 1065, 1034, 1013, 986, 959, 920, 901, 828, 814, 763, 734, 724, 698, 668. 
MS (EI, 70 eV): m/z (%) = 312 (6), 311 (38), 310 (23), 309 (100), 295 (6), 255 (8), 245 (12), 240 (6), 239 
(11), 238 (9), 226 (8), 226 (8), 224 (23), 203 (13), 202 (8), 177 (11), 176 (12). 
HR-MS (EI, 70 eV): [C18H15ClN2O], calc.: 309.0795; found: 309.0797 [M-H+]. 
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3-Allyl-4-(4,4-dimethyloxazolinyl)benzonitrile (148i) 
 
4-(4,4-Dimethyloxazolinyl)benzonitrile (148i, 200 mg, 1.0 mmol) was metalated with TMPMgCl·LiCl 
(35, 1.08 mL, 1.2 mmol, 1.11 M solution in THF) according to TP-4. CuCN·2LiCl (1.2 mL, 1.2 mmol, 1 M 
solution) was added and the reaction mixture was stirred for 0.5 h. Then allyl bromide (109 mg, 0.9 
mmol) was added and the reaction was allowed to warm to 25 °C over 2 h. The reaction mixture was 
quenched with sat. aq. NH4Cl/NH3 solution, extracted with CH2Cl2 and dried over Na2SO4. The crude 
product was purified by column chromatography on silica (i-hexane:ethyl acetate 1:1) to afford 148i 
(187 mg, 0.78 mmol, 87%) as a yellowish solid. 
m.p.:  46 – 48 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.87 (d, J = 8.0 Hz, 1 H), 7.60 – 7.48 (m, 2 H), 6.01 – 5.84 (m, 1 H), 
5.19 – 4.97 (m, 2 H), 4.10 (d, J = 1.2 Hz, 2 H), 3.80 (d, J = 6.5 Hz, 2 H), 1.39 (s, 6 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 161.1, 141.8, 135.8, 133.8, 131.6, 130.8, 129.5, 118.3, 117.0, 114.3, 
79.1, 68.2, 37.9, 28.3. 
FT-IR (ATR, cm-1): 𝜈 = 2971, 2927, 2889, 2230, 1643, 1497, 1460, 1366, 1352, 1311, 1284, 1250, 1207, 
1193, 1175, 1084, 1042, 988, 964, 948, 921, 892, 848, 818, 730, 692. 
MS (EI, 70 eV): m/z (%) = 246 (17), 241 (10), 240 (60), 239 (84), 226 (17), 225 (100), 213 (13), 209 (10), 
195 (17), 185 (40), 171 (10), 169 (17), 168 (29), 167 (12), 156 (16), 155 (12), 154 (16), 153 (14), 142 
(26), 141 (48), 140 (40), 115 (18), 114 (17), 57 (12), 56 (14), 55 (22), 41 (15). 
HR-MS (EI, 70 eV): [C15H16N2O], calc.: 240.1263; found: 240.1262. 
 
6-(4,4-Dimethyloxazolinyl)-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-3-carbonitrile (148j) 
 
4-(4,4-Dimethyloxazolinyl)benzonitrile (147c, 200 mg, 1.0 mmol) was metalated with TMPMgCl·LiCl 
(35, 1.08 mL, 1.2 mmol, 1.11 M solution in THF) according to TP-4. CuCN·2LiCl (1.2 mL, 1.2 mmol, 1 M 
solution) was added and the reaction mixture was stirred for 0.5 h. Then, 3-bromocyclohexene 
(145 mg, 0.9 mmol) was added and the reaction was allowed to warm to 25 °C over 2 h. The reaction 
mixture was quenched with sat. aq. NH4Cl/NH3 solution, extracted with CH2Cl2 and dried over Na2SO4. 
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The crude product was purified by column chromatography on silica (i-hexane:ethyl acetate 2:1) to 
afford 148j (247 mg, 0.88 mmol, 98%) as a yellowish solid. 
m.p.: 76 – 78 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.73 (d, J = 8.0 Hz, 1 H), 7.59 (d, J = 1.7 Hz, 1 H), 7.45 (dd, J = 8.1, 
1.7 Hz, 1 H), 5.94 (ddd, J = 10.0, 5.0, 2.4 Hz, 1 H), 5.58 (dd, J = 10.3, 2.5 Hz, 1 H), 4.34 (ddt, J = 8.2, 5.6, 
2.8 Hz, 1 H), 4.06 (s, 2 H), 2.05 (tdd, J = 12.8, 6.4, 3.3 Hz, 3 H), 1.65 – 1.52 (m, 2 H), 1.40 (ddd, J = 9.1, 
7.6, 4.0 Hz, 1 H), 1.35 (s, 6H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 161.0, 147.9, 132.4, 130.5, 129.8, 129.1, 128.8, 118.6, 113.8, 78.9, 
68.4, 37.5, 31.7, 28.3, 28.2, 24.9, 20.7. 
FT-IR (ATR, cm-1): 𝜈 = 2968, 2948, 2931, 2913, 2858, 2230, 1639, 1488, 1480, 1462, 1445, 1398, 1364, 
1352, 1305, 1292, 1276, 1266, 1246, 1210, 1188, 1164, 1121, 1056, 1043, 961, 938, 922, 912, 873, 846, 
838, 820, 770, 752, 721, 686. 
MS (EI, 70 eV): m/z (%) = 281 (20), 280 (100), 279 (22), 265 (13), 251 (22), 225 (37), 223 (11), 209 (27), 
208 (74), 207 (45), 206 (16), 193 (15), 192 (21), 191 (22), 190 (34), 180 (16), 168 (10), 166 (13), 153 
(16), 152 (16), 140 (16), 74 (21), 59 (21), 55 (12), 44 (15). 
HR-MS (EI, 70 eV): [C18H20N2O], calc.: 280.1576; found: 280.1570. 
 
4'-Chloro-6-(4,4-dimethyloxazolinyl)-5-iodo-[1,1'-biphenyl]-3-carbonitrile (149a) 
 
4'-Chloro-6-(4,4-dimethyloxazolinyl)-[1,1'-biphenyl]-3-carbonitrile (148h, 131 mg, 0.5 mmol) was 
metalated with TMP2Mg·2LiCl (42, 1.11 mL, 0.6 mmol, 0.54 M) according to TP-5. I2 (253 mg, 1.0 mmol) 
was added dropwise as a 0.5 M solution THF and the reaction mixture was allowed to warm to 25 °C 
over 2 h. The reaction was quenched with sat. Na2S2O3 solution, extracted with CH2Cl2 and dried over 
Na2SO4. The crude product was purified by column chromatography on silica (CH2Cl2 100%) to afford 
149a (153 mg, 0.35 mmol, 70%) as a yellowish solid. 
m.p.: 133 – 135 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.12 (d, J = 1.5 Hz, 1 H), 7.60 (d, J = 1.5 Hz, 1 H), 7.39 (d, J = 8.5 Hz, 
2 H), 7.32 (d, J = 8.5 Hz, 2 H), 3.96 (s, 2 H), 1.20 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 160.8, 143.1, 140.9, 138.8, 136.2, 135.0, 132.5, 130.0, 128.5, 
116.3, 115.0, 97.2, 79.7, 68.6, 27.6. 
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FT-IR (ATR, cm-1): 𝜈 = 2948, 2922, 2858, 1639, 1488, 1480, 1462, 1445, 1398, 1364, 1352, 1305, 1292, 
1276, 1266, 1246, 1210, 1185, 1043, 961, 938, 922, 912, 873, 838, 820, 773. 
MS (EI, 70 eV): m/z (%) = 438 (8), 437 (47), 436 (40), 435 (100), 421 (6), 380 (5), 370 (19), 351 (7), 349 
(21), 238 (7), 211 (5), 203 (7), 202 (17), 188 (7), 176 (9), 175 (8), 55 (9).  
HR-MS (EI, 70 eV): [C18H14ClIN2O], calc.: 434.9761; found: 434.9753 [M-H+]. 
 
5-Allyl-4'-chloro-6-(4,4-dimethyloxazolinyl)-[1,1'-biphenyl]-3-carbonitrile (149b) 
 
4'-Chloro-6-(4,4-dimethyloxazolinyl)-[1,1'-biphenyl]-3-carbonitrile (148h, 131 mg, 0.5 mmol) was 
metalated with TMP2Mg·2LiCl (42, 1.11 mL, 0.6 mmol, 0.54 M) according to TP-5. CuCN·2LiCl (0.6 mL, 
0.6 mmol) was added at -20 °C and the reaction was stirred for 0.5 h. Allyl bromide (49 mg, 0.45 mmol) 
was added, the reaction was allowed to warm to 25 °C over 4 h and was then quenched with sat. aq. 
NH4Cl/NH3 solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by 
column chromatography on silica (CH2Cl2) to afford 149b (137 mg, 0.39 mmol, 87%) as a white solid. 
m.p.: 170 – 173 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.56 (d, J = 1.5 Hz, 1 H), 7.49 (d, J = 1.7 Hz, 1 H), 7.40 - 7.45 (m, 2 
H), 7.35 - 7.40 (m, 2 H), 6.00 (ddt, J = 17.0, 10.2, 6.6 Hz, 1 H), 5.18 - 5.23 (m, 1 H), 5.11 - 5.18 (m, 1 H), 
3.68 (s, 2 H), 3.57 (d, J = 6.6 Hz, 2 H), 1.19 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 166.9, 140.3, 139.5, 139.4, 136.6, 135.6, 134.8, 132.2, 131.0, 
130.1, 128.8, 118.0, 117.7, 113.1, 54.9, 51.1, 36.9, 24.5. 
FT-IR (ATR, cm-1): 𝜈 = 3264, 2924, 2237, 1630, 1603, 1555, 1494, 1470, 1455, 1445, 1432, 1416, 1387, 
1364, 1327, 1300, 1262, 1238, 1092, 1016, 994, 927, 913, 891, 872, 844, 837, 831, 801, 758, 733, 714, 
700, 677. 
MS (EI, 70 eV): m/z (%) = 352 (20), 351 (42), 350 (53), 349 (100), 346 (39), 337 (21), 335 (62), 278 (20), 
220 (32), 219 (77), 216 (20), 214 (22), 191 (48), 190 (59), 105 (20), 85 (19), 77 (79), 71 (23), 69 (22), 57 
(40), 55 (50), 51 (26), 43 (27), 43 (20), 41 (37). 
HR-MS (EI, 70 eV): [C21H18ClN2O], calc.: 349.1108; found: 349.1098 [M-H+]. 
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4-Chloro-2'-(4,4-dimethyloxazolinyl)-4''-(trifluoromethyl)-[1,1':3',1''-terphenyl]-5'-carbonitrile 
(149c) 
 
4'-Chloro-6-(4,4-dimethyloxazolinyl)-[1,1'-biphenyl]-3-carbonitrile (148h, 131 mg, 0.5 mmol) was 
metalated with TMP2Mg·2LiCl (42, 1.11 mL, 0.6 mmol, 0.54 M) according to TP-5, then 4-
iodobenzotrifluoride (122 mg, 0.45 mmol), Pd(dba)2 (9 mg, 0.02 mmol) and P(o-furyl)3 (7 mg, 0.03 
mmol) were added. The reaction was allowed to warm to 25 °C over 3 h and was then quenched with 
sat. aq. NH4Cl solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified 
by column chromatography on silica (CH2Cl2/diethyl ether 10:1) to afford 149c (178 mg, 0.39 mmol, 
87%) as a yellowish solid. 
m.p.: 181 – 183 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.67 (m, 4 H), 7.55 (d, J = 7.9 Hz, 2 H), 7.43 – 7.33 (m, 4 H), 3.62 
(s, 2 H), 0.91 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 159.1, 142.7, 142.4, 141.9 (d, J = 1.7 Hz), 136.5, 134.8, 132.5, 
132.4, 131.8, 130.6 (q, J = 32.7 Hz), 130.0, 129.2, 128.6, 125.3 (q, J = 272.3 Hz), 125.2 (q, J = 3.7 Hz), 
122.6, 119.9, 117.6, 113.9, 79.4, 68.2, 27.3. 
FT-IR (ATR, cm-1): 𝜈 = 2971, 2930, 2242, 1662, 1492, 1324, 1299, 1294, 1284, 1176, 1160, 1129, 1111, 
1093, 1072, 1061, 1039, 1017, 959, 924, 904, 893, 846, 828, 820, 766, 708, 663. 
MS (EI, 70 eV): m/z (%) = 456 (10), 455 (34), 454 (32), 453 (100), 399 (8), 397 (5), 389 (5), 381 (5), 368 
(13), 363 (13), 347 (5), 332 (6), 364 (6), 55 (16). 
HR-MS (EI, 70 eV): [C25H18ClF3N2O], calc.: 453.0982; found: 453.0972 [M-H+]. 
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4 Metalation and Functionalization of the Tropolone Scaffold 
4.1 Preparation of Starting Materials 
5-Bromo-2-methoxytropone (154) was synthesized in 5 steps from 1,4-cyclohexadiene using modified 
literature procedures: 
 
7,7-Dibromo-bicyclo[4.1.0]hept-3-ene (154-S1) 
The title compound was synthesized from 1,4-cyclohexadiene using a modified procedure by Hofmann 
et al.186 Potassium tert-butoxide (11.2 g, 100 mmol) was dried in vacuo for 6 h and was then suspended 
in n-pentane (200 mL). The suspension was cooled to 0 °C and 1,4-cyclohexadiene (16.0 g, 200 mmol) 
was added, followed by the addition of bromoform (8.75 mL, 25.3 g, 100 mmol) over 15 min. The 
reaction was stirred at r.t. for 2 h and was then quenched by the addition of water (200 mL). The 
organic layer was separated and the aqueous phase was extracted with n-pentane (3 x 150 mL). The 
combined organic extracts were dried over Na2SO4 and concentrated. Purification of the crude product 
by column chromatography using n-pentane as an eluent afforded the title compound as colorless 
crystals (14.4 g, 57 mmol, 57%). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.51 (s, 2 H), 2.53 – 2.38 (m, 2 H), 2.17 – 2.03 (m, 2 H), 1.92 (dd, J 
= 5.4, 2.4 Hz, 2 H). 
 
(1α,3β,4β,6α)-4-Acetoxy-7,7-dibromobicyclo[4.1.0]heptan-3-ol (154-S2) 
The title compound was synthesized using a modified procedure by Banwell et al.187 154-S1 (14.0 g, 
57 mmol) and silver acetate (19.0 g, 114 mmol) were dissolved in acetic acid (280 mL) and iodine 
(17.3 g, 68 mmol) was added over 15 min. Upon complete addition, water (1.0 mL, 57 mmol) was 
                                                          
186 K. Hofmann, S. F. Orochena, S. M. Sax, G. A. Jeffrey, J. Am. Chem. Soc. 1959, 81, 992. 
187 M. G. Banwell, J. N. Lambert, M. E. Reum, R. Onrust, Org. Prep. Proced. Int. 1988, 20, 393. 
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added and the reaction was stirred for 48 h in the dark. Water and solid Na2CO3 were added, the layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 x 150 mL). The combined organic 
layers were washed successively with sat. aq. NaHCO3 solution, 20% aq. NaHSO3 solution, water and 
sat. aq. NaCl-solution, then dried over Na2SO4 and concentrated. The residue was purified by column 
chromatography using i-hexane:ethyl acetate 3:2 as an eluent affording 154-S2 as a white solid (14.4 g, 
44 mmol, 78%) 
1H-NMR (400 MHz, CDCl3, ppm): δ = 4.76 (td, J = 6.1, 3.3 Hz, 1 H), 3.79 – 3.68 (m, 1 H), 2.45 – 2.29 (m, 
2 H), 2.21 – 2.08 (m, 1 H), 2.02 (s, 3 H), 1.94 – 1.75 (m, 3 H), 1.68 (ddd, J = 15.2, 7.7, 4.1 Hz, 1 H). 
 
(1α,4β,6α)-4-Acetoxy-7,7-dibromobicyclo[4.1.0]heptan-3-one (154-S3) 
The title compound was prepared using a modified procedure by Banwell.187 154-S2 (13.1 g, 40 mmol) 
was dissolved in CH2Cl2 (400 mL) and PCC (25.9 g, 120 mmol) was added at room temperature. The 
reaction mixture was stirred for 4 h at r.t. and was then filtered through a pad of celite using CH2Cl2 as 
an eluent. The solvents were removed in vacuo and the residue was purified by column 
chromatography using CH2Cl2:ethyl acetate 2:1 as an eluent to provide 154-S3 as a white solid (11.4 g, 
35 mmol, 88%) 
1H-NMR (400 MHz, CDCl3, ppm): δ = 5.12 (dd, J = 13.0, 7.5 Hz, 1 H), 2.90 – 2.62 (m, 3 H), 2.28 (ddd, J = 
10.3, 8.3, 1.8 Hz, 1 H), 2.18 (dd, J = 10.1, 4.5 Hz, 1 H), 2.12 (s, 3 H), 2.01 (ddd, J = 14.2, 13.1, 4.5 Hz, 1 
H). 
 
5-Bromo-2-hydroxycyclohepta-2,4,6-triene-1-one (154-S4) 
The title compound was prepared by dissolving 154-S3 (5.0 g, 16 mmol) in methanol/H2O (600 mL, 95:5 
mixture) and addition of K2CO3 (6.6 g, 48 mmol). The reaction was stirred for 16 h and was then diluted 
with 2 M HCl (400 mL). The mixture was extracted with CH2Cl2 (3 x 200 mL), the combined organic 
extracts were dried over Na2SO4 and concentrated. Recrystallisation from CHCl3 and hexane provided 
154-S4 as yellow crystals (2.9 g, 14 mmol, 89%). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 9.04 (s, 1 H), 7.66 (d, J = 12.2 Hz, 2 H), 7.10 (d, J = 12.2 Hz, 2 H). 
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5-Bromo-2-methoxy-cyclohepta-2,4,6-triene-1-one (154) 
Alcohol 154-S4 (2.5 g, 12.4 mmol) was dissolved in THF (100 mL) and the solution was cooled to 0 °C. 
(Trimethylsilyl)diazomethane (8.05 mL, 16.1 mmol, 2 M solution in hexane) and MeOH (25 mL) were 
added successively and the reaction was stirred for 1 h at 0 °C. The reaction mixture was treated with 
sat. aq. NH4Cl and H2O, the phases were separated and the aquoues phase was extracted with CH2Cl2 
(3 x 50 mL). The combined organic extracts were dried over Na2SO4 and concentrated. The residue was 
purified by column chromatography on silica using CH2Cl2:diethyl ether 1:1 as an eluent to yield 154 as 
a brown solid (2.20 g, 9.4 mmol, 76%)  
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.47 – 7.36 (m, 2 H), 7.00 (d, J = 12.2 Hz, 1 H), 6.48 (d, J = 12.1 Hz, 
1 H), 3.92 (s, 3 H). 
 
2-Benzyloxytropone (156)188 
Tropolone (151, 1.22 g, 10.0 mmol) and Bu4NOH (40% in H2O, 6.3 mL, 10.0 mmol) were stirred under 
at r.t. for 1 h. A solution of benzyl chloride (1.27 g, 10.0 mmol) in CH2Cl2 (25 mL) was added slowly at 
room temperature. The reaction was heated to reflux for 8 h and was then diluted with H2O (20 mL). 
The aqueous layer was extracted with CH2Cl2 (3 × 25 mL). The combined organic extracts were dried 
over Na2SO4 and concentrated. Purification of the crude product by chromatography on silica gel 
(CH2Cl2:ethyl acetate 2:1) obtained the title compound as a brown solid (1.29 g, 6.1 mmol, 61%). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.43 – 7.14 (m, 7 H), 7.02 – 6.74 (m, 3 H), 5.23 (s, 2H). 
 
 
4.2 Typical Procedures  
Typical procedure for the zincation of 5-bromo-2-methoxytropone (154) using TMPZnCl·LiCl (36) (TP-
6): 
A dry and argon-flushed Schlenk flask was charged with a solution of 5-bromo-2-methoxytropone (154, 
1.0 equiv) in dry THF (0.5 M solution). The solution was cooled to -30 °C and TMPZnCl·LiCl (36, 1.4 
equiv) was added dropwise. The reaction was stirred for 0.5 h at -30 °C to yield the corresponding zinc 
reagent. The completion of metalation was checked by TLC of reaction aliquots quenched with iodine 
in THF. 
                                                          
188 I. Tamburlin-Thumin, M. P. Crozet, J.-C. Barrière, Synthesis 1999, 7, 1149. 
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Typical procedure for the zincation of 2-benzyloxytropone (156) using TMPZnCl·LiCl (36) (TP-7): 
A dry and argon-flushed Schlenk flask was charged with a solution of 2-benzyloxytropone (156, 1.0 
equiv) in dry THF (0.5 M solution). The solution was cooled to 0 °C and TMPZnCl·LiCl (36, 2.0 equiv) was 
added dropwise. The reaction was stirred for 10 min at 0 °C to yield the corresponding zinc reagent. 
The completion of metalation was checked by TLC of reaction aliquots quenched with iodine in THF. 
Typical procedure for the addition of Grignard reagents to arylated 2-benzyloxytropones (157) (TP-
8): 
The arylated 2-benzyloxytropone of type 157 (1.0 equiv) was dissolved in THF (0.5 M solution), the 
mixture was cooled to -78 °C and the Grignard reagent (1.2 equiv) was added dropwise. The reaction 
was allowed to warm to room temperature over 4 h, followed by the addition of sat. aq. NH4Cl. The 
mixture was extracted with ethyl acetate and the combined organic extracts were dried over Na2SO4. 
 
4.3 Metalation and Functionalization of 5-Bromo-2-methoxytropone 
4-Bromo-2-iodo-7-methoxycyclohepta-2,4,6-trien-1-one (155a) 
 
5-Bromo-2-methoxytropone (154, 108 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.6 mL, 
0.7 mmol, 1.16 M solution) according to TP-6. The reaction mixture was then cooled to -78 °C and I2 
(152 mg, 0.6 mmol) dissolved in THF (2.0 mL) was added. The reaction was allowed to warm to room 
temperature over 4 h and was then quenchend with sat. aq. Na2S2O3 solution, extracted with CH2Cl2 
and dried over Na2SO4. The crude product was purified by column chromatography on silica 
(CH2Cl2:diethyl ether 4:1) to afford 155a (167 mg, 0.49 mmol, 98%) as a yellow solid. 
m.p.: 195 – 196 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.76 (d, J = 2.0 Hz, 1 H), 7.44 (dd, J = 10.7, 2.0 Hz, 1 H), 6.53 (d, J = 
10.6 Hz, 1 H), 3.92 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 175.2, 159.1, 149.4, 134.8, 120.3, 120.2, 111.4, 57.0. 
FT-IR (ATR, cm-1): 𝜈 = 3086, 3049, 1584, 1558, 1541, 1451, 1347, 1260, 1249, 1234, 1172, 1118, 1024, 
957, 903, 889, 848, 771, 741, 727, 714. 
MS (EI, 70 eV): m/z (%) = 342 (57), 340 (58), 312 (13), 311 (15), 299 (22), 297 (22), 260 (17), 213 (32), 
212 (31), 197 (15), 185 (66), 183 (65), 172 (45), 170 (46), 157 (15), 133 (28), 75 (29), 74 (20), 63 (100). 
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HR-MS (EI, 70 eV): [C8H6BrIO2], calc.: 339.8596; found: 339.8585. 
 
2,4-Dibromo-7-methoxycyclohepta-2,4,6-trien-1-one (155b) 
 
5-Bromo-2-methoxytropone (154, 108 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.6 mL, 
0.7 mmol, 1.16 M solution) according to TP-6. The reaction mixture was then cooled to -78 °C and Br2 
(0.03 mL, 96 mg, 0.6 mmol) was added. The reaction was allowed to warm to room temperature over 
4 h and was then quenchend with sat. aq. Na2S2O3 solution, extracted with CH2Cl2 and dried over 
Na2SO4. The crude product was purified by column chromatography on silica (CH2Cl2:diethyl ether 4:1) 
to afford 155b (109 mg, 0.37 mmol, 74%) as a yellow solid. 
m.p.: 175 – 176 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.44 (d, J = 2.0 Hz, 1 H), 7.47 (dd, J = 10.7, 2.0 Hz, 1 H), 6.61 – 6.38 
(m, 1 H), 3.94 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 173.3, 161.9, 142.8, 137.0, 134.6, 119.5, 111.6, 56.9. 
FT-IR (ATR, cm-1): 𝜈 = 3094, 3054, 1600, 1583, 1576, 1569, 1564, 1559, 1545, 1540, 1533, 1368, 1340, 
1264, 1254, 1238, 1173, 1123, 1028, 967, 901, 895, 846, 752, 737. 
MS (EI, 70 eV): m/z (%) = 297 (4), 296 (24), 294 (48), 292 (26), 265 (26), 264 (21), 251 (25), 223 (32), 18 
(69), 183 (62), 170 (21), 63 (100). 
HR-MS (EI, 70 eV): [C8H6Br2O2], calc.: 291.8735; found: 291.8746. 
 
4-Bromo-7-methoxy-2-(4-methoxyphenyl)cyclohepta-2,4,6-trien-1-one (155c) 
 
5-Bromo-2-methoxytropone (154, 108 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.6 mL, 
0.7 mmol, 1.16 M solution) according to TP-6. Then, 4-iodoanisole (105 mg, 0.45 mmol), Pd(dba)2 
(9 mg, 3 mol%) and P(o-furyl)3 (7 mg, 6 mol%) were added. The reaction mixture was allowed to warm 
to r.t. over 4 h and was then quenched with sat. aq. NH4Cl solution, extracted with CH2Cl2 and dried 
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over Na2SO4. The crude product was purified by column chromatography on silica (CH2Cl2:ethyl acetate 
9:1) to afford 155c (103 mg, 0.32 mmol, 70%) as a yellowish solid. 
m.p.: 133 – 134 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.69 (d, J = 2.1 Hz, 1 H), 7.47 – 7.40 (m, 2 H), 7.34 (dd, J = 10.4, 2.1 
Hz, 1 H), 6.97 – 6.89 (m, 2 H), 6.47 (d, J = 10.4 Hz, 1 H), 3.92 (s, 3 H), 3.84 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 179.0, 164.7, 159.9, 146.2, 140.1, 132.5, 132.2, 130.8, 121.5, 
113.6, 110.8, 56.6, 55.4. 
FT-IR (ATR, cm-1): 𝜈 = 3075, 2918, 2829, 1595, 1579, 1565, 1507, 1350, 1250, 1240, 1218, 1183, 1175, 
1170, 1117, 1109, 1032, 976, 825, 812, 805. 
MS (EI, 70 eV): m/z (%) = 323 (11), 322 (87), 321 (62), 320 (92), 319 (51), 291 (20), 241 (20), 198 (100), 
183 (45), 155 (25), 127 (34). 
HR-MS (EI, 70 eV): [C15H13BrO3], calc.: 320.0048; found: 320.0040. 
 
4-(3-Bromo-6-methoxy-7-oxocyclohepta-1,3,5-trien-1-yl)benzonitrile (155d) 
 
5-Bromo-2-methoxytropone (154, 108 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.6 mL, 
0.7 mmol, 1.16 M solution) according to TP-6. Then, 4-iodobenzonitrile (103 mg, 0.45 mmol), Pd(dba)2 
(9 mg, 3 mol%) and P(o-furyl)3 (7 mg, 6 mol%) were added. The reaction mixture was allowed to warm 
to r.t. over 4 h and was then quenched with sat. aq. NH4Cl solution, extracted with CH2Cl2 and dried 
over Na2SO4. The crude product was purified by column chromatography on silica (CH2Cl2:ethyl acetate 
2:1) to afford 155d (114 mg, 0.36 mmol, 81%) as a yellowish solid. 
m.p.: 141 – 142 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.74 – 7.66 (m, 2 H), 7.65 (d, J = 2.1 Hz, 1 H), 7.59 – 7.51 (m, 2 H), 
7.46 (dd, J = 10.5, 2.0 Hz, 1 H), 6.54 (d, J = 10.8 Hz, 1 H), 3.95 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 178.0, 165.5, 144.8, 144.5, 141.2, 134.5, 131.9, 130.2, 121.2, 
118.7, 112.1, 111.1, 56.8. 
FT-IR (ATR, cm-1): 𝜈 = 3088, 2978, 1712, 1570, 1363, 1296, 1255, 1245, 1217, 1174, 1130, 1112, 1087, 
992, 925, 845, 753, 697, 685. 
MS (EI, 70 eV): m/z (%) = 316 (11), 317 (61), 316 (37), 315 (62), 314 (26), 286 (18), 236 (18), 206 (40), 
194 (17), 193 (100), 190 (20), 165 (23), 164 (51), 87 (19). 
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HR-MS (EI, 70 eV): [C15H10BrNO2], calc.: 314.9895; found: 314.9880. 
 
4-Bromo-2-(4-(dimethylamino)phenyl)-7-methoxycyclohepta-2,4,6-trien-1-one (155e) 
 
5-Bromo-2-methoxytropone (154, 108 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.6 mL, 
0.7 mmol, 1.16 M solution) according to TP-6. Then, 4-iodo-N,N-dimethylaniline (111 mg, 0.45 mmol), 
Pd(dba)2 (9 mg, 3 mol%) and P(o-furyl)3 (7 mg, 6 mol%) were added. The reaction mixture was allowed 
to warm to r.t. over 4 h and was then quenched with sat. aq. NH4Cl solution, extracted with CH2Cl2 and 
dried over Na2SO4. The crude product was purified by column chromatography on silica (CH2Cl2:ethyl 
acetate 2:1) to afford 155e (101 mg, 0.30 mmol, 67%) as a yellowish solid. 
m.p.: 195 – 196 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.70 (d, J = 2.0 Hz, 1 H), 7.49 – 7.40 (m, 2 H), 7.27 (dd, J = 10.4, 2.1 
Hz, 1 H), 6.77 – 6.66 (m, 2 H), 6.44 (dd, J = 10.4, 0.8 Hz, 1 H), 3.91 (s, 3 H), 3.00 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 179.4, 164.2, 150.7, 146.5, 139.0, 131.4, 130.6, 127.4, 121.7, 
111.7, 110.7, 56.6, 40.4. 
FT-IR (ATR, cm-1): 𝜈 = 2925, 2840, 1593, 1587, 1567, 1516, 1356, 1253, 1242, 1228, 1167, 1111, 946, 
898, 850, 818. 
MS (EI, 70 eV): m/z (%) = 336 (5), 335 (19), 334 (5), 333 (21), 332 (3), 211 (17), 70 (12), 61 (17), 45 (16), 
43 (100). 
HR-MS (EI, 70 eV): [C16H16BrNO2], calc.: 333.0364; found: 333.0359. 
 
4-Bromo-7-methoxy-2-(3-nitrophenyl)cyclohepta-2,4,6-trien-1-one (155f) 
 
5-Bromo-2-methoxytropone (154, 108 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.6 mL, 
0.7 mmol, 1.16 M solution) according to TP-6. Then, 1-iodo-3-nitrobenzene (112 mg, 0.45 mmol), 
Pd(dba)2 (9 mg, 3 mol%) and P(o-furyl)3 (7 mg, 6 mol%) were added. The reaction mixture was allowed 
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to warm to r.t. over 4 h and was then quenched with sat. aq. NH4Cl solution, extracted with CH2Cl2 and 
dried over Na2SO4. The crude product was purified by column chromatography on silica (CH2Cl2:ethyl 
acetate 2:1) to afford 155f (134 mg, 0.40 mmol, 89%) as a light yellow solid. 
m.p.: 177 – 178 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.29 (t, J = 2.0 Hz, 1 H), 8.23 (ddd, J = 8.3, 2.3, 1.1 Hz, 1 H), 7.78 
(dt, J = 7.8, 1.3 Hz, 1 H), 7.70 (d, J = 2.0 Hz, 1 H), 7.57 (t, J = 8.0 Hz, 1 H), 7.47 (dd, J = 10.5, 2.1 Hz, 1 H), 
6.55 (d, J = 10.5 Hz, 1 H), 3.95 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 178.0, 165.6, 148.1, 144.2, 141.3, 141.3, 135.7, 134.6, 129.0, 
124.5, 123.3, 121.2, 111.2, 56.8. 
FT-IR (ATR, cm-1): 𝜈 = 3063, 1604, 1590, 1572, 1527, 1347, 1266, 1249, 1218, 1118, 1098, 1084, 994, 
894, 879, 837, 806, 729, 695, 687, 653. 
MS (EI, 70 eV): m/z (%) = 337 (32), 336 (19), 335 (38), 334 (12), 320 (99), 318 (98), 290 (40), 288 (34), 
260 (31), 148 (49), 246 (45), 139 (100).  
HR-MS (EI, 70 eV): [C14H10BrNO4], calc.: 334.9793; found: 334.9774. 
 
Ethyl 3-(3-bromo-6-methoxy-7-oxocyclohepta-1,3,5-trien-1-yl)benzoate (155g) 
 
5-Bromo-2-methoxytropone (154, 108 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.6 mL, 
0.7 mmol, 1.16 M solution) according to TP-6. Then, ethyl 3-iodobenzoate (124 mg, 0.45 mmol), 
Pd(dba)2 (9 mg, 3 mol%) and P(o-furyl)3 (7 mg, 6 mol%) were added. The reaction mixture was allowed 
to warm to r.t. over 4 h and was then quenched with sat. aq. NH4Cl solution, extracted with CH2Cl2 and 
dried over Na2SO4. The crude product was purified by column chromatography on silica (CH2Cl2:ethyl 
acetate 3:1) to afford 155g (120 mg, 0.33 mmol, 73%) as a light yellow solid. 
m.p.: 219 – 220 °C (decomp.). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.08 (t, J = 1.7 Hz, 1 H), 8.06 (dt, J = 7.7, 1.5 Hz, 1 H), 7.69 (d, J = 
2.1 Hz, 1 H), 7.65 (dt, J = 7.8, 1.4 Hz, 1 H), 7.48 (td, J = 7.7, 0.6 Hz, 1 H), 7.42 (dd, J = 10.5, 2.1 Hz, 1 H), 
6.51 (dd, J = 10.6, 0.7 Hz, 1 H), 4.39 (q, J = 7.1 Hz, 2 H), 3.94 (s, 3 H), 1.39 (t, J = 7.1 Hz, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 178.4, 166.3, 165.2, 145.8, 140.9, 140.1, 133.9, 133.7, 130.6, 
130.3, 129.6, 128.1, 121.4, 110.9, 61.1, 56.7, 14.4. 
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FT-IR (ATR, cm-1): 𝜈 = 2925, 2852, 1779, 1720, 1609, 1578, 1312, 1252, 1166, 1113, 1058, 1034, 978, 
911, 766, 671. 
MS (EI, 70 eV): m/z (%) = 334 (1), 317 (87), 316 (44), 315 (81), 314 (33), 286 (21), 206 (59),  194 (23), 
190 (29), 164 (100), 139 (21). 
HR-MS (EI, 70 eV): [C15H11BrO4], calc.: 333.9841; found: 333.9838 [M-Et]+.  
 
4.4 Metalation of 2-Benzyloxytropone 
2-(Benzyloxy)-7-iodocyclohepta-2,4,6-trien-1-one (157a) 
 
2-Benzyloxytropone (156, 106 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.86 mL, 
1.0 mmol, 1.16 M solution) according to TP-7. The reaction mixture was then cooled to -78 °C and I2 
(253 mg, 1.0 mmol) dissolved in THF (2.0 mL) was added. The reaction was allowed to warm to room 
temperature over 4 h and was then quenchend with sat. aq. Na2S2O3 solution, extracted with CH2Cl2 
and dried over Na2SO4. The crude product was purified by column chromatography on silica 
(CH2Cl2:diethyl ether 5:1) to afford 157a (152 mg, 0.45 mmol, 89%) as a brown solid. 
m.p.: 101 – 103 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.52 (dd, J = 9.4, 1.0 Hz, 1 H), 7.47 – 7.41 (m, 2 H), 7.40 – 7.29 (m, 
3 H), 7.09 – 6.99 (m, 1 H), 6.84 (d, J = 9.9 Hz, 1 H), 6.57 – 6.42 (m, 1 H), 5.23 (s, 2 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 175.9, 159.0, 146.8, 135.2, 133.2, 128.7, 128.3, 127.2, 126.7, 
122.1, 114.8, 71.3. 
FT-IR (ATR, cm-1): 𝜈 = 3028, 1580, 1572, 1458, 1451, 1274, 1232, 1194, 1179, 1098, 983, 881, 775, 743, 
735, 694.  
MS (EI, 70 eV): m/z (%) = 339 (1), 338 (3), 232 (19), 211 (9), 105 (9), 91 (100), 65 (9). 
HR-MS (EI, 70 eV): [C14H11IO2], calc.: 337.9804; found: 337.9798. 
 
2-(Benzyloxy)-7-bromocyclohepta-2,4,6-trien-1-one (157b) 
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2-Benzyloxytropone (156, 106 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.86 mL, 
1.0 mmol, 1.16 M solution) according to TP-7. The reaction mixture was then cooled to -78 °C and 1,2-
dibromotetrachloroethane (325 mg, 1.0 mmol) dissolved in THF (2.0 mL) was added. The reaction was 
allowed to warm to room temperature over 4 h and was then quenchend with sat. aq. Na2S2O3 
solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (CH2Cl2:diethyl ether 4:1) to afford 157b (122 mg, 0.42 mmol, 83%) as an off-
white solid. 
m.p.: 98 – 100 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.42 (d, J = 2.0 Hz, 1 H), 7.43 – 7.36 (m, 6 H), 7.36 – 7.30 (m, 1 H), 
6.61 (d, J = 10.7 Hz, 1 H), 5.23 (s, 2 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 173.5, 160.8, 142.6, 137.5, 134.7, 134.4, 128.8, 128.5, 127.2, 
120.0, 114.3, 71.5. 
FT-IR (ATR, cm-1): 𝜈 = 3065, 1583, 1460, 1449, 1279, 1236, 1198, 1100, 981, 977, 887, 776, 767, 754, 
727, 693. 
MS (EI, 70 eV): m/z (%) = 289 (2), 186 (8), 92 (8), 91 (100), 59 (25), 45 (29), 43 (70). 
HR-MS (EI, 70 eV): [C14H11BrO2], calc.: 289.9942; found: 289.9934. 
 
2-(Benzyloxy)-7-(cyclohex-2-en-1-yl)cyclohepta-2,4,6-trien-1-one (157c) 
 
2-Benzyloxytropone (156, 106 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.86 mL, 
1.0 mmol, 1.16 M solution) according to TP-7. CuCN·2LiCl (0.6 mL, 0.6 mmol, 1 M solution) was added 
at 0 °C and the reaction mixture was stirred for 0.5 h. Then 3-bromocyclohexene (97 mg, 0.6 mmol) 
was added and the reaction was allowed to warm to 25 °C over 2 h. The reaction mixture was quenched 
by the addition of sat. aq. NH4Cl/NH3 solution, extracted with CH2Cl2 and dried over Na2SO4. The crude 
product was purified by column chromatography on silica (i-hexane:ethyl acetate 2:1) to afford 157c 
(137 mg, 0.47 mmol, 94%) as a yellow oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.49 – 7.43 (m, 2 H), 7.41 – 7.27 (m, 4 H), 6.95 – 6.74 (m, 3 H), 
5.97 (dtd, J = 9.9, 3.7, 2.2 Hz, 1 H), 5.55 (dq, J = 10.1, 2.4 Hz, 1 H), 5.19 (s, 2 H), 4.19 (tp, J = 5.6, 2.7 Hz, 
1 H), 2.19 – 2.10 (m, 1 H), 2.07 (tq, J = 5.9, 2.6 Hz, 2 H), 1.73 – 1.53 (m, 2 H), 1.40 (dddd, J = 12.6, 8.8, 
6.8, 3.4 Hz, 1 H). 
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13C-NMR (100 MHz, CDCl3, ppm): δ = 179.5, 163.1, 153.7, 135.9, 135.3, 130.6, 130.0, 129.6, 128.6, 
128.0, 127.6, 127.1, 114.7, 70.9, 38.3, 29.9, 25.2, 20.7. 
FT-IR (ATR, cm-1): 𝜈 = 3016, 2923, 2857, 1591, 1572, 1495, 1461, 1453, 1371, 1268, 1244, 1222, 1184, 
1175, 1146, 1128, 1080, 1059, 1027, 1002, 976, 910, 889, 872, 848, 803, 733, 694. 
MS (EI, 70 eV): m/z (%) = 292 (5), 203 (14), 202 (89), 187 (5), 135 (8), 115 (6), 92 (9), 91 (100). 
HR-MS (EI, 70 eV): [C20H20O2], calc.: 292.1463; found: 292.1456. 
 
2-Benzoyl-7-(benzyloxy)cyclohepta-2,4,6-trien-1-one (157d) 
 
2-Benzyloxytropone (156, 106 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.86 mL, 
1.0 mmol, 1.16 M solution) according to TP-7. CuCN·2LiCl (0.6 mL, 0.6 mmol, 1 M solution) was added 
at 0 °C and the reaction mixture was stirred for 0.5 h. Then benzoyl chloride (141 mg, 1.0 mmol) and 
the reaction was allowed to warm to 25 °C over 2 h. The reaction mixture was quenched by the addition 
of sat. aq. NH4Cl/NH3 solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was 
purified by column chromatography on silica (i-hexane:ethyl acetate 4:1) to afford 157d (120 mg, 
0.38 mmol, 76%) as a brown oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.91 – 7.77 (m, 2 H), 7.56 – 7.50 (m, 1 H), 7.46 – 7.28 (m, 8 H), 
7.14 (ddd, J = 10.9, 9.8, 1.2 Hz, 1 H), 6.96 – 6.88 (m, 2 H), 5.24 (s, 2 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 196.9, 178.7, 165.5, 146.7, 136.2, 135.5, 135.1, 134.5, 133.3, 
129.3, 128.8, 128.6, 128.3, 127.4, 127.2, 115.0, 71.1. 
FT-IR (ATR, cm-1): 𝜈 = 2972, 2860, 1673, 1593, 1581, 1497, 1277, 1232, 1198, 1178, 1064, 1030, 944, 
906, 753, 733, 696, 676, 662. 
MS (EI, 70 eV): m/z (%) = 317 (6), 316 (24), 181 (7), 105 (30), 91 (100), 77 (24), 65 (6). 
HR-MS (EI, 70 eV): [C21H16O3], calc.: 316.1099; found: 316.1096. 
 
2-(Benzyloxy)-7-(cyclopropanecarbonyl)cyclohepta-2,4,6-trien-1-one (157e) 
 
2-Benzyloxytropone (156, 106 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.86 mL, 
1.0 mmol, 1.16 M solution) according to TP-7. CuCN·2LiCl (0.6 mL, 0.6 mmol, 1 M solution) was added 
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at 0 °C and the reaction mixture was stirred for 0.5 h. Then cyclopropanecarbonyl chloride (104 mg, 
1.0 mmol) and the reaction was allowed to warm to 25 °C over 2 h. The reaction mixture was quenched 
by the addition of sat. aq. NH4Cl/NH3 solution, extracted with CH2Cl2 and dried over Na2SO4. The crude 
product was purified by column chromatography on silica (i-hexane:ethyl acetate 2:1) to afford 157e 
(95 mg, 0.34 mmol, 68%) as a brown oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.53 (dd, J = 8.8, 1.1 Hz, 1 H), 7.47 – 7.43 (m, 2 H), 7.42 – 7.30 (m, 
3 H), 7.10 (ddd, J = 10.9, 9.8, 1.2 Hz, 1 H), 6.89 (ddd, J = 10.7, 8.7, 0.7 Hz, 1 H), 6.83 (d, J = 9.8 Hz, 1 H), 
5.25 (s, 2 H), 2.41 (tt, J = 7.8, 4.6 Hz, 1 H), 1.27 – 1.18 (m, 2 H), 1.00 (dq, J = 7.4, 3.6 Hz, 2 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 205.6, 179.1, 166.1, 146.2, 136.3, 135.1, 135.0, 128.8, 128.4, 
127.3, 127.0, 114.0, 71.2, 21.2, 12.8. 
FT-IR (ATR, cm-1): 𝜈 = 3007, 1673, 1614, 1592, 1572, 1490, 1453, 1376, 1274, 1248, 1191, 1155, 1058, 
1025, 969, 956, 921, 907, 862, 734, 695. 
MS (EI, 70 eV): m/z (%) = 280 (3), 174 (8), 92 (7), 91 (100), 65 (7). 
HR-MS (EI, 70 eV): [C18H16O3], calc.: 280.1099; found: 280.1092. 
 
(E)-2-(Benzyloxy)-7-(3-oxooct-1-en-1-yl)cyclohepta-2,4,6-trien-1-one (157f) 
 
2-Benzyloxytropone (156, 106 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.86 mL, 
1.0 mmol, 1.16 M solution) according to TP-7, followed by addition of (E)-1-iodooct-1-ene (143 mg, 
0.6 mmol), Pd(dba)2 (9 mg, 3 mol%) and P(o-furyl)3 (7 mg, 6 mol%) at 0 °C. The reaction mixture was 
allowed to warm to r.t. over 4 h and was then quenched by the addition of sat. aq. NH4Cl solution, 
extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (CH2Cl2:ethyl acetate 6:1) to afford 157f (90 mg, 0.38 mmol, 75%) as a yellow 
oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.56 (dd, J = 8.9, 1.3 Hz, 1 H), 7.49 – 7.44 (m, 2 H), 7.41 – 7.34 (m, 
2 H), 7.34 – 7.27 (m, 1 H), 7.01 (dt, J = 15.8, 1.6 Hz, 1 H), 6.94 – 6.75 (m, 3 H), 6.39 (dt, J = 15.6, 7.0 Hz, 
1 H), 5.22 (s, 2 H), 2.28 (qd, J = 7.1, 1.5 Hz, 2 H), 1.49 (ddd, J = 12.2, 8.2, 6.5 Hz, 2 H), 1.41 – 1.23 (m, 6 
H), 0.96 – 0.79 (m, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 179.1, 163.2, 144.4, 136.3, 135.8, 132.4, 130.7, 129.1, 128.7, 
128.1, 127.5, 127.1, 115.1, 70.9, 33.6, 31.8, 29.2, 29.0, 22.6, 14.2. 
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FT-IR (ATR, cm-1): 𝜈 = 2953, 2924, 2855, 1721, 1698, 1590, 1572, 1557, 1496, 1453, 1377, 1365, 1270, 
1193, 1177, 1079, 1027, 1002, 968, 907, 849, 801, 734, 695, 652. 
MS (EI, 70 eV): m/z (%) = 322 (5), 237 (18), 231 (25), 147 (15), 91 (100), 59 (13). 
HR-MS (EI, 70 eV): [C22H26O2], calc.: 322.1933; found: 322.1963. 
 
2-(Benzyloxy)-7-(4-methoxyphenyl)cyclohepta-2,4,6-trien-1-one (157g) 
 
2-Benzyloxytropone (156, 106 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.86 mL, 
1.0 mmol, 1.16 M solution) according to TP-7, followed by addition of 4-iodoanisole (140 mg, 
0.6 mmol), Pd(dba)2 (9 mg, 3 mol%) and P(o-furyl)3 (7 mg, 6 mol%) at 0 °C. The reaction mixture was 
allowed to warm to r.t. over 4 h and was then quenched by the addition of sat. aq. NH4Cl solution, 
extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (CH2Cl2:ethyl acetate 4:1) to afford 157g (124 mg, 0.39 mmol, 77%) as a 
yellow solid. 
m.p.: 105 – 106 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.51 – 7.41 (m, 5 H), 7.40 – 7.28 (m, 3 H), 6.96 – 6.90 (m, 3 H), 
6.90 – 6.79 (m, 2 H), 5.21 (s, 2 H), 3.83 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 179.5, 164.7, 159.5, 147.3, 136.8, 135.8, 133.5, 131.0, 130.9, 
128.7, 128.1, 127.5, 127.2, 114.8, 113.4, 71.0, 55.3. 
FT-IR (ATR, cm-1): 𝜈 = 3003, 2905, 1597, 1592, 1583, 1575, 1508, 1270, 1241, 1219, 1199, 1189, 1178, 
1094, 1073, 1030, 992, 834, 823, 811, 767, 758, 739, 695 
MS (EI, 70 eV): m/z (%) = 318 (10), 212 (12), 199 (32), 171 (12), 128 (10), 91 (40), 59 (22), 43 (100). 
HR-MS (EI, 70 eV): [C21H18O3], calc.: 318.1256; found: 318.1251. 
 
2-(Benzyloxy)-7-(4-chlorophenyl)cyclohepta-2,4,6-trien-1-one (157h) 
 
2-Benzyloxytropone (156, 106 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.86 mL, 
1.0 mmol, 1.16 M solution) according to TP-7, followed by addition of 1-chloro-4-iodobenzene 
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(143 mg, 0.6 mmol), Pd(dba)2 (9 mg, 3 mol%) and P(o-furyl)3 (7 mg, 6 mol%) at 0 °C. The reaction 
mixture was allowed to warm to r.t. over 4 h and was then quenched by the addition of sat. aq. NH4Cl 
solution, extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (i-hexane:ethyl acetate 2:1) to afford 157h (136 mg, 0.42 mmol, 83%) as a 
yellow solid. 
m.p.: 98 – 100 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.48 – 7.28 (m, 10 H), 7.00 (ddd, J = 10.7, 9.5, 1.2 Hz, 1 H), 6.95 – 
6.80 (m, 2 H), 5.24 (s, 2 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 179.1, 165.0, 146.5, 139.5, 137.3, 135.5, 133.9, 131.9, 130.9, 
128.7, 128.2, 128.1, 127.3, 127.2, 114.7, 71.0. 
FT-IR (ATR, cm-1): 𝜈 = 1583, 1555, 1493, 1454, 1271, 1219, 1210, 1181, 1155, 1092, 1073, 1013, 955, 
917, 896, 846, 824, 799, 793, 751, 723, 705, 695, 665, 656. 
MS (EI, 70 eV): m/z (%) = 324 (1), 322 (4), 216 (12), 181 (6), 92 (6), 91 (100), 43 (28). 
HR-MS (EI, 70 eV): [C20H15ClO2], calc.: 322.0761; found: 322.0754. 
 
2-(Benzyloxy)-7-(4-(trifluoromethyl)phenyl)cyclohepta-2,4,6-trien-1-one (157i) 
 
2-Benzyloxytropone (156, 106 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.86 mL, 
1.0 mmol, 1.16 M solution) according to TP-7, followed by addition of 4-iodobenzotrifluoride (163 mg, 
0.6 mmol), Pd(dba)2 (9 mg, 3 mol%) and P(o-furyl)3 (7 mg, 6 mol%) at 0 °C. The reaction mixture was 
allowed to warm to r.t. over 4 h and was then quenched with sat. aq. NH4Cl solution, extracted with 
CH2Cl2 and dried over Na2SO4. The crude product was purified by column chromatography on silica (i-
hexane:ethyl acetate 2:1) to afford 157i (164 mg, 0.46 mmol, 91%) as a yellow solid. 
m.p.: 123 – 124 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.65 (d, J = 8.2 Hz, 2 H), 7.58 (d, J = 8.1 Hz, 2 H), 7.50 – 7.39 (m, 3 
H), 7.40 – 7.35 (m, 2 H), 7.35 – 7.29 (m, 1 H), 7.04 (ddd, J = 10.7, 9.6, 1.1 Hz, 1 H), 6.95 – 6.84 (m, 2 H), 
5.25 (s, 2 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 178.9, 165.3, 146.4, 144.7 (d, J = 1.7 Hz), 137.6, 135.4, 132.4, 
129.8 (q, J = 32.4 Hz), 129.8, 128.7, 128.2, 127.2, 127.1, 124.9 (q, J = 3.8 Hz), 124.2 (q, J = 272.0 Hz), 
114.7, 71.1. 
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FT-IR (ATR, cm-1): 𝜈 = 1597, 1582, 1497, 1325, 1275, 1222, 1155, 1102, 1096, 1063, 1011, 993, 853, 
839, 761, 752, 733, 693, 685. 
MS (EI, 70 eV): m/z (%) = 356 (4), 265 (7), 250 (16), 181 (6), 92 (9), 91 (100), 65 (8). 
HR-MS (EI, 70 eV): [C21H15F3O2], calc.: 356.1024; found: 356.1037. 
 
2-(Benzyloxy)-7-(4-(dimethylamino)phenyl)cyclohepta-2,4,6-trien-1-one (157j) 
 
2-Benzyloxytropone (156, 106 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.86 mL, 
1.0 mmol, 1.16 M solution) according to TP-7, followed by addition of 4-iodo-N,N-dimethylaniline 
(148 mg, 0.6 mmol), Pd(dba)2 (9 mg, 3 mol%) and P(o-furyl)3 (7 mg, 6 mol%) at 0 °C. The reaction 
mixture was allowed to warm to r.t. over 4 h and was then quenched with sat. aq. NH4Cl solution, 
extracted with CH2Cl2 and dried over Na2SO4. The crude product was purified by column 
chromatography on silica (i-hexane:ethyl acetate 2:1) to afford 157j (128 mg, 0.39 mmol, 77%) as a 
yellow solid. 
m.p.: 119 – 120 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.51 – 7.43 (m, 5 H), 7.40 – 7.33 (m, 2 H), 7.33 – 7.27 (m, 1 H), 
6.90 – 6.84 (m, 2 H), 6.84 – 6.80 (m, 1 H), 6.78 – 6.70 (m, 2 H), 5.22 (s, 2 H), 2.99 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 179.8, 164.3, 150.4, 147.7, 136.0, 135.9, 130.6, 130.0, 128.8, 
128.6, 128.0, 127.6, 127.2, 115.1, 111.8, 71.0, 40.5. 
FT-IR (ATR, cm-1): 𝜈 = 2925, 2811, 1595, 1587, 1571, 1522, 1444, 1360, 1264, 1222, 1214, 1199, 1180, 
1173, 1153, 1079, 1067, 967, 945, 894, 819, 802, 795, 766, 755, 733, 697. 
MS (EI, 70 eV): m/z (%) = 332 (7), 331 (33), 241 (15), 213 (19), 221 (100), 197 (14), 184 (50), 168 (13), 
91 (21). 
HR-MS (EI, 70 eV): [C22H21NO2], calc.: 331.1572; found: 331.1569. 
 
2-(Benzyloxy)-7-(thiophen-2-yl)cyclohepta-2,4,6-trien-1-one (157k) 
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2-Benzyloxytropone (156, 106 mg, 0.5 mmol) was metalated with TMPZnCl·LiCl (36, 0.86 mL, 
1.0 mmol, 1.16 M solution) according to TP-7, followed by addition of 2-iodothiophene (126 mg, 
0.6 mmol), Pd(dba)2 (9 mg, 3 mol%) and P(o-furyl)3 (7 mg, 6 mol%) at 0 °C. The reaction mixture was 
allowed to warm to r.t. over 4 h and was then quenched with sat. aq. NH4Cl solution, extracted with 
CH2Cl2 and dried over Na2SO4. The crude product was purified by column chromatography on silica (i-
hexane:ethyl acetate 9:1) to afford 157k (118 mg, 0.40 mmol, 80%) as a yellow oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.01 (dd, J = 9.0, 1.3 Hz, 1 H), 7.64 (dd, J = 3.9, 1.2 Hz, 1 H), 7.52 
(dd, J = 5.2, 1.1 Hz, 1 H), 7.48 – 7.43 (m, 2 H), 7.40 – 7.28 (m, 3 H), 7.12 (dd, J = 5.1, 3.9 Hz, 1 H), 7.05 – 
6.86 (m, 3 H), 5.24 (s, 2 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 177.2, 163.8, 140.4, 138.9, 135.6, 133.7, 131.3, 130.6, 128.7, 
128.2, 127.3, 127.2, 127.1, 126.1, 115.3, 71.2. 
FT-IR (ATR, cm-1): 𝜈 = 3063, 2865, 1583, 1561, 1452, 1413, 1368, 1267, 1233, 1188, 1176, 1086, 1050, 
1028, 1015, 954, 888, 851, 741, 693, 661. 
MS (EI, 70 eV): m/z (%) = 295 (3), 294 (16), 267 (6), 262 (5), 188 (6), 175 (14), 147 (16), 115 (6), 91 
(100), 65 (8). 
HR-MS (EI, 70 eV): [C18H14O2S], calc.: 294.0715; found: 294.0710. 
 
4.5 Addition of Grignard Reagents to 7-Aryl-2-benzyloxytropones 
2-(4-Chlorophenyl)-7-phenylcyclohepta-2,4,6-trien-1-one (159a) 
 
Compound 159a was prepared from 2-(benzyloxy)-7-(4-chlorophenyl)cyclohepta-2,4,6-trien-1-one 
(157h, 65 mg, 0.2 mmol) and phenylmagnesium chloride (0.15 mL, 0.24 mmol, 1.64 M solution in THF) 
according to TP-8. The crude product was purified by column chromatography on silica (i-hexane:ethyl 
acetate 6:1) to afford 159a as a yellow solid (36 mg, 0.12 mmol, 62%). 
m.p.: 114 – 115 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.57 – 7.46 (m, 4H), 7.43 – 7.29 (m, 7H), 7.10 – 6.96 (m, 2H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 186.6, 151.0, 149.5, 140.1, 138.5, 134.5, 134.4, 134.3, 132.3, 
131.8, 130.7, 129.2, 128.3, 128.3, 128.2. 
FT-IR (ATR, cm-1): 𝜈 = 2923, 1573, 1489, 1347, 1091, 932, 824, 799, 778, 769, 746, 729, 695, 674, 665. 
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MS (EI, 70 eV): m/z (%) = 294 (24), 293 (34), 292 (62), 291 (70), 264 (28), 229 (68), 228 (26), 113 (22), 
43 (100). 
HR-MS (EI, 70 eV): [C19H12ClO], calc.: 291.0577; found: 291.0573 [M-H+]. 
 
2-Phenyl-7-(4-(trifluoromethyl)phenyl)cyclohepta-2,4,6-trien-1-one (159b) 
 
Compound 159b was prepared from 2-(benzyloxy)-7-(4-(trifluoromethyl)phenyl)cyclohepta-2,4,6-
trien-1-one (157i, 71 mg, 0.2 mmol) and phenylmagnesium chloride (0.15 mL, 0.24 mmol, 1.64 M 
solution in THF) according to TP-8. The crude product was purified by column chromatography on silica 
(i-hexane:ethyl acetate 6:1) to afford 159b as a yellow solid (47 mg, 0.14 mmol, 72%). 
m.p.: 148 – 149 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.64 (s, 4 H), 7.56 – 7.51 (m, 2 H), 7.44 – 7.33 (m, 5 H), 7.13 – 6.98 
(m, 2 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 186.3, 151.6, 149.7, 143.9, 139.9, 135.1, 134.8, 132.9, 131.8, 
130.1 (q, J = 32.6 Hz), 129.6, 129.2, 128.4, 128.2, 125.0 (q, J = 3.8 Hz), 124.1 (q, J = 272.1 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 2922, 1617, 1574, 1324, 1316, 1292, 1272, 1192, 1184, 1168, 1154, 1129, 1105, 
1070, 1060, 1018, 1004, 932, 836, 798, 780, 754, 738, 715, 693, 672. 
MS (EI, 70 eV): m/z (%) = 327 (19), 326 (88), 325 (100), 298 (41), 283 (20), 257 (15), 229 (47), 228 (40), 
226 (15). 
HR-MS (EI, 70 eV): [C20H13F3O], calc.: 326.0918; found: 326.0897. 
 
2-(4-Methoxyphenyl)-7-(4-(trifluoromethyl)phenyl)cyclohepta-2,4,6-trien-1-one (159c) 
 
Compound 159c was prepared from 2-(benzyloxy)-7-(4-(dimethylamino)phenyl)cyclohepta-2,4,6-
trien-1-one (157j, 66 mg, 0.2 mmol) and p-anisylmagnesium chloride (0.26 mL, 0.24 mmol, 0.94 M 
solution in THF) according to TP-8. The crude product was purified by column chromatography on silica 
(i-hexane:ethyl acetate 3:1) to afford 159c as a yellow solid (40 mg, 0.12 mmol, 61%). 
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m.p.: 94 – 96 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.60 – 7.53 (m, 3 H), 7.27 (ddd, J = 14.4, 8.1, 1.4 Hz, 3 H), 6.98 – 
6.83 (m, 4 H), 6.74 – 6.68 (m, 2 H), 3.82 (s, 3 H), 2.98 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 188.4, 159.5, 150.5, 148.7, 147.6, 132.6, 132.1, 131.0, 131.0, 
130.4, 130.2, 129.9, 127.2, 113.6, 111.8, 55.3, 40.3. 
FT-IR (ATR, cm-1): 𝜈 = 2922, 1600, 1570, 1505, 1438, 1352, 1288, 1244, 1225, 1202, 1176, 1163, 1030, 
835, 824, 802, 794, 761.  
MS (EI, 70 eV): m/z (%) = 332 (1), 221 (5), 330 (1), 303 (7), 73 (6), 70 (12), 61 (17), 45 (15), 43 (100). 
HR-MS (EI, 70 eV): [C22H21NO2], calc.: 331.1572; found: 331.1565. 
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5 Cobalt-Catalyzed Negishi Cross-Coupling of (Hetero)Arylzinc Reagents 
with Primary and Secondary Alkyl Bromides and Iodides 
5.1 Preparation of Starting Materials 
The following starting materials were prepared by standard procedures:  
Protection of the alcohol: The respective diol (1.0 equiv) was dissolved in DMF (0.5 M solution), then 
imidazole (1.2 equiv) and TBSCl (1.2 equiv) were added portionwise. The reaction mixture was stirred 
for 12 h, then sat. aq. NH4Cl solution was added and the phases were separated. The aqueous phase 
mixture was extracted with diethyl ether and the combined organic layers were dried over Na2SO4. 
After removal of the solvent, the residue was subjected to column chromatography on silica to afford 
the TBS-protected alcohol. 
Iodination: A suspension of I2 (1.2 equiv) in CH2Cl2 (0.5 M solution) was cooled to 0 °C and PPh3 was 
added portionwise. The reaction mixture was stirred for 1 h, then NMI (1.2 equiv) was added, followed 
by the addition of the TBS-protected cycloalcohol (1.0 equiv). The reaction mixture was stirred for 2 h 
and allowed to warm to 25 °C. Sat. aq. NH4Cl solution was added, the phases were separated and the 
aqueous phase was extracted with CH2Cl2. The combined organic layers were dried over Na2SO4. After 
removal of the solvent, the residue was subjected to column chromatography on silica (i-hexane) to 
yield the TBS-protected alkyl iodide. 
 
tert-Butyl((2-iodocyclohexyl)oxy)dimethylsilane189 
 
d.r.: 25:75 (trans/cis). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 4.53 - 4.39 (m, 1 H), 3.36 (s br, 1 H), 2.32 - 2.20 (m, 1 H), 1.96 - 
1.84 (m, 1 H), 1.79 - 1.60 (m, 3 H), 1.57 - 1.30 (m, 3 H), 0.95 (s, 9 H), 0.14 (s, 3 H), 0.08 (s, 3 H). 
 
tert-butyl((4-iodopentan-2-yl)oxy)dimethylsilane190 
                                                          
189 M. R. Detty, M, D. Seidler, J. Org. Chem. 1981, 46, 1283. 
190 K. Moriya, D. Didier, M. Simon, J. M. Hammann, G. Berionni, K. Karaghiosoff, H. Zipse, H. Mayr, P. Knochel, Angew. Chem. 
Int. Ed. 2015, 54, 2754. 
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d.r.: 50:50 (syn/anti) 
1H-NMR (300 MHz, CDCl3, ppm): δ = 4.17 (ddq, J = 7.9, 6.85, 6.84 Hz, 1 H), 3.92 (qt, J = 6.11, 6.10 Hz, 1 
H), 2.19 (ddd, J = 14.4, 8.0. 6.6 Hz, 1 H), 1.93 (d, J = 6.8 Hz, 3 H), 1.70 (dt, J = 14.1, 6.5 Hz, 1 H), 1.12 
(d, J = 6.0 Hz, 3 H), 0.89 (s, 9 H), 0.074 (s, 3 H), 0.068 (s, 3 H).  
 
tert-Butyl((4-iodotetrahydrofuran-3-yl)oxy)dimethylsilane168a 
 
2,5-Dihydrofuran (10.0 mmol) was dissolved in DME (70 mL) and H2O (25 mL) and the mixture was 
cooled to -20 °C. NIS (15 mmol) was added portionwise and the reaction was stirred for 5 h. Sat. aq. 
NaCl solution was added, the phases were separated and the aqueous phase was extracted with ethyl 
acetate. The combined organic layers were dried over Na2SO4 and the solvents were evaporated. The 
residue was dissolved in DMF and imidazole (16 mmmol) and TBSCl (12 mmol) were added 
portionwise. The reaction was stirred for 12 h at 25 °C and then NH4Cl was added. The phases were 
separated and the aqueous phase was extracted with diethy ether. The combined organic layers were 
dried over Na2SO4, the solvent was evaporated and the residue was subjected to column 
chromatography on silica (pentane/diethyl ether) yielding the title compound (2.4 g, 73% yield) as 
colorless oil. 
d.r.: 99:1 (trans/cis).  
1H-NMR (300 MHz, CDCl3, ppm): δ = 4.58 (dt, J = 4.4, 2.2 Hz, 1 H), 4.36 - 4.17 (m, 2 H), 4.10 - 3.97 (m, 
2 H), 3.66 (dd, J = 9.3, 2.1 Hz, 1 H), 0.87 (s, 9 H), 0.14 - 0.01 (m, 6 H). 
 
tert-Butyl((2-iodocyclopentyl)oxy)dimethylsilane189 
 
Cyclopentene (10.0 mmol) was dissolved in DME (70 mL) and H2O (25 mL) and the mixture was cooled 
to -20 °C. NIS (15 mmol) was added portionwise and the reaction was stirred for 5 h. Sat. aq. NaCl 
solution was added, the phases were separated and the aqueous phase was extracted with ethyl 
acetate. The combined organic layers were dried over Na2SO4 and the solvents were evaporated. The 
residue was dissolved in DMF and imidazole (16 mmmol) and TBSCl (12 mmol) were added 
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portionwise. The reaction was stirred for 12 h at 25 °C and then NH4Cl was added. The phases were 
separated and the aqueous phase was extracted with diethy ether. The combined organic layers were 
dried over Na2SO4, the solvent was evaporated and the residue was subjected to column 
chromatography on silica (pentane/diethyl ether) yielding the title compound (2.5 g, 76% yield) as 
colorless oil. 
d.r.: 99:1 (trans/cis). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 4.43 (ddd, J = 6.3, 3.6, 3.3 Hz, 1 H), 4.06 - 3.98 (m, 1 H), 2.41 - 2.28 
(m, 1 H), 2.16 - 1.97 (m, 2 H), 1.80 (quin, J = 7.4 Hz, 2 H), 1.60 - 1.49 (m, 1 H), 0.89 (s, 9 H), 0.10 (s, 3 H), 
0.07 (s, 3 H). 
 
5.2 Typical Procedures 
Typical procedure for the metalation of (hetero)arenes using TMP2Zn·2MgCl2·2LiCl (48) (TP-9): 
A dry and argon-flushed 10 mL Schlenk-tube was charged with a solution of the corresponding 
(hetero)arene (1.4 mmol, 1.0 equiv) in dry THF (1 mL). TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 
1.91 mL, 0.6 equiv) was added dropwise at the given temperature and the reaction mixture was stirred 
at this temperature. The completion of the metalation was checked by GC-analysis of reaction aliquots 
quenched with a solution of I2 in dry THF. 
Typical procedure for the cobalt-catalyzed cross-coupling of (hetero)arylzinc reagents with alkyl 
halides (TP-10): 
A dry and argon-flushed 10 mL Schlenk-tube was charged with a solution of CoCl2·2LiCl (1 M in THF) 
(0.2 mmol, 0.2 mL, 20 mol%) and dry THF (1.0 mL). The respective alkyl iodide or bromide (1.0 mmol, 
1.0 equiv) and TMEDA (0.3 mmol, 45 mg, 30 mol%) were added via syringe. The reaction mixture was 
cooled to 0 °C and a solution of the freshly prepared zinc reagent (1.4 mmol, 1.4 equiv) was added 
dropwise over 5 min. The reaction was allowed to warm to 25 °C and was monitored by GC-analysis 
(undecane C11H24 was used as an internal standard). Upon consumption of the starting material, 
saturated aqueous NH4Cl solution (5 mL) and ethyl acetate (5 mL) were added, the phases were 
separated and the aqueous phase was extracted with ethyl acetate (3 x 50 mL). The combined organic 
layers were dried over Na2SO4, the solvents were evaporated and the residue was subjected to column 
chromatography yielding the respective title compound. 
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5.3 Cobalt-Catalyzed Negishi Cross-Coupling Reactions of (Hetero)Arylzinc Reagents 
with Alkyl Halides 
Ethyl 2-cyclohexyl-3-fluorobenzoate (162a)191 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to ethyl 3-fluorobenzoate (160, 
235 mg, 1.4 mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm 
to 25 °C, stirred for 8 h and was then added dropwise according to TP-10 to iodocyclohexane (210 mg, 
1.0 mmol) in THF (1.0 mL). After standard work-up, the solvent was evaporated in vacuo. The crude 
product was purified by column chromatography on silica using i-hexane:ethyl acetate (99:1) as an 
eluent to afford 162a as a colorless oil (87%, 218 mg, 0.87 mmol). 
1H-NMR 300 MHz, CDCl3, ppm): δ = 7.35 (ddd, J = 7.6, 1.5, 0.4 Hz, 1 H), 7.04-7.20 (m, 2 H), 4.36 (q, J = 
7.1 Hz, 2 H), 3.01-3.13 (m, 1 H), 1.68-1.93 (m, 7 H), 1.39 (t, J = 7.1 Hz, 3 H), 1.26-1.37 (m, 3 H). 
 
Ethyl 3-fluoro-2-isopentylbenzoate (162b) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to ethyl 3-fluorobenzoate (160, 
235 mg, 1.4 mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm 
to r.t., stirred for 8 h and was then added dropwise according to TP-10 to 1-iodo-3-methylbutane 
(198 mg, 1.0 mmol) in THF (1.0 mL). After standard work-up, the solvent was evaporated in vacuo. The 
crude product was purified by column chromatography on silica using i-hexane:ethyl acetate (9:1) as 
an eluent to afford 162b as a colorless oil (63%, 150 mg, 0.63 mmol). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.62 – 7.58 (m, 1 H), 7.23 – 7.11 (m, 2 H), 4.36 (q, J = 7.1 Hz, 0.4, 
2 H), 3.03 – 2.89 (m, 2 H), 1.71 – 1.59 (m, 1 H), 1.51 – 1.43 (m, 2 H), 1.39 (t, J = 7.1 Hz, 3 H), 1.08 – 0.88 
(d, J = 6.4 Hz, 6 H). 
                                                          
191 S. Wunderlich, P. Knochel, Angew. Chem. Int. Ed. 2009, 48, 9717. 
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13C-NMR (75 MHz, CDCl3, ppm): δ = 167.0, 161.2 (d, J = 246.1 Hz), 132.3 (d, J = 4.6 Hz), 131.8 (d, J = 
17.3 Hz), 126.5 (d, J = 9.3 Hz), 125.9 (d, J = 3.5 Hz), 118.4 (d, J = 23.9 Hz), 61.1, 39.7, 28.5, 24.1, 22.4, 
14.2. 
FT-IR (ATR, cm-1): 𝜈 = 2956, 2871, 1456, 1366, 1257, 1172, 1257, 1099, 1025, 907, 755. 
MS (EI, 70 eV): m/z (%) = 238 (20), 195 (20), 193 (18), 183 (10), 182 (86), 167 (52), 163 (17), 154 (20), 
153 (41), 149 (59), 08 (12). 
HR-MS (EI, 70 eV): [C14H19FO2], calcd.: 238.1369; found: 238.1356. 
 
Ethyl 2-(4-ethoxy-4-oxobutyl)-3-fluorobenzoate (162c) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to ethyl 3-fluorobenzoate (160, 
235 mg, 1.4 mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm 
to r.t., stirred for 8 h and was then added dropwise according to TP-10 to either ethyl 4-iodobutanoate 
(X = I, 242 mg, 1.0 mmol) or 4-ethyl bromobutanoate (X = Br, 195 mg, 1.0 mmol) in THF (1.0 mL). After 
standard work-up, the solvent was evaporated in vacuo. The crude product was purified by column 
chromatography on silica using i-hexane:ethyl acetate (92:8) as an eluent to afford 162c as a colorless 
oil (X = I: 58%, 164 mg, 0.58 mmol; X = Br: 38%, 107 mg, 0.38 mmol). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.67 – 7.60 (m, 1H), 7.25 – 7.11 (m, 2H), 4.34 (q, J = 7.1 Hz, 0.4, 
2H), 4.17 – 4.04 (m, 2H), 3.00 (q, J = 7.3 Hz, 2H), 2.35 (t, J = 7.7 Hz, 2H), 1.99 – 1.86 (m, 2H), 1.37 (t, J = 
7.1 Hz, 3H), 1.23 (t, J = 7.1 Hz, 3H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 173.3, 166.6 (d, J = 3.5 Hz), 161.3 (d, J = 244.6 Hz), 132.2 (d, J = 4.2 
Hz), 130.4 (d, J = 17.6 Hz), 127.0 (d, J = 9.0 Hz), 126.2 (d, J = 3.4 Hz), 118.6 (d, J = 24.0 Hz), 61.1, 60.2, 
34.1, 25.6, 25.1, 14.2. 
FT-IR (ATR, cm-1): 𝜈 = 2981, 1720, 1456, 1367, 1258, 1174, 1129, 1059, 1024, 934, 757, 732. 
MS (EI, 70 eV): m/z (%) = 237 (45), 236 (55), 208 (15), 194 (21), 191 (15), 190 (18), 163 (31), 162 (12), 
153 (16), 149 (32), 135 (16), 133 (11). 
HR-MS (EI, 70 eV): [C15H19FO4], calcd.: 282.1267; found: 282.1271. 
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Ethyl 2-(3-cyanopropyl)-3-fluorobenzoate (162d) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to ethyl 3-fluorobenzoate (160, 
235 mg, 1.4 mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm 
to r.t., stirred for 8 h and was then added dropwise according to TP-10 to either 4-iodobutanenitrile (X 
= I, 195 mg, 1.0 mmol) or 4-bromobutanenitrile (X = Br, 148 mg, 1.0 mmol) in THF (1.0 mL). After 
standard work-up, the solvent was evaporated in vacuo. The crude product was purified by column 
chromatography on silica using i-hexane:ethyl acetate (97:3) as an eluent to afford 162d as a colorless 
oil (X = I: 71%, 167 mg, 0.71 mmol; X = Br: 51%, 120 mg, 0.51 mmol). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.04 - 7.96 (m, 1 H), 7.05 – 6.90 (m, 2 H), 4.36 (q, J = 7.2 Hz, 2 H), 
3.18 – 3.03 (m, 2 H), 2.41 (t, J = 7.2 Hz, 2 H), 2.06 – 1.88 (m, 2 H), 1.40 (t, J = 7.2 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 166.1, 165.2 (d, J = 254.1 Hz), 154.5 (d, J = 8.4 Hz), 133.8 (d, J = 9.3 
Hz), 125.6 (d, J = 2.8 Hz), 119.4, 117.8 (d, J = 21.6 Hz), 113.7 (d, J = 21.0 Hz), 61.1, 33.5, 26.7, 16.9, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 2254, 1715, 1458, 1261, 1139, 1056, 1020, 905, 760, 725. 
MS (EI, 70 eV): m/z (%) = 235 (2), 217 (4), 190 (16), 189 (25), 188 (5), 167 (45), 109 (5). 
HR-MS (EI, 70 eV): [C13H14FNO2], calcd.: 235.1009; found: 235.1006. 
 
Ethyl 2-(4-((tert-butyldimethylsilyl)oxy)pentan-2-yl)-3-fluorobenzoate (162e) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to ethyl 3-fluorobenzoate (160, 
235 mg, 1.4 mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm 
to r.t., stirred for 8 h and was then added dropwise according to TP-10 to tert-butyl((4-iodopentan-2-
yl)oxy)dimethylsilane (328 mg, 1.0 mmol) in THF (1.0 mL). After standard work-up, the solvent was 
evaporated in vacuo. The crude product was purified by column chromatography on silica using i-
hexane:ethyl acetate (95:5) as an eluent to afford 162e as a colorless oil (70%, 258 mg, 0.70 mmol, d.r. 
52:48). 
Signals of both diastereomers are given: 
EXPERIMENTAL PART 
 
156 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.38 (dddd, J = 13.3, 7.6, 1.5, 0.6 Hz, 2H), 7.25 – 7.02 (m, 4H), 4.34 
(qdd, J = 7.1, 4.1, 2.1 Hz, 4H), 3.85 – 3.64 (m, 2H), 3.56 – 3.43 (m, 2H), 2.07 – 1.70 (m, 5H), 1.47 – 1.30 
(m, 13H), 1.10 (dd, J = 6.1, 1.7 Hz, 6H), 0.92 – 0.81 (m, 18H), 0.04 – -0.07 (m, 12H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 167.9 (d, J = 3.8 Hz), 167.9 (d, J = 3.9 Hz), 162.4 (d, J = 248.3 Hz), 
162.1 (d, J = 247.1 Hz), 134.5 (d, J = 14.9 Hz), 134.0 (d, J = 6.5 Hz), 133.8 (d, J = 14.8 Hz), 133.5 (d, J = 
6.6 Hz), 127.0 (d, J = 9.4 Hz), 126.8 (d, J = 9.4 Hz), 125.1 (d, J = 3.5 Hz), 124.8 (d, J = 3.5 Hz), 118.9 (d, J 
= 24.0 Hz), 118.6 (d, J = 23.8 Hz), 67.9, 66.7, 61.3 45.5, 45.1, 31.0, 30.5, 25.9, 25.8, 23.8, 23.7, 20.3, 
19.4, 18.0, 18.0, 14.2, -4.4, -4.5, -4.8, -4.9. 
FT-IR (ATR, cm-1): 𝜈 = 2959, 2930, 2857, 1723, 1451, 1367, 1278, 1255, 1178, 1142, 1037, 909, 834, 
808, 773, 733. 
MS (EI, 70 eV): m/z (%) = 311 (73), 265 (27), 223 (19), 163 (24), 159 (6), 149 (19), 121 (4), 103 (10), 75 
(24), 73 (16). 
HR-MS (EI, 70 eV): [C16H24FO3Si], calcd.: 311.1479; found: 311.1488. 
 
Ethyl 2-(3-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-fluorobenzoate (162f) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to ethyl 3-fluorobenzoate (160, 
235 mg, 1.4 mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm 
to r.t., stirred for 8 h and was then added dropwise according to TP-10 to tert-butyl((3-
iodocyclohexyl)oxy)dimethylsilane (340 mg, 1.0 mmol) in THF (1.0 mL). After standard work-up, the 
solvent was evaporated in vacuo. The crude product was purified by column chromatography on silica 
using i-hexane:ethyl acetate (98:2) as an eluent to afford 162f as a colorless oil (79%, 301 mg, 
0.79 mmol, d.r. 51:49). 
Signals of both diastereomers are given: 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.41 (d, J = 7.3 Hz, 1 H), 7.32 (d, J = 7.6 Hz, 1 H), 7.16 - 7.25 (m, 2 
H), 7.05 - 7.15 (m, 2 H), 4.24 - 4.48 (m, 4 H), 4.15 (br, 1 H), 3.54 - 3.68 (m, 2 H), 3.13 - 3.24 (m, 1 H), 
2.05 - 2.16 (m, 1 H), 1.64 - 2.01 (m, 12 H), 1.44 - 1.61 (m, 2 H), 1.40 (t, J = 7.1 Hz, 3 H), 1.40 (t, J = 7.1 
Hz, 3 H), 1.33 - 1.37 (m, 1 H), 0.91 (s, 9 H), 0.89 (s, 9 H), 0.08 (s, 3 H), 0.06 (s, 3 H), 0.04 (s, 3 H), 0.02 (s, 
3 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 168.5 (d, J = 3.7 Hz), 168.2 (d, J = 3.7 Hz), 162.6 (d, J = 248.0 Hz), 
162.3 (d, J = 248.0 Hz), 134.8 (d, J = 6.6 Hz), 133.6 (d, J = 6.6 Hz), 132.9 (d, J = 14.7 Hz), 132.4 (d, J = 14.7 
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Hz), 127.2 (d, J = 8.8 Hz), 127.0 (d, J = 9.5 Hz), 125.1 (d, J = 3.7 Hz), 124.5 (d, J = 3.70 Hz), 119.1 (d, J = 
24.2 Hz), 118.6 (d, J = 24.2 Hz), 71.7, 67.0, 61.4, 40.1 (d, J = 4.4 Hz), 37.8 (d, J = 1.5 Hz), 37.7, 37.6, 35.7, 
33.1 (d, J = 1.5 Hz), 32.9, 30.7 (d, J = 2.9 Hz), 29.8 (d, J = 4.4 Hz), 25.9, 25.8, 24.8, 20.4, 18.2, 18.1, 14.3, 
14.3, -4.6, -4.9. 
FT-IR (ATR, cm-1): 𝜈 = 2930, 2857, 1724, 1453, 1367, 1280, 1269, 1251, 1230, 1174, 1140, 1120, 1091, 
1057, 1038, 1026, 981, 856, 834, 805, 773, 758. 
MS (EI, 70 eV): m/z (%) = 365 (2), 335 (8), 325 (7), 324 (24), 323 (100), 305 (5), 278 (9), 277 (43), 260 
(5), 259 (25), 249 (19), 235 (9), 227 (10), 221 (10), 203 (19)m 202 (8), 185 (29), 183 (22), 175 (12), 165 
(15), 147 (19), 133 (13). 
HR-MS (EI, 70 eV): [C21H33FO328Si], calc.: 365.1948; found: 365.1939 [M+-CH3]. 
 
tert-Butyl 4-(2-(ethoxycarbonyl)-6-fluorophenyl)piperidine-1-carboxylate (162g) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to ethyl 3-fluorobenzoate (160, 
235 mg, 1.4 mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm 
to r.t., stirred for 8 h and was then added dropwise according to TP-10 to tert-butyl 4-iodopiperidine-
1-carboxylate (311 mg, 1.0 mmol) in THF (1.0 mL). After standard work-up, the solvent was evaporated 
in vacuo. The crude product was purified by column chromatography on silica using i-hexane:ethyl 
acetate (9:1) as an eluent to afford 162g as a colorless oil (79%, 277 mg, 0.79 mmol). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.41 (d, J = 1.4 Hz, 1 H), 7.27 – 7.06 (m, 2 H), 4.36 (q, J = 7.1, 2 H), 
4.21 (d, J = 13.2 Hz, 2 H), 3.40 – 3.25 (m, 1 H), 2.82 – 2.65 (m, 2 H), 2.17 – 1.95 (m, 2 H), 1.72 (d, J = 1.7 
Hz, 2 H), 1.47 (s, 9 H), 1.38 (t, J = 7.1 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 167.8, 162.1 (d, J = 249.1 Hz), 154.9, 133.6 (d, J = 6.9 Hz), 131.9 (d, 
J = 14.3 Hz), 127.5 (d, J = 8.9 Hz), 125.3 (d, J = 3.8 Hz), 119.2 (d, J = 23.9 Hz), 79.3, 61.4, 44.7, 37.9, 29.9, 
28.5, 14.2. 
FT-IR (ATR, cm-1): 𝜈 = 2978, 2863, 1719, 1684, 1450, 1424, 1366, 1275, 1244, 1165, 1118, 1018, 905, 
758, 728. 
MS (EI, 70 eV): m/z (%) = 292 (3), 278 (5), 252 (6), 251 (26), 250 (6), 222 (31), 203 (5), 132 (3), 57 (11). 
HR-MS (EI, 70 eV): [C19H26FNO4], calcd.: 351.1846; found: 351.1831. 
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Ethyl 2-((1R,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-fluorobenzoate (162h)192 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to ethyl 3-fluorobenzoate (160, 
235 mg, 1.4 mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm 
to r.t., stirred for 8 h and was then added dropwise according to TP-10 to tert-butyl((2-iodocyclohexyl)-
oxy)dimethylsilane (340 mg, 1.0 mmol) in THF (1.0 mL). After standard work-up, the solvent was 
evaporated in vacuo. The crude product was purified by column chromatography on silica using i-
hexane:ethyl acetate (99:1) as an eluent to afford 162h as a colorless oil (68%, 259 mg, 0.68 mmol, d.r. 
99:1 (trans:cis)). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.39 (d, J = 7.7 Hz, 1 H), 7.22 – 7.05 (m, 2 H), 4.36 (q, J = 7.1 Hz, 2 
H), 4.03 – 4.12 (m, 1 H), 3.21 – 3.31 (m, 1 H), 1.86 – 2.01 (m, 3 H), 1.70 – 1.82 (m, 2 H), 1.27 – 1.42 (m, 
6 H), 0.61 (s, 9 H), -0.10 (s, 3 H), -0.42 (s, 3 H). 
 
Ethyl 2-((1R,2S)-2-((tert-butyldimethylsilyl)oxy)cyclopentyl)-3-fluorobenzoate (162i) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to ethyl 3-fluorobenzoate (160, 
235 mg, 1.4 mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm 
to r.t., stirred for 8 h and was then added dropwise according to TP-10 to tert-butyl((2-
iodocyclopentyl)oxy)dimethylsilane (326 mg, 1.0 mmol) in THF (1.0 mL). After standard work-up, the 
solvent was evaporated in vacuo. The crude product was purified by column chromatography on silica 
using i-hexane:ethyl acetate (98:2) as an eluent to afford 162i as a colorless oil (69%, 253 mg, 
0.69 mmol, d.r. 99:1 (trans:cis)). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.43 (d, J = 7.6 Hz, 1 H), 7.21 (td, J = 7.9, 5.3 Hz, 1 H), 7.09 - 7.17 
(m, 1 H), 4.42 - 4.50 (q, J = 7.3 Hz, 1 H), 4.34 (m, 2 H), 3.51 - 3.66 (m, 2 H), 2.10 - 2.21 (m, 1 H), 2.07 - 
2.01 (m, 1 H), 1.75 - 1.96 (m, 3 H), 1.58 - 1.70 (m, 1 H), 1.38 (t, J = 7.1 Hz, 3 H), 0.74 (s, 9 H) -0.20 (s, 3 
H), -0.31 (s, 3 H). 
                                                          
192 A. K. Steib, T. Thaler, K. Komeyama, P. Mayer, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 3303. 
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13C-NMR (100 MHz, CDCl3, ppm): δ = 167.9 (d, J = 4.4 Hz), 161.9 (d, J = 246.5 Hz), 135.1 (d, J = 6.6 Hz), 
131.58 (d, J = 13.2 Hz), 127.0 (d, J = 9.5 Hz), 124.9 (d, J = 2.9 Hz), 118.5 (d, J = 23.5 Hz), 79.0 (d, J = 5.1 
Hz), 61.3, 48.4 (d, J = 2.2 Hz), 36.0, 30.3 (d, J = 3.7 Hz), 25.7, 22.9, 17.9, 14.2, -5.25, -5.34. 
FT-IR (ATR, cm-1): 𝜈 = 2956, 2930, 2857, 1724, 1472, 1454, 1283, 1250, 1181, 1128, 1112, 1084, 1061, 
1025, 1007, 937, 892, 866, 835, 813, 774, 758, 668. 
MS (EI, 70 eV): m/z (%) = 351 (1), 321 (6), 311 (5), 310 (17), 309 (71), 265 (7), 264 (23), 263 (100), 245 
(9), 235 (15), 221 (10), 189 (28), 171 (27), 75 (26), 73 (23). 
HR-MS (EI, 70 eV): [C20H31FO328Si], calc.: 351.1792; found: 351.1785 [M+-CH3]. 
 
Ethyl 2-((3S,4R)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl)-3-fluorobenzoate (162j) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 m, 1.91 mL) was added to ethyl 3-fluorobenzoate (160, 
235 mg, 1.4 mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm 
to r.t., stirred for 8 h and was then added dropwise according to TP-10 to tert-butyl((4-
iodotetrahydrofuran-3-yl)oxy)dimethylsilane (328 mg, 1.0 mmol) in THF (1.0 mL). After standard work-
up, the solvent was evaporated in vacuo. The crude product was purified by column chromatography 
on silica using i-hexane:ethyl acetate (95:5) as an eluent to afford 162j as a colorless oil (55%, 202 mg, 
0.55 mmol, d.r. 99:1 (trans:cis)). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.84 (dd, J = 8.7, 6.1 Hz, 1 H), 7.08 (dd, J = 10.5, 2.6 Hz, 1 H), 6.95 
(dd, J = 8.7, 7.7 Hz, 1 H), 4.40 – 4.28 (m, 4 H), 4.23 – 4.19 (m, 1 H), 4.12 – 4.01 (m, 1 H), 3.86 (dd, J = 
8.7, 3.9 Hz, 1 H), 3.75 – 3.65 (m, 1 H), 1.44 – 1.33 (m, 3 H), 0.84 (d, J = 0.6 Hz, 9 H), -0.01 – -0.08 (m, 6 
H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 166.7, 165.1 (d, J = 252.4 Hz), 146.1 (d, J = 8.1 Hz), 132.6 (d, J = 9.3 
Hz), 126.8 (d, J=3.3 Hz), 114.5 (d, J=23.1 Hz), 113.4 (d, J=21.6 Hz), 79.8, 75.1, 73.6, 61.1, 50.7, 25.7, 
17.9, 14.2, -4.9. 
FT-IR (ATR, cm-1): 𝜈 = 2930, 2857, 1719, 1608, 1585, 1472, 1272, 1248, 1112, 1084, 1009, 906, 835, 
777, 729.0 
MS (EI, 70 eV): m/z (%) = 311 (64), 237 (8), 235 (7), 191 (18), 163 (18), 149 (7), 117 (8), 75 (12). 
HR-MS (EI, 70 eV): [C15H20FO4Si], calcd.: 311.1115; found: 311.1088 [M+-t-Bu]. 
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2-Cyclohexyl-3-fluorobenzonitrile (163a) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to 3-fluorobenzonitrile (170 mg, 1.4 
mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was stirred at r.t. for 12 h and 
was then added dropwise according to TP-10 to iodocyclohexane (210 mg, 1.0 mmol) in THF (1.0 mL). 
After standard work-up, the solvent was evaporated in vacuo. The crude product was purified by 
column chromatography on silica using i-hexane:ethyl acetate (20:1) as an eluent to afford 163a as a 
white solid (84%, 171 mg, 0.84 mmol). 
m.p.: 73-74 °C 
1H NMR (400 MHz, CDCl3, ppm): δ = 7.40 - 7.47 (m, 1 H), 7.21 - 7.31 (m, 2 H), 3.02 - 3.17 (m, 1 H), 1.84 
- 2.04 (m, 4 H), 1.80 (m, 3 H), 1.23 - 1.54 (m, 3 H). 
13C NMR (100 MHz, CDCl3, ppm): δ = 161.3 (d, J = 248.7 Hz), 137.8 (d, J = 16.9 Hz), 129.4 (d, J = 3.7 Hz), 
128.0 (d, J = 9.5 Hz), 121.0 (d, J = 24.2 Hz), 117.7 (d, J = 3.7 Hz), 113.5 (d, J = 8.8 Hz), 30.8, 30.7, 26.7, 
25.7. 
FT-IR (ATR, cm-1): 𝜈 = 2935, 2854, 2232, 1572, 1462, 1449, 1248, 1240, 1223, 1193, 1160, 1135, 1002, 
948, 890, 860, 795, 733. 
MS (EI, 70 eV): m/z (%) = 204 (5), 203 (33), 202 (19), 188 (12), 186 (7), 175 (17), 174 (31), 162 (34), 161 
(21), 160 (14), 149 (22), 148 (43), 147 (100), 146 (10), 135 (17), 134 (38), 133 (13), 120 (10), 107 (9). 
HR-MS (EI, 70 eV): [C13H14FN], calc.: 203.1110; found: 203.1107. 
 
 
2-(4-((tert-butyldimethylsilyl)oxy)pentan-2-yl)-3-fluorobenzonitrile (163b) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to 3-fluorobenzonitrile (170 mg, 1.4 
mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was stirred at r.t. for 12 h and 
was then added dropwise according to TP-10 to tert-butyl((4-iodopentan-2-yl)oxy)dimethylsilane 
(328 mg, 1.0 mmol) in THF (1.0 mL). After standard work-up, the solvent was evaporated in vacuo. The 
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crude product was purified by column chromatography on silica using i-hexane:ethyl acetate (9:1) as 
an eluent to afford 163b as a colorless oil (63%, 202 mg, 0.63 mmol, d.r. 52:48). 
Signals of both diastereomers are given: 
1H-NMR (300 MHz, CDCl3, ppm): δ = 7.43 – 7.19 (m, 6 H), 3.86 – 3.58 (m, 3 H), 3.53 – 3.21 (m, 3 H), 
2.13 – 1.57 (m, 6 H), 1.41 – 1.32 (m, 3 H), 1.23 (dd, J = 7.0, 2.7 Hz, 3 H), 1.19 – 1.09 (m, 8 H), 0.90 – 0.79 
(m, 18 H), 0.07 – -0.12 (m, 12 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 162.8, 161.9, 161.6, 159.5, 158.6, 158.3, 141.0, 140.8, 140.5, 140.3, 
138.3, 138.1, 137.8, 129.4, 129.3, 129.3, 129.2, 129.2, 128.2, 128.2, 128.1, 128.0, 128.0, 127.9, 121.0, 
120.6, 119.3, 119.3, 119.0, 118.9, 117.8, 117.8, 117.5, 117.5, 117.4, 117.3, 113.7, 113.6, 110.9, 110.9, 
110.8, 110.7, 68.1, 67.9, 67.4, 66.6, 66.4, 66.1, 65.3, 47.8, 46.5, 46.0, 45.0, 44.9, 30.0, 29.3, 25.9, 25.8, 
25.8, 24.1, 24.0, 23.7, 21.9, 20.6, 20.2, 19.2, 18.0, 18.0, -4.1, -4.2, -4.3, -4.4, -4.8, -4.8, -4.9, -5.0. 
FT-IR (ATR, cm-1): 𝜈 = 2958, 2857, 1462, 1362, 1252, 1091, 1050, 1038, 906, 834, 774, 797, 730. 
MS (EI, 70 eV): m/z (%) = 264 (17), 222 (26), 208 (12), 130 (13), 77 (6), 75 (22), 73 (8), 57 (5), 43 (6). 
HR-MS (EI, 70 eV): [C14H19FNOSi], calcd.: 264.1220; found: 264.1259. 
 
3-Fluoro-2-(4,4,4-trifluorobutyl)benzonitrile (163c) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to 3-fluorobenzonitrile (170 mg, 1.4 
mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was stirred at r.t. for 12 h and 
was then added dropwise according to TP-10 to iodocyclohexane (210 mg, 1.0 mmol) in THF (1.0 mL). 
After standard work-up, the solvent was evaporated in vacuo. The crude product was purified by 
column chromatography on silica using i-hexane:ethyl acetate (20:1) as an eluent to afford 163c as a 
yellow oil (52%, 120 mg, 0.52 mmol). 
1H NMR (400 MHz, CDCl3, ppm): δ = 7.44 - 7.51 (m, 1 H), 7.28 - 7.40 (m, 2 H), 2.97 (t, J = 7.70 Hz, 2 H), 
2.09 - 2.29 (m, 2 H), 1.85 - 2.02 (m, 2 H). 
13C NMR (100 MHz, CDCl3, ppm): δ = 160.8 (d, J = 248.7 Hz), 132.0 (d, J = 19.1 Hz), 129.0 (d, J = 5.1 Hz), 
128.9, 126.8 (q, J = 276.1 Hz), 120.5 (d, J = 22.7 Hz), 116.7 (d, J = 4.40 Hz), 114.5 (d, J = 5.9 Hz) 33.3 (q, 
J = 29.1 Hz), 26.9 (d, J = 2.2 Hz), 22.3 - 22.2 (m). 
FT-IR (ATR, cm-1): 𝜈 = 2950, 2232, 1578, 1465, 1441, 1392, 1339, 1316, 1279, 1251, 1208, 1131, 1112, 
1021, 970, 936, 793, 733, 681, 658. 
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MS (EI, 70 eV): m/z (%) = 231 (13), 148 (3), 147 (3), 135 (8), 134 (100), 107 (11), 97 (5), 83 (6), 71 (6), 
69 (13), 57 (11), 55 (7), 44 (34), 43 (12). 
HR-MS (EI, 70 eV): [C11H9F4N], calc.: 231.0671; found: 231.0665. 
 
2-Cyclohexylbenzofuran (163d) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to benzofuran (165 mg, 1.4 mmol) 
in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm to r.t., stirred for 
12 h and was then added dropwise according to TP-10 to iodocyclohexane (210 mg, 1.0 mmol) in THF 
(1.0 mL). After standard work-up, the solvent was evaporated in vacuo. The crude product was purified 
by column chromatography on silica using i-hexane as an eluent to afford 163d as a colorless oil (71%, 
142 mg, 0.70 mmol). 
m.p.: 35 – 37 °C. 
1H NMR (400 MHz, CDCl3, ppm): δ =  7.47 - 7.56 (m, 1 H), 7.43 (d, J = 7.3 Hz, 1 H), 7.13 - 7.25 (m, 2 H), 
6.36 (s, 1 H), 2.78 (tt, J = 11.1, 3.4 Hz, 1 H), 2.07 - 2.23 (m, 2 H), 1.86 (ddd, J = 12.5, 3.1, 2.9 Hz, 2 H), 
1.71 - 1.81 (m, 1 H), 1.22 - 1.59 (m, 5 H). 
13C NMR (100 MHz, CDCl3, ppm): δ = 164.1, 154.3, 128.9, 123.0, 122.3, 120.2, 110.7, 99.7, 37.6, 31.3, 
26.1, 25.9. 
FT-IR (ATR, cm-1): 𝜈 = 3048, 2932, 2925, 2854, 2847, 1599, 1592, 1584, 1471, 1453, 1421, 1299, 1256, 
1248, 1220, 1183, 1162, 1149, 1124, 1104, 1007, 946, 922, 890, 883, 856, 830, 797, 786, 749, 736, 728, 
690, 685. 
MS (EI, 70 eV): m/z (%) = 201 (10), 200 (72), 199 (3), 171 (10), 158 (14), 157 (100), 145 (10), 144 (41), 
132 (13), 131 (31), 128 (11), 115 (20). 
HR-MS (EI, 70 eV): [C14H16O], calc.: 200.1201; found: 200.1191. 
 
2-i-Propylbenzofuran (163e) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to benzofuran (165 mg, 1.4 mmol) 
in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm to r.t., stirred for 
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12 h and was then added dropwise according to TP-10 to 2-iodopropane (170 mg, 1.0 mmol) in THF 
(1.0 mL). After standard work-up, the solvent was evaporated in vacuo. The crude product was purified 
by column chromatography on silica using i-hexane as an eluent to afford 163e as colorless oil (61%, 
98 mg, 0.61 mmol). 
1H NMR (400 MHz, CDCl3, ppm): δ = 7.47 - 7.53 (m, 1 H), 7.43 (d, J = 7.8 Hz, 1 H), 7.13 - 7.26 (m, 2 H), 
6.38 (s, 1 H), 3.09 (spt, J = 6.9 Hz, 1 H), 1.36 (d, J = 6.9 Hz, 6 H). 
13C NMR (100 MHz, CDCl3, ppm): δ = 164.9, 154.5, 128.8, 123.0, 122.3, 120.3, 110.7, 99.7, 28.2, 20.9. 
FT-IR (ATR, cm-1): 𝜈 = 2967, 2929, 2874, 1586, 1467, 1454, 1385, 1301, 1253, 1236, 1182, 1167, 1127, 
1105, 1067, 1045, 1009, 942, 926, 884, 795, 750, 738, 684. 
MS (EI, 70 eV): m/z (%) = 160 (15), 146 (11), 145 (74), 125 (16), 115 (21), 113 (17), 111 (18), 97 (30), 95 
(12), 85 (28), 57 (100), 83 (22), 82 (11), 81 (25), 71 (53), 70 (22), 69 (41), 67 (17), 56 (28), 55 (40), 43 
(86), 43 (17), 41 (58). 
HR-MS (EI, 70 eV): [C11H12O], calc.: 160.0888; found: 160.0887. 
 
2-n-Butylbenzofuran (163f) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to benzofuran (165 mg, 1.4 mmol) 
in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm to r.t., stirred for 
12 h and was then added dropwise according to TP-10 to 1-iodobutane (184 mg, 1.0 mmol) in THF 
(1.0 mL). After standard work-up, the solvent was evaporated in vacuo. The crude product was purified 
by column chromatography on silica using i-hexane:ethyl acetate (95:5) as an eluent to afford 163f as 
a colorless oil (63%, 110 mg, 0.63 mmol). 
1H NMR (400 MHz, CDCl3, ppm): δ = 7.56 – 7.41 (m, 2 H), 7.28 – 7.14 (m, 2 H), 6.40 (s 1 H), 2.85 – 2.72 
(t, J = 7.4 Hz, 2 H), 1.85 – 1.67 (m, 2 H), 1.55 – 1.35 (m, 2 H), 0.99 (t, J = 7.3 Hz, 3 H). 
13C NMR (100 MHz, CDCl3, ppm): δ = 159.7, 154.6, 129.0, 123.0, 122.3, 120.1, 110.6, 101.7, 29.8, 28.1, 
22.3, 13.8. 
FT-IR (ATR, cm-1): 𝜈 = 2957, 2930, 1601, 1587, 1454, 1252, 1168, 945, 905, 795, 749, 738. 
MS (EI, 70 eV): m/z (%) = 174 (12), 133 (1), 132 (13), 131 (54), 115 (21), 103 (16), 77 (31). 
HR-MS (EI, 70 eV): [C12H14O], calc.: 174.1045; found: 174.1054. 
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2-Cyclohexylbenzothiophene (163g) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to thiobenzofuran (188 mg, 1.4 
mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm to r.t., 
stirred for 12 h and was then added dropwise according to TP-10 to iodocyclohexane (210 mg, 
1.0 mmol) in THF (1.0 mL). After standard work-up, the solvent was evaporated in vacuo. The crude 
product was purified by column chromatography on silica using i-hexane as an eluent to afford 163g 
as a white solid (72%, 156 mg, 0.72 mmol). 
m.p.: 60 – 62 °C. 
1H NMR (400 MHz, CDCl3, ppm): δ =  7.78 (d, J = 8.1 Hz, 1 H), 7.68 (d, J = 7.8 Hz, 1 H), 7.31 (t, J = 7.5 Hz, 
1 H), 7.21 - 7.28 (m, 1 H), 7.02 (s, 1 H), 2.89 (tt, J = 11.3, 3.4 Hz, 1 H), 2.04 - 2.19 (m, 2 H), 1.87 (dt, J = 
12.7, 3.1 Hz, 2 H), 1.71 - 1.81 (m, 1 H), 1.37 - 1.60 (m, 4 H), 1.20 - 1.36 (m, 1 H). 
13C NMR (100 MHz, CDCl3, ppm): δ = 153.0, 140.0, 138.6, 123.9, 123.3, 122.7, 122.2, 118.1, 40.0, 35.0, 
26.4, 26.0. 
FT-IR (ATR, cm-1): 𝜈 = 3056, 2938, 2922, 2853, 2844, 1534, 1456, 1446, 1436, 1295, 1264, 1234, 1194, 
1172, 1128, 1067, 1016, 987, 930, 892, 861, 846, 819, 798, 736, 725, 706, 658. 
MS (EI, 70 eV): m/z (%) = 217 (12), 216 (67), 187 (7), 175 (6), 174 (17), 173 (100), 171 (5), 161 (19), 160 
(27), 148 (21), 147 (36), 134 (22), 129 (10), 128 (9), 115 (17), 45 (10). 
HR-MS (EI, 70 eV): [C14H16S], calc.: 216.0973; found: 216.0966. 
 
4-iso-Propyl-3,6-dimethoxypyridazine (163h) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to 3,6-dimethoxypyridazine (196 
mg, 1.4 mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to warm to 
r.t. for 4 h and was added dropwise according to TP-10 to 2-iodopropane (170 mg, 1.0 mmol) in THF 
(1.0 mL). After standard work-up, the solvent was evaporated in vacuo. The crude product was purified 
by column chromatography on silica using i-hexane:ethyl acetate (9:1) as an eluent to afford 163h as 
a colorless oil (69%, 126 mg, 0.69 mmol). 
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1H NMR (400 MHz, CDCl3, ppm): δ = 6.75 (s, 1 H), 4.06 (s, 3 H), 4.02 (s, 3 H), 3.07 (spt, J = 6.9 Hz, 1 H), 
1.20 (d, J = 6.9 Hz, 6 H). 
13C NMR (100 MHz, CDCl3, ppm): δ = 162.6, 160.5, 142.0, 116.2, 54.5, 54.3, 27.0, 21.1. 
FT-IR (ATR, cm-1): 𝜈 = 2951, 2875, 1617, 1462, 1390, 1381, 1367, 1330, 1231, 1202, 1183, 1139, 1122, 
1094, 1081, 1054, 1026, 1012, 927, 892, 771, 724, 666. 
MS (EI, 70 eV): m/z (%) = 182 (100), 181 (87), 167 (91), 154 (23), 153 (16), 151 (14), 137 (21), 96 (12), 
86 (12), 84 (19), 83 (15), 74 (12), 71 (13), 69 (34), 67 (25), 59 (19), 57 (23), 56 (14), 55 (24), 53 (27), 45 
(90), 45 (17), 44 (33). 
HR-MS (EI, 70 eV): [C9H14N2O2], calc.: 182.1055; found: 182.1052. 
 
4-Cyclohexyl-3,6-dimethoxypyridazine (163i) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to 3,6-dimethoxypyridazine 
(196  mg, 1.4 mmol) in THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was allowed to 
warm to r.t. for 4 h and was added dropwise according to TP-10 to iodocyclohexane (210 mg, 1.0 mmol) 
in THF (1.0 mL). After standard work-up, the solvent was evaporated in vacuo. The crude product was 
purified by column chromatography on silica using i-hexane:ethyl acetate (8:2) as an eluent to afford 
163i as a colorless oil (61%, 135 mg, 0.61 mmol). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 6.64 (d, J = 0.9 Hz, 1 H), 3.98 (s, 3 H), 3.95 (s, 3 H), 2.73 – 2.48 (m, 
1 H), 1.86 – 1.64 (m, 5 H), 1.45 – 1.06 (m, 5 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 162.5, 160.4, 140.9, 116.5, 54.4, 54.2, 36.6, 31.6, 26.3, 25.9. 
FT-IR (ATR, cm-1): 𝜈 = 2929, 2854, 1617, 1465, 1389, 1370, 1247, 1227, 1150, 1038, 1013, 1006, 906, 
879, 750, 726. 
MS (EI, 70 eV): m/z (%) = 222 (64), 221 (62), 193 (26), 191 (38), 167 (15), 163 (13), 154 (10), 40 (14). 
HR-MS (EI, 70 eV): [C12H18N2O2], calcd.: 222.1368; found: 222.1366. 
 
4-(2-Oxo-2H-chromen-3-yl)butanenitrile (163j) 
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TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to coumarin (204 mg, 1.4 mmol) in 
THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was stirred for 1 h at r.t. and was then 
added dropwise according to TP-10 to 4-iodobutanenitril (195 mg, 1.0 mmol) in THF (1.0 mL). After 
standard work-up, the solvent was evaporated in vacuo. The crude product was purified by column 
chromatography on silica using i-hexane:ethyl acetate (9:1) as an eluent to afford 163j as a yellowish 
solid (76%, 162 mg, 0.76 mmol). 
m.p.: 102 – 104 °C. 
1H NMR (400 MHz, CDCl3, ppm): δ = 7.61 (s, 1 H) 7.44 - 7.55 (m, 2 H) 7.25 - 7.36 (m, 2 H) 2.76 (t, J = 7.5 
Hz, 2 H) 2.44 (t, J = 7.0 Hz, 2 H) 2.06 (qd, J = 7.3, 7.1 Hz, 2 H). 
13C NMR (100 MHz, CDCl3, ppm): δ = 161.4, 153.3, 140.2, 131.2, 127.4, 127.2, 124.5, 119.2, 119.1, 
116.5, 30.2, 23.6, 16.7. 
FT-IR (ATR, cm-1): 𝜈 = 2923, 2360, 2244, 1716, 1634, 1620, 1605, 1455, 1421, 1284, 1175, 1069, 1016, 
922, 772, 763, 742, 712. 
MS (EI, 70 eV): m/z (%) = 234 (5), 214 (13), 213 (56), 212 (7), 174 (12), 173 (100), 172 (8), 161 (11), 160 
(92), 259 (61), 144 (10), 132 (15), 131 (42), 128 (7), 126 (8), 115 (42), 102 (8), 77 (17), 63 (7). 
HR-MS (EI, 70 eV): [C13H11NO2], calc.: 213.0790; found: 213.0790. 
 
3-Cyclohexyl-2H-chromen-2-one (163k): 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to coumarin (204 mg, 1.4 mmol) in 
THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was stirred for 1 h at r.t. and was then 
added dropwise according to TP-10 to iodocyclohexane (210 mg, 1.0 mmol) in THF (1.0 mL). After 
standard work-up, the solvent was evaporated in vacuo. The crude product was purified by column 
chromatography on silica using i-hexane:ethyl acetate (95:5) as an eluent to afford 163k as a white 
solid (66%, 151 mg, 0.66 mmol). 
m.p.: 93 – 95 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.47 – 7.36 (m, 3 H), 7.29 – 7.17 (m, 2 H), 2.82 – 2.68 (m, 1 H), 
2.00 – 1.66 (m, 5 H), 1.50 – 1.15 (m, 5 H). 
13C-NMR (100 MHz, CDCl3, ppm): δ = 161.5, 152.7, 136.3, 134.8, 130.4, 127.3, 124.10, 119.6, 116.2, 
38.2, 32.1, 26.5, 26.1. 
FT-IR (ATR, cm-1): 𝜈 = 1706, 1609, 1456, 988, 904, 755, 726. 
EXPERIMENTAL PART 
 
167 
MS (EI, 70 eV): m/z (%) = 228 (46), 227 (9), 171 (34), 146 (13), 128 (9), 115 (24), 43 (19). 
HR-MS (EI, 70 eV): [C15H16O2], calcd.: 228.1150; found: 228.1145. 
 
3-(4-((tert-Butyldimethylsilyl)oxy)pentan-2-yl)-2H-chromen-2-one (163l) 
 
TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to coumarin (204 mg, 1.4 mmol) in 
THF (1.0 mL) at 0 °C according to TP-9. The reaction mixture was stirred for 1 h at r.t. and was then 
added dropwise according to TP-10 to tert-butyl((4-iodopentan-2-yl)oxy)dimethylsilane (328 mg, 1.0 
mmol) in THF (1.0 mL). After standard work-up, the solvent was evaporated in vacuo. The crude 
product was purified by column chromatography on silica using i-hexane:ethyl acetate (9:1) as an 
eluent to afford 163l as a colorless oil (88%, 305 mg, 0.88 mmol, d.r. 62:38). 
Signals of both diastereomers are given: 
1H NMR (400 MHz, CDCl3, ppm): δ = 7.42 - 7.51 (m, 6 H), 7.32 (d, J = 8.3 Hz, 2 H), 7.23 - 7.29 (m, 2 H), 
3.76 - 3.95 (m, 2 H), 3.02 - 3.18 (m, 2 H), 1.83 - 1.95 (m, 2 H), 1.59 - 1.71 (m, 2 H), 1.26 (m, 6 H), 1.19 
(d, J = 6.1 Hz, 6 H), 0.89 (d, J = 2.5 Hz, 9 H), -0.08 - 0.12 (m, 12 H). 
13C NMR (100 MHz, CDCl3, ppm): δ = 161.1 (2 C), 152.9, 137.1, 136.9, 134.9, 1345, 130.5 (2 C), 127.2 
(2 C), 124.2 (2 C), 119.5 (2 C), 116.3, 67.0, 66.4, 45.2, 45.0, 31.8, 31.2, 25.9 (2 C), 24.1, 23.9, 20.4, 19.8, 
18.1, -4.2 (2 C), -4.7 (2 C). 
FT-IR (ATR, cm-1): 𝜈 = 2958, 2928, 2856, 1722, 1610, 1456, 1373, 1254, 1177, 1142, 1132, 1121, 1094, 
1051, 1030, 1006, 989, 972, 922, 834, 807, 773, 753, 735, 721. 
MS (EI, 70 eV): m/z (%) = 331 (2), 291 (7), 290 (23), 289 (100), 216 (7), 215 (35), 179 (20), 173 (8), 157 
(5), 115 (12), 75 (27), 73 (15), 57 (5), 41 (9). 
HR-MS (EI, 70 eV): [C20H30O328Si], calc.: 331.1729; found: 331.1720 [M+-CH3]. 
 
2-(sec-Butyl)-4H-thiochromen-4-one (163m) 
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TMP2Zn·2MgCl2·2LiCl (48, 0.84 mmol, 0.44 M, 1.91 mL) was added to thiochromone (227 mg, 1.4 
mmol) in THF (1.0 mL) at -40 °C according to TP-9. The reaction mixture was stirred for 1 h and was 
then added dropwise according to TP-10 to 2-iodobutane (184 mg, 1.0 mmol) in THF (1.0 mL). After 
standard work-up, the solvent was evaporated in vacuo. The crude product was purified by column 
chromatography on silica using i-hexane:ethyl acetate (8:2) as an eluent to afford 163m as a colorless 
oil (51%, 111 mg, 0.51 mmol). 
1H-NMR (300 MHz, CDCl3, ppm): δ = 8.46 (d, J = 7.8 Hz, 1 H), 7.58 – 7.50 (m, 2 H), 7.45 – 7.42  (m, 1 H), 
6.86 (s, 1 H), 2.76 – 2.43 (m, 1 H), 1.79 – 1.56 (m, 2 H), 1.31 (d, J = 6.9 Hz, 3 H), 0.90 (t, J = 7.4 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm): δ = 180.7, 161.9, 137.6, 131.2, 128.4, 127.4, 126.4, 122.7, 44.1, 30.0, 
21.0, 11.9. 
FT-IR (ATR, cm-1): 𝜈 = 1617, 1591, 1439, 1326, 1100, 904, 778, 723, 689, 668. 
MS (EI, 70 eV): m/z (%) = 218 (77), 190 (92), 176 (62), 161 (51), 136 (41), 128 (19), 69 (7). 
HR-MS (EI, 70 eV): [C13H14OS], calc.: 218.0767; found: 218.0765. 
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6 Cobalt-Catalyzed Negishi Cross-Couplings of (Hetero)Arylzinc 
Reagents with (Hetero)Aryl Halides 
6.1 Preparation of Organometallic Reagents 
Preparation of zinc reagents (165a-d, f, h-n) 
LiCl (1.1 equiv) was dried under high vacuum and allowed to cool to room temperature, then Mg 
turnings (1.2 equiv), ZnCl2 solution (1 M in THF, 1.1 equiv) and THF (1 M solution relating to the aryl 
bromide) were added. The reaction mixture was cooled to 0 °C and the corresponding aryl bromide 
(1.0 equiv) was added dropwise. The reaction was stirred until iodolysis of a reaction aliquot indicated 
full consumption of the starting material. 
Preparation of zinc reagents (165e, g) 
The corresponding aryl bromide (1.0 equiv) was dissolved in THF (1 M solution relating to the aryl 
bromide) and the reaction mixture was cooled to -30 °C. Then i-PrMgCl.LiCl was added dropwise and 
the reaction was stirred at this temperature until reaction aliquots quenched with iodine showed full 
consumption of the starting material. Transmetalation with ZnCl2 solution (1 M in THF, 1.1 equiv) at 
0 °C (1 h) provided the corresponding zinc reagent.  
 
6.2 Preparation of Starting Materials 
The following starting materials were prepared according to literature procedures. The spectral data 
of known compounds are in full agreement with the cited literature. 
2-Bromoquinoline-3-carbonitrile (173a)193 
 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.51 (s, 1 H), 8.12 – 8.09 (m, 1 H), 7.95 – 7.87 (m, 2 H), 7.72 (ddd, 
J = 8.2, 6.9, 1.2 Hz, 1 H). 
 
 
                                                          
193 N. Boudet, J. R. Lachs, P. Knochel, Org. Lett. 2007, 9, 5525-5528. 
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Ethyl 2-bromoquinoline-4-carboxylate (173b)194 
 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.66 (s, 1 H), 8.25 (d, J = 8.5 Hz, 1 H), 7.93 (d, J = 8.1 Hz, 1 H), 7.88 
(ddd, J = 8.5, 7.0, 1.4 Hz, 1 H), 7.68 (ddd, J = 8.1, 7.0, 1.1 Hz, 1 H), 4.49 (q, J = 7.2 Hz, 2 H), 1.47 (t, J = 
7.1 Hz, 3 H). 
 
2-Bromo-4-(4-chlorophenyl)pyrimidine (173d)194 
 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.58 (d, J = 5.2 Hz, 1 H), 8.04 (m, 2 H), 7.65 (d, J = 5.2 Hz, 1 H), 7.52 
– 7.43 (m, 2 H). 
 
6.3 Typical Procedure 
Typical procedure for the cobalt-catalyzed cross-coupling of organozinc reagents (TP-11): 
A dry and argon-flushed 10 mL Schlenk-tube, equipped with a stirring bar and a septum, was charged 
with a solution of CoCl2·2LiCl (1 M in THF) (0.05 mmol, 50 L, 5 mol%) and dry THF (1.0 mL). The 
respective aryl halide (1.0 mmol, 1.0 equiv) and HCO2Na (0.5 mmol, 34 mg, 50 mol%) were added at 
room temperature. Then, a solution of the appropriate zinc reagent (1.2 mmol, 1.2 equiv) was added 
dropwise over 15 min via syringe. The reaction was stirred and monitored by GC-analysis (C11H24 was 
used as an internal standard). Upon consumption of the starting material, saturated aqueous NH4Cl 
solution (5 mL) and ethyl acetate (5 mL) were added, the phases were separated and the aqueous 
phase was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over 
Na2SO4. The solvents were evaporated and the residue was subjected to column chromatography on 
silica yielding the respective title compound. 
                                                          
194 M. Mosrin, M. Petrera, P. Knochel, Synthesis 2008, 22, 3697-3702. 
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6.4 Kinetic Investigation of the Cross-Coupling Reaction 
For observation of the effect of sodium formate, the course of the cross-coupling reaction with and 
without sodium formate was investigated over several hours by GC. For this experiment, the reaction 
of 2-bromopyridine (167) and p-anisylzinc chloride (166a) was performed as described above (TP-11) 
using 50 mol% HCO2Na or no additive on a 1 mmol scale and the average GC-yields of three runs were 
used using undecane (C11H24) as an internal standard (Scheme 81). 
 
Scheme 81: Cobalt-catalyzed cross-coupling of 2-bromopyridine (167) and p-MeOC6H4ZnCl (168). 
  
Table 15. Yield of the reaction with and without HCO2Na over the time course of 11 h. 
time [h] 
yield of 168  
without HCO2Na [%] 
yield of 168 
with HCO2Na [%] 
1 8 10 
1,5 16 18 
2 26 28 
3 35 39 
4 47 52 
5 58 66 
6 68 85 
8 74 92 
9 79 94 
10 80 95 
11 80 95 
 
The chart of both reactions shows that the rate of the cross-coupling reaction stays equal, but the 
addition of HCO2Na causes a higher reaction yield (92% vs. 74% after 8 h at r.t.) due to suppression of 
undesired side reactions (Figure 4). 
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Figure 4. Depiction of the time course of the cobalt-catalyzed cross-coupling reaction of 2-bromopyridine (167) and p-
anisylzinc chloride (165a) with (blue) or without HCO2Na (red) over time. 
 
 
6.5 Cobalt-Catalyzed Cross-Coupling of (Hetero)Arylzinc Reagents with (Hetero)Aryl 
Halides 
2-(4-Methoxyphenyl)quinoline (166): 
 
Isolated yield: 207 mg, 0.88 mmol, 88% yield; colorless crystals 
Purification: i-hexane:ethyl acetate 7:3 
m.p.: 124 – 125 °C. 
1H-NMR (300 MHz, CDCl3, ppm): δ= 8.20 – 8.09 (m, 4 H), 7.84 – 7.76 (m, 2 H), 7.71 (ddd, J = 8.4, 6.9, 
1.5 Hz, 1 H), 7.49 (ddd, J = 8.1, 6.9, 1.1 Hz, 1 H), 7.08 – 6.99 (m, 2 H), 3.87 (s, 3 H). 
13C-NMR (75 MHz, CDCl3, ppm):δ = 160.8, 156.9, 148.3, 136.6, 132.3, 129.6, 129.5, 128.9, 127.5, 126.9, 
125.91, 118.5, 114.2, 55.4. 
FT-IR (ATR, cm-1): 𝜈 = 2960, 2920, 1594, 1495, 1467, 1430, 1289, 1247, 1174, 1156, 1028, 975, 948, 
811, 789, 748, 726. 
MS (EI, 70 eV): m/z (%) = 237 (2), 236 (16), 235 (100), 234 (3), 220 (21), 192 (23), 191 (24), 190 (6). 
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HR-MS (EI, 70 eV): [C16H13ON], calcd.: 235.0997; found: 235.0998. 
 
2-(4-Methoxyphenyl)pyridine (168) 
 
Isolated yield: 161 mg, 0.87 mmol, 87% yield; white solid 
Purification: i-hexane:ethyl acetate 4:1 
m.p.: 53 – 54 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.65 (ddd, J = 4.9, 1.8, 1.0 Hz, 1 H), 7.99 – 7.91 (m, 2 H), 7.75 – 
7.62 (m, 2 H), 7.17 (ddd, J = 7.1, 4.8, 1.5 Hz, 1 H), 7.05 – 6.94 (m, 2 H), 3.86 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 160.5, 157.1, 149.5, 136.7, 132.0, 128.2, 121.4, 119.8, 114.1, 55.4. 
FT-IR (ATR, cm-1): 𝜈 = 2997, 2836, 1603, 1586, 1512, 1460, 1432, 1272, 1243, 1175, 1151, 1112, 1036, 
1021, 1005, 838, 776, 736, 717. 
MS (EI, 70 eV): m/z (%) = 186 (12), 185 (100), 170 (22), 142 (29), 141 (15), 61 (9). 
HR-MS (EI, 70 eV): [C12H11NO], calcd.: 185.0841; found: 185.0836. 
 
1-(4'-Methoxy-3',5'-dimethyl-[1,1'-biphenyl]-2-yl)ethan-1-one (170a) 
 
Isolated yield: 165 mg, 0.65 mmol, 65% yield for X = Cl; colorless oil 
              188 mg, 0.74 mmol, 74% yield for X = Br 
Purification: i-hexane:ethyl acetate 9:1 
1H-NMR (400 MHz, CDCl3, ppm): δ= 7.51 (dd, J = 7.5, 1.0 Hz, 1 H), 7.47 (td, J = 7.5, 1.5 Hz, 1 H), 7.40 – 
7.33 (m, 2 H), 6.98 (s, 2 H), 3.76 (s, 3 H), 2.32 (s, 6 H), 2.02 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 205.2, 156.9, 140.8, 140.3, 136.1, 131.2, 130.6, 130.1, 129.3, 
127.7, 127.1, 59.8, 30.4, 16.1. 
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FT-IR (ATR, cm-1): 𝜈 = 2932, 1684, 1471, 1443, 1419, 1353, 1276, 1235, 1194, 1165, 1116, 1088, 1007, 
966, 889, 871, 761, 741, 700. 
MS (EI, 70 eV): m/z (%) = 255 (12), 254 (67), 253 (10), 240 (12), 239 (73), 224 (14), 196 (10), 165 (10), 
70 (12), 61 (17), 45 (15), 43 (100). 
HR-MS (EI, 70 eV): [C17H18O2], calcd.: 254.1307; found: 254.1301. 
 
1-(3'-Fluoro-[1,1':4',1''-terphenyl]-2-yl)ethan-1-one (170b) 
 
Isolated yield: 194 mg, 0.67 mmol, 67% yield; white solid 
Purification: i-hexane:ethyl acetate c 98:2 to 90:10 
m.p.: 85 – 87 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 7.65 – 7.56 (m, 3 H), 7.59 – 7.50 (m, 1 H), 7.53 – 7.35 (m, 6 H), 
7.22 – 7.16 (m, 1 H), 7.17 (s, 1 H), 2.19 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 204.1, 159.6 (d, J = 249.5 Hz), 141.8 (d, J = 8.1 Hz), 140.6, 138.9 
(d, J = 1.8 Hz), 135.2 (d, J = 1.4 Hz), 130.9, 130.8 , 130.3, 129.0 (d, J = 3.0 Hz), 128.5, 128.49, 128.3, 
128.1, 127.9 (d, J = 6.4 Hz), 125.0 (d, J = 3.4 Hz), 116.4 (d, J = 23.7 Hz), 30.5. 
19F-NMR (376 MHz, CDCl3, ppm):δ = -117.39. 
FT-IR (ATR, cm-1): 𝜈 = 3060, 1686, 1474, 1404, 1354, 1274, 1235, 1183, 893, 834, 759, 746, 722, 696, 
682. 
MS (EI, 70 eV): m/z (%) = 292 (6), 291 (33), 290 (73), 289 (16), 276 (23), 275 (100), 273 (10), 255 (13), 
246 (22), 225 (22), 141 (14), 139 (49), 111 (15). 
HR-MS (EI, 70 eV): [C20H15FO], calcd.: 290.1107; found: 290.1103. 
 
(4'-(Dimethylamino)-[1,1'-biphenyl]-2-yl)(phenyl)methanone (170c) 
 
Isolated yield: 219 mg, 0.73 mmol, 73% yield; yellowish crystals 
Purification: i-hexane:ethyl acetate 9:1 
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m.p.: 114 – 116 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 7.67 – 7.61 (m, 2 H), 7.49 (td, J = 7.5, 1.5 Hz, 1 H), 7.45 – 7.40 (m, 
2 H), 7.40 – 7.31 (m, 2 H), 7.25 – 7.21 (m, 2 H), 7.13 – 7.07 (m, 2 H), 6.56 – 6.48 (m, 2 H), 2.83 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 199.3, 149.7, 141.2, 138.6, 137.5, 132.7, 130.2, 130.0, 129.8, 
129.7, 128.7, 128.1, 128.1, 126.0, 112.2, 40.4. 
FT-IR (ATR, cm-1): 𝜈 = 1664, 1613, 1594, 1526, 1479, 1448, 1350, 1315, 1281, 1247, 1222, 1204, 1169, 
1161, 1149, 932, 922, 824, 776, 766, 720, 704, 690, 676. 
MS (EI, 70 eV): m/z (%) = 303 (3), 302 (25), 301 (100), 300 (38), 224 (9), 180 (5), 152 (7), 105 (7). 
HR-MS (EI, 70 eV): [C21H19NO], calcd.:  301.1467; found: 301.1462. 
 
2'-Benzoyl-3-fluoro-[1,1'-biphenyl]-4-carbonitrile (170d) 
 
Isolated yield: 295 mg, 0.98 mmol, 98% yield; colorless oil 
Purification: i-hexane:ethyl acetate 8:2 
1H-NMR (400 MHz, CDCl3, ppm): δ= 7.70 – 7.64 (m, 2 H), 7.65 – 7.60 (m, 1 H), 7.58 – 7.41 (m, 5 H), 
7.39 – 7.32 (m, 2 H), 7.18 – 7.10 (m, 2 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 197.5, 162.7 (d, J = 259.7 Hz), 147.9 (d, J = 8.2 Hz), 138.8, 138.4 
(d, J = 1.9 Hz), 137.0, 133.5, 133.2, 130.9, 129.9, 129.9, 129.4, 128.6, 128.5, 125.5 (d, J = 3.4 Hz), 116.9 
(d, J = 20.2 Hz), 113.8, 100.1 (d, J = 15.5 Hz). 
19F-NMR (376 MHz, CDCl3, ppm):δ = -106.19 – -106.31 (m). 
FT-IR (ATR, cm-1): 𝜈 = 3061, 1660, 1619, 1448, 1412, 1279, 1260, 928, 902, 832, 762, 737, 724, 703, 
689, 680. 
MS (EI, 70 eV): m/z (%) = 302 (19), 301 (88), 300 (19), 273 (8), 272 (16), 225 (11), 224 (77), 196 (19), 
195 (21), 105 (100), 76 (43). 
HR-MS (EI, 70 eV): [C20H12FNO], calcd.:  301.0903; found: 301.0897. 
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Cyclopentyl(4'-methoxy-[1,1'-biphenyl]-2-yl)methanone (170e) 
 
Isolated yield: 213 mg, 0.76 mmol, 76% yield; white solid 
Purification: i-hexane:ethyl acetate 95:5 
m.p.: 99 – 101 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 7.51 – 7.42 (m, 1 H), 7.44 – 7.33 (m, 3 H), 7.30 – 7.22 (m, 2 H), 
6.98 – 6.91 (m, 2 H), 3.85 (s, 3 H), 2.79 – 2.65 (m, 1 H), 1.74 – 1.53 (m, 4 H), 1.51 – 1.29 (m, 4 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 212.2, 159.3, 141.4, 139.3, 132.9, 130.0, 130.0, 129.9, 127.7, 
126.9, 114.1, 55.3, 51.1, 30.3, 26.2. 
FT-IR (ATR, cm-1): 𝜈 = 2941, 1673, 1609, 1518, 1463, 1439, 1307, 1256, 1211, 1186, 1180, 1039, 998, 
834, 822, 781, 766, 727. 
MS (EI, 70 eV): m/z (%) = 281 (4), 280 (21), 212 (19), 211 (100), 168 (14), 139 (9), 61 (9), 43 (53). 
HR-MS (EI, 70 eV): [C19H20O2], calcd.:  280.1463; found: 280.1458. 
 
1-(3'-((tert-Butyldimethylsilyl)oxy)-5-fluoro-[1,1'-biphenyl]-2-yl)ethan-1-one (170f) 
 
Isolated yield: 224 mg, 0.68 mmol, 68% yield; colorless oil 
Purification: i-hexane:ethyl acetate 95:5 
1H-NMR (400 MHz, CDCl3, ppm): δ= 7.57 (dd, J = 8.5, 5.8 Hz, 1 H), 7.29 (t, J = 7.9 Hz, 1 H), 7.13 – 7.03 
(m, 2 H), 6.92 – 6.86 (m, 2 H), 6.81 (t, J = 2.0 Hz, 1 H), 1.99 (s, 3 H), 0.99 (s, 9 H), 0.21 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 203.3, 163.6 (d, J = 252.0 Hz), 156.0, 143.1 (d, J = 8.5 Hz), 141.1 
(d, J = 1.7 Hz), 137.0 (d, J = 3.1 Hz), 130.5 (d, J = 9.2 Hz), 129.9, 121.9, 120.4, 120.3, 116.9 (d, J = 22.0 
Hz), 114.5 (d, J = 21.5 Hz), 30.4, 25.7, 18.2, -4.4. 
FT-IR (ATR, cm-1): 𝜈 = 2930, 2859, 1688, 1600, 1572, 1473, 1307, 1279, 1260, 1241, 1216, 1174, 968, 
872, 838, 823, 810, 780, 706, 694. 
MS (EI, 70 eV): m/z (%) = 344 (15), 288 (18), 287 (73), 272 (26), 271 (54), 269 (32), 253 (28), 213 (24), 
75 (15), 70 (11), 61 (15), 45 (12), 43 (100). 
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HR-MS (EI, 70 eV): [C20H25FO2Si], calcd.:  344.1608; found: 344.1603. 
 
(5-Chloro-4'-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)(phenyl)methanone (170g) 
 
Isolated yield: 321 mg, 0.89 mmol, 89% yield; white solid 
Purification: i-hexane:ethyl acetate 9:1 
m.p.: 80 – 81 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 7.68 – 7.61 (m, 2 H), 7.52 – 7.45 (m, 6 H), 7.39 – 7.29 (m, 4 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 197.0, 142.5, 141.7, 137.2, 137.0, 136.6, 133.4, 130.5, 130.1, 
129.8, 129.9 (q, J = 32.4 Hz), 129.2, 128.4, 127.9, 125.4 (q, J = 3.8 Hz), 123.9 (q, J = 272.1 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 1666, 1591, 1581, 1321, 1278, 1247, 1166, 1152, 1109, 1096, 1066, 1031, 1014, 
928, 896, 844, 828, 815, 800, 767, 704, 686, 675. 
MS (EI, 70 eV): m/z (%) = 362 (13), 361 (16), 360 (42), 359 (23), 325 (20), 284 (18), 282 (53), 220 (24), 
105 (47), 77 (20), 70 (14), 61 (18), 45 (14), 43 (100). 
HR-MS (EI, 70 eV): [C20H12ClF3O], calcd.:  360.0529; found: 360.0522. 
 
(4-Chloro-2-(1-methyl-1H-indol-6-yl)phenyl)(phenyl)methanone (170h) 
 
Isolated yield: 210 mg, 0.61 mmol, 61% yield; yellow oil 
Purification: i-hexane:ethyl acetate 8:2 
1H-NMR (400 MHz, CDCl3, ppm): δ= 7.61 – 7.55 (m, 2 H), 7.52 – 7.47 (m, 2 H), 7.43 (tdd, J = 4.4, 1.4, 
0.7 Hz, 2 H), 7.36 (ddd, J = 7.6, 6.2, 2.2 Hz, 1 H), 7.07 – 7.04 (m, 2 H), 6.92 (d, J = 3.1 Hz, 1 H), 6.81 – 
6.75 (m, 2 H), 6.32 (dd, J = 3.1, 0.7 Hz, 1 H), 3.65 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 197.9, 166.5, 163.9, 142.1, 138.9, 136.0, 132.4, 132.3, 131.4, 
130.5, 130.3, 128.5, 126.4, 122.9, 121.5, 115.1, 114.9, 109.0, 101.2, 32.8. 
FT-IR (ATR, cm-1): 𝜈 = 2943, 2252, 1662, 1586, 1470, 1448, 1280, 1245, 1091, 905, 727. 
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MS (EI, 70 eV): m/z (%) = 347 (11), 346 (10), 345 (28), 344 (15), 267 (6), 104 (4), 76 (40< 58 (4), 42 (11). 
HR-MS (EI, 70 eV): [C22H16ClNO], calcd.:  345.0920; found: 345.0919. 
 
(4-Fluorophenyl)(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)methanone (170i) 
 
 
Isolated yield: 251 mg, 0.73 mmol, 73% yield; white solid 
Purification: i-hexane:ethyl acetate 95:5 
m.p.: 98 – 99 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 7.65 – 7.58 (m, 2 H), 7.55 (ddd, J = 7.6, 5.4, 3.5 Hz, 1 H), 7.48 – 
7.38 (m, 5 H), 7.33 – 7.27 (m, 2 H), 6.96 – 6.88 (m, 2 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 196.6, 166.9, 164.4, 143.7, 139.7, 138.7, 133.7, 132.6 (d, J = 9.4 
Hz), 130.2, 129.7, 129.4 (q, J = 283 Hz), 129.2, 128.8, 125.3 (q, J = 4.3 Hz), 122.3, 115.6 (d, J = 24.1 Hz). 
FT-IR (ATR, cm-1): 𝜈 = 3061, 1660, 1617, 1596, 1504, 1407, 1325, 1304, 1259, 1225, 1160, 1113, 1104, 
1067, 926, 843, 838, 765, 745, 733, 673. 
MS (EI, 70 eV): m/z (%) = 345 (12), 344 (53), 343 (23), 275 (15), 249 (38), 201 (15), 152 (10), 123 (54), 
95 (20), 85 (10), 83 (16). 
HR-MS (EI, 70 eV): [C20H12F4O], calcd.:  344.0824; found: 344.0818. 
 
(4-Fluorophenyl)(2-(1-methyl-1H-indol-6-yl)phenyl)methanone (170j) 
 
Isolated yield: 204 mg, 0.62 mmol, 62% yield; orange oil 
Purification: i-hexane:ethyl acetate 8:2 
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1H-NMR (400 MHz, CDCl3, ppm): δ= 7.59 – 7.54 (m, 2 H), 7.48 (dd, J = 2.0, 0.5 Hz, 1 H), 7.44 (dd, J = 
1.7, 0.8 Hz, 1 H), 7.38 – 7.25 (m, 3 H), 7.17 – 7.12 (m, 2 H), 7.08 – 7.00 (m, 2 H), 6.92 (d, J = 3.1 Hz, 1 H), 
6.32 (dd, J = 3.2, 0.8 Hz, 1 H), 3.64 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 198.2, 144.2, 137.5, 137.2, 136.2, 135.9, 132.8, 130.4, 130.2, 
130.0, 129.8, 129.5, 128.5, 128.0, 126.3, 122.7, 121.5, 109.1, 101.4, 32.8. 
FT-IR (ATR, cm-1): 𝜈 = 2943, 2250, 1661, 1597, 1503, 1473, 1303, 1284, 1240 , 1148, 931, 907, 756, 729. 
MS (EI, 70 eV): m/z (%) = 330 (20), 329 (87), 328 (43), 300 (17), 234 (16), 165 (10), 164 (11), 95 (7), 58 
(7), 42 (17). 
HR-MS (EI, 70 eV): [C22H16FNO], calcd.:  329.1216; found: 329.1214. 
 
Ethyl 2-(4-methoxyphenyl)nicotinate (172a) 
 
Isolated yield: 180 mg, 0.70 mmol, 70% yield; colorless oil 
Purification: i-hexane:ethyl acetate 95:5 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.64 (dd, J = 4.8, 1.8 Hz, 1 H), 7.96 (dd, J = 7.8, 1.8 Hz, 1 H), 7.47 – 
7.36 (m, 2 H), 7.18 (dd, J = 7.8, 4.8 Hz, 1 H), 6.95 – 6.78 (m, 2 H), 4.11 (q, J = 7.1 Hz, 2 H), 3.75 (s, 3 H), 
1.04 (t, J = 7.1 Hz, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 168.4, 160.2, 158.2, 151.0, 137.7, 132.5, 130.0, 127.1, 121.0, 
113.6, 61.5, 55.2, 13.8. 
FT-IR (ATR, cm-1): 𝜈 = 2982, 1714, 1608, 1582, 1515, 1428, 1298, 1280, 1250, 1175, 1130,1095, 1054, 
1024, 838, 780. 
MS (EI, 70 eV): m/z (%) = 257 (13), 229 (13), 228 (100), 212 (11), 185 (18), 169 (12), 142 (13), 141 (19), 
114 (14). 
HR-MS (EI, 70 eV): [C15H15NO3], calcd.:  257.1052; found: 257.1053. 
 
Methyl 2-(3-(benzyloxy)phenyl)nicotinate (172b) 
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Isolated yield: 226 mg, 0.71 mmol, 71% yield; yellow oil 
Purification: i-hexane: ethyl acetate 7:3 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.71 (dd, J = 4.8, 1.8 Hz, 1 H), 8.01 (dd, J = 7.8, 1.8 Hz, 1 H), 7.40 – 
7.25 (m, 7 H), 7.18 – 7.17 (m, 1 H), 7.04 – 6.96 (m, 2 H), 5.05 (s, 2 H), 3.62 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 168.5, 158.8, 158.5, 151.2, , 141.4, 137.8, 136.9, 129.2, 128.6, 
127.9, 127.6, 127.2, 121.6, 121.3, 115.7, 114.6, 70.0, 52.4. 
FT-IR (ATR, cm-1): 𝜈 = 2960, 2254, 1635, 1587, 1560, 1483, 1403, 1313, 1190, 1078, 968, 952, 902, 722. 
MS (EI, 70 eV): m/z (%) = 319 (28), 161 (8), 91 (8), 90 (103), 83 (5), 58 (6), 43 (11). 
HR-MS (EI, 70 eV): [C20H17NO3], calcd.:  319.1208; found: 319.1203. 
 
Methyl 2-(4-(dimethylamino)phenyl)nicotinate (172c) 
 
Isolated yield: 232 mg, 0.91 mmol, 91% yield; yellow oil 
Purification: i-hexane:ethyl acetate 9:1 to 2:1 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.71 (dd, J = 4.8, 1.8 Hz, 1 H), 7.98 (dd, J = 7.7, 1.8 Hz, 1 H), 7.54 – 
7.45 (m, 2 H), 7.20 (dd, J = 7.8, 4.8 Hz, 1 H), 6.81 – 6.70 (m, 2 H), 3.76 (s, 3 H), 3.01 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 169.7, 158.4, 151.1, 150.9, 137.7, 129.7, 127.4, 126.1, 120.1, 
111.8, 52.4, 40.4. 
FT-IR (ATR, cm-1): 𝜈 = 1717, 1607, 1579, 1565, 1525, 1422, 1356, 1313, 1282, 1216, 1193, 1169, 1122, 
1094, 1053, 945, 824, 777, 751. 
MS (EI, 70 eV): m/z (%) = 257 (17), 256 (100), 255 (53), 241 (43), 225 (14), 98 (12), 44 (15). 
HR-MS (EI, 70 eV): [C15H16N2O2], calcd.:  256.1212; found: 256.1208. 
 
2-(4-(Methoxymethoxy)phenyl)nicotinonitrile (172d) 
 
Isolated yield: 145 mg, 0.60 mmol, 60% yield; white solid 
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Purification: i-hexane:ethyl acetate 2:1 
m.p.: 84 – 85 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.84 (dd, J = 4.8, 1.8 Hz, 1 H), 8.04 (dd, J = 7.9, 1.8 Hz, 1 H), 7.95 – 
7.87 (m, 2 H), 7.32 (dd, J = 7.9, 4.8 Hz, 1 H), 7.20 – 7.12 (m, 2 H), 5.25 (s, 2 H), 3.50 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 160.5, 159.0, 152.6, 141.9, 130.7, 130.4, 121.1, 118.0, 116.3, 
106.8, 94.2, 56.2. 
FT-IR (ATR, cm-1): 𝜈 = 2225, 1607, 1581, 1574, 1552, 1517, 1432, 1410, 1306, 1256, 1248, 1209, 1178, 
1155, 1108, 1038, 982, 948, 934, 851, 828, 812, 803, 771, 719. 
MS (EI, 70 eV): m/z (%) = 241 (4), 240 (27), 210 (24), 179 (5), 167 (5), 45 (100), 43 (23). 
HR-MS (EI, 70 eV): [C14H12N2O2], calcd.:  240.0899; found: 240.08942. 
 
Ethyl 6-(4-methoxyphenyl)nicotinate (172e) 
 
Isolated yield: 230 mg, 0.89 mmol, 89% yield; white solid 
Purification: i-hexane:ethyl acetate 4:1 
m.p.: 81 – 82 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 9.24 (dd, J = 2.2, 0.8 Hz, 1 H), 8.30 (dd, J = 8.3, 2.2 Hz, 1 H), 8.08 – 
7.99 (m, 2 H), 7.74 (dd, J = 8.4, 0.9 Hz, 1 H), 7.06 – 6.96 (m, 2 H), 4.42 (q, J = 7.1 Hz, 2 H), 3.88 (s, 3 H), 
1.42 (t, J = 7.1 Hz, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 165.5, 161.2, 160.4, 150.9, 137.7, 130.9, 128.8, 123.7, 118.9, 
114.3, 61.3, 55.4, 14.3. 
FT-IR (ATR, cm-1): 𝜈 = 2839, 1706, 1592, 1583, 1561, 1475, 1461, 1379, 1366, 1285, 1247, 1182, 1144, 
1131, 1112, 1033. 
MS (EI, 70 eV): m/z (%) = 259 (17), 257 (100), 256 (3), 231 (30), 215 (9), 214 (10), 213 (51), 186 (10), 
184 (9), 157 (15). 
HR-MS (EI, 70 eV): [C15H15NO3], calcd.:  257.1052; found: 257.1048. 
 
 
 
EXPERIMENTAL PART 
 
182 
Ethyl 6-(2-fluoro-[1,1'-biphenyl]-4-yl)nicotinate (172f) 
 
Isolated yield: 283 mg, 0.88 mmol, 88% yield; white solid 
Purification: i-hexane:ethyl acetate 9:1 
m.p.: 111 – 112 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 9.30 (dd, J = 2.2, 0.9 Hz, 1 H), 8.37 (dd, J = 8.3, 2.2 Hz, 1 H), 7.97 – 
7.90 (m, 1 H), 7.91 (t, J = 0.9 Hz, 1 H), 7.83 (dd, J = 8.3, 0.9 Hz, 1 H), 7.65 – 7.54 (m, 3 H), 7.52 – 7.44 (m, 
2 H), 7.44 – 7.37 (m, 1 H), 4.45 (q, J = 7.1 Hz, 2 H), 1.44 (t, J = 7.1 Hz, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 165.2, 161.4, 159.0 (d, J = 2.5 Hz), 158.9, 151.1, 139.3 (d, J = 7.9 
Hz), 138.0, 135.2 (d, J = 1.4 Hz), 131.1 (d, J = 3.8 Hz), 130.5 (d, J = 13.7 Hz), 129.0 (d, J = 3.1 Hz), 128.6, 
128.1, 127.9, 125.0, 123.0 (d, J = 3.3 Hz), 119.7, 115.0 (d, J = 24.9 Hz). 
19F-NMR (375 MHz, CDCl, ppm): δ = -117.20. 
FT-IR (ATR, cm-1): 𝜈 = 1712, 1593, 1470, 1417, 1380, 1287, 1274, 1261, 1155, 1124, 1024, 1011, 897, 
851, 829, 780, 761, 740, 728, 718, 694. 
MS (EI, 70 eV): m/z (%) = 322 (19), 321 (100), 293 (35), 277 (11), 276 (57), 248 (14), 221 (21), 220 (18), 
170 (13), 44 (10), 43 (24). 
HR-MS (EI, 70 eV): [C20H16FNO2], calcd.:  321.1165; found: 321.1158. 
 
2-(4-Methoxy-3,5-dimethylphenyl)-5-(trifluoromethyl)pyridine (172g) 
 
Isolated yield: 242 mg, 0.86 mmol, 86% yield; colorless oil 
Purification: i-hexane:ethyl acetate 4:1 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.90 (dt, J = 2.5, 0.9 Hz, 1 H), 7.93 (ddd, J = 8.3, 2.4, 0.7 Hz, 1 H), 
7.82 – 7.75 (m, 1 H), 7.69 (2 H), 3.77 (s, 3 H), 2.37 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 160.5 (d, J = 1.5 Hz), 158.9, 146.4 (q, J = 4.1 Hz), 133.8 (q, J = 3.5 
Hz), 133.4, 131.5, 127.9, 124.3 (q, J = 33.0 Hz), 123.9 (q, J = 272.8 Hz), 119.6, 59.7, 16.3. 
FT-IR (ATR, cm-1): 𝜈 = 2929, 1606, 1567, 1476, 1326, 1199, 1164, 1125, 1075, 1012, 839, 718. 
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MS (EI, 70 eV): m/z (%) = 282 (16), 281 (100), 280 (3), 267 (16), 266 (79), 238 (34), 222 (15), 61 (12). 
HR-MS (EI, 70 eV): [C15H14ClF3NO], calcd.:  281.1027; found: 281.1020. 
 
2-(3-Methoxyphenyl)-5-(trifluoromethyl)pyridine (172h) 
 
Isolated yield: 185 mg, 0.73 mmol, 73% yield; colorless crystals 
Purification: i-hexane:diethyl ether 10:1 
m.p.: 53 – 55 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.95 – 8.93 (m, 1 H), 7.98 (ddd, J = 8.3, 2.4, 0.8 Hz, 1 H), 7.84 (d, J 
= 8.4 Hz, 1 H), 7.63 (dd, J = 2.6, 1.6 Hz, 1 H), 7.58 (ddd, J = 7.7, 1.7, 1.0 Hz, 1 H), 7.42 (t, J = 8.0 Hz, 1 H), 
7.03 (ddd, J = 8.3, 2.7, 1.0 Hz, 1 H), 3.91 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 160.4 (d, J = 1.4 Hz), 160.2, 146.5 (q, J = 4.1 Hz), 139.4, 133.9 (q, 
J = 3.5 Hz), 130.0, 124.9 (td, J = 31.4 Hz), 123.8 (q, J = 273.9 Hz), 120.1, 119.6, 116.1, 112.4, 55.4. 
FT-IR (ATR, cm-1): 𝜈 = 2956, 2838, 1608, 1589, 1566, 1476, 1328, 1304, 1296, 1242, 1220, 1180, 1166, 
1124, 1082, 1052, 1033, 1014, 945, 881, 853, 843, 793, 782, 764, 717, 691. 
MS (EI, 70 eV): m/z (%) = 254 (12), 253 (100), 252 (95), 224 (51), 223 (54), 222 (54), 154 (20), 141 (21), 
44 (23), 43 (64). 
HR-MS (EI, 70 eV): [C13H10F3NO], calcd.:  253.0714; found: 253.0716. 
 
6-(3-((tert-Butyldimethylsilyl)oxy)phenyl)nicotinonitrile (172i) 
 
Isolated yield: 261 mg, 0.84 mmol, 84% yield; white solid 
Purification: i-hexane:ethyl acetate 95:5 
m.p.: 69 – 70 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.93 (dd, J = 2.2, 0.9 Hz, 1 H), 7.99 (dd, J = 8.3, 2.2 Hz, 1 H), 7.81 
(dd, J = 8.4, 0.9 Hz, 1 H), 7.61 (ddd, J = 7.8, 1.7, 1.0 Hz, 1 H), 7.54 (t, J = 2.1 Hz, 1 H), 7.37 (t, J = 7.9 Hz, 
1 H), 6.97 (ddd, J = 8.1, 2.5, 1.0 Hz, 1 H), 1.01 (s, 9 H), 0.24 (s, 6 H). 
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13C-NMR (100 MHz, CDCl3, ppm):δ = 160.3, 156.4, 152.4, 139.8, 138.8, 130.1, 122.3, 120.3, 120.1, 
119.1, 117.1, 107.9, 25.7, 18.2, -4.3. 
FT-IR (ATR, cm-1): 𝜈 = 2928, 2857, 2229, 1594, 1582, 1553, 1464, 1432, 1373, 1310, 1288, 1259, 1252, 
1236, 1217, 1206, 936, 892, 830, 799, 779, 760, 739, 690, 681, 662. 
MS (EI, 70 eV): m/z (%) = 311 (2), 310 (6), 295 (2), 254 (19), 253 (100), 43 (11). 
HR-MS (EI, 70 eV): [C18H22N2OSi], calcd.:  310.1501; found: 310.1499. 
 
6-(4-Methoxyphenyl)nicotinonitrile (172j) 
 
Isolated yield: 176 mg, 0.84 mmol, 84% yield; white solid 
Purification: i-hexane:ethyl acetate 9:1 
m.p.: 104 – 106 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.88 (dd, J = 2.2, 0.9 Hz, 1 H), 8.03 – 7.99 (m, 2 H), 7.96 – 7.90 (m, 
1 H), 7.78 – 7.73 (m, 1 H), 7.03 – 6.99 (m, 2 H), 3.87 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 161.8, 160.0, 152.4, 139.6, 129.8, 128.86, 118.9, 117.2, 114.4, 
106.8, 55.4. 
FT-IR (ATR, cm-1): 𝜈 = 3053, 2841, 2220, 1607, 1587, 1515, 1474, 1442, 1378, 1303, 1245, 1169, 1113, 
1042, 1017, 817, 757. 
MS (EI, 70 eV): m/z (%) = 210 (22), 196 (1), 195 (5), 179 (1), 168 (1), 167 (9), 166 (4), 141 (1), 140 (2), 
86 (3), 84 (5) 
HR-MS (EI, 70 eV): [C13H10N2O], calcd.: 210.0793 found: 210.0788. 
 
2-(3-((tert-Butyldimethylsilyl)oxy)phenyl)quinoline-3-carbonitrile (174a) 
 
Isolated yield: 328 mg, 0.92 mmol, 92% yield; yellow oil 
Purification: i-hexane:ethyl acetate 8:2 
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1H-NMR (400 MHz, CDCl3, ppm): δ= 8.59 (d, J = 0.8 Hz, 1 H), 8.14 (dq, J = 8.2, 1.0 Hz, 1 H), 7.86 - 7.80 
(m, 2 H), 7.60 (ddd, J = 8.2, 7.1, 1.2 Hz, 1 H), 7.52 (ddd, J = 7.7, 1.7, 1.0 Hz, 1 H), 7.42 - 7.32 (m, 2 H), 
6.95 (ddd, J = 8.1, 2.5, 1.0 Hz, 1 H), 0.95 (s, 9 H), 0.20 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 157.7, 155.9, 148.6, 144.2, 139.0, 132.9, 130.0, 129.8, 128.0, 
127.7, 125.1, 122.1, 121.9, 120.8, 117.9, 105.6, 25.7, 18.2, -4.3. 
FT-IR (ATR, cm-1): 𝜈 = 3064, 2856, 2225, 1715, 1619, 1582, 1557, 1460, 1440, 1287, 1250, 1220, 944, 
900, 831, 774, 730. 
MS (EI, 70 eV): m/z (%) = 305 (17), 304 (71), 303 (237), 287 (23), 274 (14), 273 (35), 144 (14). 
HR-MS (EI, 70 eV): [C22H24N2OSi], calcd.:  360.1658; found: 360.1657. 
 
Ethyl 2-(4-methoxyphenyl)quinoline-4-carboxylate (174b) 
 
Isolated yield: 199 mg, 0.65 mmol, 65% yield; white solid 
Purification: i-hexane:ethyl acetate 9:1 
m.p.: 80 – 82 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.66 (dd, J = 8.6, 0.7 Hz, 1 H), 8.30 (s, 1 H), 8.17 – 8.08 (m, 3 H), 
7.70 (ddd, J = 8.4, 6.8, 1.4 Hz, 1 H), 7.54 (ddd, J = 8.3, 6.8, 1.3 Hz, 1 H), 7.04 – 6.94 (m, 2 H), 4.50 (q, J = 
7.1 Hz, 2 H), 3.85 (s, 3 H), 1.46 (t, J = 7.1 Hz, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 166.6, 161.1, 156.3, 149.2, 136.0, 131.4, 130.1, 129.8, 128.9, 
127.3, 125.4, 123.7, 119.8, 114.3, 61.9, 55.4, 14.4. 
FT-IR (ATR, cm-1): 𝜈 = 2981, 1714, 1504, 1271, 1244, 1232, 1194, 1178, 1151, 1136, 1113, 1023, 835, 
797, 780, 736, 678. 
MS (EI, 70 eV): m/z (%) = 309 (2), 308 (24), 307 (100), 236 (12), 235 (57), 234 (12), 191 (23), 190 (10). 
HR-MS (EI, 70 eV): [C19H17NO3], calcd.:  307.1208; found: 307.1203. 
 
2-(3-((tert-Butyldimethylsilyl)oxy)phenyl)pyrimidine (174c) 
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Isolated yield: 264 mg, 0.92 mmol, 92% yield; colorless oil 
Purification: i-hexane:ethyl acetate 9:1 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.80 (d, J = 4.8 Hz, 2 H), 8.04 (ddd, J = 7.8, 1.6, 1.0 Hz, 1 H), 7.94 
(dd, J = 2.5, 1.6 Hz, 1 H), 7.35 (t, J = 7.9 Hz, 1 H), 7.18 (t, J = 4.8 Hz, 1 H), 6.97 (ddd, J = 8.1, 2.6, 1.0 Hz, 
1 H), 1.01 (s, 9 H), 0.24 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 164.6, 157.2, 156.1, 139.1, 129.5, 122.6, 121.2, 119.8, 119.1, 25.7, 
18.2, -4.4. 
FT-IR (ATR, cm-1): 𝜈 = 2931, 2858, 1713, 1553, 1450, 1422, 1409, 1281, 1250, 1225, 1177, 1150, 939, 
834, 816, 796, 779, 690. 
MS (EI, 70 eV): m/z (%) = 287 (3), 286 (12), 230 (6), 229 (20), 288 (100), 213 (5), 167 (5). 
HR-MS (EI, 70 eV): [C16H22N2OSi], calcd.:  286.1501; found: 286.1496. 
 
4-(4-Chlorophenyl)-2-(3,5-dimethoxyphenyl)pyrimidine (174d) 
 
Isolated yield: 281 mg, 0.89 mmol, 86% yield; white solid 
Purification: i-hexane:ethyl acetate 4:1 
m.p.: 113 – 114 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.84 (dd, J = 5.3, 0.9 Hz, 1 H), 8.21 – 8.11 (m, 2 H), 7.76 (d, J = 2.4 
Hz, 2 H), 7.57 (dd, J = 5.3, 1.1 Hz, 1 H), 7.55 – 7.46 (m, 2 H), 6.63 (t, J = 2.4 Hz, 1 H), 3.92 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 164.3, 162.6, 161.0, 157.9, 139.8, 137.3, 135.3, 129.2, 128.5, 
114.5, 106.1, 103.5, 55.6. 
FT-IR (ATR, cm-1): 𝜈 = 3019, 2840, 1604, 1595, 1568, 1543, 1493, 1471, 1435, 1421, 1405, 1380, 1291, 
1208, 1158, 1088, 1068, 1045, 1011, 930, 869, 828, 810, 791, 774, 702, 689, 663. 
MS (EI, 70 eV): m/z (%) = 329 (7), 328 (36), 327 (38), 326 (100), 325 (64), 298 (8), 297 (19), 296 (17), 
295 (10), 163 (11). 
HR-MS (EI, 70 eV): [C18H15ClN2O2], calcd.:  326.0822; found: 326.0814. 
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2-(2-Fluoro-[1,1'-biphenyl]-4-yl)-4-methylpyrimidine (174e) 
 
Isolated yield: 200 mg, 0.76 mmol, 76% yield; white solid 
Purification: i-hexane:ethyl acetate 9:1 
m.p.: 94 – 95 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.66 (d, J = 5.1 Hz, 1 H), 8.34 – 8.23 (m, 2 H), 7.67 – 7.60 (m, 2 H), 
7.57 (t, J = 8.0 Hz, 1 H), 7.51 – 7.44 (m, 2 H), 7.43 – 7.36 (m, 1 H), 7.08 (d, J = 5.0 Hz, 1 H), 2.61 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 167.4, 163.0 (d, J = 2.9 Hz), 160.0 (d, J = 247.2 Hz), 156.9, 139.1 
(d, J = 8.1 Hz), 135.5 (d, J = 1.5 Hz), 131.0 (d, J = 13.7 Hz), 130.8 (d, J = 3.7 Hz), 129.0 (d, J = 3.1 Hz), 
128.5, 128.0, 124.0 (d, J = 3.3 Hz), 119.0, 115.8 (d, J = 25.1 Hz), 24.4. 
FT-IR (ATR, cm-1): 𝜈 = 2252, 1578, 1557, 1436, 1416, 1390, 904, 832, 828, 797, 768, 723, 697. 
MS (EI, 70 eV): m/z (%) = 266 (1), 265 (20), 264 (100), 263 (4), 249 (11), 198 (6), 197 (27), 196 (6), 170 
(6).  
HR-MS (EI, 70 eV): [C17H13FN2], calcd.:  264.1063; found: 264.1056. 
 
2-(3,5-Dimethoxyphenyl)-4,6-dimethylpyrimidine (174f) 
 
Isolated yield: 158 mg, 0.65 mmol, 65% yield; white solid 
Purification: i-hexane:ethyl acetate 4:1 
m.p.: 127 – 128 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 7.63 (d, J = 2.4 Hz, 2 H), 6.93 (s, 1 H), 6.58 (t, J = 2.4 Hz, 1 H), 3.89 
(s, 6 H), 2.53 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 166.7, 163.8, 160.9, 140.3, 118.2, 105.9, 103.3, 55.5, 24.2. 
FT-IR (ATR, cm-1): 𝜈 = 2926, 2834, 1610, 1584, 1540, 1465, 1450, 1440, 1427, 1384, 1360, 1318, 1284, 
1240, 1203, 1170, 1154, 1096, 1057, 1002, 985, 941, 926, 877, 867, 835, 812, 794, 754, 690. 
MS (EI, 70 eV): m/z (%) = 245 (4), 244 (25), 243 (23), 215 (6), 214 (7), 191 (8),  88 (5), 70 (10). 
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HR-MS (EI, 70 eV): [C14H16N2O2], calcd.:  244.1212; found: 244.1204. 
 
tert-Butyl (3-(4,6-diphenyl-1,3,5-triazin-2-yl)phenyl) carbonate (174g) 
 
Isolated yield: 260 mg, 0.61 mmol, 61% yield; white solid 
Purification: i-hexane:ethyl acetate 4:1 
m.p.: 182 – 183 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.81 – 8.73 (m, 4 H), 8.67 (dt, J = 7.8, 1.3 Hz, 1 H), 8.56 (dd, J = 2.5, 
1.6 Hz, 1 H), 7.67 – 7.54 (m, 7 H), 7.46 (ddd, J = 8.1, 2.5, 1.1 Hz, 1 H), 1.62 (s, 9 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 171.7, 170.8, 151.8, 151.5, 138.0, 136.1, 132.6, 129.6, 129.0, 
128.7, 126.3, 125.5, 121.7, 83.9, 27.8. 
FT-IR (ATR, cm-1): 𝜈 = 2982, 1757, 1519, 1447, 1363, 1253, 1218, 1147, 909, 770, 732, 689. 
MS (EI, 70 eV): m/z (%) = 426 (1), 326 (21), 325 (100), 104 (18), 103 (21), 57 (33). 
HR-MS (EI, 70 eV): [C26H23N3O3+H+], calcd.:  426.1812; found: 426.1811. 
 
4,6-Bis(4-methoxyphenyl)pyrimidine (176) 
 
The title compound was prepared from 4,6-dichloropyrimidine (175) according to TP-11 using 2.4 equiv 
of the appropriate zinc species (165a). 
Isolated yield:  225 mg, 0.77 mmol, 77% yield (1 mmol scale) 
2.13 g, 7.29 mmol, 73% yield (10 mmol scale); white solid 
Purification: i-hexane:ethyl acetate 7:1 
m.p.: 147 – 148 °C. 
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1H-NMR (400 MHz, CDCl3, ppm): δ= 9.14 (d, J = 1.3 Hz, 1 H), 8.09 – 8.01 (m, 4 H), 7.91 (d, J = 1.3 Hz, 1 
H), 7.03 – 6.93 (m, 4 H), 3.83 (s, 6 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 163.9, 161.9, 159.0, 129.6, 128.7, 114.4, 111.0, 55.5. 
FT-IR (ATR, cm-1): 𝜈 = 3009, 1602, 1583, 1506, 1457, 1443, 1379, 1298, 1255, 1231, 1170, 1112, 1021, 
825, 804, 780. 
MS (EI, 70 eV): m/z (%) = 293 (20), 292 (100), 277 (19), 41 (9), 249 (6), 234 (5), 146 (8). 
HR-MS (EI, 70 eV): [C18H16N2O2], calcd.:  292.1212; found: : 292.1205. 
 
1-Methyl-6-(pyrimidin-2-yl)-1H-indole (177a) 
 
Isolated yield:  144 mg, 0.69 mmol, 69% yield (1 mmol scale); white solid 
  1.51 g, 7.22 mmol, 72% yield (10 mmol scale) 
Purification: i-hexane:ethyl acetate 7:3 
m.p.: 123 – 124 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.75 – 8.67 (m, 3 H), 8.29 (dd, J = 8.7, 1.7 Hz, 1 H), 7.34 (dt, J = 8.8, 
0.8 Hz, 1 H), 7.09 – 6.99 (m, 2 H), 6.53 (dd, J = 3.1, 0.9 Hz, 1 H), 3.77 (s, 3 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 166.0, 157.1, 138.4, 129.7, 129.1, 128.7, 121.9, 121.8, 118.1, 
109.2, 102.5, 33.0. 
FT-IR (ATR, cm-1): 𝜈 = 3098, 1612, 1563, 1552, 1433, 1404, 1339, 1277, 1240, 1148, 919, 790, 769, 728, 
698. 
MS (EI, 70 eV): m/z (%) = 209 (100), 208 (24), 156 (24), 155 (12), 104 (10), 85 (20), 83 (30). 
HR-MS (EI, 70 eV): [C13H11N3], calcd.:  209.0953; found: 209.0950. 
 
2-(Thiophen-3-yl)pyrimidine (177b) 
 
Isolated yield: 99 mg, 0.61 mmol, 61% yield; white solid 
Purification: i-hexane:ethyl acetate 8:2 
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m.p.: 97 – 99 °C. 
1H-NMR (400 MHz, CDCl3, ppm): δ= 8.67 (d, J = 4.9 Hz, 2 H), 8.23 (dd, J = 3.1, 1.2 Hz, 1 H), 7.83 (dd, J 
= 5.1, 1.2 Hz, 1 H), 7.32 (dd, J = 5.1, 3.1 Hz, 1 H), 7.06 (t, J = 4.9 Hz, 1 H). 
13C-NMR (100 MHz, CDCl3, ppm):δ = 161.9, 157.2, 141.5, 127.9, 127.3, 126.1, 118.6. 
FT-IR (ATR, cm-1): 𝜈 = 3117, 2925, 2360, 1566, 1557, 1530, 1435, 1376, 866, 804, 773, 698. 
MS (EI, 70 eV): m/z (%) = 244 (11), 163 (15), 162 (19), 161 (42), 135 (12), 110 (12), 109 (78), 58 (41), 57 
(12), 49 (11), 42 (9). 
HR-MS (EI, 70 eV): [C8H6N2S], calcd.:  162.0252; found: 162.0243. 
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D             APPENDIX 
1 X-Ray Structures 
Ethyl 2-(4-(ethoxycarbonyl)phenyl)oxazole-5-carboxylate (138j) 
 
 
 
Crystal Data 
Empirical formula C15H15N1O5 
Formula weight 289.28 
Crystal size [mm] 0.04 x 0.06 x 0.12 
T [K] 173 
Radiation Mo 
Diffractometer XCalibur 
Crystal system monoclinic 
Space group P21/c 
a [Å] 6.0862 (4) 
b [Å] 33.4685 (19) 
c [Å] 6.8474 (4) 
 [°] 90 
 [°] 93.235 (2) 
[°] 90 
V [Å3] 1392.57 (15) 
Z 4 
calcd [g cm-3] 1.380 
 [mm-1] 0.105 
F(000) 608 
range [°] 3.0 – 25.4 
Index ranges -7 ≤ h ≤ 7 
 -40 ≤ k ≤ 40 
 -8 ≤ l ≤ 8 
Reflns. collected 24185 
Reflns. observed 2067 
Reflns. unique 2562 
 (Rint = 0.036) 
R1 (Fobs) 0.0356 
R(F2) 0.0987 
S 1.03 
Peak/hole [e Å3] 0.24/-0.17 
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Ethyl 4-(5-cyanooxazol-2-yl)benzoate (138l) 
 
Crystal Data 
Empirical formula C13H10N2O3 
Formula weight 242.23 
Crystal size [mm] 0.17 x 0.20 x 0.39 
T [K] 100 
Radiation Mo 
Diffractometer XCalibur 
Crystal system monoclinic 
Space group P21/n 
a [Å] 4.5247 (2) 
b [Å] 28.9366 (17) 
c [Å] 9.1022 (6) 
 [°] 90 
 [°] 99.297 (6) 
[°] 90 
V [Å3] 1176.09 (12) 
Z 4 
calcd [g cm-3] 1.368 
 [mm-1] 0.099 
F(000) 171 
range [°] 4.2 – 26.4 
Index ranges -5 ≤ h ≤ 5 
 -36 ≤ k ≤ 26 
 -11 ≤ l ≤ 11 
Reflns. collected 7943 
Reflns. observed 1765 
Reflns. unique 2387 
 (Rint = 0.043) 
R1 (Fobs) 0.0739 
R(F2) 0.1380 
S 1.13 
Peak/hole [e Å3] 0.27/-0.25 
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2-(4-Chlorophenyl)-7-phenylcyclohepta-2,4,6-trien-1-one (159a) 
  
Crystal Data 
Empirical formula C19H13ClO 
Formula weight 292.74 
Crystal size [mm] 0.17 x 0.20 x 0.39 
T [K] 123 
Radiation Mo 
Diffractometer Xcalibur 
Crystal system triclinical 
Space group P1 
a [Å] 3.899 (2) 
b [Å] 7.3033 (5) 
c [Å] 12.6436 (7) 
 [°] 98.100 (5) 
 [°] 95.517 (5) 
[°] 101.420 (5) 
V [Å3] 346.53 (4) 
Z 1 
calcd [g cm-3] 1.403 
 [mm-1] 0.270 
F(000) 152 
range [°] 4.7 – 31.7 
Index ranges -5 ≤ h ≤ 5 
 -9 ≤ k ≤ 9 
 -16 ≤ l ≤ 16 
Reflns. collected 5815 
Reflns. observed 3412 
Reflns. unique 3070 
 (Rint = 0.0269) 
R1 (Fobs) 0.0456 
R(F2) 0.0799 
S 1.026 
Peak/hole [e Å3] 0.29/-0.17 
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2 List of Abbreviations 
Ac acetyl 
acac acetylacetonate 
Alk alkyl 
aq aqueous 
Ar Aryl 
ATR attenuated total reflection (IR) 
Bn Benzyl 
Boc tert-butyloxycarbonyl 
Bu butyl 
calc. calculated 
conc. concentrated 
CPhos 2-dicyclohexylphosphino-2′,6′-bis(N,N-dimethylamino)biphenyl 
Cy cyclohexyl 
δ chemical shifts in ppm (parts per million) 
dba trans,trans-dibenzylidenacetone 
DMBA 2,5-dimethylbenzoic acid 
DME 1,2-dimethoxyethane 
DMF N,N-dimethylformamide 
DMPU N,N'-dimethylpropyleneurea 
E electrophile 
EI electron impact ionization 
equiv equivalent 
ESI electrospray ionization 
Et ethyl 
FG functional group 
FLP frustrated Lewis pairs 
GC gas chromatography 
HRMS high resolution mass spectrometry 
IPent 1,3-bis(diisopentylphenyl)-imidazol-2-ylidene 
IPr 1,3-bis(diisopropylphenyl)-imidazol-2-ylidene 
i-Pr iso-propyl 
IR infrared  
J coupling constant (NMR) 
M molarity 
m meta 
m.p. melting point 
Me methyl 
MOM methoxymethyl 
MS mass spectrometry 
NEP N-ethyl-2-pyrrolidone 
NMP N-methyl-2-pyrrolidone 
NMR nuclear magnetic resonance 
o ortho 
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p para 
PEPPSI pyridine-enhanced precatalyst preparation stabilization and initiation 
Ph phenyl 
phen phenanthroline 
Piv pivaloyl 
PPAR peroxisome proliferator-activated receptor 
R organic substituent 
r.t. room temperature 
RuPhos 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl 
sat. saturated 
SPhos 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl 
TAAR trace amine-associated receptor 
TBS tert-butyldimethylsilyl 
t-Bu tert-Butyl 
TEA triethylamine 
tfp tris(o-furyl)phosphine 
THF tetrahydrofuran 
TLC thin layer chromatography 
TMEDA N,N,N',N'-tetramethylethylenediamine 
TMP 2,2,6,6-tetramethylpiperidyl 
TMS trimethylsilyl 
Ts 4-toluenesulfonyl 
TTMPP tris(2,4,6-trimethoxyphenyl)phosphine 
XPhos 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl 
ZACA Zr-catalyzed asymmetric carboalumination 
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